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ABSTRACT
CHARACTERIZING MIGRATORY SIGNALING PATHWAYS OF TRANSPLANTABLE RETINAL
PROGENITOR CELLS AND PHOTORECEPTOR PRECURSOR CELLS TOWARD RESTORATION OF
DEGENERATIVE RETINA –
A SYSTEMS BIOLOGY APPROACH
BY
UCHENNA JOHN UNACHUKWU

ADVISER: DR. STEPHEN REDENTI

A common feature of several heterogeneous diseases that result in retinal degeneration (RD) is
photoreceptor loss, leading to an irreversible decline in visual function [15-17]. There are no cell
replacement treatments available for RD diseases such as age-related macular degeneration (AMD) and
retinitis pigmentosa (RP). Although many RD cases are of a genetic origin, a promising strategy to treat
diseased phenotypes is by replacing lost photoreceptor cells, for synaptic integration and restoration of
visual function. To advance photoreceptor-replacement strategies as a practical therapy, in light of highly
restricted integration rates reported across studies, this body of research focused on defining the
molecular mechanisms facilitating migration of transplantable photoreceptor precursors in the retinal
microenvironment. To accomplish this work we utilized bioinformatics, bioengineering and molecular
biologic techniques for a systems level approach.

Guided by classic neuronal migration models, we hypothesized that transplanted photoreceptor
precursors navigate to specific retinal lamina in part due to cell surface receptor expression and in
response to spatially gradated directional ligand cues provided by the host retinal microenvironment.
Given the neural origin of the mammalian retinal system, we also predicted that these chemotactic
receptor-ligand pairs trigger intracellular signaling events in migrating photoreceptors analogous to
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canonical migration pathways exhibited by neuronal precursors. For a comprehensive account of these
motility-deterministic biochemical interactions, we first performed in silico bioinformatics modeling of PPC
transplantation into light-damaged retina by matching microarray datasets between PPC receptors and
ligands in the light-damaged retinal microenvironment. We then refined the gene expression network data
to focus on motility deterministic interactions at the interface of the PPC cell-surface receptors and
extracellular ligands of the damaged retina. Our in silico network modeling generated a library of ligandreceptor pairs associated with cellular movement specific for this retinal transplantation paradigm and the
intracellular signaling pathways induced by candidate chemotactic ligands.

Working from predicted interactions of in silico paired PPC receptors and retinal ligands, we then
performed cell migration analysis to evaluate whether exposure to stromal derived factor-1α (SDF-1α)
would guide the motility of PPCs and RPCs in vitro. We also assessed the chemotactic effects of
epidermal growth factor (EGF) on RPCs. Cell surface expression of C-X-C chemokine receptor type 4
(CXCR4) receptors on PPCs and RPCs, and EGF receptor expression on RPCs were verified via
immunocytochemical staining and validated by Western blot analysis. Boyden chamber analysis was
used as an initial high-throughput screen to verify the motogenic effects of the ligands on PPCs and
RPCs. We determined that RPC motility was optimally stimulated in these chambers by EGF
concentrations in the range of 20-400ng/ml, with decreased stimulation at higher concentrations,
suggesting concentration-dependence of EGF-induced motility. Both RPCs and PPCs also demonstrated
a concentration-dependent chemotactic response to an optimal SDF-1α concentration of 100ng/ml.

Using bioinformatics downstream signaling pathway analysis of the EGF and SDF-1α ligands in a retinaspecific gene network, we predicted a chemotactic function for EGF involving the MAPK and JAK-STAT
intracellular signaling pathways. Based on targeted inhibition studies, we show that ligand binding,
phosphorylation of EGFR and activation of the intracellular STAT3 and PI3Kinase signaling pathways are
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necessary to drive RPC motility. The JAK-STAT pathway was also implicated in transducing similar
motogenic effects on PPCs with SDF-1α induction.

To test our hypothesis of the gradated nature of ECM ligand effects on both ontogenetic retinal cell types,
we employed engineered microfluidic devices to generate quantifiable steady-state gradients of EGF and
SDF-1α coupled with live-cell tracking, and analyzed the dynamics of individual RPC and PPC motility.
Microfluidic analysis, including center of mass and maximum accumulated distance, revealed that EGF
induced motility is chemokinetic in EGFR expressing RPCs with optimal activity observed in response to
low concentration gradients. On the other hand, PPCs and RPCs exhibited significant chemotaxis
towards the source of SDF-1α with longer accumulated Euclidean distances and Center of Mass (COM)
compared to controls. We also ascertained that receptor mediated signaling was requisite for ligandinduced motility by using the CXCR4 inhibitor, AMD 3100, to antagonize the SDF-1α receptor. CXCR4
receptor inhibition resulted in decreases of PPC and RPC movement in uniform and steady state
gradients for a number of migration indices measured.

To advance translational application of the characterized chemotactic signaling potential of transplantable
photoreceptor precursors, we performed computational drug analysis of our newly identified motilitydeterministic networks, to develop a library of FDA approved drugs and small molecules predicted to
potentially influence the expression of target motility signaling mechanisms in photoreceptor progenitor
cells. Using the Expression2Kinases software and LINCS drug computational algorithm, we were able to
identify pharmacological drug targets that modulate the biochemical activity of transcriptional regulatory
genes which govern the expression of candidate receptor protein targets, and provide preliminary results
validating the up-regulatory effect of candidate drug aminophenazone on SDF-1α receptor CXCR4
expression. Results from this study demonstrate the applicability of our systems level in silico modeling of
matched transplantable cell surface-receptors and transplantation site ligands to predict molecular
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signaling guiding migration. Verification of in silico predictions, using molecular and microfluidic analysis
provide important data for defining cell response properties to specific ligands present during
transplantation into the retinal microenvironment. The drug computational analysis provides a
translational perspective to our in silico modeling paradigms extending its applicability.

Future studies will validate the functionality of resolved ligand-receptor pairs from our in silico library and
characterize down-stream signaling guiding motility and homing. This systems level paradigm can
effectively be applied to defining the molecular basis of transplantable cell migration in vivo toward
improved efficiency for repair of retina and other neural tissue types.
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CHAPTER 1
Photoreceptor loss is a feature of the progression of macular degenerative diseases and retinopathies
and a leading cause of blindness in the developed world [38, 39]. There are more than 1.6 million
recorded cases of age related macular dystrophy (AMD) and 5.3 million patients with diabetic retinopathy
in the U.S. alone [40]. In cases with significant photoreceptor degeneration there is permanent vision loss
with no available restorative treatment. Disease progression is often irreversible and there are currently
no effective strategies to replace lost photoreceptors. Significant efforts to identify effective treatments for
individuals at high risk for developing such debilitating eye diseases are currently underway [39, 41].
Experimental approaches to treat photoreceptor degeneration and loss include vector-mediated gene
therapy [42-44], stimulation of endogenous repair mechanisms by dedifferentiation of resident quiescent
progenitor cells [45, 46] and cell replacement therapies facilitated by sub-retinal transplantation into host
retina [47-52]. In this introductory chapter, we discuss some key molecular mechanisms involved in retinal
degenerative diseases with special emphasis on disorders involving photoreceptor loss, outline current
reparative strategies and their shortcomings. We then explore models of cell migration in neural tissues
toward informing our hypothesis that chemotactic signaling mechanisms between transplantable
photoreceptor precursors (PPCs) and host retina is involved in guiding PPC migration into host retina. We
describe a systems-level approach defining migration of transplantable replacement cells for
photoreceptor replacement and vision restoration. We also discuss how this paradigm may be applied to
predicting cell replacement transplantation outcomes in other organ systems and disease phenotypes.

1.1:

PHOTORECEPTOR LOSS AND RETINAL DEGENERATIVE DISEASES

1.1.1:

Brief Anatomy and Physiology of the Mammalian Retina

The retina involves a complex neural circuitry responsible for transducing light into patterns of electrochemical impulses providing information to the visual cortex. Figure 1.1A displays the structural
organization of the retina bordered by the retinal pigment epithelium (RPE), choroid (C) and sclera (S) of
the eye. Retinal architecture is conserved across mammalian and non-mammalian species with six
classes of neurons, including two types of light sensitive or photoreceptor cells: cones (daytime color
vision) and rods (low light sensors). Photoreceptor signaling is processed through horizontal and vertical
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circuits involving horizontal cells, bipolar cells, amacrine cells, Muller glia and ganglion cells. In the outer
plexiform layer (OPL), the synaptic terminals of rods and cones connect with horizontal and bipolar cells.
These two cell types modify the incoming signals from photoreceptors and then relay them to the
dendrites of the amacrine and ganglion cells via synapses in the inner plexiform layer (IPL). The amacrine
cells further process the incoming signals (e.g. motion detection), whereas the ganglion cells relay the
visual information to the brain via their axons forming the optic nerve (Figure 1.1B) [22, 31].

Rod and cone photoreceptors are elongated unipolar neurons consisting of morphologically and
functionally distinct regions that function in the primary events of light detection. Figure 1.1C displays a
schematic of typical rod photoreceptor cell highlighting the outer segment, which is designed to carry out
photo-transduction by capturing light and generating a proportional electrical chemical signal. The outer
segment disks contain photopigment molecules initiating the phototransduction cascade. Disks and
phototransduction molecules undergo continual renewal processes in which newly synthesized
membrane is added at the proximal region of the outer segment and distal outer segments are
phagocytized by RPE cells. A thin, non-motile cilium links the outer segment to the inner segment, a
cellular compartment that contains mitochondria, endoplasmic reticulum, golgi apparatus, and other
subcellular organelles. Adjoining the inner segment is the cell body containing the nucleus. This region
further extends into the synaptic region where the electrical-chemical signaling generated in the
photoreceptor cell is transmitted to other neurons of the retina [2, 53].

For light to be detected by rods, it must first be absorbed by the visual pigment rhodopsin embedded in
the disks of outer segments. Rhodopsin is a G protein-coupled receptor consisting of two parts. One part
is a protein called opsin, and the other is 11-cis retinal. The G protein associated with the receptor is
termed transducin. Photoexcitation is initiated when a photon converts the 11-cis retinal chromophore of
rhodopsin to its all-trans isomer. This reaction leads to the formation of Meta II rhodopsin (R*) and
activation of the visual cascade. R* catalyzes transducin activation via the exchange of GDP for GTP on
its α-subunit (T-α). This in turn, leads to the activation of phosphodiesterase (PDE) and the hydrolysis of
cyclic guanosine monophosphate (cGMP) to 5'-GMP. The decrease in intracellular cGMP causes the
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A

B

C

LIGHT

Figure 1.1: Structural Organization of the
Mammalian Retina – A) A cutaway view of
the retina (left) shows the neural retina (R),
the retinal pigment epithelium (RPE), the
choroid (C) and the sclera (S). The location
of the subretinal space is indicated (top right)
between the neural retina and RPE that is
bordered by the choriocapillaris and larger
choroidal vessels. The magnified retinal
cross section (bottom right) shows layering
of the ganglion cell layer, the inner and outer
plexiform layers and the inner and outer
nuclear layers [22]. B) The outer plexiform
layer
constitute
synaptic
connections
between rod and cone photoreceptors and
bipolar and horizontal cells which along with
amacrine cells also synapse with ganglion
cells at the inner plexiform layer. Incident
light travels through these layers of retinal
neurons beginning at the ganglion cell layer
to activate the light sensitive rod and cone
photoreceptors [31]. C) Schematic anatomy
of a typical rod photoreceptor cell
highlighting an outer segment stacked with
specialized
discs
involved
in
phototransduction. A thin, non-motile cilium
links the outer segment to the inner
segment, a cellular compartment that
contains the mitochondria, endoplasmic
reticulum, golgi apparatus, and other
subcellular organelles. Adjoining the inner
segment is the cell body containing the
nucleus. This region further extends into the
synaptic region where the electrical signal
generated in the photoreceptor cell is
transmitted to other neurons of the retina [2].
Figures A was adapted from ‘Diseases of the
retina. D'Amico DJ. The New England
journal of medicine (1994), 331:95-106.’
Figure B was adapted from ‘Tubby proteins:
the plot thickens. Carroll K., Gomez C.,
Shapiro L. Nat Rev Mol Cell Biol. (2004),
5:55-64.’ Figure C was adapted from
‘Photoreceptor
membrane
proteins,
phototransduction, and retinal degenerative
diseases. The Friedenwald Lecture. Molday
RS. IOVS (1998), 39:2491-2513.’
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cGMP-gated channels in the adjoining plasma membrane to close and the rod cell to become
hyperpolarized. Under this condition, glutamate release at the synaptic region of the rod cell is inhibited.
The closure of cGMP-gated channels also causes Ca
+

2+

Na /Ca -K

+

exchanger continues to pass Ca

2+

2+

levels in the outer segment to decrease since the

from the outer segment. After photoexcitation, the

photoreceptor cell returns to its dark state by the shutdown of the visual cascade system and re-synthesis
of cGMP. Rhodopsin is inactivated by ATP-dependent phosphorylation at its C terminus and the
subsequent binding of arrestin. Transducin and PDE are inactivated by the hydrolysis of GTP to GDP on
T-α by its intrinsic GTPase activity [2, 27]. Figure 1.2 depicts this mechanism of phototransduction in
mammals. The signal generated is transmitted through different retinal neurons, finally reaching ganglion
cells that form the optic nerve and projects to the brain.

Figure 1.2: Mechanism of phototransduction in the mammalian photoreceptor - Two specialized morphologically
distinct rod and cone photoreceptor cells derived from neurons capture light using the same molecular mechanism. Gprotein coupled receptor Opsins in outer segment discs of these cells absorb photons and form a signaling state, which
can bind to and activate their G proteins by catalyzing the exchange of GDP to GTP. The GTP-bound Gα dissociates
from Gβγ exposing its active site. Activated Gα binds to its effector, PDE (cyclic nucleotide phosphodiesterase), and
activates it. PDE breaks the phosphodiester bond of cyclic guaniosine monophosphate (cGMP) producing 5’GMP, and
the decrease in the concentration of cGMP causes CNG (cyclic nucleotide gated) channels to close, creating a
hyperpolarization response in the photoreceptor cells. The hyperpolarization of the membrane potential of the
photoreceptor cell modulates the release of neurotransmitters to downstream cells. The light signal is transmitted through
different cells, finally reaching ganglion cells which form the optic nerve and project to the brain [27]. Adapted from
‘Evolution of opsins and phototransduction. Shichida Y., Matsuyama T. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2009),
364:2881-2895.
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1.1.2:

An Overview of Retinal Degenerative Diseases

Retinal degenerative diseases can broadly be categorized into outer and inner retinal pathologies [50].
Outer retinal diseases often result in the death of light-sensitive photoreceptors and are the focus of
reparative strategies articulated in this study. Inner retinal pathologies can affect both bipolar and retinal
ganglion cells (RGCs) disrupting flow of information through the visual pathway. The incidence of
Glaucoma leading to the death of RGCs, is expected to rise to 79.6 million people affected worldwide by
2020 [54, 55] and remains the most common inner retinal disorder. Disruption of the retinal pigment
epithelia (RPE), although not a part of the retina, can cause secondary photoreceptor loss due to the key
role of the tissue monolayer in maintaining photoreceptor homeostasis by phagocytosis of the outer
segment, nutrient cycling and supplementation [30]. Leber’s congenital amaneurosis (LCA) is an inherited
retinal degenerative disease caused by defects in the RPE enzyme RPE65 which prevents 11-cis-retinal
recycling and impairing the visual cycle, leading to photoreceptor degeneration [44]. Despite various
etiologies, a number of degenerative retinopathies culminate in the irreversible loss of photoreceptors and
vision. Table 1.1 displays the current leading causes of irreversible visual impairment and the regions of
the eye affected by these disorders are schematically depicted in Figure 1.3 [25].

Retinal Disease
Cataract
Age-related
Degeneration (AMD)
Glaucoma

Incidence
8.4–29.7% of patients over 43 years
Macular

Diabetic Retinopathy (DR)
Retinitis Pigmentosa (RP)

6–22% of patients over 70 years
1–4% of patients over 45 years
74.9–92.3% of diabetic patients over 30
years
1 in 4,000 people

Table 1.1: The Incidence rates of the leading causes of irreversible visual
impairment

Among outer retinal pathologies, age-related macular degeneration (AMD) is the leading cause of
irreversible blindness in human populations over 55 years of age [30, 56]. It is predicted that, AMD arises
as the result of chronic, low-grade inflammation in the central outer retina, which leads to degeneration of
the retinal pigment epithelium (RPE), its basement membrane, and Bruch’s membrane. Illustration in
Figure 1.4A and 1.4B compares the RPE of a 3-year-old to an 80-yearold person respectively to help 	
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explain pathogenesis of the disease [56]. Under normal conditions, each RPE cell is responsible for the
phagocytosis of millions of photoreceptor outer segment discs. Over a lifetime, the incomplete digestion
of phagosomes results in accumulation of the lysosomal protein lipofuscin, which is toxic to RPE cells,
and extra cellular deposits (drusen and basal laminar deposits) that contain complement complexes and
other inflammatory markers [57]. In addition, Bruch’s membrane doubles in thickness reducing the import
of nutrients and the export of waste from the RPE, and impairing the ability of the RPE to adhere to its

Figure 1.3: Leading Causes of Irreversible Visual Impairment –
Globally, some of the most prevalent retinal diseases are schematically
represented at their sites of occurrence in either the anterior or posterior
segments of the eye. The incidence rates of these disorders are also
depicted in Table 1.1. Glaucoma is typically considered a disease of the
anterior
eye
segment
since
treatments
are
directed
at
increasing/decreasing fluid flow at the ciliary body, however, the visionthreatening pathology affects the ganglion cells and optic nerve of the
posterior segment. In the posterior segment, degenerative retinal
diseases include those affecting photoreceptors such as retinitis
pigmentosa (RP) and retinal pigment epithelium such as atrophic macular
degeneration (AMD). Retinal vascular diseases of the posterior segment
would include diabetic retinopathy (DR) and neovascular macular
degeneration (AMD). Figure is adapted from, ‘Stemming vision loss with
stem cells. Marchetti V, Krohne TU, Friedlander DF. J Clin Invest. (2010),
120:3012-3021’ [25].
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A

B

C

D

E

Figure 1.4: Age-determined comparative
analogy of the Pathogenesis of AgeRelated Macular Degeneration (AMD) –
Illustrations of Figures A and B compare the
retinal pigment epithelium (RPE) of a 3-year
old to an 80-year old respectively highlighting
phenotypes of the retinal diseases. Over time,
apical pseudopodial RPE processes (APRP)
surround outer segments of the rods and
cones phagocytizing shed disks which become
encapsulated in the phagosomes and are
digested in phagolysosomes in the cell
cytoplasm of the RPE. The contents of the
phagolysosomes are incompletely degraded
within acid lysosomal compartments of
phagosomes and form the residual bodies that
are the substrates for lipofuscin formation.
Following lipofuschin formation, one of its
autofluorescent chromophores, retinoid A2E,
can induce photonic toxicity by incident light
damaging DNA and cell membranes and
causing inflammation and apoptosis. The
resulting porous and thickened Bruch’s
membrane and the attenuation of the
choriocapillaris are damaging phenotypes
leading
to
induced
apoptosis
of
photoreceptors. Drusen accumulation of
inflammatory cytokines and extracellular
material between the Bruch’s membrane and
RPE causing geographic atrophy of the RPE is
also depicted in Figure B. C) Optical
coherence tomography (OCT) images are also
shown, of a normal retina (top panel) and a
retina with pigmented epithelium detachment
due to choroidal neovascularization (CNV)
(indicated by the white arrows) in wet agerelated macular degeneration (AMD) (bottom
panel). D) Confluent soft Drusen accumulation
(white arrows) always indicates onset of agerelated macular degeneration in the macula
(bottom panel) when compared to normal
retina (top panel). E) The visual field in a
normal retina (top panel) is also compared to
the visual field in late stage AMD. Adapted
from ‘Stem cells in retinal regeneration: past,
present and future.’ Ramsden C.M., Carr A.F.,
Smart M.J.K., Da Cruz L., Coffey P.J.
Development (2013),140:2576-2585 [30].

basement membrane. In late-stage wet AMD, fluid accumulation occurs as the result of
neovascularization from the choroid through Bruch’s membrane and the RPE into the subretinal space
and occasionally through the retina as shown in Figure 1.4C. This neovascularization is stimulated by the
presence of excess vascular endothelial growth factor (VEGF) on the apical side of the RPE, which
promotes the growth of fenestrated, leaky capillaries that allow the build up of fluid. Occasional

7

hemorrhaging of these fragile vessels occlude the macula resulting in scarring. In the late-stage case of
dry AMD, this gradual deterioration of RPE health leads to subsequent photoreceptor loss [22, 30, 56].

AMD and other outer retinal diseases have a polygenic inheritance component associated with their
pathologies. Figure 1.5 displays a typical photoreceptor outer segment disk with its adjoining plasma
membrane and the various embedded proteins associated with phototransduction and photoreceptor
homeostasis. Importantly, the diseases associated with mutations in these proteins are also specified and
are tabulated in Table 1.2 along with their localized occurrence in the retina [2]. Notably, the autosomal
recessive form of retinitis pigmentosa (ARRP) is depicted, although the disorder can be inherited as a
dominant or X-linked type. ARRP mostly affects the rod visual system and patients report problems with
night blindness and progressive peripheral visual field loss, leading to tunnel vision which is often
followed by blindness. Of the 1 in 4000 people affected, the most common ARRP subtype occurs due to
mutations in the gene encoding rhodopsin but many subtypes also begin with the primary failure of the
retinal pigment epithelium (RPE) and Muller glia [2, 30] (Table 1.2). Stargardt’s disease is an autosomal
recessive macular dystrophy with juvenile onset, clinically presenting as yellow flecks in the macular
region, progressive loss of central vision and bilateral atrophy of the macular region of the retina and
RPE. Stargardt’s is the most common cause of macular disease in children, with an incidence of 1:10,000
live births [2, 30]. The yellow flecks correspond to the abnormal build up of lipofuscin in the
photoreceptors and subsequently the RPE, after photoreceptor phagocytosis. The most common form of
the disease STGD1 is reportedly caused by mutations in the ATP binding cassette transporter (ABCR)
gene coding for a retinal rod-specific ABC protein usually localized to the rim region of rod outer segment
disk membranes [58, 59]. Homozygous and compound heterozygous mutations in the ABCR gene have
also been implicated in autosomal recessive retinitis pigmentosa (ARRP) and cone-rod dystrophy [58]
(Table 1.2). The pleiotropic and polygenic nature of several retinal degenerative diseases and their
definitive and chronic phenotypes of progressive photoreceptor and vision loss have inspired the current
reparative strategies outlined in the next section – Gene therapy and Cell-based therapies.
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Figure 1.5: Distribution of disease-linked proteins in the rod outer segment
(ROS) - Retinal diseases linked to mutations in these proteins are also displayed. A
complete listing of these proteins, their associated diseases and retinal occurrences
also provided in Table 1.2. ADRP (autosomal dominant retinitis pigmentosa), ARRP
(autosomal recessive retinitis pigmentosa), CSNB (congenital stationary night
blindness), CD (cone dystrophy), CRD (cone-rod dystrophy), MD (macular
dystrophy), Stgdt MD (Stargardt's macular dystrophy), XLRS1 (X-linked retinoschists
1), XLRP3 (X-linked retinitis pigmentosa 3) [2]. Adapted from, The Friedenwald
Lecture; Photoreceptor Membrane Proteins, Phototransduction, and Retinal
Degenerative Diseases; Molday R.S. IOVS (1998), 39:2491-2513.
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Protein
Rhodopsin

Localization
Rod cells

Phosphodiesterase (α, β)

Rod cells

cGMP-gated channel (α)

Disease
Autosomal dominant retinitis pigmentosa (ADRP)
Autosomal recessive retinitis pigmentosa (ARRP)
Congenital stationary night blindness (CSNB)
Autosomal recessive retinitis pigmentosa (ARRP)
Congenital stationary night blindness (CSNB)
Autosomal recessive retinitis pigmentosa (ARRP)

Guanylate cyclase (Ret GC1)

Cone and rod cells

Calcium-binding protein
(GCAP1)
Arresttn

Cone and rod cells

Rliodopsin kinase
Transducin (α)
Peripherin/rds

Rod cells
Rod cells
Rod and cone cells

Rom-1
ABCR/RIM

Rod and cone cells
Rod cells

RPGR
CRALBP

Rod cells
RPE and Muller cells

X-linked retinitis pigmentosa (RP3)
Autosomal recessive retinitis pigmentosa (ARRP)

CRX (transcriptional factor)

Rod and cone cells

RPE65

RPE cells

Leber's congenital amaurosis (LCA)
cone-rod dystrophy (CRD)
Leber's congenital amaurosis (LCA)
Autosomal recessive retinitis pigmentosa (ARRP)
Sorby's macular dystrophy
X-linked retinoschisis

TIMP3
XLRS1

Rod cells

Leber's congenital amaurosis (LCA)
cone-rod dystrophy (CRD)
Cone dystrophy (CRD)
Congenital stationary night blindness (CSNB) (Oguchi
disease)
Congenital stationary night blindness (Oguchi disease)
Congenital stationary night blindness (Nougaret disease)
Autosomal dominant retinitis pigmentosa (ADRP)
Macular Dystrophy (MD), Pattern Dystrophy and Digenic
ADRP
Digenic ADRP
Stargardt's MD, Autosomal recessive retinitis pigmentosa
(ARRP), Cone dystrophy (CRD) and Age-Related
Macular Dystrophy (AMD)

Bruch's membrane
Extracellular
(photoreceptors)
Myosin VIIA
Photoreceptors/RPE
Usher syndrome (USHI)
Bestrophin
RPE
Best's Macular Dystrophy (VMDd2)
Table 1.2: Proteins Associated with Retinal Diseases - Many of these genes code for photoreceptor-specific proteins
that play key roles in photo-transduction and outer segment morphogenesis. Adapted from, The Friedenwald Lecture;
Photoreceptor Membrane Proteins, Phototransduction, and Retinal Degenerative Diseases; Molday R.S. IOVS 1998;
39:2491-2513 [2].

1.2:

CURRENT REPARATIVE STRATEGIES FOR RETINAL DEGENERATION

1.2.1:

Gene Therapy For Retinal Degenerative Diseases

In its simplest form, gene therapy for retinal diseases involves the replacement or silencing of defective or
absent genes in dysfunctional retinal cell populations to repair local or systemic components of visual
function. Current progress in this field suggests that vision repair can be achieved using targeted viral
transfection, manipulation of inducible gene switches, introduction of ribozyme technology or RNA
inhibition (RNAi, siRNA) to remove or inactivate mutant proteins, and/or ex-vivo cellular manipulation with
subsequent tissue transfer of transfected cells [5]. Retinal tissue contained within the posterior globe of
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the eye is particularly suitable for gene therapy because the small quantities of viral vectors or donor cells
required to deliver genes minimizes the risk of vector dissemination to other body organs. The
transparent nature of the anterior eye also allows vector transport to be closely monitored, and retinal
electrophysiological functions can easily be assessed to determine efficacy of gene therapies [44, 60, 61].
Additionally, the blood-retinal barrier further protects these vector antigens from local immune responses
that may cause inflammations that limit transgene expression [44, 60, 62].

The monolayer of the retinal pigment epithelium (RPE) can be virally-transduced more efficiently than the
multi-layered neural retina whose complex synaptic arrangements complicate designs of disease-specific
treatments [44]. Indeed, partial correction of RPE function has a substantial impact on photoreceptor
function and survival. In a landmark study of retinal gene therapy for mutation in the RPE65 gene that
converts all trans-retinoids to 11-cis retinoids, treatment by subretinal injection of the AAV2 or AAV4
vectors containing a normal gene copy resulted in restoration of rod photoreceptor function and
consequently improved visual mobility in dim light [63, 64]. For fast retinal dystrophies as found in rd1
(retinal degeneration) strain of mice, inoculation of diseased organs with gene-corrected viral vectors may
not effectively counter the rate of photoreceptor loss. As such, treatment of the rd1 mice, which has a
mutation in the Pde6b gene that encodes βPDE, an essential protein in the phototransduction cascade,
has proved elusive [65, 66]. Additionally, mutations in the genes coding for the main visual pigments of
photoreceptors such as rhodopsin, result in dominant genetic diseases and are therefore unlikely to
benefit from gene replacement therapy compared to recessive forms of mutant genes causing
photoreceptor dysfunction [44]. Mutations in genes encoding proteins involved in the functioning of the
connecting cilium in photoreceptors (Figure 1.1C), result in syndromic effects with widespread
pathologies because cilium proteins are also found in many ciliated cells in the body. Usher syndrome
type 1B for example also leads to hearing loss and balance problems due to mutations in the ubiquitous
myosin (Ex. MYO7A) gene and development of therapy for this condition poses additional challenges
although certain ciliopathies result only in photoreceptor defects [44, 67].
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Recombinant adeno-associated viruses (rAAV) are currently the favored vectors for use in retinal gene
therapies as they elicit minimal immune responses [62], and have shown considerable success in
transducing cells at all layers of the retina either through intravitreal injections targeting ganglion cells, or
subretinal entry routes targeting photoreceptors and the RPE [44, 60] (Figure 1.6). The success of the
vector also depends on the AAV serotype, as different serotypes preferentially target specific retinal cells
[60]. Lentiviral (LV) vectors are also being used for treatments in some animal studies, but have been
observed to be less efficient, a feature suspected to be due to their larger size and their subsequent
inability to bypass the outer limiting membrane and reach photoreceptors following subretinal injection
[60]. The incorporation of promoters specific to the targeted cell type during viral vector design also
increases their transfection potential [60, 68]. Besides the commonly used cytomegalovirus (CMV)
enhancer-promoter and CAG promoter that combines the CMV enhancer with the chicken β-actin (CBA)
promoter, RPE-specific expression has been enhanced using promoter fragments of RPE65 and VMD2,
a gene encoding the bestrophin protein that causes macular dystrophic Best disease when mutated [5,
60]. Photoreceptor targeting in the murine retina was successfully achieved using rhodopsin and
rhodopsin kinase promoters, and the combination of serotype and cell-specific promoters typically lead to
significantly higher tissue-restricted gene expression [69]. For safe and effective gene therapies, these
cell-specific promoters may also serve as target regulatory sites to control the expression and behavior of
the gene following insertion in host retinal tissue [5]. In one instance, the expression of an antagonists to
a gene product was linked to an upstream modulator of the gene by attaching a complementary response
sequence of the upstream modulator to a transfected gene thereby controlling the availability of the
protein and effectively creating a local auto-regulatory pathway [70].
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The physiology and progression of a particular retinal degenerative disease also determines the
effectiveness of gene therapeutic approaches employed. Early stage retinal degeneration may be more
amenable to vector-mediated gene transfer protocols supplemented with anti-apoptotic factors that
restrict further retinal cell loss, while end-stage disease states can benefit from strategies that attempt to
transfer light-inducible pigments such as Channelrhodopsin-2 to residual non-damaged inner retinal cells
to make them intrinsically photosensitive [60, 71]. However, as the retina degenerates, viral transduction
of the remaining retinal layers may be less effective because of the structural changes associated with
retinal damage. Nevertheless, there is no evidence as yet that currently available vectors are ideal for
gene transfer in human retina [66]. Table 1.3 lists select clinical trials currently in progress using gene
therapy and their hosting institutions, and even though some studies are yielding promising restorative
results for degenerating retina, this therapeutic approach remains at an early stage of development [68].

Figure 1.6: Vector delivery systems commonly
employed in gene therapy for retinal degenerative
diseases - A) Intravitreal injection of vector. B)
Subretinal vector injection. Adapted from, ‘Gene
Therapy for Age-Related Macular Degeneration.’
Keegan D., Del Priore L.V. Retinal Physician, 2006. [5]
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Retinal disease

Vector

Mechanism of
action

Sponsor/institution

AMD (exudative)

AAV2‑sFLT01

Genzyme/Sanofi

Choroidermia

rAAV2.REP‑1

Expresses
anti‑VEGF
protein
Encodes REP‑1

Leber’s congenital
amaurosis
Retinitis pigmentosa
(AR)
Stargardt’s

AAV2‑hRPE65 v2
rAAV2‑VMD2‑hMERTK

Produces RPE65
gene
Produces MERTK

Imperial College of
London. Oxford Univ/
Moorfields
Children’s Hospital of
Philadelphia
King Khaled Eye Hospital

Clinical
Study
Phase
I
I
III
I

Expresses ABC4
Oxford Biosceinces/Sanofi I
gene
Usher’s syndrome
UshStat
Produces MY07A
Oxford Biomedica
I
(1B)
protein
Table 1.3: Select on-going clinical trials of gene therapy for retinal diseases. The phases of most of these
clinical trials depict the infantile stage of this therapeutic strategy. Adapted from ‘Gene therapy for retinal diseases.
Samiy N. J. Ophthalmic. Vis. Res. (2014), 9: 506-9’ [68]. AMD (age‑related macular degeneration); AR (autosomal
recessive); REP‑1 (rab‑escort protein); VEGF, vascular endothelial growth factor); AAV2 (adeno‑associated virus 2);
rAAV2 (recombinant adeno‑associated virus 2).

1.2.2:

StarGen

Cell-Based Therapy For Retinal Degenerative Diseases

When compared to other regions of the central nervous system (CNS), the mammalian retina is a more
amenable target for reparative cell-based therapies that may alleviate retinal degenerative diseases
because its membranous expanse within the posterior segment of the eye eases access for sub-tenon,
intravitreal, sub-retinal and systemic transplantation of donor replacement cells [5, 50]. Analogous to
gene-replacement therapies, tools for assessing the effectiveness of retinal cell replacement therapies
post-treatment and for measuring retinal structure and visual function are among the most effective
compared to similar paradigms employed in other major body organs [50].

Because the mammalian retina does not regenerate, terminal loss of retinal neurons due to disease or
trauma suggests that a practical strategy to restore sight could involve cell replacement via
transplantation [1, 48, 72]. Photoreceptor loss represents the final and irreversible end stage of several
retinal diseases. Heterogeneous phenotypes characterizing some retinal pathologies have led to effective
experimental strategies involving gene-specific or cell-type specific approaches. For instance,
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replacement of diseased retinal pigment epithelium (RPE) via traditional surgical transplantation of
autologous RPE tissue in patients with age-related macular degeneration (AMD) has proven more
effective than neural sub-retinal transplantation protocols, because the RPE is a monolayer, not requiring
migration of transplanted cells or complex synaptic connectivity [72-74]. Photoreceptor replacement is
challenging but probable due to their basic sensory physiology and signaling via a single synapse to
downstream retinal neurons [72]. Bull et al (2011) [50] schematically localized experimental ports for
current cell-based treatment models in the eye and is depicted in Figure 1.7.

Figure 2.7: Schematic of ports in the eye for experimental stem cell-based therapies for retinal
diseases currently under investigation. The possibility of using stem cells for replacement and/or
rescue therapies is being explored for several common neurodegenerative retinopathies. Abbreviations: *
= treatment currently in clinical trial; AMD, age-related macular degeneration; ES, embryonic stem cells;
RGC, retinal ganglion cell; RP, retinitis pigmentosa; RPE, retinal pigment epithelium. Figure is adapted
from ‘Concise review: toward stem cell-based therapies for retinal neurodegenerative diseases. Bull N.D.,
Martin K.R. Stem Cells (2011), 29:1170-1175 [24].

Cell-based therapies can broadly be categorized into regenerative or replacement and trophic or rescue
treatment strategies [73-75]. Regenerative therapies utilize partially or fully differentiated cells such as
RPE or photoreceptor precursors that have been isolated or expanded, and/or derived from pluripotent
embryonic or adult retinal stem cells. These cells are intended to replace the damaged endogenous cells
to restore retinal function [30]. In the trophic or rescue approach, grafted stem cells remain
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undifferentiated and through a paracrine effect induce the resident tissue to self-restore and proliferate by
secreting trophic cytokines or via cell-to-cell interactions [73, 74, 76]. Therapeutic replacement of neurons
in the mature retina can be complicated as newly engrafted cells must not only differentiate into the
appropriate neuronal cell type, but also regenerate appropriate synaptic connections within a highly
ordered, hard-wired, spatially organized neural network. Given the complexity of this task, it is likely that
trophic cell-based therapies will attain clinical development more quickly than regenerative therapies.
However, trophic therapies can only hope to halt disease progression in the retina, whereas regenerative
applications may be able to reverse functional vision loss and actually improve visual impairment [50, 75].
Tables 1.4A and 1.4B lists current pre-clinical and clinical studies that have shown potential for use in
treating retinal degenerative diseases [75]. In some instances as with RPE cell transplantation for
treatment of Best disease and some forms of retinitis pigmentosa, a combination of replacement and
rescue therapies is adopted where human embryonic stem cells (hESCs) and induced pluripotent stem
cells can be differentiated into RPE cells which integrate easily with host photoreceptors and also secrete
trophic substance that support the photoreceptor cells [77-80].
Table 1.4A
Disease

Cell type

Rd1 and rd10 mouse

BMHSC

Intravitreal

Rhodopsin knockout
mouse

BMMSC

Subretinal

Rescue photoreceptors

Ischemic retinopathy

Endothelial progenitor
cells

Intravitreal

Vascular repair and reversal of
ischemic injury

Human ESCs

Intravitreal, Subretinal

Replace photoreceptors

ESC-derived RPE

Subretinal

RCS rat

BMMSC

Intravenous

RCS rat

hES-RPE

Subretinal

Rescue photoreceptors
Rescue photoreceptors and
preserved retinal function
Rescue photoreceptors and
improved visual function
Rescue photoreceptors and
improved visual function
Rescue photoreceptors and
improved visual function
Rescue photoreceptors and
improved visual function
Rescued photoreceptors
Reversed mislocalization of cone
pigment and prevented functional
deterioration

Rd1, mnd and CRX
mouse
-/RPE65 mouse

RCS rat
RCS rat

-/-

Human neural progenitor
cells
Human iPSC-derived
RPE

Delivery route

Subretinal
Subretinal

RCS rat

hUTSC

Subretinal

Elov14 mouse

hES-RPE

Subretinal

Ush2a mouse

Forebrain-derived
progenitor cells

Subretinal

Effect
Rescue photoreceptors (primarily
cones)
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Table 1.4B
Disease
STGD and
AMD (GA)

Institution/Sponsor
Advanced Cell
Technology, USA

Cell Source
hESCderived RPE

Delivery
Subretinal
injection of
suspension
postvitrectom
y

WHO Identifier
NCT01469832
NCT01345006
NCT01344993

AMD

University College
London and Pfizer,
UK

hESCderived
RPE
monolayer

NCT01691261

AMD (GA)

Stem Cells Inc., USA

NCT01632527

(McGill et al.,2012)

AMD (GA)

Janssen R&D, USA

Neuralised
human
foetal stem
cells
hUTSC

NCT01226628

(Lund et al., 2007)

AMD (GA),
RP, conerod
dystrophy
and
ischaemic
retinopathy
AMD (GA),
RP,
RVO and
DR
RP

University of Sao
Paolo, Brazil

Autologous
BMHSC

Subretinal on
a plastic
polymer patch
postvitrectomy
Subretinal
Injection
postvitrectomy
Microcatheter via
sclera and
choroid
Intravitreal
injection

Center/PI
Jules Stein-UCLA
(Schwartz)
Wills Eye Hospital
(Regillo)
Moorfields Eye
Hospital (Bainbridge)
(Carr et al., 2009)

NCT01518127
NCT01560715
NCT01518842
NCT01068561

University of Sao
Paulo, Brazil
(Siqueira et al.)

University of
California, Davis,
USA

Autologous
BMHSC

Intravitreal
injection

NCT01736059

(Park et al., 2012)

Mahidol University,
BMMSC
Intravitreal
NCT01531348
N/A
Thailand
injection
DR
Tehran University of
Autologous
Intravitreal
IRCT20111129
(Larijani et al.,
Medical Sciences,
BMMSC
injection
1414N29
2012)
Iran
DR
General Hospital of
BMMSC
N/A
ChiCTR-TNRC
(Li et al., 2012)
the Chinese People’s
11001491
Armed
Police Force, China
AMD and
All India Institute of
Autologous
Intravitreal
CTRI/2010/091/ (Kumar et al.,
RP
Medical Sciences,
BMHSC
injection
000639
2012)
India
Table 1.4: Cell-based therapies for retinal diseases – Current cell based therapies can be categorized into
rescue/trophic and regenerative/replacement treatment strategies depending on the purpose of the
transplantation study. A) Pre-clinical trials using animal models that have shown potential in the treatment of
retinal diseases [75]. B) Clinical trials currently underway and registered with the World Health Organization
(WHO), the cell types transplanted and the sponsoring institution where these studies are being performed.
Abbreviations: ESC (embryonic stem cells), iPSC (induced pluripotent stem cell), AMD (age-related macular
degeneration), GA (geographic atrophy), RP (retinitis pigmentosa), hES-RPE (human embryonic stem cellderived retinal pigment epithelium), hUTSC (human umbilical tissue-derived stem cells), BMHSC (bone marrowderived haematopoeitic stem cell), BMMSC (bone marrow-derived mesenchymal stem cell), DR, diabetic
retinopathy, RVO (retinal vein occlusion), STGD (Stargardt’s disease). Adapted from ‘The promise of stem cells
for age-related macular degeneration and other retinal degenerative diseases. Zarbin M. Drug Discovery Today:
Therapeutic Strategies (2013),10:e25-e33’ [75], and ‘Stem cells in retinal regeneration: past, present and future.
Ramsden C.M., Carr A.F., Smart M.J.K., Da Cruz L., Coffey P.J. Development (2013),140:2576-2585’ [30].
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Stem cells, with their capacity for proliferative expansion and the potential to generate multiple cell types,
are a practical source of cells for cell-based therapies because they can be produced en masse safely
and induced to differentiate into ocular cell types with potential for replacement and rescue therapy [50,
72, 75]. Two transcription factors Nanog and Oct4, are associated with helping to keep the cells in an
undifferentiated state with the capacity for self-renewal [75]. Many studies in animal models suggest that
stem cells have the capacity to regenerate lost photoreceptors and retinal neurons and improve vision
[30, 46, 81, 82]. An overview of putative stem cell sources currently in use for clinical and pre-clinical trials
in retinal degenerative models, and their differentiation capacities, is provided in Table 1.5 [83]. The
major types of stem cells utilized include embryonic stem cell (ESCs), induced pluripotent stem cells
(iPSCs), mesenchymal stem cells (MSCs), and retinal progenitor cells (RPCs).

Type of cell
Embryonic stem cells (ESCs)
Retinal stem cells
Neural stem cells
Retinal progenitor cells
(RPCs)
Retinal Muller glia
Retinal astrocytes
Retinal microglia
Mesenchymal stem cells

Location
Blastocyst
Ciliary margin in rodent and
human eyes
Ciliary epithelium, optic nerve
Fetal or neonatal retinas

Differentiation capacity
Totipotent (any cell type); photoreceptors in vitro
Various cell types including photoreceptors,
bipolar cells, Müller glia in vitro
Neurons and glia; photoreceptors
Neurons and specialized support cells in vitro

Inner nuclear layer of the retina
Lamina-specific retinal neurons
Nerve fiber layer of the retina
Limited neurogenic potential
All retinal layers
Neurons and glia in vitro?
Bone marrow, adipose tissue,
Various cell types including photoreceptors and
umbilical cord
retinal pigment epithelium in vitro
Induced pluripotent
Generated from differentiated
Photoreceptors, RGCs
stem cells (IPSCs)
somatic cells
Table 1.5: Putative cell sources for cell-based therapies in retinal degenerative disease models. Adapted from
‘Cell-replacement therapy and neural repair in the retina. Schmeer C., Wohl S., Isenmann S. Cell and Tissue
Research (2012), 349:363-374’ [83].

Figure 1.8 describes the generation of ESCs and IPSCs. Embryonic stem cells are isolated from the 8cell inner cell mass of blastocyst-stage embryos cultured on monolayer fibroblasts Figure 1.8A or from
similar cloned blastocysts, generated through the process of somatic cell nuclear transfer Figure 1.8B.
ESCs have self-renewal capabilities as well as the ability to differentiate into all adult cell types derived
from the three embryonic germ layers [21, 84]. Studies have shown that ESCs can differentiate into
photoreceptor progenitors, photoreceptors, or retinal pigment epithelium (RPE) in mice and humans [8588]. A recent study showed that transplantation of retinal cells derived from human ESCs into the
-/-

subretinal space of adult Crx mice promoted their differentiation into functional photoreceptors with
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improved light responses [16]. Although ESCs are promising in retinal replacement therapies, they have
also been associated with teratoma formation [89] and immune rejection issues [90], and there remains
ethical concerns with fetal cell use even though ESCs can now be obtained without embryo destruction
[91]. Another major limitation to the use of ESCs is the inability to control their differentiation as we are
just beginning to understand the developmental cues that differentiate ESCs into the specific
neuroprogenitors suitable for repair of damaged retinal tissues [72].

The use of induced pluripotent stem cells (iPSCs) resolves most of the ethical issues associated with the
use of ESCs as they are formed in vitro as pluripotent ESC-like cells reprogrammed from terminally
differentiated somatic cells by retroviral transduction of transcription factors: Oct3/4, Sox2, Klf4 and cMyc, and are therefore not of embryonic origin Figure 1.8C [21, 92, 93]. iPSCs have similar
developmental potential as ESCs, contribute to the development of all cell types in chimeric animals,
including the germ line, and can mimic normal retinogenesis [93-95]. The use of defined transcriptional
activators to generate cell-type specific iPSCs offers a treatment regimen that does not require the use of
immunosuppressive drugs to prevent rejection due to the limited antigenicity, and proffers a targetable
repair mechanism for genetic defects [90]. Figure 1.8D displays schematic of a potential treatment
strategy for dystrophic retinopathies using autologous iPSCs where patient keratinocytes can be
reprogrammed into iPSCs for sub-retinal re-implantation into donor retina by intraocular surgery [25].
iPSCs can provide an unlimited supply source of desired cell-type specificities. However, the cytogenetic
protocol associated with IPSC generation is subject to transient genetic instabilities that increase the risk
of viral integrations and oncogene expression [96]. iPSC cytogenesis can also leave an epigenetic
memory of the tissue of origin that may influence cell differentiation efforts for applications in disease
modeling or treatment, or the IPSCs may harbor disease-causing genes of the donor [75].
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d Treatment strategy using autologous IPSCs

Figure 1.8: Generation of Embryonic Stem Cells (ESCs) and Induced Pluripotent Stem
Cells (IPSCs) - A) After removal of the zona pellucida from supernumerary blastocysts ESCs can
be isolated as epiblasts and cultured on mitotically inactivated mouse embryonic fibroblasts. B)
ESCs can also be isolated from cloned blastocysts generated through somatic cell nuclear
transfer. C) Delivery of a cocktail of transcription factors to somatic cells, such as dermal
fibroblasts, reprograms them to a pluripotent state, providing a source of fully autologous induced
pluripotent stem cells (iPSCs). Whatever their mode of derivation, all pluripotent stem cells have
the capacity to differentiate into derivatives of each of the three embryonic germ layers:
endoderm, ectoderm and mesoderm. D) An exemplary treatment strategy for
degenerative/dystrophic retinopathies using autologous iPSC-derived keratinocytes for
subsequent sub-retinal re-implantation into patient retina by intraocular surgery. This strategy
limits immune rejection of retinal grafts but can harbor disease-causing genes endogenous to
host. Figures adapted from ‘The challenge of immunogenicity in the quest for induced
pluripotency. Fairchild P.J. Nat Rev Immunol. (2010),10:868-875’ [21] and Stemming vision loss
with stem cells. Marchetti V., Krohne T.U., Friedlander D.F. J Clin Invest. (2010), 120:3012-3021
[25].’
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Mesenchymal Stem Cells (MSCs) are a bone marrow-derived cell population, independent of the
hematopoietic system, which have the ability to self-renew as well as give rise to multiple tissue types [97,
98]. Other sources of MSCs have been described including adipose tissue, placenta, cord blood and liver
[99-101]. Adult Royal College of Surgeons (RCS) rat MSCs can be induced to express photoreceptorspecific markers rhodopsin, opsin, and recoverin in vitro following induction using signaling factors such
as activin A, taurine, and epidermal growth factors (EGF). After transplantation, these MSCs integrated
into the host retina forming structures similar to the photoreceptor layer, and expressed photoreceptorspecific markers [102, 103]. Besides integrating into host retina, MSCs injected into the subretinal space
can also slow progression of retinal cell degeneration [103]. Because of its autologous characteristic,
relative ease of isolation, decreased immunogenicity and less controversial nature, MSCs remain a
popular choice of pluripotent stem cells for treatment of retinal diseases (see Table 1.4) [30, 73, 74, 104,
105]. The broad developmental plasticity of MSCs was originally thought to contribute to their
demonstrated efficacy in experimental animal models of retinal disease and in human clinical trials,
however, new evidence suggest their rescue capabilities via secretion of soluble factors may contribute
more significantly to retinal tissue repair than through their trans-differentiation potential [72, 75, 105].

Retinal progenitor cells (RPCs) are derived from fetal or neonatal retinas, and comprise an immature cell
population that is responsible for generation of all retinal cells during embryonic development [90, 106].
Previous studies report that RPCs can proliferate, generate new retinal neurons and retinal support cells
in vitro and in vivo, and can migrate into retinal layers following transplantation [17, 107]. However, with
RPCs, as with ES or iPSC derived cells, migration and integration rates following transplantation are
extremely low in healthy and diseased retina [108-111], a limitation attributed to an absence of research
defining the molecular mechanisms underlying transplanted cell migration in host retina [112].
Notwithstanding the physiological limitations of these cells, comparative grafting studies reveal RPCs as
an optimal choice of cells for transplantation studies [113, 114], and in our current study, we explore the
potential of these cells as therapeutic donor cells. In the next section, we explore the two major cell-based
treatment strategies currently being utilized in models of retinal degeneration – Cell rescue and cell
replacement therapies.
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1.2.2.1: Cell-Based Trophic Therapies For Retinal Degenerative Diseases
Cell-based trophic/rescue therapies for retinal diseases can be summarily categorized into two
applications – repair by endogenous cell regeneration and trans-differentiation, and paracrine biochemical
rescue using transplanted stem cells.

1.2.2.1.1: Retinal Repair By Endogenous Cell Regeneration And Trans-differentiation
Amphibians such as newts have been shown to regenerate whole retina from the retinal pigment
epithelium (RPE) [115] and in a few instances from innate retinal progenitor cells located at the periphery
of the neural retina in the circumferential germinal zone (CGZ) [116]. Teleost fish are more limited in their
regenerative capabilities compared to amphibians and employ a Muller glia-derived regenerative
response to source replacement retinal progenitor cells in retinal and optic nerve damage [117, 118].
Neural retinal regeneration in these species occurs without the addition of exogenous factors and without
preserving the vascular membrane of the eye. Adult birds cannot regenerate damaged retina but
embryonic and post-hatch chick have demonstrated limited regenerative effects via an RPE-dependent
event only through the first few days post-hatch [119-121]. In contrast to amphibians, teleost fish, and
birds, the mammalian retina does not add retinal neurons after birth [117].

Even though mammals cannot actively regenerate damaged retina post-birth, current research supports
the possibility that analogous retinal cell types in other vertebrates can self-renew and thus mammals
may retain an intrinsic regenerative potential that can be harnessed for retinal repair if the proper stimuli
were provided [105]. Some resident adult stem cells that are multipotent fall into this category and can
differentiate into multiple cell types of a single lineage. For instance, it was possible to activate Muller
cells in vivo to differentiate along rod photoreceptor lineage in the outer nuclear layer via canonical Notch
and Wnt signaling pathways using exogenous factors in juvenile rats [122]. Subsets of adult rodent retinal
stem cells localized in the pigmented ciliary margin clonally proliferate in vitro to form sphere colonies of
cells that can differentiate into retinal-specific cell types, including rod photoreceptors, bipolar neurons,
and Muller glia [123-125]. Muller glia also express low levels of retinal progenitor markers [126] and can
generate neurons and glia in culture [127], but for retinal ganglion cells (RGCs), they show very limited
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capacity of regenerating optic nerve axons in the absence of exogenous stimulation [128, 129]. Human
RPE also harbor multipotent cells that can be stimulated to trans-differentiate into neuronal sub-types and
thus may serve as a potential source of progenitors for repair [130].

While strategies to direct these innate functional cells to differentiate into retinal neurons in mammals
seem to be promising therapies for retinal diseases, there is a need to delineate the regenerative
biochemical markers and molecular mechanisms that drive or limit robust regenerative responses. It is
also important to understand how these regenerative mechanisms differ from gliotic or fibrotic responses
following retinal damage in mammals, and how they can be modulated to avoid fibrosis, tumorigenesis
and epiretinal membrane formation deleterious to any reparative endogenous cell regeneration strategies
[117]. Potential retinal progenitor populations capable of regeneration in the mature and/or damaged
retina may also be too limited in number to replace lost cells or reverse damaged photoreceptor
phenotypes [131].

Recent observations of spontaneous generation of ESC- [132, 133] and IPSc-derived [134] organ-like
eye-cup and retinal tissues exhibiting markers of differentiated photoreceptors, demonstrate a source for
large populations of regenerative cells at an early ontogenetic stage for use in reparative strategies.
Retinal tissue from these spontaneous generation experiments can provide different cell phenotypes, at
different stages of development for cell replacement therapy [135, 136], the treatment method touted as
the most feasible strategy for treating retinal disease due to photoreceptor loss [30].

1.2.2.1.2:

Retinal Rescue By Paracrine Effects Of Transplanted Retinal Cells

Paracrine signaling is a form of cell signaling in which the target cell is near (“para” = near) the signalreleasing cell and both cells are of different lineages as opposed to autocrine signaling where both signalreleasing and induced cells are of the same type. To be useful for cell-based paracrine rescue,
transplanted cells must generate needed trophic factors and not proliferate in an uncontrolled manner. In
a preclinical model of glaucoma, for example, intravitreal injected somatic neural stem cells and bone
marrow-derived mesenchymal stem cells substantially reduce rates of retinal ganglion cell death [137,
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138]. Additionally, upon stimulation by pro-inflammatory agents such as tumor necrosis factor (TNF),
bone marrow-derived mesenchymal stem cells release anti-inflammatory cytokines, modulating local
inflammation, and improved vascular permeability for endogenous repair [105]. Both bone marrowderived hematopoietic and mesenchymal stem cells (MSCs) injected intravitreally exerted trophic rescue
effects on photoreceptors in animal models of retinal light-damage, retinal ischemia, and diabetic
retinopathy [139-141]. Human umbilical cord MSCs injected into the optic tract after a lesion have also
rescued RGCs and promoted regrowth to the superior colliculus in rats [142]. Evolving interest in the
paracrine signaling effect of candidate trophic factors has led to its being employed in many current
clinical trials (Table 1.4B) [73, 74, 105], but the efficacy of this treatment strategy for degenerated retina
with marked photoreceptor loss remains limited, but may be valuable in concert with cell transplantation
[72, 143].

1.2.2.2:

Cell Replacement Therapy For Retinal Degenerative Diseases

Cell replacement strategies for retinal tissue have been shown to be feasible in animal models using
retinal progenitor cells, single RPE cells or RPE monolayers derived from embryonic stem cells (ESCs),
neural progenitor cells (NPCs), induced pluripotent stem cells (iPSCs), or early postnatal retinal precursor
cells [1, 16, 48, 49, 72, 83, 144]. In these studies, bolus injections of retina fragments, retinal cell
suspensions, or fetal retinal sheets are transplanted into host retina via intravitreal or subretinal
administration [48, 109, 110, 145, 146]. Subretinal transplantation is a delicate process involving surgical
formation of a transient retinal detachment to provide a subretinal space between the photoreceptor layer
and RPE. Intravitreal injection on the other hand, even though less invasive, requires transplanted cells to
migrate through the viscous vitreous cavity, inner limiting membrane and inner retina (See Figure 1.6).
Notwithstanding the route of administration employed, optimal efficacy of most retinal cell transplantation
experiments is still hindered by extremely poor retinal graft integration [138, 147, 148].

1.2.2.2.1: Replacement of Retinal Pigment Epithelium
Subretinal transplantation of healthy RPE cells, either freshly isolated or generated from ESCs, into RCS
rats demonstrated photoreceptor protection with preservation of neuronal connectivity and visual function
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[149]. While it is surgically feasible to transplant whole monolayer RPE into the subretinal space of AMD
patients, allogeneic transplants without immune-supression have led to fibrosis and tissue rejection, and
this occurs in spite of the immune-privileged status of the sub-retinal space [150, 151]. Somatic cell
nuclear transfer techniques can largely overcome this immunogenicity problem [146], however the
restoration of vision will always be limited in the face of chronic photoreceptor apoptosis caused by
recurrent and progressed disease environments [152]. Autologous RPE transplants also have the
disadvantage of carrying the same genetic predisposition that caused the pathological condition [25, 83].
RPE tissue transplanted into the fovea of AMD patients after choroidal neovascular membrane removal
maintained only transient central visual function with decline after 5 to 6 years [153, 154]. Additionally,
induced pluripotent stem cells (iPSCs) are observed to spontaneously differentiate into RPE cells and
form highly differentiated RPE monolayers upon culture [144]. RPE replacement therapy has been touted
as one of the most promising paradigms for patients with early AMD (Table 1.4) as RPE cells do not
require synaptic connectivity to integrate, and these cells supplement and preserve photoreceptor
function [149]. An area of concern is the mild but chronic immune rejection elicited when RPE allografts
are transplanted in rats and other mammals.

1.2.2.2.2:

Replacement of Retinal Ganglion Cells

Compared to photoreceptor replacement, the replacement of RGCs is much more complex because it not
only requires the migration and integration of donor cells into the ganglion cell layer and differentiation
into RGC-like cells but also the extension of long axonal processes through the myelinated regions of the
optic nerve to target synaptic sites in the brain [155]. ESCs [156], MSCs [157], RPCs [158] and Muller
glia–derived stem cells [159] have been reported to migrate and integrate into the retina depleted of
RGCs or populated by apoptotic RGCs. Foetal neurons also appear better able to survive transplantation
surgery than adult neurons [160]. Nevertheless, evidence for synaptic integration and functional
improvement remains elusive [138, 155]. iPS-derived retinal ganglion-like cells have also been generated
from mouse tail-tip fibroblasts, but are unable to integrate into normal retina following transplantation
[161].
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1.2.2.2.3:

Replacement Of Photoreceptors

Transplantation studies have shown that a sub-fraction of freshly dissociated photoreceptor precursor
cells (PPCs) from post-natal day 1-6 mouse retinas can integrate into adult host retina, exhibit
photoreceptor morphology and improve light-responsiveness [1, 51]. These PPC populations have been
characterized as post-mitotic, committed to a photoreceptor cell fate, and exhibit appropriate
photoreceptor integration following transplantation in animal models [10, 148, 162]. Sub-populations
already expressing rhodopsin are even more likely to integrate into the outer nuclear layer (ONL) and
form morphologically mature photoreceptors [148]. Additionally, at an early post-natal developmental
stage, the propensity for these cells to form tumors in situ is largely absent [72, 75]. It has been
postulated that the observed preference of adult mammalian host retina for fate-committed photoreceptor
precursor cells (PPCs) may be due to its inability to provide exogenous factors required for multi-stage
differentiation of other transplantable multipotent retinal progenitors [72, 148]. Similar transplants using
cultured or freshly dissociated cells older than the first postnatal week do not result in significant
photoreceptor morphology following transplantation [148]. Developmentally, mouse post-natal day 0-6
coincides with the time of birth of rod photoreceptors as shown in Figure 1.9A, active neuroblast migration
from the neuroepithelium, and onset of opsin expression [148, 163]. It would be ideal to use human
photoreceptor precursors in clinical studies but sourcing them from second-trimester human fetuses
(Figure 1.9B), is a limiting factor and confounded by ethical constraints [83, 162].

In summary, subretinal transplantation studies have demonstrated extremely limited numbers of new
photoreceptor morphologic and functional integration in host retina using either RPCs and PPCs [48, 162,
164] or ESCs and iPSCs directed toward a photoreceptor fate in vitro prior to transplantation [49, 95].
Additionally, of the cells that successfully migrate into the host retina, only a small percentage (0.5-3%)
have been shown to integrate in the appropriate retino-neural laminar loci and/or express ontogenetic
photoreceptor morphology or markers [16, 17, 148, 162, 165, 166].
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Figure 1.9: Photoreceptor genesis and maturation in mouse and human. The relative numbers of cone
and rod precursor cells that are born over time are shown for mouse and human retinogenesis. A) In mice,
cones are generated prenatally as early as embryonic day (E)11. Rods, which vastly outnumber cones, are
generated from around E12 to postnatal day (P) 10, peaking at around time of birth with subsequent decline
with maturation. This peak time of rod genesis also coincides with the onset of expression of S opsin and
rhodopsin with M opsin expression beginning at ~P6. The inset panel shows double fluorescent detection of
cone (red staining) and rod precursors (green staining)) in mouse retina at E18, superimposed on a phase
contrast picture that reveals the outer neuroblastic layer (ONBL). Newly generated photoreceptors tend to
reside near the edge of the retina. B) In humans, cones and rods are generated around foetal week (Fwk) 8
and Fwk 10, respectively. Generation of cones is completed prenatally common with mice, whereas that of
rods continues into the early postnatal period. Expression of photopigments begin well before birth, but
functional maturation of photoreceptors continues postnatally. RPE (retinal pigment epithelium). Figure is
adapted from ‘Transcriptional regulation of photoreceptor development and homeostasis in the mammalian
retina. Swaroop A., Kim D., Forrest D. Nat. Rev. Neurosci. (2010),11:563-576’ [10]

Normal and diseased retinal tissue and RPE secrete diffusible molecules that influence migratory
decision-making of transplanted cells [145, 167, 168], evidenced by increased donor cell integration after
manipulation of the chemical environment of the retina [165, 169]. To advance retinal cell replacement
strategies, it is essential that the biochemical cross-talk between transplantable cells and transplantation
microenvironmental signals be better understood.

1.3:

DEVELOPING HYPOTHESES FOR SUCCESSFUL PHOTORECEPTOR CELL REPLACEMENT

In this thesis investigation, we focus on improving photoreceptor cell replacement strategies because
such efforts may contribute to the repair and/or reversal of degenerating photoreceptor phenotypes
characteristic of several retinal disease types. According to Table 1.4, very few photoreceptor
replacement therapies have been implemented for human treatment in part due to the limited integration
rates reported in pre-clinical transplantation studies. This reparative strategy might thus seem unattractive
for clinical development but it leaves unanswered questions for which testable hypotheses can be
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intelligently developed. Additionally, with growing interest in the paracrine rescue effects of grafted retinal
stem cells on host damaged retinal tissue [73, 74, 104], an effective transplantation model will offer the
dual benefit of both replacing and rescuing dystrophic retina.

In general, for photoreceptor cell replacement to be feasible as a therapeutic treatment for vision loss,
sub-retinally transplanted cells have to migrate through the interphotoreceptor matrix (IPM) and integrate
in proportions large enough to affect/reverse the degenerated phenotype in a damaged host retina [146,
148, 162]. The mature retina is implastic and inhibitory to cellular migration [83]. Progressed retinal
degeneration leads to physical barriers to migration including meshes of heparan and chondroitin sulfate
proteoglycans, inhibitory extracellular matrix (ECM) molecules, accumulated microglia [145, 170, 171],
and limiting membranes of the outer and inner retina [172, 173]. Improved transplantation success has
been observed in part due to photoreceptor progenitor matrix metalloproteinase release and experimental
disruptions of ECM molecules and inhibitory limiting membranes in the retina [145, 167, 172]. In addition,
newly engrafted cells must differentiate into functional photoreceptors and generate appropriate synaptic
connections within a highly ordered, hard-wired, spatially organized neural network [50, 75]. This synaptic
integration also has to restore damaged retinal architecture and visual function to experimentally
acceptable levels [16, 170, 174]. An important finding in many studies is that cell replacement strategies
worked best in young and newly damaged retinal microenvironments [175, 176]. Although these
conclusions have since been challenged [148, 172], it was observed that following injury, strong activation
of astrocytes and microglia occurs with concomitant release of cytokines to restore retinal homeostasis.
Some other authors have suggested that only if a neutralization of these pro-inflammatory and gliaactivating stimuli in diseased retina is performed a priori will successful retinal transplantation be achieved
[146, 177]. Recently, ectopic expression of target growth factors in recipient retinal tissue improved
survival and integration of transplanted photoreceptor precursors further demonstrating support for the
crucial reparative role played by the retina’s extrinsic trophic cues [43, 165].

It is apparent that grafted photoreceptor precursor cells require optimal extracellular environments that
facilitate the appropriate intrinsic signaling repertoire for successful homing and integration in damaged
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retina. These biochemical environments are chiefly provided by the diffusible and bound chemicals in the
host damaged retinal IPM, RPE and neural retinal lamina. A fundamental understanding of the effects of
these local physical and chemical environments on the fate and long-term survival of transplanted retinal
precursors in diseased retina is thus essential to the efficacy of photoreceptor replacement therapies, but
has not been thoroughly investigated [112, 177]. We believe that only after such basic scientific,
mechanism-driven studies are performed, will photoreceptor replacement strategies yield predictable
outcomes with each cell type and retinal environment under investigation. To begin to delineate
mechanism of migration in the retina we next describe potentially analogous migratory mechanisms
active in the mammalian CNS during development and in normal and diseased physiological conditions.

1.3.1: Models Of Neuronal Migration
Appropriate migration and positioning of neurons during brain development is essential for the
construction of functional synaptic circuitry. Although the generation, migration, and differentiation of
neurons were once considered to end soon after birth in mammals, a significant number of neurons are
born and migrate post-natally and well into adulthood [20, 178, 179]. Studies of neuronal migratory
processes have revealed mechanisms underlying healthy nervous tissue organization as well as
pathologies leading to diseased and disorganized tissue. In humans, defects in neuronal migration can
cause developmental diseases including epilepsy [180], and advance adult-disease processes such as
metastasis and invasion of neuroblastoma and glioma [181]. In birds and rats postnatal neural progenitor
migration is required for learning and memory [182].

Two main types of migratory processes predominate during mammalian brain development (Figure 1.10).
Radial migration is generally characterized by intimate, reciprocal interactions between migrating neurons
and the processes of radial glial cells. Post-mitotic neurons migrate radially from the ventricular zone
towards the pial surface, past previously generated neuronal layers to reach the top of the cortical plate,
where their migration terminates and they assemble into layers with distinct patterns of connectivity [183,
184]. Tangential migration is defined as a mode of non-radial neuronal translocation that does not require
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specific interactions with radial glial cell processes [184, 185]. Neurons that eventually become pyramidal
or glutamatergic cortical neurons tend to migrate radially, whereas GABA (γ-aminobutyric acid)-

Figure
1.10:
Radial
and
tangential
migration
of
neurons in the developing
cortex - Radially migrating
neurons either use somal
translocation with a long leading
process (a) or migrate in close
apposition (b) to a radial glial
process
(blue).
Tangentially
migrating neurons (purple) travel
along corticofugal fibres (green),
or use marginal zone neurons
(yellow) or the pial membrane
(grey) as migratory guides.
Figure adapted from ‘Neuronal
migration in the adult brain: are
we there yet? Ghashghaei HT,
Lai C, Anton ES. Nat Rev
Neurosci. 2007;8:141-151.’ [20]

interneurons migrate tangentially [186]. Neurons can switch dynamically between tangential and radial
modes of migration, as has been observed in cortical interneurons [187]. In post-natal rodents, three brain
regions

- the cerebellum (CB), hippocampus (Hipp) and rostral migratory stream (RMS) maintain

prominent neuronal migratory processes (Figure 1.11). In addition, a very small number of neurons are
predicted to migrate into the hypothalamus near the time of birth [188]. A highly restricted pattern of
neuronal migration is observed in the early postnatal human brain, including populations of elongated
neurons around the periphery of the lateral ventricles and subgranular zone (SGZ) neuroblasts that
migrate over short distances to the adjacent dentate gyrus (DG) (Figure 1.11) [20, 189, 190]. Given that
the most extensive neuronal migration in adult mammals occurs in the RMS of rodents, it often serves as
a model system to study the factors that control both radial and tangential neuronal dispersion [20].
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During brain development in mammals, neuroblasts born in the anterior subventricular zone (SVZ)
migrate rostrally in a stream over long distances towards the olfactory bulb (OB) where they either settle
into the deep granule cell layer, or in the superficial periglomerular layer of the bulb and differentiate into
GABA-containing and dopaminergic local circuit interneurons (Figure 1.11) [178, 179, 182, 190, 191].
Through this route, new interneurons are continuously fed into the olfactory bulb — the first central relay
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Figure 1.11: Sites of neuronal migration in the postnatal and adult mammalian brain – A) In rodent brains
postnatal neuronal migration is evident in three main areas: the cerebellum (CB), the hippocampus (Hipp) and the
rostral migratory stream (RMS). A small number of neurons also complete their migration into the hypothalamus
(Hyp) at around the time of birth. Distinct germinal zones (green) give rise to neurons that migrate to adjacent target
zones (red). Lighter shade indicates that migration in these regions occurs primarily during the very early postnatal
period and does not persist into adulthood. B) Cells born in the anterior subventricular zone (SVZ, insert) initiate
their migration from the SVZ (1) as chains (2) streaming towards the olfactory bulb (OB), where they end their
migration (3). Abbreviations: EGL (external granule cell layer), IGL (internal granule cell layer), OE (olfactory
epithelium), SGZ (subgranular zone). Figure adapted from ‘Neuronal migration in the adult brain: are we there yet?
Ghashghaei HT, Lai C, Anton ES. Nat Rev Neurosci. 2007;8:141-151.’ [20]

station of olfactory sensory input — which has an ongoing demand for functional rewiring as a result of
continuous death and replacement of receptor neurons in the olfactory epithelium [191]. Neuroblasts
uniquely migrate as chains tangentially in the RMS in a highly directed manner with no dispersion into
surrounding tissues, and then switch to radial migration upon reaching the olfactory bulb indicating the
presence of orienting cues in or around the RMS. Cumulative evidence suggest that these cues are
gradient combinations of diffusible and substrate-bound repulsive, motogenic and chemoattractive
molecules secreted by neighboring SVZ cells [192],

and micro-architectural astroglial tubes that

encapsulate chains of migrating neuroblasts, serving as locomotory guidance substrates [20]. These glial
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tubes can also initiate physiological switching of some neuroblast populations from a motile phase into a
mitotic phase, through contact-mediated mechanisms [193].

Gradients of semaphorins and Slit-1 and Slit-2 emanating from the septum and tissues surrounding the
SVZ repel neuroblasts and initiate migration away from the SVZ [182, 194-196]. Astroglia-derived
migration inducing activity (MIA) and heparan sulphate proteoglycans in the ECM further modulate this
chemorepulsive function of Slit proteins [182, 197, 198]. Local chemoattractive cues Netrin-1 and its
receptors neogenin and DCC (deleted in colorectal cancer), and prokineticin2 (PK2) and its receptors
PRK1 and PRK2 also assist in initiating neuroblast migration by chemo-attraction towards the OB (Figure
1.12A) [194]. Optimal levels of adhesion between neuroblasts maintain their movement in chains due to
the expression of polysialated neuronal cell adhesion molecule (PSA-NCAM) which enhances hemophilic
interactions between NCAMs on neuroblasts and enables them easily slide along each other within
astroglial tubes (Figure 1.12B) [195]. These PSA-NCAM+ migrating neuroblasts also express the
tyrosine kinase receptor ErbB4 and its ligands, neuregulins 1 and 2 (NRG1 and NRG2), and Eph tyrosine
kinase receptors and their ephrin ligands in correlate to maintained orientation of the leading edge of
polarized axio-tangential migrating neuroblasts [20, 199]. On arrival to the mature olfactory bulb,
neuroblasts express the transcription factor ARX (aristaless-related homeobox gene) facilitating entry into
the OB. Reelin and tenascin-R then act as detachment signals causing radial dispersion of neuroblasts
from chains (Figure 1.12C) [20, 200, 201].

1.3.1.1:

Positional Steering During the Migration of Neurons and Other Cell Systems

The ability of migrating neurons to follow the same stereotypic pathways and be precisely guided by their
outgrowing processes to target destinations, was part of an early proposal by renowned neuroscientist
Ramón y Cajal termed the chemotropic theory of axon guidance [202, 203]. This theme was resounded in
findings by Gundersen and Barrett where lumbosacral dorsal-root ganglions from chick embryos rapidly
altered their direction of growth on exposure to an extracellular gradient of nerve growth factor (NGF)
[204]. Since then, several guidance systems of diffusible molecules have been characterized that
emanate from target neural destinations or are secreted locally by tissue microenvironments resulting in
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concentration gradients of the molecules relative to their output sources [202, 205-207]. Understanding
the mechanisms of directed neuronal migration to these and other conserved gradient systems will
facilitate strategies towards guided migration of RPCS and PPCs in retinal neural tissue. Directional cell
migration is facilitated in two ways: by intrinsic cell directionality and by external regulation [26, 208].

1.3.1.1.1:

Cell Migration Due to Intrinsic Cell Directionality

While environmentally derived cues exert a potent influence on the migratory behavior of neuroblasts,
migrating neural progenitors in the mature brain intrinsically polarize and extend a leading process in the
direction of migration from a somatic region marked by clustered centrosome and golgi bodies (Figure
1.13A) [20]. This cell polarizability with defined leading and trailing edges is essential for efficient cellular
migration and can be observed when cells respond to a non-directional motogenic signals such as the
uniform application of growth factors [209-211]. Cell polarity is well conserved and has been studied in
many cells including epidermal and mesenchymal cells [212, 213], and in diverse conditions such as
wound healing, immune surveillance and embryogenesis [26]. Forward movement of the centrosome
facilitates nuclear translocation towards the leading process because microtubules extending from the
centrosome are wrapped around the nucleus as observed in migrating cerebellar neurons [214].
Concurrently, centrosomal microtubular networks extend anteriorly to the edge of specialized tips of the
polarized leading process known as growth cones (Figure 1.13B). Growth cones are tasked with sensing
and rapidly responding to guidance signals, and with sustaining the intrinsic propagation of polarized
cells. Growth cones are composed of lamellipodia containing cross-linked networks of actin filaments, and
filopodia composed of bundled F-actin that probe the extracellular environment (Figure 1.13B) [33, 215].
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Figure 1.12: Canonical stages of Neuronal Migration in Mammals – A) Neuronal
migration from the sub-ventricular zone (SVZ) is initiated following repulsion by septal
chemo-repulsive factors (SLIT and ROBO), chemo-attraction by Netrin-1 and its receptor
DCC motogenic mediation by glial tube-derived migration-inducing activity (MIA, orange).
B) Neuroblasts migrate as chains sliding along each other. Maintenance of chain migration
is dependent on the continued motogenic activity of MIA, neuregulin 1–ErbB4 interactions
(both purple), adhesion mediated by the polysialated form of neuronal cell adhesion
molecule (PSA-NCAM, yellow) and extracellular matrix (ECM)–integrin signaling (blue).
Once the neurons reach the end of the rostral migratory stream, the entrance of migrating
cells into the olfactory bulb depends on the transcriptional activity of aristaless-related
homeobox gene (Arx). Termination of migration in the olfactory bulb is regulated by
secreted reelin and its receptor, apolipoprotein-E receptor 2 (ApoER2), and by their
downstream target, disabled 1 (DAB1). Tenascin-R also initiates the detachment of
neuroblasts from their chains and their radial migration into the olfactory bulb. Arrows
indicate the direction of migration from the sub-ventricular zone towards the olfactory bulb.
Figure adapted from ‘Neuronal migration in the adult brain: are we there yet? Ghashghaei
H.T., Lai C., Anton E.S. Nat Rev Neurosci. 2007;8:141-151.’ [20]
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Figure 1.13: Models of neuroblast migratory processes in the developing retina - (A) Interkinetic nuclear
migration (IKNM) showing the characteristic apical-to-basal nuclear oscillation in proliferative neuroepithelial cells
as they progress through the cell cycle. IKNM is a conserved process which typically occurs pre-natally in most
mammalian systems and through the initial post-natal weeks [13]. B-D) Modes of whole retinal cell migration –
Following cell cycle exit, progenitor cells can use resident retinal precursors and glial cells as scaffolds to migrate to
the appropriate lamina depth in the inner retina in guided migration (B) or they can extend cytoplasmic processes to
anchor between the inner limiting (ILM) and outer limiting membranes (OLM) allowing for translocation of its cell
body to the mature retinal loci with ultimate retraction of the processes in somal translocation (C). In unconstrained
migration (D), retinal precursors send neurites to explore the environment and migrate to their functional positions
with no apical or basal attachments [29]. These modes of migration are not mutually exclusive as some retinal cells
employ multiple migration strategies. Figures 1.13A is adapted from ‘Nuclear migration during retinal development.
Baye LM, Link BA. Brain Research. 2008;1192:29-36.’ Figure 1.13B is adapted from ‘Godinho L. LB. Cell Migration.
In: Evelyne Sernagor SE, Bill Harris, Rachel Wong, ed. Retinal Development: Cambridge University Press;
2006:59-74.’

This peripheral actin network is located at the proximal portion of the growth cone and associates with the
microtubules at the distal region of the axon shaft contributing to the assembly and translocation of
microtubules into the growth cone. The regulation of actin polymerization at the leading edge of filopodia
and lamellipodia, actin depolymerization in proximal regions of the growth cone, and of the rate of F-actin
retrograde flow within both filopodia and lamellipodia together control growth cone advancement and
retraction. The Rho family of small GTP-binding proteins plays a pivotal role in this regulatory process by
catalyzing the hydrolysis and switching between bound GTP (active) and GDP (inactive) molecular states,
profoundly affecting on actin cytoskeletal and microtubule dynamics [33, 208, 215-218]. This regulation of
actin polymerization is phenotypically expressed as the multiple retracting and extending protrusions of
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the leading edge of CNS neurons typically elicited by local chemical signals [219]. Additionally, the Par
(partitioning defective) complex, consisting of PAR3, PAR6 and atypical protein kinase C (aPKC) is key to
cell polarity and connects Rho GTPase signalling, centrosome reorientation, microtubule stabilization and
membrane trafficking to the regulation of directional persistence during intrinsic cell migration [26]. A Rac1 mechanism, independent of canonical Rho-GTPase signaling, was also found to regulate switches
between intrinsically persistent random and directional cell migration by controlling the number of
peripheral lamellipodia and the total number of membrane protrusions that can mediate changes in the
direction of cell migration [220]. External signals including external guidance molecules, ECM topography
and adhesion receptors, in tandem with the intrinsic cell polarity converge on the Rho GTPases to
regulate the number and orientation of lamellipodia (Figure 1.14), with the orientation of the most stable
lamellipodial branch determining the direction of cell migration [26, 219]. Understanding how these factors
are integrated to regulate directional migration is challenging and remains to be elucidated in retinal or
CNS transplantation paradigms.
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Figure 1.14: Intrinsic Polarizability and Growth Cones in Neuronal Migration – A) It is theorized that in
physiological conditions, diseased states or in the presence of uniform concentrations of chemokines, most cells
display intrinsic polarity by producing a leading process (blue) to form in the direction of migration. Clustering of
the centrosome (red) and the Golgi apparatus (green) seem to mark the area of a neuron from which the initial
polarized process extension occurs. Forward movement of the centrosome allows the nucleus to translocate in the
direction of migration as the cell’s trailing process (purple) detaches and repositions itself [20]. B) At the tip of the
leading process are specialized growth cones made of lamellipodia of cross-linked actin filaments and filopodia of
actin subunits. Growth cones sense attractive or repulsive guidance signals and extend or retract through
regulation of the rates of actin polymerization and depolymerization at the plus (+) and minus (−) ends of actin
filaments, respectively, and of F-actin retrograde flow [33]. Figure A is adapted from ‘Neuronal migration in the
adult brain: are we there yet? Ghashghaei H.T., Lai C., Anton E.S. Nat Rev Neurosci. 2007;8:141-151.’ Figure B is
adapted from ‘Signaling at the growth cone: ligand-receptor complexes and the control of axon growth and
guidance. Huber A.B., Kolodkin A.L., Ginty D.D. Annual review of neuroscience. 2002;26:509-563.’

1.3.1.1.2:

Directional Cell Migration By External Regulation

If a motogenic stimulus is presented as an external gradient or with another external guidance cue, a
steering or compass mechanism coupled to the intrinsic cell polarizability described above responds to
the asymmetric environmental factor [26]. The cell then undergoes directed migration [26, 208]. Directed
migration is maintained by the stabilization of the filopodial and lamellipodial protrusions that sustain the
orientation of the leading edge [221, 222], and by the intrinsic capacity with which such directed
movements can persist, a property that is cell-type specific and quantifiable during chemokinesis [26].
Generally, attractive guidance cues have been reported to promote actin polymerization events and
prevent retrograde actin flow, while in contrast repulsive guidance cues exert reciprocal effects on these
processes [33, 208]. In addition, the nature of asymmetric environmental cues will often define the type of
directed migration. Cells undergo chemotaxis in response to soluble cues [215], haptotaxis in response to
graded adhesion to the underlying substrate [223], electrotaxis in response to electric fields [224],
durotaxis in response to mechanical signals in the environment [225, 226], and even phototaxis to light
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and geotaxis to gravitational fields in simpler organisms [225, 227]. Typically, a combination of these
external stimuli and the corresponding cell response mechanism is at play during cell migration in most
biological systems.

Specific to our study of photoreceptor cell transplantation, it is expected that PPCs will exhibit durotactic
responses to the variability in structural motifs between the sub retinal space transplantation site and the
laminar substrata of the neural retina [228, 229]. PPCs are also expected to respond to haptotactic cues
in the host retina as they interact with topographically attached chemical moieties of the IPM [112, 147,
167, 230, 231]. Natural microenvironments in living tissues contain multiple embedded components within
extracellular matrices composed of spatially oriented fibrils forming one-, two-, or three-dimensional
structural montages with relative degrees of pliability [26]. Serving as physical cues, these topographical
arrangements can geometrically constrain adhesion sites to guide migration. Fibroblasts have been
observed to migrate towards more rigid surfaces during durotaxis which supposedly better stabilized
lamellipodial protrusions [225]. Oligodendrocytes, hippocampal neurons and many other cell types
polarize and migrate along grooved patterns in fabricated ECM lamina [232, 233]. Fibroblasts also
migrate more rapidly with spindle-shaped or uni-axial morphology and pronounced uni-directionality in
one- and three-dimensional matrices [234, 235] compared to two-dimensional laminar where they
adopted a more flattened cell morphology with multiple lamellipodial extrusions that promote more
random migration (Figure 1.15). Additionally, the centrosome and Golgi complex were oriented towards
the posterior of the cell in one- and three-dimensional topographies but towards the anterior of the cell on
2D substrates [26].
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Figure 1.15: Control of lamellipodial protrusions
promotes directional migration. Directional migration
is a result of regulated formation of lamellipodia during
both intrinsic and directed cell motility. Various signals,
including external guidance cues, the topography of the
extracellular matrix, the intracellular polarity machinery
and adhesion receptors, can converge on the Rho
GTPases to direct the adhesion and cytoskeletal
remodelling that is necessary for lamellipodium
formation. A) Increased numbers of lateral lamellipodia
can result in random intrinsic migration and a reduced
capacity to respond to external cues during directed cell
migration. B) Restricting lateral lamellipodium formation
results in a single dominant leading edge, directionally
persistent intrinsic cell migration and enhanced directed
migration during chemotaxis.

1.3.1.2:

Chemical Gradients Influence Directional Migration of Cells

Haptotaxis and durotaxis of cells occur in a fluid microenvironments with tissue specific biochemical
compositions in vivo. We aim to model in vivo signaling in this work to study chemotaxis of transplantable
neurons. Additionally, dynamic metabolic activity, spatial-temporal loci of interacting tissue subsets and
fluxes in levels of diffusible and bound molecules are expected to influence cell migration in retinal tissue
[205, 222, 236]. Figure 1.16 compares two common types of cell responses to soluble chemical gradients
– chemokinesis and chemotaxis. Chemokinesis occurs when a chemical applied to the cell either
symmetrically or asymmetrically, stimulates cell migration without determining the direction of migration.
Chemotaxis occurs when a soluble factor is applied asymmetrically and dictates the direction of cell
migration [221, 237-239]. Cell behavior in these environments are quantifiable in terms of the positional
displacement of the center of mass of single cells or distinct population of cells, directionality and turning
angle (θ) as was performed in this study assessing RPC and PPC motility. Prior to chemical stimulation,
or during chemokinesis, these parameters describe intrinsic cell directionality. During chemotaxis they
characterize directed migration. Factors that increase directionality during chemokinesis can promote
chemotaxis whereas factors that decrease directionality can inhibit chemotaxis [218, 240].

For a growth cone to be guided by a gradient, it must be able to sense a sufficiently large difference in
ligand concentration over its length. Two non-neuronal mechanisms for gradient detection by growth
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Figure 1.16: Topographical control of directional migration – A) When plated
on 2D surfaces, cells produce multiple lamellae (indicated by arrowheads),
whereas cells in an oriented 3D matrix or on 1D lines produce a single lamella
and have a uni-axial or spindle morphology. The centrosome and Golgi complex
(asterisks) are oriented towards the posterior of the cell in 3D and 1D
topographies but towards the anterior of the cell on 2D substrates. Cells either in
a 3D matrix or on a 1D line have a single directional axis of travel (dashed lines),
whereas the 2D surface promotes multiple axes and reduces directional
migration. B) Migration on a 1D substrate is similar to that in a 3D matrix. The
upper panel shows a confocal image of NIH 3T3 fibroblasts migrating through a
3D cell-derived matrix (fibronectin is shown in blue). The cells have a uniaxial
phenotype and a posterior-oriented Golgi complex (red). Microtubules are shown
in green. A similar morphology is seen in fibroblasts migrating on 1D lines (lower
panel). White arrows indicate the direction of migration. Figures adapted from
‘Random versus directionally persistent cell migration. Petrie RJ, Doyle AD,
Yamada KM. Nat. Rev. Mol. Cell Bio. 2009;10:538-549 [26] .

cones have been proposed: 1) internal amplification of a small percentage change in external ligand
concentration across the width of the growth cone and 2) a shifting internal baseline that reduces the
effective concentration at one edge of the growth cone to zero [241]. The maximal distance over which a
gradient can be detected regardless of the mechanism of detection has been resolved to be about 1cm
and the shape of the gradient determines the mechanism of gradient detection [241, 242]. Gradientinduced steering of cells has been widely observed in many cell systems. Cortical interneurons were
observed to respond to chemoattractant signals by generating new leading process branches that were
better aligned with the source of the chemical gradient both in vivo and in vitro and not by reorienting
previously existing branches [219]. In some other instances, graded distribution of receptors to guidance
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molecules determined appropriate positioning and response of specific axons to Slit-Robo guidance
mechanisms for midline axons [217]. Molecules distributed in gradients both in the peripheral olfactory
system and basal forebrain influence movement of gonadotropic (GnRH) neurons to their hypothalamic
destination [188]. In the establishment of the topography of thalamic axons in the cerebral cortex, netrin-1
gradients form long-range chemoattractive cues that stimulate migration of rostro-medial thalamic axons
in the ventral telencephalon [243]. Bone-marrow derived cells also mobilize to damaged regions of the
brain and retina releasing stromal-derived factor (SDF-1α), hepatocyte growth factor (HGF) and leukemia
inhibitory factor (LIF) [244]. Applying chemical gradients to mediums used for studying PPC replacement
paradigms is an experimentally supported investigational strategy and in most cell systems, fluidic
technology has enabled the micro-systemic generation of variety of gradients in manipulative ECM
environments. For this thesis study, we fabricate a bridged µ-lane microfluidic device capable of
generating and independently sustaining mathematically quantifiable ligand gradients over 72 hours. This
microdevice fabrication and implementation for PPC studies was performed with supervision from my
thesis committee member, Professor Maribel Vazquez.

1.3.1.2: Bioinformatics analysis simplifies the characterization of signaling for neuronal migratory systems
Along the migratory route, neuroblasts receive different stimuli from extracellular cues that collectively
guide migration. As a result, a number of intracellular signaling molecules are activated. Subtypes of
migrating neuroblasts have been found to share majority of intracellular signaling components that
integrate external stimuli via overlapping canonical signaling pathways, and several molecular hubs have
been identified that centralize these connections in the migration of most neuronal sub-types [195, 196,
245]. Identified network hubs include cell division protein kinase 5 (Cdk5), disabled homolog 1 (Dab1),
ras-related C3 botulinum toxin substrate 1 (Rac1) and focal adhesion kinase (FAK) [245]. Whilst these
valuable studies reveal key molecules affecting neuronal migration, many of which were cytoskeleton
proteins, during the last decade, interest has grown towards the identification of whole pathways and
understanding their complex interactions [246]. Bioinformatics tools have been employed to mine
databases that compile microarray gene expression data of many cell systems and species at target
physiological states [6, 246]. This powerful approach allows statistically defined nodal construction of
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experimentally defined molecular connectivity, the filling in of connection gaps, and can be used to predict
whole signaling pathways, tasks that would be difficult to resolve using experimental data from one
system only. Bioinformatics analysis has been successfully employed in predicting intracellular
connectivity between genes involved in chemotactic pathways of migrating neuroblasts during
neurogenesis and in adult neuronal progenitors in the sub-ventricular zone (SVZ) and cortex [245, 247252], and in angiogenetic processes of migrating retinal endothelial tip cells [253]. These bioinformatics
findings are usually validated by experimental testing that provides functional proof of a molecule’s or
network’s involvement in a specific function, cell or tissue system. Using this technique, the involvement
of the cytoskeletal remodeling pathway combining calmodulin signaling and Akt1-DNA transcription
networks in neuroblast migration were confirmed for murine neuroblasts using invivo and invitro
techniques such as gene silencing and chemotactic assays [247]. In this thesis study, we employ the
Ingenuity Pathway Analysis bioinformatics software technology to predict incident extracellular cues and
relevant signaling pathways influencing migration of PPCs upon transplantation into a light-damaged
retinal model, and delineate epidermal growth factor-induced intracellular signaling pathways in RPCs.

1.3.2: Models Of Retinal Cell Migration
Migratory processes during retinogenesis in mammals begins before birth and continues throughout early
postnatal development. In humans, motility involved in retinogenesis has been studied during the prenatal gestational ages of 6.5-18 weeks [254, 255], with reported localized niches of migrating retinal
progenitor cells during late development. In the formation of the mammalian retina, neuroblasts typically
migrate from the neuroepithelium of the optic cup primarily in an apical-to-basal direction with subtle
tangential displacements to form an even stratification of mature retinal cell types. Coordinated regulation
of cell proliferation, cell cycle exit, cell type determination and morphogenesis, directed cellular migration
and homeostatic synaptic partnering between heterogeneous retinal cells is required to establish the
exquisite cyto-architecture of the mature retina [256, 257]. During the initial cell proliferative stage in
retinal development, neuroepithelial progenitors exhibit interkinetic nuclear migration (IKNM), the process
in which their nuclei migrate in an apical-to-basal manner through the length of the cell and in phase with
their cell cycles (Figure 1.17A). M phase and cytokinesis in retinal progenitors were observed to occur
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mostly when they were positioned at the apical surface near the RPE while G1, S and G2 phases
occurred at more basal locations [13, 258]. Studies suggest that IKNM aids in the spatial asymmetrical
positioning of cell bodies of retinal neuroblasts, which consequently determines cells that will continue to
be mitotically active and thus their cell fates as they temporally form the outer and inner retina. Actinmyosin cytoskeletal networks (actomyosin) are reported to be the main drivers of nuclear migration [259]
while cytoplasmic microtubule-based motor systems of dynein-dynactin and kinesin play minor roles, in a
process that is highly conserved among various species [13, 260]

Following terminal mitosis at the apical surface of the neuroepithelium, newborn retinal cells migrate to
their appropriate laminar position within the retina by employing multiple strategies. The modes of whole
cell migration can be classified as guided cell migration, somal (nuclear) translocation or unconstrained
(free) migration (Figure 1.17B-D), which are not necessarily mutually exclusive forms of motility because
some retinal cell types have been observed to employ multiple migration strategies [29, 258]. In somal
(nuclear) translocation, the neuroepithelial cells extend a leading (basally-directed) process through which
the nucleus translocates until it reaches the appropriate strata in the lamina and then it retracts its apically
and basally-directed processes [13, 20, 258] (Figure 1.17C). Somal translocation has been demonstrated
for retinal ganglion cell and bipolar cell precursors [261, 262] and cone photoreceptor precursors also
exhibit some degree of nuclear translocation despite their attachment and eventual somal positioning
adjacent to the outer limiting membrane [263]. Rods also extend a basally directed process, particularly at
later developmental stages, that does not reach the inner retinal surface [264]. Continued proliferation of
the neuroepithelium also pushes early-born rods and cones deeper into the retina [263].

Newborn amacrine cells have been shown to move using unconstrained migration in which dynamic and
non-polarized neurites appear to sample the local environment en-route to the inner nuclear layer (Figure
1.17D) [265]. Guided cell migration is similar to migration observed in the developing cerebral cortex
where glial cells provide the substrates and cues for cell positioning. However, within the retina, adjacent
neuroepithelial cells including terminal Muller glia cells all provide the scaffold for migrating post-mitotic
retinal progenitors and this process is utilized to some extent in both somal translocation and free
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migration (Figure 1.17A) [13, 263]. Horizontal cells exhibit a unique bi-directional migratory behavior
where they overshoot the inner limiting membrane (ILM) and coalesce within the future amacrine cell
layer before migrating back to their final destination [266]. In the mouse retina, this bi-directionality in
horizontal cell movement requires the transcription factor gene Lim1 [256, 267], while in the chick retina,
horizontal cells seemed to mirror this motogenic function but also re-enter the mitotic phase deep in the
inner retina before migrating apically back to the horizontal cell layer [266, 268, 269].

Important molecules and signaling pathways facilitating directed migration in the retina include those
associated with apical cell junctions of neuroepithelia, which either regulates adhesion between cells or
facilitates polarized secretion of guidance molecules [258]. Membrane-bound receptors such as
dystroglycan and integrins as well as intracellular signaling molecules such as integrin-linked kinases and
focal adhesion kinases also mediate directed cell migration [258]. Localized endogenous expression of
epidermal growth factor (EGF) [270] and stromal-derived factor 1 (SDF1) [271-273] and their receptors in
specific retinal lamina have also been linked to directional motogenic functions for retinal cell precursors.
Slit1-Robo3 signaling downregulates N-cadherin based adhesion to allow for migration of retinal ganglion
cell precursors in the developing optic chiasm of both zebrafish embryos and new born mice [215, 274,
275], and Netrin-1 and Sema-3 expression in the optic chiasm guide glial precursor migration via the optic
nerve towards infantile rat retina [276].
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In contrast to organizing migratory processes observed during development, in late stage retinal disease,
disorganizing migratory processes ensue.

For example, in proliferative vitreoretinopathy, RPE cells

Figure 1.17: Chemokinesis Vs. Chemotaxis – Chemokinesis occurs when a
factor, applied to the cell either symmetrically or asymmetrically, stimulates cell
migration without determining the direction of migration. Chemotaxis occurs
when a soluble factor is applied asymmetrically and dictates the direction of cell
migration. The behavior of a motile cell exposed to these different treatments
can be quantified. A) A cell at three time points as it migrates in a uniform
concentration. B) A cell at three timepoints as it migrates in a gradient of
increasing concentration of a motogen. At each time point, the migration can be
defined by the centre of the cell mass, the distance travelled between positions
(path length), the turning angle (θ) and the net displacement. This information
can be used to describe the rate and directionality of migration. Directionality is
defined as the displacement divided by the total path length of the cell. If a cell
is migrating more randomly, directionality decreases and vice-versa. Figure
adapted from ‘Figures adapted from ‘Random versus directionally persistent
cell migration. Petrie RJ, Doyle AD, Yamada KM. Nat. Rev. Mol. Cell Bio.
2009;10:538-549 [26]

migrate into the retina and onto the vitreal surface through retinal tears and form cell assemblies in the
vitreous known as epiretinal membranes [277]. However, in the tissue remodeling process that follows
retinal detachment, Muller cells and radial glia of the retina hypertrophy and grow extensively into the
sub-retinal space, where as photoreceptors retract their axons as their senesces begins and migrate
deeper in the outer nuclear layer [278]. Horizontal and ganglion cells also extend neurites into the
subretinal space and vitreous following retinal detachment [278]. Similar Muller cell reactivity and
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proliferation towards the site of injury has also been described in mammalian models of N-methyl-Daspartate neurotoxicity [46], and retinal laser photocoagulation [279].

1.4:

SUMMARY HYPOTHESES AND THESIS OBJECTIVES

Our review of the pathophysiology of retinal diseases and their phenotypic manifestations reveals that an
effective strategy to repair damaged retina will involve replacement of lost photoreceptors. Stem and
progenitor cell-replacement therapy offers good restorative potential for damaged retinal tissue compared
to most other treatment protocols. However, the efficacy of current cell-transplantation methods is limited
due to poor migration, homing, and integration of transplanted cells in the host retina. Our developing
understanding of the biochemical complexity involved in PPC navigation through the IPM site of
transplantation to make synaptic connections in the neural retina layer will help define for the first time the
chemotactic mechanisms guiding migration of transplanted retinal stem/progenitor cells within normal and
damaged neural retina. This research may contribute to the advancement of photoreceptor cell
replacement strategies to restore retinal architecture and light detection [49, 112, 145]. We suggest that
in transplantation studies, RPCs and PPCs are navigating to specific retinal lamina as a result of cell
surface receptor expression and in response to spatially gradated directional cues provided by the host
retinal microenvironment. Given the molecular basis of neuronal and retinal cell migration during
development and in adults, we also believe that the extracellular cues in host retinal microenvironments
will modulate intrinsic motility signals in grafted RPCs and PPCs and trigger analogous overlapping
canonical signaling pathways that govern cell migration as well as novel molecular interconnectivities.
Our ultimate goal in this study is to provide experimental data toward development of strategies that will
target grafted cells to their specific lamina and thus improve integration rates for vision restoration. To
perform this task, we propose to 1) delineate extracellular chemotactic factors, their cognate cell-surface
receptors and intracellular motility deterministic signaling pathways governing transplanted photoreceptor
precursor cell (PPC) migration in the retina using a combination of bioinformatics, gene expression
profiling and proteomics analysis, and 2) functionally evaluate RPC and PPC migratory and homing
responses to identified chemotactic and haptotactic factors, and signaling cascades using high-
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throughput chemotactic assays, and in steady state gradients generated in retinal biomimetic microfluidic
devices.

In achieving our objectives, we have been able to compile a comprehensive library of chemotactic
molecules whose interactions potentially guide transplanted RPC and PPC migration in a host damaged
retina model with high statistical probability. Network designs of these molecular interactions shed more
light on basic stem cell biology, retino-neural progenitor chemotaxis and retinal neurogenesis. These insilico tasks were performed using a novel cost-effective protocol designed to facilitate the analysis of
microarray genomic data. Predictions of molecular signaling interactions were validated using microfluidic
gradient generators with transferrable technology for use in stem cell migration research to repair other
diseased organ systems with specific cell subtypes and extracellular matrix chemotactic parameters.
Lastly, we have presented our findings at conferences and published in peer-reviewed journals in our
commitment to advancing efforts that promote basic and translational stem cell research. Chapter 2 of
this thesis study describes the bioinformatics methodology employed to resolve molecular mechanisms
governing PPC migration, while chapter 3 describes the proteomic and chemotactic assays used to
validate the bioinformatics findings. We then report results of assessments of the chemotactic potential of
two key extracellular matrix ligands Epidermal Growth Factor (EGF) and Stromal-Derived Factor (SDF1α) in chapters 4 and 5 respectively, resolved from our analysis signaling network systems of motility of
retinal precursor cells. We conclude in Chapter 6 by showcasing translational application of our
bioinformatics paradigms to statistically predict drugs and small molecules that can induce migratory PPC
phenotypes favorable to successful integration in the retina post-transplantation, and provide preliminary
results of efficacy tests of our drug selection on RPC motility.
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CHAPTER 2: BIOINFORMATICS ANALYSIS METHODS FOR RETINAL STEM CELL MIGRATION

2.1

OVERVIEW OF BIOINFORMATICS ANALYSIS - FROM GENE TRANSCRIPT TO NETWORK

PATHWAY FUNCTION
Bioinformatics has traditionally involved the computational analysis of large molecular biology datasets
drawn from protein structure experiments. Since the elucidation of whole genome sequences and the
advent of high throughput sequencing techniques, gene expression at the transcriptome and proteomic
levels has been measured simultaneously and repeatedly for different cells, tissues, organs, individuals
and their physiological states. Such high-throughput expression profiling can be used to: 1) reveal
signaling pathways and genes, whose expression states govern underlying biological conditions; 2)
compare the level of gene transcription in clinical conditions to identify diagnostic or prognostic
biomarkers, classify diseases that are indistinguishable by microscopic examination, monitor gene
response to therapy, and understand the mechanisms involved in the genesis of disease processes [280,
281]. Genome-wide expression information can principally be generated by cDNA Microarrays,
GeneChips (High-Density Oligonucleotide arrays), serial analysis of gene expression (SAGE) and
expressed sequence tags (ESTs) technologies [280]. GeneChips and SAGE measure absolute mRNA
transcript levels per cell, while cDNA microarrays measure gene expression relative to a reference state
to yield an expression ratio [280, 282]. A large amount of data is produced using these techniques and
the first major bioinformatics task is to organize and store this information, in different repositories such as
GEO (the NCBI Gene Expression Omnibus), the Stanford Microarray Database, Array Express and
Express DB (Harvard) [283, 284].

An early goal was to facilitate interpretation of cDNA microarray results verified by independent research
groups. Toward this goal, the minimum information about a microarray experiment (MIAME) [285] was
developed to standardize the annotation, organization and reporting of the microarray-based gene
expression data. MIAME requires that the biological properties of the samples and phenotypes, the
experimental conditions, transformation and normalization techniques accompany data obtained from the
microarray-based assays. MIAME has since been further modified to provide minimum information about
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high throughput sequencing experiments (MINSEQE) and similar variations that accommodate
improvements next generation sequencing technologies [286].

A basic outline of cDNA microarray analysis involves; total RNA extraction from experimental sample and
reference sample, followed by reverse-transcription to cDNA then labeling with fluorescent probes and
hybridization to complementary DNA sequences affixed in an orderly manner at specific locations (spots)
on the microarray slide. The amount of cDNA bound to a spot will be directly proportional to the initial
number of RNA molecules present for that gene [282]. Upon excitation at different wavelengths, the
intensity of the emitted fluorescence of the different dyes corresponds to the amount of bound nucleic
acid, which is used to calculate expression ratios for the sample relative to the reference set after
negating background intensities. Raw intensity values are firstly numerically transformed to equivocate
intensities to the direction of differential gene expression (up- or down-regulation), and normalized relative
to the expression of one or more reference genes whose levels are assumed to be constant between
samples. This allows for comparison of microarray data independent of the original hybridization
intensities and eliminates variations inherent in sample preparations and during experimentation [287].
Gene expression data obtained can be absolute measurements of the expression level of a gene in
abstract units, relative measurements where the expression level of a gene is normalized to its
expression in a reference condition/sample, discrete values assigned based on a pre-defined threshold
intensity or as vectors in a three-dimensional space where genes and biological conditions are used to
form a matrix in the vector space [282]. Gene expression data for all genes under an experimental
condition – sample expression profile – or for a gene across different experimental conditions – gene
expression profile – is then analyzed to obtain meaningful biological information.
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2.2:

ANALYSIS OF GENE EXPRESSION DATA

2.2.1:

Rationale for Analyzing Gene Expression Data

Analysis of gene expression data is primarily based on comparison of gene or sample expression profiles.
Patterns derived from such analysis provide insights into the underlying biology of sets of genes or
samples. In order to compare expression profiles, we need a measure to quantify how similar or dissimilar
are the genes being considered. A variety of distance measures are commonly utilized to calculate
similarity in expression profiles including Euclidean distance measurements between expression vectors
per condition and Pearson or Ranked correlation coefficients that measure mean differences in
magnitude, shape and/or ranking of expression profiles by condition [282]. Clustering methods are then
further applied to resolved expression data sets to classify genes or samples hierarchically or nonhierarchically into groups based on similarities in behavior and relationships between gene sets.
Following the analysis of expression profiles, significant inferences into biological processes can be made
based on assumptions that genes with similar expression profiles are regulated by the same set of
transcription factors, have similar transcription factor binding sites, likely encode proteins that interact or
have related functions, or highlight evolutionarily conserved functional modules [288-290]. Protein-protein
interaction and transcription factor binding sites can then be predicted, transcriptional regulons
delineated, and functional pathways designed [282, 291].

2.2.2:

Gene Ontology

Data analysis protocols described above are important to begin to define the biological meaning of output
obtained from preliminary analysis of microarray data. The genetic information represents independent
events however, in biology, these events occur in a highly coordinated and interdependent manner and
thus benefit from bioinformatics software packages, which can elucidate such interdependencies. Since
the automation of gene ontological analysis was accelerated in 2002 with the launch of Onto-Express and
DAVID programs [292], several analytic platforms have been designed to correlate expression profiles
with cytogenetic location, biochemical and molecular

function,

biological

processes, cellular
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components, and cellular roles of the translated proteins [19]. Some software platforms such as Ingenuity
Pathway Analysis (IPA) maintain and regularly curate their own database (knowledgebase) in an
algorithmically defined architecture for gene expression analysis [293]. Figure 2.1 graphically displays an
evolutionary history of Gene Ontology (GO)-based functional analysis software [19]. In our current
project, we selectively employed two bioinformatics software packages – Ingenuity Pathway Analysis
(IPA) and the database for annotation, visualization and integrated discovery (DAVID).

Figure 2.1: History and Evolution of automated gene Ontological software technologies –
Since the launch of Onto-Express data analysis software platform in 2002 [19], several
computational software platforms have been designed to analyze microarray based genetic
surveys and match the explosion in quantity and variance of genomic data types acquired from
novel high throughput genomic and proteomic technologies. The database for annotation,
visualization and integrated discovery (DAVID) was used in our studies to verify results of Ingenuity
Pathway Analysis (IPA)-based preliminary predictive analysis of chemotactic molecules influencing
migration of retinal progenitor cells. Figure adapted from ‘Ontological analysis of gene expression
data: current tools, limitations, and open problems. Khatri P, Draghici S. Bioinformatics 2005;
21:3587-3595.’

2.2.3:

Mechanisms of Knowledgebase Architectural Platforms

The necessity for downstream in-silico bioinformatics analysis of gene expression data became most
apparent when it was realized that direct inferences could not be made between statistically defined and
clustered genetic data and biological function because most genes serve multiple context-dependent
functions and not all changes in mRNA levels can be directly correlated to experiments being conducted
[294]. Expertly curated databases assigning genes to various functional categories are firstly used to
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annotate candidate gene lists, a process known as Gene Ontology (GO). The candidate gene lists are
obtained after pre-processing expression profiles of samples or genes from microarray analysis, or
chosen through an enrichment of hypothesis-driven selection of molecules from vast literature review
available. GO annotation tools are provided in separate modules as with KEGG, DGEM or DAVID, as part
of commercial microarray gene-chip applications such as Affymetrix or incorporated into comprehensive
pathway analysis tools as IPA or Partek [294]. Beyond GO classifications, promoter and regulatory
network analysis as well as molecular pathway analysis can be performed.

In delineating molecular pathways, the functional interactions between genes are emphasized by
mapping a list of differentially expressed genes onto functional network pathways designed from vastaccumulated, constantly curated published data describing molecular interactions. These molecular
interactions are also statistically ranked to predict significant associations between an inputted
experimental data set and the pathways defined within the database. Metabolic and kinase-based
signaling pathways can be defined and inputting expression levels allows monitoring of transcriptionally
regulated signaling pathways [294]. As most cellular processes involve more than one pathway, multiple
pathway analysis can be performed to describe emergent networks and functional outcomes. Currently,
optimal network analyses tools, like IPA, combine GO associations, pathway analysis, transcriptional and
promoter sequence information with efficient data mining tools.

2.3:

DELINEATING MOTILITY-DETERMINISTIC SIGNALING PATHWAYS IN RPCs and PPCs

2.3.1: Approaches to identifying potential chemotactic factors and signaling pathways for RPC and PPC
migration
Being of the same embryonic origin, we performed bioinformatics analysis of migratory mechanisms in
mammalian retinal tissue and cells, guided by analytic techniques employed to define signaling
mechanisms of neuronal progenitor movement in the brain during development and for chemotaxis of
adult neurons. As RPC migration has been associated with laminar positioning during retinal
development, is known to be guided by intracellular and local environmental cues, and likely involves a
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complex transcriptional regulatory cascade [256] [295]. We employed a bioinformatics approach to
account for the myriad of biochemical interactions predicted to govern such chemotactic phenomena in
retino-neural systems. Our ultimate goal was to define a library of candidate chemotactic molecules that
modulate transplanted RPC and PPC migration and homing to their laminar position in host retina and to
characterize the intracellular signaling mechanisms facilitating such cellular response. The functionality of
the selected molecules and their signaling pathways can then be evaluated in vitro to test the hypothesis
that in silico predictions of RPC and PPC motility can be applied to modulate motility-deterministic
mechanisms. The characterization of these migratory, mechanisms capable of guiding successful
migration of RPCs and PPCs is essential for increasing the efficacy of current photoreceptor replacement
strategies.

During central nervous system development and adult neurogenesis in the vertebrate brain, several
extracellular matrix factors have been shown to interact through overlapping canonical intracellular
signaling pathways to direct neuroblast migration and integration [195, 196, 245, 296, 297]. In the subventricular zone (SVZ) and cortex, the expression of Netrin and its receptors neogenin and DCC (deleted
in colorectal cancer), prokineticin2 (PK2) and its receptors PRK1 and PRK2, and insulin-like growth factor
(IGF-1) have all been implicated in attraction of neuroblasts [194, 296] ,while semaphorins and Slit-1 and
Slit-2 expression in the SVZ and septum are thought to repel neuroblasts away from the SVZ during late
stage adult neurogenesis [194-196]. The function of Slit proteins are further mediated by astrocytederived migration inducing activity (MIA) factor secreted in the olfactory bulb (OB) [197]. Several
intracellular molecular hubs such as protein kinase 5 (Cdk5), disabled homolog 1 (Dab1), ras-related C3
botulinum toxin substrate 1 (Rac1) and focal adhesion kinase (FAK) [245] have been identified that
centralize, control and translate extracellular signals for migration of most neuronal sub-types. Molecular
pathways such as the cytoskeletal remodeling pathway involving calmodulin signaling and Akt1-DNA
transcription networks have also been implicated in neuronal migration [247]. According to Ghashghaei et
al [195], coordination of extracellular matrix, cell adhesion molecules, and cell-surface kinase or integrin
signaling receptors such as tyrosine kinase receptor ErbB4 and its ligands neuregulins 1 and 2 (NRG1
and NRG2), is required to maintain migration of neuroblasts. We predicted that RPCs in the retina would
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respond to analogous canonical networks of guidance mechanisms directing migrating neural cells in the
SVZ and cortex given their ontogenetic relationship [241, 298, 299].

The elucidation of major neuronal signaling pathways and molecular networks arose from statistically
significant predictions of molecular connectivity resolved with bioinformatics technologies [245, 247-252].
Similarly, expression profiles of post-natal retina [300], retinal pigment epithelia [301], retinal progenitor
cells (RPCs) [302, 303], and migratory retinal endothelial cells [253] begin to describe signaling events in
the retinal environment. In the research of this thesis, we begin to delineate migratory signaling of RPCs
and PPCs by employing three successive bioinformatics methodologies: 1) Analysis of literature-derived
candidate genes and pathways specific for retinal progenitor motility, 2) Mining genomic expression data
of PPCs for potential chemotactic receptors, and 3) Analysis of chemotactic ligands from microarray data
of normal and damaged retinal tissue. Computation of transcript gene expression was performed on an
Ingenuity Pathway Analysis (IPA) (Ingenuity® Systems, www.ingenuity.com, Redwood City, CA) software
platform. Development of our final IPA based microarray data analysis was built upon techniques learned
through our initial literature-derived migratory gene identification and enrichment.

2.3.2:

Enrichment analysis of literature-derived candidate genes and pathways specific for retinal cell

motility

Initial literature review of possible chemotactic molecules for RPCs and PPCs either during retinal
development or in adult niches for reparative purposes, yielded a dearth of information specific for the
tissue type, with most correlates documenting motility studies using cells of the nervous system and
cancerous cells [195, 238, 245, 303]. However, using neuronal motility as a guide, we compiled a small
library of seven (7) extracellular cues, prioritized by the efficiency of their receptor binding interactions in
activating downstream signals that stimulate movement in the neural cell systems studied [196, 304].
These molecules are key players in a symphony orchestrated both during axon guidance and positioning
in embryonic nervous system development and in early stage adult neurogenesis in the subventricular
zone (SVZ) and subgranular regions of the brain where resident pools of slow-dividing, glia-like stem cells
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generate progenitors that migrate along the rostral migratory stream (RMS) towards the olfactory bulb
[33, 194-196]. The molecules represent members of major chemokine families including Netrin, ephrins
and Slit proteins and are presented in Table 2.1 along with their characteristic motility functions in neural
cell types. These cues served as seed genes input into the Ingenuity Pathway Analysis (IPA) software to
generate interacting receptors, cytoplasmic and nuclear signaling pathways that intersect to yield a
predictive model network biased towards activity in mouse neural tissue and retina (Figure 2.2). Genes
that mapped to defined networks in IPA knowledgebase were labeled Network Eligible (NE) (N=32) and
are presented in Table 2.2. The predictive network for motility in retino-neural systems was then verified
with DAVID bioinformatics software [47, 48] by mapping the same 7-molecule library as gene identifiers
onto a precompiled annotated gene knowledgebase architecture as has previously been performed [305].
NE genes were then correlated to canonical pathways in IPA to define sub-networks of interacting genes
within our NE database by analyzing the number of NE genes that mapped to a canonical pathway using
a Fisher’s exact test that generated p-values for the probability of associations between NE and
canonical pathway.

The top three canonical signaling pathways correlated with NE molecules were axonal guidance
(p=8.12E-21), Ephrin receptor (p=1.54E-17) and FGF (p=2.39E-06) signaling. Two of the three canonical
network pathways overlay the predictive network pathway map shown in Figure 2.2. Functions
associated with these pathways include neuronal migration, cell morphology and nervous system
development. A mammalian retinal tissue-specific enrichment analysis of NE molecules was then
performed in IPA by predicting direct and indirect, upstream and downstream molecular connections to
NE molecules that map to the top three canonical signaling pathways identified. By predicting second
messenger signaling
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Protein or
Chemical
Reelin

Encoding
Gene
RELN

Biological Function

Netrin 1

NTN1

SLIT-1,

SLIT

Exhibits chemoattractant or repellant biological activity on
neurons/cells depending on receptor; axon guidance, retinal neurite
extension, guided migration of immature neurons; gradient-induced
attractive and repulsive activity sorts ventral telenchephalic neurons
to distinct cortical domains [243, 311-317]
Regulating axon guidance and branching, and neural migration;
expression in the sub-ventricular zone (SVZ) and septum repel
neuroblasts towards the olfactory bulb; increasing dendritic growth
and branching [33, 318, 319]

Eph-Type A
Receptor 7

EPHA 7

Regulates neuronal migration; Proteolytic activity on extracellular
matrix adhesion molecules such as fibronectin, laminin and
collagen; Neuronal positioning during embryogenesis; Required for
the normal complement of rod bipolar cells to provide synaptic input
to type AII amacrine cells; Chemorepellant [306-310],

Subcellular
localization
Extracellular matrix
serine protease
produced by neurons
in the Ganglion Cell
layer (GCL) of the
retina
Produced by target
axons in neural
microenvironment
Extracellular matrix

Receptor/Ligand
ApoER2 (Apolipoprotein E receptor2) or Very Low Density Lipoprotein
Receptor (VLDLR)

Chemoattraction:
Deleted in Colorectal Cancer (DCC)
receptor Chemorepulsion:
UNC5 – Uncoordinated locomotion
5 receptor
ROBO (Roundabout) receptor

Receptor tyrosine kinase that binds GPI-anchored ephrin-A family of Plasma Membrane
Ephrin A5 cognate ligand
ligands leading to contact-dependent bidirectional signaling,
regulating brain development and activates components of the ERK
signaling pathway. Involved in the guidance of corticothalamic axons
and proper topographic mapping of retinal axons to the colliculus
[320-322].
Tenascin R
TNR
Reorientation from tangential to radial migration in mitral cells;
Extracellular matrix
Immunoglobulin superfamily
neurite outgrowth, neural cell adhesion and modulation of sodium
glycoprotein
recognition receptor molecule F3
channel function. the extracellular matrix glycoprotein tenascin-R,
expressed in the adult mouse olfactory bulb, initiates both the
detachment of neuroblasts from chains and their radial migration
[194, 201, 323].
Insulin-like
IGF-1
Implicated in post-natal migration of neuroblasts in sub-ventricular
Extracellular matrix
Insulin-like Growth Factor Receptor
Growth
zone (SVZ) into rostral migratory stream; Ectopic expression in
(IGF1R)
Factor
retina promotes migration and integration of sub-retinally
transplanted photoreceptor precursors [194, 324, 325].
Eph-Type B
EPHB2
Positively regulate progenitor proliferation while also disrupting
Transmembrane
Ephrin B ligand
receptor B2
neuroblast migration in the postnatal SVZ [319, 326].
protein
Table 2.1: Preliminary literature Review for Mammalian Retino-neural Chemotactic Genes - An extensive literature search for genes whose expression
correlate to cellular movement, axonal positioning and homing functions during retinal and neural embryonic development, and neuroblast recruitment activities in
adult tissues, were compiled and used as seed input genes in Ingenuity Pathway Analysis (IPA) bioinformatics software. This in-silico analysis attempts to grow the
input gene connectivity, biased for retino-neural tissues, and identifying downstream signaling targets that may influence retinal progenitor (RPC) cell migration. As
seen above, these genes represent the major chemokine families including Netrin, ephrins and Slit proteins.
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Figure 2.2: Predictive Network Pathway for Retinal Progenitor Cell
Migration – An initial seven-molecule library compiled from literature review for
chemotactic genes in retino-neural tissues was expounded using the Ingenuity
Pathway Analysis knowledgebase, specified for their occurrence in mammalian
retinal tissue and for cellular movement function, to yield a predictive model
network of downstream signals influencing RPC migration. Both direct and
indirect interactions between the Network Eligible (NE) genes (N=32) are
highlighted in the network categorized by subcellular localization in the cell. An
overlay of active canonical networks reveals axonal guidance (p=8.12E-21) and
ephrin receptor signaling (p=1.54E-17) as possible underlying signaling
pathways governing RPC motility.
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Symbol
APOE
CXCL12
DAB1
EEF1A2
EFNB1
EPHA7
EPHB2
ERBB4
FABP7
FGF1
FGFR1
HIF1A
IGF1
LIF
LRP8
MAPK1
NEO1
NOS1
NR1H3

Entrez Gene Name
apolipoprotein E
chemokine (C-X-C motif) ligand 12
disabled homolog 1 (Drosophila)
eukaryotic translation elongation factor 1 alpha 2
ephrin-B1
EPH receptor A7
EPH receptor B2
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)
fatty acid binding protein 7, brain
fibroblast growth factor 1 (acidic)
fibroblast growth factor receptor 1
hypoxia inducible factor 1
insulin-like growth factor 1 (somatomedin C)
leukemia inhibitory factor (cholinergic differentiation factor)
apolipoprotein e receptor
mitogen-activated protein kinase 1
neogenin 1
nitric oxide synthase 1 (neuronal)
nuclear receptor subfamily 1, group H, member 3

Family
transporter
cytokine
other
translation regulator
other
kinase
kinase
kinase
transporter
growth factor
kinase
transcription regulator
growth factor
cytokine
transmembrane receptor
kinase
transcription regulator
enzyme
ligand-dependent nuclear
receptor
NRG1
neuregulin 1
growth factor
NTN1
netrin 1
other
OTX2
orthodenticle homeobox 2
transcription regulator
PAX6
paired box 6
transcription regulator
PRL
prolactin
cytokine
PROK2
prokineticin 2
other
RAX
retina and anterior neural fold homeobox
transcription regulator
RELN
reelin
peptidase
SEMA3C
sema domain, (semaphorin) 3C
other
SLIT1
slit homolog 1 (Drosophila)
other
SLIT2
slit homolog 2 (Drosophila)
other
SOX2
SRY (sex determining region Y)-box 2
transcription regulator
VEGFA
vascular endothelial growth factor A
growth factor
Table 2.2: IPA Network Eligible Genes – Candidate retino-neural chemotactic seed gene connectivity were
expounded using Ingenuity Pathway Analysis (IPA) bioinformatics to yield 32 Network Eligible (NE) genes
predicted to influence retinal progenitor cell (RPC) migration. These genes were then used to design the
function-specific networking pathway depicted in Figure 2.2.

selective to the canonical signaling molecules, we further exclude interactions not relevant to cell motility,
while expressing other cytoplasmic and nuclear gene connections possible in the network. This operation
produced an enriched novel predictive network of interacting signaling pathways that expanded the data
set for retino-neural motility genes to N=51. The expanded network, depicted in Figure 2.3, annotated
molecular interactions pertaining to microtubule dynamics, cell proliferation and migration. Dominant
interdependent biochemical signaling identifies the extracellular protein Reelin (RELN) regulation of
Disabled-1 (DAB1) via the low density lipoprotein receptor-related protein 8 (LRP8) [49] and the mitogen-
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activated protein kinase (MAPK) pathway activated by insulin-like growth factor 1 (IGF1), fibroblast
growth factor 1 (FGF1), and vascular endothelial growth factor A (VEGFA). These signaling processes
are critical for directing the migration of cortical neurons and microtubule function for neuronal lamination
during brain development [50]. Additionally, the extensive overlapping connectivity between molecules
depicted in Figure 2.3 as well as the numerous indirect relationships suggests that in a similar manner to
the brain, signaling processes mediating progenitor migration in the retinal microenvironment is highly
regulated via second messenger pathways.

Following the enrichment network analysis, ligands that may serve as targets for retinal progenitor cell
migration studies included the extracellular cytokine reelin (RELN) which is active in neuronal migration
[51, 52], brain derived neurotrophic factor (BDNF) active in axonal guidance [53], fibroblast growth factor
(FGF) and plasminogen activator (PLAT), both expressed during survival, proliferation and migration [24,
54], and insulin-like growth factor (IGF-1). Cell-surface receptors predicted to be involved in directional
migration include ionotropic glutamate (NMDA-GRIN, NMDA-Ca2+), ephrin (Eph), FGF receptor and
CXC-motif chemokine receptor type 4 (CXCR4) [55]. For clarity, candidate molecules identified in the
enrichment model are presented as matching ligand-receptor pairs and non-matched ligands and
receptors in Table 2.3. Priority is given to the matched pairs, as the likelihood of a biochemical interaction
is more likely if the cognate ligand or receptor are present in the molecular milieu. Priority is also given to
ligand and/or receptors present specifically in mammalian retinal tissue. The matched pair NeuregulinErbB receptor signaling has previously been described in the nervous system to stimulate cerebellar
granular cell migration along radial glial fibers during development [327] and isoforms of the ligand act as
short and long range chemoattractants, providing directional guidance to GABAergic interneurons
migrating from the subpallium to the developing cortex of mice [328]. In developing rat retina, the
expression of Neuregulin and an ErbB isoform have also been postulated to regulate retinal ganglion cell
dendrite growth that actuates their migration to the RGC layer from the ventricular surface, and the
consequent formation of synaptic connections with amacrine cells [329]. Upregulation of chemokine type
4 (CXCR4) and its ligand CXCL12 in the inner limiting membrane of the developing human fetal retina
have been associated with the differentiation of angioblasts and their migration to sites of vessel
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assembly [330]. Target chemotactic interactions resolved from this enrichment analysis were proposed to
typically govern retinal progenitor cell migration.

Figure 2.3: Enrichment Analysis of IPA-predicted retinal chemotactic molecules and signaling pathways Predictive network pathway from Figure 2.2 was further enriched to include second-messenger signaling upstream
and downstream the network eligible (NE) genes for a comprehensive account of all possible chemotactic retinoneural interactions. Both direct and indirect genetic connectivity are depicted categorized by their subcellular
localization in the cell. Some discernable signaling pathways for RPC motility in the network include Reelin
signaling which targets DAB1; the MAPK pathway that is activated by IGF1, FGF1 and VEGFA; and ApoE binding
to LRP8.
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Description
chemokine (C-X-C motif) ligand 12

Receptor
CXCR4

Description
chemokine receptor type 4

FGF1
FGF2
RELN
EFNB1

fibroblast growth factor 1 (acidic)
Fibroblast Growth factor 2
reelin
ephrin-B1

FGFR1
FGFR1
LRP8
EPHB2

NRG1

neuregulin 1

ERBB4

fibroblast growth factor receptor 1
fibroblast growth factor receptor 1
apolipoprotein e receptor
EPH receptor B2
Erythroblastic leukamia viral
oncogene homolog 4

SEMA3C

sema domain, (semaphorin) 3C

EPHB2

SLIT1

slit homolog 1 (Drosophila)

GRIN1

SLIT2

slit homolog 2 (Drosophila)

GRIN2A

VEGFA

vascular endothelial growth factor A

GRIN2B

PLAT

Plasminogen Activator, tissue

EFNB1

Ephrin-B1

CCL5
NRG1
APP
IGF1
BCAR1

Chemokine (C-C motif) ligand 5
neuregulin 1
Amyloid beta (A4) precursor protein
insulin-like growth factor 1
Breast cancer anti-estrogen resistant

Non-Matched

Matched

Ligand
CXCL12

GRIN2C

EPH receptor B2
Glutamate Receptor, Ionotropic, Nmethyl D-aspartate 1
Glutamate Receptor, Ionotropic, Nmethyl D-aspartate 2A
Glutamate Receptor, Ionotropic, Nmethyl D-aspartate 2B
Glutamate Receptor, Ionotropic, Nmethyl D-aspartate 2C

NTN1
Netrin 1
BDNF
Brain-derived neurotrophic factor
Table 2.3: Predicted Ligand-Receptor Interactions from Enrichment Network Analysis – Our predictive motility
network-signaling model was enriched by adding up- and downstream second-messenger molecular connectivity.
The new gene list was then used to create an enrichment model of RPC motility signaling networks (Figure 2.3) and
key matched and non-matched ligands and receptors are presented in this table. Selection priority is given to the
matched ligand-receptor pairs as they identify possible candidates for future invitro function validation tests for
motility. Some original seed input genes including RELN, NTN1 and SLIT recur in this list, also emphasize their
possible role in regulating RPC motility.

2.3.3:

Mining genomic annotations of photoreceptor precursors for potential chemotactic factors

The enrichment analysis performed above synthesizes networks of molecular connectivity from gene
annotations provided in the Ingenuity Pathway Analysis knowledgebase. Hierarchies of functional clusters
and tissue-specific gene groupings used in the analysis are generally compiled from results of peerreviewed investigations into specific biological phenomena. As the accuracy and inclusive nature of the
gene knowledgebase depends on the breadth and frequency of data curating process (usually quarterly),
it is possible that important cell-specific physiological information might be absent when the software
analytical tools are employed. For a comprehensive account of cell-specific signaling interactions
governing migratory processes observed in RPCs and PPCs, we employed a back-end approach by
mining relevant source genomic databases publicly available and using IPA bioinformatics. RPC and PPC

61

migration has previously been associated with laminar positioning during retinal development, is guided
by intracellular and local environmental cues, and likely involves a complex transcriptional regulatory
cascade [256, 295]. We thus explored the following microarray datasets of mouse rod and cone PPCs
available in the Gene Omnibus (GEO) database [331], obtained around peak periods of rod genesis
(post-natal day 4) [332] and cone genesis (embryonic day 17.5) [333] - 1) P4 mouse Rho-EGFP rod
progenitors (GEO Accession GSE29318) [332]; 2) E17.5 mouse Bac‐Crx‐EGFP cone progenitors (GEO
Accession GSE25607) [333]. These ontogenetic stages also coincide with active migration periods of
PPCs to their laminar loci, prior to onset of terminal cell type differentiation processes [256, 263]. Tissuespecific genetic data have previously been used in a similar way to formulate statistically significant
predictions of molecular connectivity in chemotactic pathways of migrating adult neural progenitors in the
sub-ventricular zone (SVZ) and cortex [245, 252] and in angiogenetic processes of migratory retinal
endothelial tip cells [253].

After uploading each microarray data set into IPA, rod and cone genes were mapped to their
corresponding identifier in IPA’s knowledgebase and resolved as cone (n=20,200) and rod (19,206)
network eligible (NE) molecules. The NE data sets was then biased towards their occurrence in
mammalian retinal and nervous tissue and overlaid onto the IPA global molecular interactions platform.
Gene networks were algorithmically generated based on connectivity in the tissues specified. Analysis of
the networks using the right-tailed Fisher’s exact test identified biological functions most significantly
correlated to the molecules in the network and p-values determined the probability that each biological
function assigned to that network was due to chance alone. The top associated network functions
identified in both data sets included tissue morphology, cellular movement, cell-to-cell signaling,
embryonic and nervous system development. Network molecules associated with the cellular movement
function (3.79E-02<p>7.96E-03) were then used to design predictive pathways of rod and cone PPC
migration (Figures 2.4 and 2.5 respectively). The pathway from the rods data set overlapped with axon
guidance and G-protein coupled receptor (GPCR) signaling canonical pathways, while cytokine-based
acute phase response signaling, Neuregulin, GPCR and IL-6 signaling were identified for cone genes. As
neural cell responses to extracellular motogenic cues involve ligand-receptor interactions [245],
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extracellular and plasma membrane-bound molecules common to both the rod (N=79) and cone (N=132)
signaling pathways were merged and receptor-ligand relationships appropriately matched. A sample of
the results set is presented in Table 2.4. The table depicts some members of the chemokine receptor
family that bind C-C or CXC motif ligands, of which up-regulation of chemokine type 4 (CXCR4) in the
inner limiting membrane of the developing human fetal retina has been associated with the differentiation
of angioblasts and their migration to sites of vessel assembly [330]. The epidermal growth factor (EGF)
family of ligands that include ampiregullin, EGF, TGF-alpha, heparin-binding EGF (HB-EGF), betacellulin
and epiregulin is also well represented and their migratory role in nervous systems has been well studied
[334]. The representation of the matrixin family members, collagenase MMP-8 and stromelysin MMP-3,
and their suppressants, tissue inhibitors of MMPs (TIMP) suggests active regulation of progenitor
development, ECM degradation and retinal tissue remodeling processes [335]. Elevated matrix
metalloproteinase (MMP) expression has also been reported to induce an environment permissive for
migration and integration of photoreceptor progenitors and decreased deposition of inhibitory ECM
molecules [336, 337]. Following the data mining protocol employed, four signaling pathways were
eminent – Neuregulin-ErBB receptor signaling, Chemokine (C-C or CXC) signaling, Epidermal Growth
Factor Receptor (EGFR) signaling, and Matrixin (MMP) regulatory signaling. To further our investigations
we performed in vitro validation of the chemotactic effect of a member of the EGFR signaling family –
EGF - on RPCs as described in Chapter 4.
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Figure 2.4: Predicted molecular interactions governing the migration of Rod Photoreceptor
Progenitors - Using IPA core analysis tool, rod gene microarray data was specified for their expression
in mammalian retino-neural tissue and statistically mapped to the cellular movement functional cluster
(p=7.96E-03). Results depict only direct molecular interactions with specified sub-cellular locations (ECM,
Plasma membrane, Cytoplasm and Nucleus) of the genes, overlaid with cell chemotaxis and homing
function identifiers Top resolved pathways include G-Protein coupled receptor signaling, Axon guidance
and Neuregulin signaling pathways.
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Figure 2.5: Predicted molecular interactions governing the migration of Cone Photoreceptor
Progenitors - Using IPA core analysis tool, cone gene microarray data was specified for their expression
in mammalian retino-neural tissue and statistically mapped to the cellular movement functional cluster
(p=3.79E-02). Results depict only direct molecular interactions with specified sub-cellular location (ECM,
Plasma membrane, Cytoplasm and Nucleus) of the genes, overlaid with cell chemotaxis and homing
function identifiers. Top resolved signaling pathways include Neuregulin and Epidermal growth factor
signaling pathways, and cytokine-mediated acute phase response signaling.
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Resolved Interacting Cognate Molecules
Ligands
Symbol
AREG/A
REGB
EGF
BTC

Nomenclature

Receptor/Co-Factor
Symbol

Nomenclature

EGFR

epidermal growth factor
receptor

ERBB4

v-erb-a erythroblastic
leukemia viral oncogene
homolog 4 (avian)

amphiregulin
epidermal growth factor

TGFA

betacellulin
v-erb-b2 erythroblastic leukemia viral
oncogene homolog 2,
transforming growth factor, alpha

NRG1

neuregulin 1

EREG

epiregulin

HBEGF

heparin-binding EGF-like growth factor

NRG1

neuregulin 1

ERBB3

CCL1

chemokine (C-C motif) ligand 1

CCR8

CCL2

chemokine (C-C motif) ligand 2

CCL17

chemokine (C-C motif) ligand 17

CCL22

chemokine (C-C motif) ligand 22

Ccl9
CCL3L1/
CCL3L3

chemokine (C-C motif) ligand 9

ERBB2

v-erb-b2 erythroblastic
leukemia viral oncogene
homolog 3 (avian)
chemokine (C-C motif)
receptor 8

CCR4

chemokine (C-C motif)
receptor 4

CCR1

chemokine (C-C motif)
receptor 1

CCR6

chemokine (C-C motif)
receptor 6

CCR3

chemokine (C-C motif)
receptor 3

chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating activity,
alpha)
chemokine (C-X-C motif) ligand 2
chemokine (C-X-C motif) ligand 6
(granulocyte chemotactic protein 2)

CXCR2

chemokine (C-X-C motif)
receptor 2

CXCL16

chemokine (C-X-C motif) ligand 16

CXCR6

chemokine (C-X-C motif)
receptor 6

IFNA16
IFNA1/IF
NA13
IL6

interferon, alpha 16
IFNAR1

interferon (alpha, beta
and omega) receptor 1

interleukin 6 (interferon, beta 2)

IL11

interleukin 11

OSM

oncostatin M

IL1A

interleukin 1, alpha

IL1B

IL1R1

LEP

interleukin 1, beta
single immunoglobulin and toll-interleukin 1
receptor (TIR) domain
leptin

NPY

neuropeptide Y

NPY5R

chemokine (C-C motif) ligand 3-like 1

CCL20

chemokine (C-C motif) ligand 20

CCL24
CCL3L1/
CCL3L3

chemokine (C-C motif) ligand 24

CXCL1
CXCL2
CXCL6

SIGIRR

chemokine (C-C motif) ligand 3-like 1

interferon, alpha 1

IL6R
IL6ST

LEPR

interleukin 6 receptor
interleukin 6 signal
transducer (gp130,
oncostatin M receptor)
interleukin 1 receptor,
type I
leptin receptor
neuropeptide Y receptor
Y5
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protein C receptor,
endothelial
serpin peptidase
PROC
inhibitor, clade E (nexin,
SERPINE
protein C (inactivator of coagulation factors Va and
plasminogen activator
1
VIIIa)
inhibitor type 1), member
1
THBD
thrombomodulin
tumor necrosis factor
TNFRSF
receptor superfamily,
RIPK1
1A
member 1A
receptor (TNFRSF)-interacting serine-threonine kinase
1
epidermal growth factor
EGFR
receptor
matrix metallopeptidase
MMP3
3 (stromelysin 1,
progelatinase)
TIMP1
TIMP metallopeptidase inhibitor 1
matrix metallopeptidase
MMP8
8 (neutrophil
collagenase)
matrix metallopeptidase
TIMP3
TIMP metallopeptidase inhibitor 3
MMP3
3 (stromelysin 1,
progelatinase)
Table 2.4: Matched Interacting Molecular Partners Common to both Rod and Cone Microarray
Data – Following network pathway designs of rod and cone gene microarray data relevant to cellular
movement function in mammalian retino-neural systems, extracellular and plasma membrane-bound
molecules common to both the rod (N=79) and cone (N=132) pathway designs were merged and
receptor-ligand relationships appropriately matched. A sample set of the results is presented in the
table, revealing four major signaling families – Epidermal Growth Factor (EGFR) signaling, Matrix
Metalloproteinase (MMP) regulation, Chemokine (C-C or CXC) signaling, and Neuregulin-ErBB
receptor signaling. The results culminate data mining efforts of relevant ontogenetic retinal tissue data
and formed the basis for selecting the initial chemotactic factors validated for their effect on retinal
progenitor cell motility using chemotactic assays.
PROCR

2.3.4:

Genomic analysis of microarray data typifying photoreceptor transplantation into damaged retinal

tissue
To characterize chemotactic cues released by damaged retina that may stimulate increased migration of
sub-retinally transplanted RPCs and PPCs as has been observed in recent studies [43, 165, 167, 172,
173], we initially proposed a comprehensive genomic and biochemical analysis strategy where a laser
microdissection procedure would be used to isolate the major retinal laminar layers so that differential
extracellular and intracellular molecular expression states of the various layers can be ascertained using
high throughput technologies as HPLC-MS, Gene-Chip microarray and RT-qPCR methods. Comparison
of molecules identified in the different lamina layers will be especially important in identifying the potential
homing cues for PPCs.
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However, we realized that our investigative goals could be achieved using efficient computational
techniques that can model the transplantation paradigms being studied. Using organism and tissuespecific ontogenetically defined microarray gene expression data available in the publicly accessed
databases with appropriate MIAME annotation, we could perform in-silico modeling of PPC
transplantation into damaged mammalian retinal tissue and obtain the desired genetic and biochemical
data. In addition to annotating genes in software-knowledgebase platforms, we can refine the data mining
protocol previously employed in section 2.3.3 by also taking into account the current relative expression
state of the respective genes when predicting their influence on PPC migration. An increasing number of
studies are utilizing bioinformatics platforms, their knowledgebase and analytical tools in a analogous
manner to understand cell and tissue specific signaling interactions [6, 338, 339], and many research
groups have similarly identified the efficacy of this non-invasive, cost-effective strategy, combining it with
traditional wet lab methods for gene function discovery [6, 23]. We took advantage of the comprehensive,
curated knowledgebase of literature findings from genomic and molecular research investigations,
available in IPA, to reveal chemotactic signaling between damaged retina ECM molecules and cell
surface PPCs receptors.

2.3.4.1: Rationale for Selecting Retinal Microarray Data
The feasibility of cell replacement as a therapeutic remedy for vision loss lies mostly in the ability of subretinally transplanted cells to move from the interphotoreceptor matrix (IPM) to the adjacent outer nuclear
layer and integrate in proportions large enough to affect/reverse the vision phenotype in an appropriate
damaged host retina [146, 148, 162]. Post-mitotic PPCs have been found to be the ideal donor cells but
sourcing them from second-trimester human fetuses, which are limited in supply, are faced with ethical
constraints [83, 162]. Even when other replacement cell sources are used, ES/iPS cell-derived PPCs still
migrate in low numbers in recipient retina [49, 95] similar to results found in studies using other
mammalian photoreceptor progenitor cells [48, 146, 162]. Additionally, of the populations that
successfully migrate into the host retina in these studies, only a small percentage (≤3%) have been
shown to integrate in the appropriate retino-neural laminar loci or express ontogenetic photoreceptor
morphology or markers [16, 17, 112, 148, 162, 165, 166]. Normal and diseased retinal extracellular
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microenvironments and retinal pigment epithelia compound glycoprotein moieties and secrete diffusible
chemicals that orchestrate intrinsic decision-making of transplanted cells [145, 167, 168], evidenced by
increased donor cell integration after genetic manipulation of the chemical architecture of the retina [165,
169]. To advance photoreceptor cell replacement strategies, it is essential that the biochemical cross talk
between specified cell grafts and host retina is better understood.

We reasoned that comparing existing time-defined molecular expression data of PPCs with gene
expression data of recipient adult damaged retinal model would begin to describe the biochemical
interactions and gene expression patterns in stasis at onset of transplantation. Our goal was to delineate
libraries of motogenic extracellular cues that directly target receptors expressed on PPCs and cause
downstream signaling and motility. For this purpose, we resolved only the plasma membrane receptor
expression profiles of the previously employed publicly available rod and cone PPC gene microarray
datasets in the Gene Omnibus (GEO) database [331] - P4 mouse Rho-EGFP rod PPCs (GEO Accession
GSE29318) [332] and E17.5 mouse Bac‐Crx‐EGFP cone PPCs (GEO Accession GSE25607) [333] using
the Ingenuity Pathway Analysis (IPA) software tool. We then matched the datasets with extracellular
matrix ligands released from a 10-week old light-damaged mouse neurosensory retina and retinal
pigment epithelia (GEO Accession GSM928109) [340].. The rod and cone PPC ontogenetic stages
coincide with active migration periods and laminar positioning during embryonic and postnatal
development [256, 263] The damaged retinal model is an established retinal degenerative model inducing
retinal oxidative stress [340].

2.3.4.2: Pre-processing of retinal microarray data
MIAME report for independent microarray datasets of rod PPCs (A), cone PPCs (B) and light-damaged
retinal tissue (C) indicated that cDNA from each cell or tissue type was hybridized on Affymetrix Mouse
Genome 430 2.0 array for (A) and Mouse 1.0 ST arrays for (B) and (C) datasets respectively in triplicates
per experimental condition for 16hrs at 45°C. Signal intensities of all replicates were quantile-normalized
using the RMA normalization algorithm filtered via the respective established threshold intensities per
experimental study. Replicate intensity values were then log2 transformed where appropriate, and a
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significance test for change in average intensities of positive versus negative FAC/MAC-sorted triplicate
gene transcripts was calculated using a two-tailed two-sample t-test with unequal variances sampled from
the same population of genes in excel spreadsheets. Transcript data was then input into the IPA
bioinformatics software program that annotates and automates the computation of fold change values.
Genes identified as having at least a two-fold change between experimental and control conditions and
whose significance test of change falls below the p-value threshold of 0.05 annotate gene products that
may affect various cellular processes, with the level of expression informing statistical predictions of cell
phenotypes.

To specifically examine the expression profile of the rod and cone PPC gene transcripts, volcano plots of
the negative logarithm of the p-value of each IPA-annotated gene transcript (Y-axis) versus a logarithmic
function to the base 2 of their respective fold change (X-axis) was performed (Figure 2.6). Approximately
26.82% of rod PPC gene transcripts exhibited statistically significant difference between negative and
positive-sorted genes less than the value of 0.05 and only 0.8% of the genes expressed more than twofold up- or downregulated states. 10.3% of cone genes expressed significant p<0.05 with about 2.27%
exhibited greater than two-fold change in expression states. Genes with high statistical significance and
large magnitude fold change criterion depict dynamic expression states that play major roles in PPC
function, and they are categorized by their subcellular localization in the extracellular matrix (ECM),
plasma membrane, cytoplasm or nucleus. Figures 2.6A and 2.6B display the rod and cone PPC gene
data sets respectively, with selected high profile criterion genes identified by numbered red circles in their
dispersed spatial locations. In the rod PPC gene data (N=38626), elevated nuclear Pax7 expression
(Circle 1; X=2.05, Y=4.7) could label the multipotent organogenesis stem cell state as with most other
Pax proteins [341] and Pax7 has been identified as one of the first cohort of transcription factors to
specify the neural plate border and initiate the expression of secondary factors as Sox9/10, FoxD3, and cMyc that specify the neural crest [341-343]. Other early developmental rod PPC genes fitting the high
expression profile criterion were identified and include the leucine-rich repeat containing 4C membrane
protein (LRRC4C) binding partner specific for Netrin G1, identified as an axon guidance-signaling
molecule that guides outgrowth of developing mouse thalamo-cortical axons to their striatum and cerebral
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cortex destinations [344], and is up-regulated in mouse retinal neovascularization models and myopia age
of onset [345, 346]. Membrane-Associated Ring Finger (C3HC4) 1, E3 Ubiquitin Protein (MARCH 1)
MARCH proteins adds ubiquitin to target lysines in substrate proteins signaling their vesicular transport
towards endosomal/lysosomal degradation and may explain photoreceptor degeneration process is
associated with the remodeling of the inner retina, at the state the cDNA lysates were prepared [60]. The
down-regulated state of another early neuronal progenitor marker lysophosphatidic acid (LPA) receptor 4
type I (LPAR4) (Circle 3; X=-1.1, Y=5.4), the ubiquitously expressed rhodopsin-like G protein–coupled
receptor (GPCRs), might identify active regulatory signaling for embryonic stem cell proliferation,
differentiation and motility as previously described for neuroblasts, fibroblasts and cancer cells [347, 348].
Ultimate validation of the rod progenitor cell state specification of our data set is by upregulated
Rhodopsin (Rho) expression (Circle 2; X= 1.62, Y=4.04) subsequent to the peak of rod genesis and
required for photoreceptor cell viability after birth and image-forming vision at low light [60, 61]. In
combination, these gene expression states describe shifts from multi-potency towards rod PPC fate and
peak genesis.
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Figure 2.6: Volcano plots of rod and cone PPC gene expression profiles – Genes with high statistical
significance (Y-axis) and large magnitude fold change values (X-axis) are of interest and their dynamic expression
indicate the important role they play in photoreceptor precursor cell fate and function. A few of these genes have
been identified (red circles) in our cDNA microarray datasets of P4 mouse Rho-EGFP rod progenitors (N=38626)
(GSE29318) (A) and E17.5 mouse Bac-Crx-EGFP cone progenitors (N=20744) (GSE25607) (B). 1) Nuclear gene
PAX7, plasma membrane proteins rhodopsin (Rho) (2) and rho-like G-protein coupled receptor LPAR4 (3) illuminate
shift in genetic specification from multi-potency towards photoreceptor cell fate specification and peak of rod
genesis. A similar maturation and differentiation profile in the cone gene array show relative high transcript levels of
semaphorin co-receptor PLXNA2 (5) suggesting premature retinal lamination and axon guidance processes while
the significantly up-regulated state of transcriptional activator NeuroD4 (6) validates the ontogenetic overlap
between cone genesis and onset of amacrine cell fate specification (E17.5) in our cone microarray dataset. Gene
array displays are categorized by subcellular location. Red dashed line indicates the p-value cut-off (0.05).
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A similar differentiation profile exists in the cone PPC gene array (N=20744) (Figure 2.6B) annotated by
IPA which exhibited high transcript levels of plexin co-receptor PLXNA2 (Circle 5; X=1.16, Y=3.77) which
is involved in the proper lamination of the inner plexiform layer (IPL), remodeling of the cytoskeleton, and
axon guidance by affecting binding affinity of semaphorins 3/6 to their receptors [61, 349]. Other global
expression studies report insignificant expression levels for PLXNA2 during mouse embryogenesis [350].
The significantly up-regulated state of the transcriptional activator NeuroD4 (Circle 6; X=2.61, Y=3.20)
required for the regulation of amacrine cell fate specification in the retina [351, 352] validates the timespecified ontogenetic overlap between cone and amacrine cell genesis (E17.5) in our cone PPC dataset.

2.3.4.3: Analysis of Microarray Data
A flowchart of our step-wise bioinformatics analysis, beginning with microarray data, is provided in Figure
2.7. Gene transcripts from rod PPCs (N=38626) and cone PPCs (N=20744) annotated in the IPA
knowledgebase were defined as mapped IDs, also termed network eligible (NE) molecules. NE molecules
were similarly resolved from transcript IDs of neurosensory retina (NSR) and retinal pigment epithelium
(RPE) of light damaged adult retina (N=23176). Following the subcellular localization of NE molecules to
their ECM, plasma membrane, cytoplasmic or nuclear loci, and a statistical cut-off for genes whose
resolved mean intensity values are significantly greater than their negative FAC-sorted analogue by a ttest p-value of 0.05, NE extracellular matrix (ECM) molecules resolved from the damaged retina NSR and
RPE dataset were then matched with NE plasma membrane receptors from the rod and cone PPC
dataset. Matched pairs included – 1) rod receptor genes matched with ECM genes from NSR (N=2013),
2) rod receptor genes matched with ECM genes from RPE (N=1945), 3) cone receptor genes matched
with ECM genes from NSR (N=735), and 4) cone receptor genes matched with ECM genes from RPE
(N=667). These matched pairings predict biochemical interactions between receptors on transplantable
rod and cone PPCs and ECM ligands present in light damaged neurosensory (NSR) and retinal pigment
epithelium (RPE).
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Figure 2.7: Flow Chart of Bioinformatics Analysis Method for Selected Microarray Datasets.
Figure description is on the next page.	
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Figure 2.7: Flow Chart of Bioinformatics Analysis Method for Selected Microarray Datasets - Schematic of work flow for
selecting genes predicted to be significantly involved in the migration of sub-retinally transplanted photoreceptor precursors in a
light-damaged model of adult retina. Normalized log transformed replicate intensity values of FAC-sorted genes were assessed
for significant difference in their expression states (p<0.05), and ratios of positive/negative intensity values of the significantly
expressed genes were then uploaded to ingenuity pathway analysis (IPA) software platform as fold change values. These
selected genes were then paired to mimic typical sub-retinal transplantation paradigms – Cone/Rod receptor paired with
released extracellular matrix molecules from light-damaged retinal tissues. A core analysis of each paired dataset mapped
constituent genes to their functional annotation in the IPA knowledgebase based on chance alone using a Fisher Exact test,
and genes involved in cellular movement were selectively used to design network pathways that account for the expression
profiles of the interacting genes and their effects on cellular movement function. Ligands predicted to activate or inhibit their
downstream cognate receptors, or whose downstream effect is inconsistent with literature findings in the IPA knowledgebase at
the current expression state, were selected and the involvement of the ligand and receptor genes in the top ten cellular
movement subcategories assessed. This analysis was used to determine candidate chemotactic ligand-receptor pairs for invitro
functional assays validating their influence on cell motility. Signaling cascades downstream candidate receptors were also
resolved using similar criteria to obtain a custom network model of statistically predicted interactions active following
transplantation of freshly isolated photoreceptor precursors into light-damaged retina.

	
  
After IPA core analysis of the four matched data sets, molecules in each dataset mapping to cellular
movement functional clusters were used to design signaling networks specifying direct ligand effects on
their paired receptor while also considering expression levels to predict downstream activating or
inhibitory effects, or an effect inconsistent with the gene interaction curated in the IPA knowledgebase
based on the state of the downstream gene in the matching gene pairs. In performing the core analysis
function on our matched datasets, the IPA network algorithm uses gene identifiers in our data to build
small networks based on their interconnectivity with molecules they connect to in the IPA knowledgebase.
A right-tailed Fisher exact test (p<0.05) is then used to calculate the probabilistic fit between the networks
and lists of biologic functions and canonical signaling pathways curated in the IPA knowledgebase,
assigning scores to networks based on the probability of associating network molecules to gene
annotations in the IPA by random chance only [83]. Canonical growth factor and cytokine signaling
pathways that significantly overlap with our matched datasets were selectively resolved given the
notoriety of these signaling-type paradigms in cell motility processes [231, 236, 272, 297, 353]. A Z-score
algorithm was then used to predict activation or inhibition of each resolved canonical signaling pathway
given the expression state of our matched dataset genes. Pathway computation takes into account both
the activation state of key molecules in our dataset when the signaling pathway is activated and the
molecules’ causal relationships with each other based on literature findings, to predict an activity pattern
for our dataset genes. These Z-score calculations are independent of p-values associated with the
canonical pathways resolved for our data set, and conventionally, Z-scores greater or less than ±2.0
indicate predictable canonical pathway activity with highest statistical confidence. As our objective was to
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define motility-deterministic cues in the ECM of recipient retina and their target receptors on PPCs,
molecules correlating to cellular movement in each data set were selected for two post-analysis
processing steps. Firstly, a connect function was used to establish direct ECM ligand binding to plasma
membrane receptors in custom motility-deterministic networks for PPC motility genes. Secondly, a
Molecule Activity Prediction (MAP) function was used to overlay individual gene expression states to
predict gene activation state-dependent motility-deterministic interactions existent upon PPCs receptors
binding NSR and RPE ligands in light-damaged retina. The molecular activity predictor algorithm uses
node genes in our dataset whose interactions are known to predict the activity of neighboring unknown
genes given their expression states, and Z-scores the prediction as a measure of statistical confidence.

To rank the degree to which each resolved directly interacting ligand-receptor pair influences cellular
movement and thus prioritize candidate ligand-receptor pairs for motility validation assays, a subsequent
MAP analysis was performed using a ‘Grow’ function tool in IPA to statistically define single gene
expression state effects on the top 10 relevant sub-types of cell motility phenomena (varied across the 4
custom networks), predicting an activation or inhibition in sub-type function. By specifying only
downstream ligand effects on scored receptor genes, we relate gene expression states to cell movement
function, determining the likelihood that a ligand/receptor interaction will activate or inhibit a chosen
cellular function. In the determination of candidate chemotactic interactions, precedence was given to the
ratio of the total number of cellular movement sub-types related to each gene in the motility network
pathways and associated with cellular movement sub-types. The top 10 relevant cellular movement subtypes were ranked by p-value calculating the probability of involvement of the cell movement sub-type
relative to gene expression states within our custom networks. Using this method, ligand-receptor
pairings in which either the ligand or receptor showed at least 80% involvement in the top 10 cellular
movement sub-types were selected for further analysis. Subsequently, an IPA Downstream Effects
analysis was performed via the ‘Grow’ function in IPA to determine nuclear and cytoplasmic molecules
related to our resolved ECM ligand and plasma membrane receptor pairs for each of the 4 datasets.
Downstream nuclear and cytoplasmic genes were selected based on a 2/4 ratio for their involvement in
the top 4 cellular movement sub-types ranked by p-value, similar to the criteria used for selecting
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candidate ligand-receptor pairs. Results of these bioinformatics analyses of microarray datasets are
presented in Chapter 5.
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CHAPTER 3: RECEPTOR EXPRESSION AND FUNCTIONAL ANALYSIS METHODS FOR RPC and
PPC MIGRATION

3.1:

EXPERIMENTAL VALIDATION OF IN SILICO PREDICTED CANDIDATE MOTOGENIC

INTERACTIONS IN RPCs and PPCs

3.1.1:

DESCRIPTION OF ANIMAL CARE METHODS EMPLOYED

All animal procedures were performed in compliance with the Association for Research in Vision and
Ophthalmology (ARVO) statement for the use of animals in ophthalmic and vision research, and the City
University of New York, Lehman College Animal Care and Use Committee (IACUC). PPCs used in
experiments were obtained from B6.SJL-Tg (Crx-GFP-ALPP)1Clc/J (Stock No.007066) post-natal day 0-5
transgenic mice (The Jackson Laboratory, Bar Harbor, Maine) which express GFP gene ubiquitously by
the cone-rod homeobox (Crx) promoter and maintained on a C57BL/6J background (Stock No.000664).
The day the vaginal plug was found was considered as embryonic day 0 (E0); and the day of birth, as
postnatal day 0 (P0).
Enucleation of Mouse Eyes
+/+

(P0-P5) Crx/GFP new born pups were sacrificed by immersion in ice. After decapitation, a longitudinal
cut beginning at the nostrils is made superiorly along the axis of the nasal palate until the frontal lobe.
Superficial cranial cuticle is laterally peeled to expose globes connected to the orbit/eye socket via the
optic nerve. Forceps are then used to enucleate eyeballs by severing the optic nerves.

3.1.2:

RETINA AND PPC ISOLATION AND CULTURE METHODS

3.1.2.1: Preparing Retinal Tissue Slices
To obtain retinal slices for immunohistochemical studies, enucleated eyes are immediately fixed in 4%
para-formaldehyde in phosphate buffered saline (PBS). Eyes are subsequently incubated in 400 mL of
10% sucrose overnight and 30% sucrose overnight successively at 4°C. Eyes are then mounted in OCT
embedding compound (TissueTek, Fisher Scientific, PA), and frozen at -20 to -80 °C. Cryosections (5-8
µm thick) are then obtained on a cryostat Microm HM500 (MICROM International, Germany) and thaw-
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mounted onto positively charged 0.5% gelatin-coated colorfrost Plus histological slides (Thermoscientific,
Rochester NY) that enhance adhesion of the tissue sections. Slides are then dried for 30mins at 37°C
and stored at -80°C for use in histologic staining protocols.

3.1.2.2: Retinal Tissue Extraction and Cell Dissociation
To obtain retinal cell suspensions, enucleated eyes were briefly submersed in 70% ethanol and then
suspended in cold Neurobasal medium (NB). An incision is made at the border between the cornea and
sclera and the neural retina is separated from the sclera, retinal pigment epithelium after the lens, optic
nerve, ciliary body, and iris are carefully removed with forceps. Detached retina tissue are warmed in a
water bath at 37 °C for 8 min and digested in pre-warmed (37 °C) trypsin (0.05%) (Sigma-Aldrich,
St.Louis, MO) in Hanks Balanced Salt Solution (HBSS) (Life Technologies, Grand Island, New York) for
20 min. Trypsinization was inhibited using FBS (20%) and DNase I (0.2%) in HBSS. Cells were
dissociated by gentle trituration in 1% BSA, 10 mM HEPES and 2 mM EDTA HBSS solution, de-clumped
by straining through a 40µm cell strainer and after a brief sedimentation period, the supernatant re2+

2+

suspended in Ca - and Mg -free HBSS and put on ice for the FACS-sorting protocol. This extraction and
dissociation procedure for photoreceptor precursor cells (PPCs) has previously been described [332, 354,
355].

3.1.2.3: Fluorescent Activated Cell Sorting (FACS)
To isolate the Crx-GFP expressing cells from dissociated retinal tissue, a FACS-sorting protocol was
carried out on a FACSAria II and FACS Diva ver 6.1.3 software (BD Biosciences). Dead cells and cell
debris are excluded from analysis by gating for a high level of GFP expression with forward scatter (FCS,
cell size) and side scatter (SSC, cell complexity) as indicators. Cell sorting into Crx.gfp-positive and
Crx.gfp-negative populations was done at a flow rate of 271 events/second and sheath pressure of 12 psi
6

through a 130µm nozzle tip, to yield a final concentration of ~2 x 10 cells/ml of sorted Crx.gfp-positive
cells. The FACS analysis protocol has previously been employed in a similar investigation [49]. The
FACS-sorted cells are counted using a trypan blue cell viability assay and used immediately for
experiments, representing our post-mitotic photoreceptor precursor cell (PPC) population. Figure 3.1A
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depicts freshly isolated PPCs imaged at 20x magnification showing intact cell body attached to an
elongated inner segment of immature rod photoreceptor by a thin outer process and lacks synaptic
extensions and outer segments.

B

A
Cell Body
Outer
Process

Inner
Segment

Figure 3.1: Experimental RPCs and PPCs – A) Freshly isolated post-mitotic P2 Crx-GFP+ PPCs imaged using wide
field fluorescence at 20x magnification. PPC morphology is compared to a mature rod photoreceptor model [1] and
reveals a thin outer segment connecting a cell body to a growing inner segment region. Development of synaptic
terminals and optically active outer segments occur with maturity and further terminal differentiation. B) P0-P3 ActinGFP+ RPCs are maintained in mitotic Neurobasal complete media with a passage cycle of 3-5 days. RPC culture
passage No. 12 was chemically fixed on a glass slide for imaging at 20x, showing characteristic neurite processes typical
of multipotent RPCs.

3.1.2.4: Retinal Progenitor Cell Culture
A second set of retinal progenitor cells (RPCs) isolated from P3-5 transgenic mice expressing green
fluorescent protein (GFP) on the actin promoter (actin-GFP) were received as a gift from the laboratory of
Dr. Michael Young at the Schepens Eye Research Institute (Massachusetts Eye and Ear, Boston, MA)
and maintained in mitotic Neurobasal (NB) complete culture medium containing 2% B-27, 1% Lglutamine, 1% penicillin–streptomycin, 1% N2 (50X), 2% Nystatin, and 93% NB only (Invitrogen-Gibco,
Rockville, MD) and 20ng/ml epidermal growth factor (Promega, Madison, Wisconsin) as previously
described [356]. These cells were passaged every three to five days incubated in 5% CO2 at 37C°, and
the number of live and dead cells are counted using the trypan blue assay (Sigma-Aldrich) at the onset of
every experimental procedure. These cells represented our retinal progenitor cell (RPC) population
(Figure 3.1B), ontogenetically distant from photoreceptor cell fate specification compared to PPCs, and
served as a comparative source of retinal stem cells throughout our studies.
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3.1.3:

Retinal Progenitor Cell Proliferation Assay

MTT cell proliferation assays (Vybrant MTT, Invitrogen, Grand Island, NY) were perfromed to examine
RPC growth in different chemotactic ligand concentrations for the same 24hr duration used in our cell
motility experiments. This assay was carried out to ensure that ligand concentration effects measured in
the course of our study were for motility only, distinguishable from cell proliferation. In n=6 wells per
condition, approximately 5000 RPCs per well were incubated in NB with 5% CO2 at 37°C overnight in
duplicate 96-well culture plates and in quadruplicate wells/plates. Media was then aspirated and replaced
with 100µl of NB media supplemented with: 0, 20, 40 and 400ng/ml epidermal growth factor (EGF)
concentrations. Wells were incubated for 24hrs, after which 10µl of 10% MTT reagent was added for 4hrs
followed by 100µl of MTT solubilization buffer overnight. Absorbance was measured at 575nm and
650nm using a Synergy Mx plate reader (BioTek Instruments Inc., Winooski, VT), and results plotted
against EGF concentrations after background correction. A standard curve was then used to correlate
absorbance units to cell number. The standard curve was created by plotting absorbance versus
increasing numbers of RPCs ranging from 1000 to 20000 cells/well obtained by serial dilution of NB
media containing a stock concentration of RPCs. A Dunnett statistical test was then used to assess
significant difference in RPC proliferation between control conditions and stimulant ligand concentrations.

3.2:

PROTEIN DETECTION METHODS

3.2.1:

IMMUNOCYTOCHEMICAL (ICC) ANALYSES OF CHEMOTACTIC RECEPTORS ON RPCs and

PPCs
Approximately 5µl of freshly dissociated FACS-sorted PPC suspension was smeared onto gelatin-coated
(0.5%, Sigma-Aldrich, St. Louis, MO) glass slides (n=6) and very briefly heat-fixed at 35 to 45°C. RPCs
from growing cultures were seeded onto n=6 laminin-coated (10µg/mL) coverslips (15mm (19/32”),
2

Thermoscientific, Rochester NY) at a density of 9,000 to 13,000 cells/cm in 6-well culture plates and
incubated overnight at 37°C for slide adherence. Some seeded RPCs were then pre-incubated in
100ng/ml stromal-derived factor (SDF-1α, Sigma-Aldrich, St. Louis, MO) or 20ng/ml epidermal growth
factor (EGF, Sigma-Aldrich, St. Louis, MO) overnight at 37°C/5% CO2 prior to chemical fixation. Adherent
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RPCs were chemically fixed for 10mins in 1% paraformaldehyde in PBS. Fixed PPCs and RPCs were
then rinsed twice with wash buffer (0.1% bovine serum albumin (BSA) in phosphate-buffered saline
(PBS)), and non-specific staining was blocked and cells permeabilized with 0.3% Triton® X-100 and 10%
normal donkey/goat serum (Sigma-Aldrich, St. Louis, MO) for 45 minutes at room temperature.

Cell staining procedures were modifications of previously described protocols [302, 357, 358]. Primary
antibodies were diluted in incubation buffer (1% BSA plus 1% normal donkey/rabbit serum plus 0.3%
Triton X-100 and 0.01% sodium azide in 1X PBS) and applied to fixed cells overnight at 4°C. Primary
antibodies used for RPC immunoblotting experiments include: mouse anti-total epidermal growth factor
receptor, (1:100, Sigma-Aldrich, St. Louis, MO) which binds both phosphorylated and non-phosphorylated
EGFR, and anti-phosphorylated epidermal growth factor receptor (1:100, Abcam, Cambridge, MA)
antibodies; Rat monoclonal anti-CXCR4 antibodies (1:50, R&D systems Mab21651, Minneapolis, MN)
were used to detect CXCR4 expression; Goat polyclonal anti-DCC (1:200, R&D Systems, Minneapolis,
MN), rabbit polyclonal anti-FGFR phosphospecific antibody (1:50, Invitrogen, Grand Island, NY), rat
monoclonal anti-GFRα-1 (1:100, R&D Systems, Minneapolis, MN), and rat monoclonal anti-ROBO1
(1:100, R&D Systems, Minneapolis, MN) antibodies were also used to detect innate expression of
receptors for Netrin-1, fibroblast growth factor-acidic (FGF-a), Glial-derived neurotrophic factor (GDNF)
and Slit homolog-1 ligands respectively. Rabbit polyclonal anti-CXCR4 antibody (1:500, Abcam Ab7199,
Cambridge, MA) was used to detect endogenous stromal derived factor-1α (SDF-1α) receptor expression
in PPCs. Rabbit anti-β-tubulin III (1:500, Sigma-Aldrich, St. Louis, MO) antibody was used as ICC positive
control for retinal stem cells. Coverslips incubated with only secondary antibody were used as negative
control. RPCs and PPCs were then washed three times (5 min each) with wash buffer and subsequently
incubated with the following secondary antibodies for 1hr at room temperature: anti-mouse TritCconjugated antibody (1:10000; R&D systems, Minneapolis, MN) for phospho- and total-EGFR detection in
RPCs; NL637 fluorochrome-conjugated goat-anti-rat (1:200; R&D systems, Minneapolis, MN) secondary
antibody for CXCR4 detection in RPCs. Dylight 594 goat-anti-rabbit secondary antibody (1:500; Jackson
ImmunoResearch, Westgrove, PA) was used for CXCR4 detection in PPCs and FGFR detection in RPCs,
and Dylight 594 goat-anti-rat antibody (1:500; Jackson ImmunoResearch, Westgrove, PA) was used to
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detect GFRα-1 and ROBO1 expression in RPCs. Dylight 594 rabbit anti-goat secondary antibodies
(1:500; Jackson ImmunoResearch, Westgrove, PA) stained DCC receptors in RPCs. After rinsing once
for 15 min and thrice for 5 min with wash buffer, cover slips were inverted onto glass slides coated with
DAPI-containing anti-fade mounting medium or TO-PRO-3 iodide in DMSO (for confocal microscopy) (Life
Technologies, Grand Island, NY). Stained nuclei, GFP

+

cell body and TritC-conjugated receptor

expression were then imaged on fluorescent and confocal microscopes. Fluorescence microscopy was
performed on an inverted fluorescent microscope (Nikon Eclipse Ti, Melville, NY) using a CFI60 Plan
Fluor 40× objective and 100× oil immersion lenses. EGFR immunostained slides were also viewed on a
confocal microscope (Leica TCS SP5). GFP-positive cells were located using epifluorescence illumination
before taking a series of XY optical sections, approximately 0.2 - 0.4 µm apart, throughout the depth of
the section. Individual XY scans are built into a stack to give an XY projection image. GFP+ fluorescence
and Dylight 594 secondary antibody were sequentially excited using the 488 nm line of an argon laser
and the 594 nm line of a HeNe laser, respectively. For CXCR4 detection, confocal images (LSM 510, Carl
Zeiss, Thornwood, NY) of stained SDF-treated and non-treated RPCs were also obtained in triplicates for
use in calculating net integrated density values of selected cell image views with Trit-C filter on an image
J platform after subtracting background mean gray values. In this procedure, pixel intensity and density
over the selected image area served as a semi-quantitative assessment of cell surface receptor
expression due to SDF-1α effects. A statistical comparison of mean integrated density values of the
selected images and background was then performed using a student’s T-test. Similar image quantitation
protocols have previously been described [359].

3.2.2:

WESTERN BLOT ANALYSES OF CHEMOTACTIC RECEPTORS
6

Ice cold lysis buffer (0.5ml per 5 X 10 cells) containing: 150mM NaCl, 1% Triton X-100, 50 mM Tris, pH
8.0, 1 mM phenylmethylsulfonyl fluoride (PMSF, Sigma-Aldrich, P7626), Halt Protease inhibitor Cocktail
(Pierce IL, 78425), and phosphatase inhibitor (Sigma-Aldrich, P5726), was added to PBS-rinsed RPC
cultures that had been pre-incubated overnight with varying concentrations of EGF (0, 20 and 40ng/ml)
and SDF (0 and 100ng/ml) concentrations, and to pellets of freshly dissociated PPCs. The cell mixture
was agitated for 30mins and then centrifuged at 12,000rpm for 20mins at 4°C. The resulting supernatant
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was used to determine protein concentration by the Bradford assay and subsequently, 25-40 µg of protein
was separated on 8% SDS-PAGE (Clear Page Gel, CBS Scientific, San Diego, CA) and then transferred
onto nitrocellulose membranes. Preliminary visualization of protein transfer to membrane is carried out
using Ponceau red staining (VWR, Bridgeport, NJ). Membranes containing RPC lysates then probed
overnight at 4°C with the following primary antibodies: monoclonal mouse anti-EGFR (1:1000, SigmaAldrich, St. Louis, MO) and anti-phospho-EGFR (1:200, Abcam, Cambridge, MA), rabbit polyclonal antiERK1/2 and anti-phospho-ERK1/2 (1:200, Santa Cruz Biotech., Dallas, TX), anti-PI3K (1:1000), rabbit
polyclonal anti-phospho-STAT3 (1:1000, Cell Signaling Technology, Danvers, MA), rabbit polyclonal antiSTAT3 (1:1000, Calbiochem, Darmstadt, Germany) and rabbit polyclonal anti-CXCR4 (1:1000,
SAB3500383 Sigma-Aldrich, St. Louis, MO) primary antibodies. PPC lysates were also probed overnight
at 4°C with monoclonal rat anti-CXCR4 (1:500, R&D systems, Minneapolis, MN). Rabbit polyclonal anti-βtubulin and heat shock protein HSP90 (1:1000, Cell Signaling Technology) were used as positive control
to correct for blotting efficiency and normalize results.

The corresponding secondary antibodies conjugated to horse-radish peroxidase (HRP) (1:1000, antirabbit IgG, anti-mouse IgG, Cell Signaling Technology, Danvers, MA) and polyclonal goat anti-rat
(1:1000, R&D systems, Minneapolis, MN) were bound to the nitrocellulose membranes for 1hr at room
temperature and X-ray detection was carried out after applying enhanced chemiluminescence substrate
mixture (ECL Plus; Pierce IL) to the membrane. Standard molecular weight markers (Bio-Rad
Laboratories, Hercules, CA) served to verify the molecular sizes for receptor detection.
Similar blotting protocols for detecting receptor proteins and intracellular signaling activity have previously
been described [360-362].

3.3:

FUNCTIONAL ANALYSES OF RPC and PPC CHEMOTAXIS

3.3.1:

MODIFIED BOYDEN CHAMBER TRANSWELL ASSAY

To assess the influence of chemical gradients on cell motility phenomena, Stephen Boyden in 1962
developed the Boyden chamber, which has since been modified to the transwell assay [363]. In the assay
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method, a chemoattractant solution is placed in the lower compartment of a culture well, wherein a
porous membrane bottom is seeded with cells and inserted in the lower compartment such that the
chemoattractant diffuses across the membrane into the upper chamber containing cells (Figure 3.2). The
resulting one-dimensional gradient induces cells seeded on the topside to migrate through the transmembrane holes to the lower compartment. Migrated cells are then fixed, stained and counted to quantify
the degree of chemotaxis induced by the gradient. The advantages of the Boyden Chamber/Transwell
Assay are that it is easy to perform, readily elicits chemotactic responses from cells, provides a
quantitative measure of the level of trans-membrane migration induced by chemotaxis, and 	
  

4

Figure 3.2: Transwell Assay – Approximately 5X10 RPC or PPCs (yellow)
suspended in a 350μl NB media solution are seeded in the upper compartment
separated from a lower compartment by an 8um pore size polyethylene
terephthalate (PET) microporous membrane insert. The porous membrane allows
upward diffusion of varying concentrations of chemotactic factors tested to the
upper compartment. The experimental set-up allows measurement of onedimensional mass transport of retinal stem cells in response to chemotactic factors.
Adapted from Corning Transwell Permeable Support and Use Guide. Available at:
http://www.corning.com/media/worldwide/cls/documents/CLS-CC010%20REV8%20DL%20(5).pdf. Accessed June 7, 2015 [11].

allows multiple assays to be run in parallel with a choice of testing varied chemotactic factors at a time,
thereby increasing the statistical strength of the observed findings [364].

3.3.1.1: Transwell Motility Assay For RPCs and PPCs
Initial screening for chemotactic response of RPCs and PPCs to uniform gradients of candidate
chemotactic factors was assessed using modifications to the Boyden chamber assay as previously
described [360, 363, 365-367] [368, 369]. Prior to transwell motility assays, diluted aliquots of all cell
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suspensions are subjected to a Trypan Blue (Sigma-Aldrich, St. Louis, MO) viability assay using a
Brightline hematocytometer cell counter (Hausser Scientific, Horsham, PA). Serum starved RPC cultures
and fresh PPC isolates were pelleted and re-suspended in neurobasal (NB) media (2% B-27, 1% Lglutamine, 1% Pen Strep, 1% N2 (50X), 2% Nystatin, and 93% NB only) supplemented with 10% fetal
4

bovine serum (FBS), at a seeding density of 5 X 10 viable cells/350µl volume, in the upper chamber of
non-coated polyethylene terephthalate (PET) membrane filters (8µm pore size, BD Falcon, NJ). These
filters insert into tissue culture wells (BD Falcon, NJ) containing 700µl volumes of NB media treated with
varying concentrations of chemotactic factors. Following incubation, the total number of cells migrating
through the micropores toward the lower well are quantified, compared to cell migration in control filters
exposed to NB media without chemotactic factors, and used as a measure of chemotaxis to candidate
chemotactic factors [363, 365, 366, 370].

The following growth factors were assessed for their chemotactic effects on RPCs. Tested concentrations
are expressed in parenthesis: Stromal derived factor-1 alpha (SDF-1α; 50, 100ng/ml; Sigma-Aldrich, St.
Louis, MO), CXCL3 (50, 100ng/ml; R&D systems, Minneapolis, MN), Tumor necrosis factor (TNF;
50,100ng/ml; R&D systems, Minneapolis, MN), Glial-derived neurotrophic factor (GDNF; 50,100ng/ml;
R&D systems, Minneapolis, MN), Epidermal growth factor (EGF; 20, 40, 400ng/ml), Glutamate (10, 50,
500µM; Sigma-Aldrich, St. Louis, MO), Gamma amino-butyric acid (GABA; 5, 10, 30µM), Netrin-1 (10, 50,
100, 200, 250ng/ml; R&D systems, Minneapolis, MN), Vascular endothelial growth factor (VEGF; 0.026,
1.026, 2.56nM; R&D systems, Minneapolis, MN), Hepatocyte growth factor (HGF; 1, 10, 100nM; R&D
systems, Minneapolis, MN), Fibroblast growth factor-acidic (FGF-acidic; 10, 40, 400, 1500ng/ml;
Invitrogen-Gibco, Rockville, MD), Transforming growth factor-alpha (TGF-α; 10, 50, 200nM; InvitrogenGibco, Rockville, MD), and Platelet-derived growth factor (PDGF-AA; 0.0001, 0.001, 0.01nM; SigmaAldrich, St. Louis, MO). Chemotactic assays for PPCs were carried out in a similar manner using the
following growth factors at the denoted concentrations: (SDF-1α; 50, 100ng/ml; Sigma-Aldrich, St. Louis,
MO), CXCL3 (50, 100ng/ml; R&D systems, Minneapolis, MN), Tumor necrosis factor (TNF; 50,100ng/ml;
R&D systems, Minneapolis, MN), Glial-derived neurotrophic factor (GDNF; 50,100ng/ml; R&D systems,
Minneapolis, MN), and Transforming growth factor-alpha (TGF-α; 50, 100ng/ml; Invitrogen-Gibco,
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Rockville, MD). Triplicate wells per treatment were incubated for 24hrs at 37°C/5% CO2. Filters were
thereafter fixed with 4% paraformaldehyde in PBS for 5 min and stained with DAPI or Hoechst 33342
nuclear stains for 10 min. Cells are scraped from the upper chamber, and the number of stained
transmigrated cells at the bottom surface of the filter were counted at five fields per filter for triplicate and
quadruplicate filters in two independent experiments using a CFI60 Plan Fluor 10× objective lens of an
inverted fluorescent microscope (Nikon Eclipse Ti, Melville, NY). Dunnett tests, ANOVA and pairwise
Tukey HSD statistics assessed significant mean differences (p<0.05) in the number of transmigrated cells
normalized to chemotaxis in control filters.

3.3.1.2: Optimizing in vitro RPC incubation for Motility Assays
Chemotaxis of RPCs to the various chemotactic factors is assessed over a 24hr in transwell experiments.
For RPCs that exhibit robust survivability in NB culture media conditions, it became imperative to
determine incubation times that support optimal ligand stimulation of the cells, given differing incubation
periods per ligand reported in retino-neural migration experiments [211, 365, 371-375]. These
optimization studies were performed in triplicates on different days using Epidermal Growth Factor (EGF)
at 40ng/ml concentration added to the lower chamber of transwell set-ups, stimulating RPCs incubated in
the upper chamber for time periods ranging from 6-48hrs. After the respective incubation time periods at
37°C/5% CO2, filters are fixed with 4% paraformaldehyde in PBS for 5 min and stained with DAPI or
Hoechst 33342 nuclear stains for 10 min. Cells are scraped from the upper chamber, and the number of
stained transmigrated cells at the bottom surface of the filter were counted at five fields per filter for
triplicate filters in two independent experiments per time duration using an inverted fluorescent
microscope. Dunnett tests are used to assess mean differences in RPC migration relative to control filters
placed in NB media without motogenic factors (p<0.05), while pairwise Tukey HSD statistics compared
migration rates across the different time periods for each chemotactic factor. in the number of
transmigrated cells normalized to chemotaxis in control filters.
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3.3.1.3: Method Improvement: Comparing Resolution Techniques For RPC Transmigration Through
Transwell Filters: Manual Microscopic Counts Vs. Fluorescence Analysis

Cell counting subsequent to chemotaxis through 8.0 µm pore filters, fixing, staining and removal of nonmigrated cells from the interior of upper chambers of transwell filters, was performed using two
comparative methods, Manual cell counting and fluorescence spectrophotometric analysis. Manual cell
counts was done by determining the number of GFP+ RPCs in five view fields per filter for triplicate filters
per condition using the 10x or 20x objective lenses in an inverted fluorescent microscope. Cell count
values are then extrapolated to actual cell numbers in the effective growth area of the filter membrane as
provided by the manufacturers. Resolved mean number of cells is then normalized to control filters across
conditions and normalized values used for further statistical analysis. The drawback of this method lies
mainly in human error during cell counting procedures. In a comparative method, we collaborated with the
Manfred Phillipp laboratory in the Chemistry Department of Herbert H. Lehman College to measure
fluorescence emission of GFP+ retinal cells as an index of transmigrated cells. In this protocol, a standard
curve was plotted using increasing numbers of GFP+ RPCs correlated to relative fluorescence units
(RFU) of detected emission spectra at 528nm after 485nm peak excitation using the high energy Xenon
flash of Synergy Mx multi-mode microplate reader (Biotek, Winooski, VT) and subtraction of background
fluorescence was firstly performed (Figure 3.3). In subsequent transwell assays, the number of migrated
cells was then determined by extrapolating RFU obtained per well to the resolved standard curve
equation (y = 0.0011x + 10.072; R² = 0.98256, (Figure 3.3). These cell numbers were then normalized
and used for further statistical analysis. After incubation periods allotted for cell transmigration in this
protocol, transwell filters are rinsed with 1X PBS and transferred to culture wells containing Hanks basedenzyme free cell dissociation media (Invitrogen-Gibco, Rockville, MD) where slow rotation for 30mins is
used to recoup transmigrated cells in the bottom surface of the filters, prior to fluorescence detection
analysis. This posed a limitation to this method as RPCs may be displaced during the washing step or not
accounted for during the dissociation step of the protocol. Manual counting protocols was thus adopted
for analyzing cell chemotaxis using Boyden Chamber assays.
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3.3.1.4: Transwell Motility Inhibition Studies
As the Boyden Chamber assay measures one dimensional mass movement of cells to ligand stimulants,
it is best suited to investigate RPC population responses to targeted antagonistic effects of inhibitors at
the receptor level and for intracellular cascade molecules. These inhibition studies are typically performed
to validate mitogen-induced signaling mechanisms under investigation, identify hub molecules in signaling
cascades, and functionally validate ligand-specific motility-deterministic pathways resolved in our
investigations [376-381]. RPCs are pre-incubated with an inhibitor for an amount of time and in
concentrations recommended by the drug manufacturer and concurred with times employed in peerreviewed publications reporting inhibition of retino-neural cells [382, 383]. The cells are then subjected to
Boyden Chamber assays using previously described protocols specific for the ligand being inhibited.
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Figure 3.3: GFP Fluorescence Standard Curve – Increasing populations of GFP+ retinal progenitor
cells (RPCs) were excited by a Synergy Mx microplate high energy laser at 485nm and subsequent
emission spectra was detected at 528nm wavelength and quantified in relative fluorescent units
(RFU) following subtraction of background fluorescence. The standard curve was then routinely used
to determine the number of migrated cells in transwell assays by measuring fluorescence emission of
membrane inserts following chemotaxis assays.

In delineating motility-deterministic EGF signaling in RPCs, cells were pre-incubated with inhibitors to
EGFR and target intracellular molecules at 37°C in 5% CO2 before loading in the upper chamber of a
transwell filter as previously described [360, 367, 384]. Inhibitor concentrations and their incubation times
are as follows: (1) monoclonal anti-EGFR (100nM, 2hrs, Sigma-Aldrich Co., St. Louis, MO), (2) STAT3
inhibitor, AG 490 (5µM, 60mins, Calbiochem, Darmstadt, Germany), (3) the cell-permeable, irreversible
and selective inhibitor of EGFR tyrosine kinase activity Tyrphostin AG1478 (200nM, 30mins), (4) ERK1/2
inhibitor PD98059 (10µM, 60mins) and (5) PI3K inhibitor Wortmanin (250nM, 60mins), all from Cell
Signaling Technology, Danvers, MA. RPCs were then allowed to transmigrate through filters inserted in
chambers containing 20ng/ml and 40ng/ml EGF concentrations for 24hr at 37°C/5% CO2. Filters were
then dipped in wells containing 4% paraformaldehyde in PBS for 5 min and stained with DAPI or Hoechst
33342 nuclear stains for 10 min. Cells were removed from the upper chamber, and the number of stained
migrated cells at the bottom surface of the filter were counted at five fields per filter for triplicate filters in
two independent experiments (n=6 each) using an inverted fluorescent microscope. A Dunnett statistical
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test was used to determine the number of migrated RPCs normalized to cell migration in control filters.
Successful inhibition of RPC migration was determined by RPC numbers in test wells that were
significantly (p<0.05) less than cell numbers in control chambers containing no inhibitors. To similarly
investigate receptor-mediated signaling by the stromal-derived factor 1 (SDF-1α) motogen, after preincubation with 5µg/ml of the highly specific SDF-1α receptor CXCR4 antagonist AMD3100 (SigmaAldrich, St. Louis, MO) for 30mins at 37°C/5% CO2, both PPC and RPC suspensions were loaded in the
upper chamber of transwell filters incubating in 100ng/ml of the ligand for 24hrs as previously described
[361, 385, 386].

3.3.2:

EVALUATING RPC and PPC CHEMOTAXIS USING MICROFLUDIC TECHNOLOGY

Chemical gradients have been shown to play essential roles in a range of cellular processes including
inflammation, motility, disease and development [236, 387]. The Boyden Chamber assay is a traditional
method for establishing one-dimensional chemical gradients perpendicular to cell growth fields, and relies
on the diffusive properties of tested biomolecules. In contrast, in vivo concentration profiles of chemical
species are heterogeneously formed by not only the molecule’s diffusive properties, but also its binding
kinetics to other biomolecules in a dynamic physicochemical microenvironment [388] and the architectural
planes defining the living tissue. Defining the spatial distribution and concentration of these molecules is
further complicated by control and feedback regulatory mechanisms in living tissues for normal
physiological activities that continually change the biochemical composition of these tissue systems [389].
As such, deciphering the true characteristics of physiologically relevant gradients and how these highly
dynamic gradients are integrated to produce specific cell responses requires a way to expose cells to one
or more biomolecular gradients, each with defined spatial and temporal distributions [205]. By doing so,
we can determine specific biomolecule concentrations and gradient profiles that elicit the most efficient
motility responses, and determine how these gradient characteristics influence the cell’s sensitivity to
other biomolecular gradients.
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Such temporal control and quantitation of stable gradients are difficult to accomplish in Boyden chamber
assays. This is due to the gradient instability created by fluid level imbalances between lower and upper
compartments during pipette-loading of the transwell culture system, which is exacerbated by the
requirement that the membrane insert, with its liquid-porous bottom, be dropped into the lower
compartment containing chemical media [364]. Lowering the porous membrane insert into the lower
compartment allows instant chemical flows to the upper chambers of the transwell filter, producing rapidly
dissipating gradients with chemical homogeneity expected in both compartments within a few hours (data
not shown). These geometric limitations of the experimental set-up (see Figure 3.2) thus restrict the
nature of chemical gradients that can be generated in this assay to mono-axial opposing gradients. Multifactorial combinatory gradients reminiscent of in vivo conditions cannot be formed, and cell responses
cannot be correlated to specific gradient characteristics. The optically translucent, but not transparent,
membrane filters used in the assay also makes such a correlation even more cumbersome as
visualization of transmigrated cells is difficult using conventional brightfield and fluorescent microscopes
[364]. As such, the Boyden Chamber assay is best suited for studying ligand-induced population-based
migration.

Microfluidic technology has proven highly valuable in the creation of biomimetic micrometer-scale
environments with predictable, reproducible, and easily-quantified biomolecule gradients in vitro [7]
compared to traditional methods as the Boyden chamber [390-392], with recent advances merging both
methodologies [393]. Microfluidic technology uses miniaturized devices to study, manipulate and
approximate isolated cell and tissue physiological processes that would have hitherto, been too complex
to characterize. These biomimetic devices are inexpensive, requiring low amounts of reagents, and allow
intrinsic gradient profiles that decrease time for analyzing cellular physiologic phenomena [394]. The use
of microfluidic technology is critical to our study for it enables us create and sustain spatial and temporal
gradients that model behavior of released chemokines in damaged retina that may influence our RPC and
PPC responses. In typical microfluidic devices, gradients are generated within micro-scale conduits fed
at both ends by differential concentrations of chemical species. Knowing the precise dimensions of the
microfluidic devices coupled with the detailed understanding of laminar flow of fluids in such microscale
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conduits enables accurate mathematical determination of the movement and distribution of chemical
species in the microchannels over defined time scales and distances. Variations of the technology have
shown the potential to create multiple biomolecular gradients, each with its own user-defined
spatiotemporal distribution, as well as complex gradient generation parameters based on the chemical
behavior of combinations of soluble and substrate-bound biomolecules [395, 396]. The ability to create
such complex, user-defined gradient environments enables quantitative elucidation of multi-gradient
signal integration and provides the specific recipes for engineering the growth, migration, and
differentiation of a variety of cell types [390, 391, 397].

3.3.2.1: The Bridged U-Lane Microfluidic Assay
To comprehensively examine migratory responses of RPCs and PPCs to quantitatively defined gradients
of candidate chemotactic molecules we used a retinal biomimetic microfluidic device, known as the
bridged µLane [7]. The bridged µLane was fabricated using lithography techniques and elastomeric
molding of Poly-dimethylsiloxane (PDMS), a flexible silicon polymer. This work was performed in
collaboration with the Maribel Vazquez Microfluidics and Nanotechnology Laboratory at the Biomedical
Engineering Department of City College of the City University of New York. When bonded to an inert
substrate, the PDMS device is designed to assist molecular diffusion of chemotropic factors down the
length of a microchannel located at the bottom of the device, due to minute convective velocities initiated
by buoyancy-driven forces. This enables the attainment of steady state gradients of these chemical
factors within short experimental times. The device has previously been shown to sustain gradient profiles
of over five orders of magnitude of chemical concentrations, and over time scales sufficient to model
dynamic chemotactic microenvironments generated in vivo [7, 398]. Quantification of ligand mass
transport within the microsystem was solved using finite element methods (FEMLab Version 3.4, Comsol
Inc., Burlington, MA). Sequential optical monitoring of individual cell movement within predictable
chemical concentrations, and at finite loci along the microchannel, permitted measurement of mechanistic
parameters governing retinal stem cell migration such as polarizability, directionality and chemosensitivity to steady state chemical gradients [391]. This microfluidic device also has the added
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advantage of not requiring automation to maintain steady state gradients for up to 72hrs [32, 398] and its
ease of fabrication enables rapid assessment of cellular chemotactic phenomena.

3.3.2.2: Design Of The Bridged U-Lane Device

The framework of the bridged µ-Lane device consists of two layers of silicon polymer polydimethylsiloxane (PDMS): the bottom layer consisting of a closed microchannel (0.1µL volume, 95µmhydraulic diameter: 90µm-depth, 100µm-width (using Dh=4A/P [399], where A is the cross-sectional area
and P is the perimeter, 1.3cm-length), connecting a source reservoir (SRR) to a sink reservoir (SKR) each
9µL-volume (2mm-height), and a top layer comprising a source chamber (SRC) and sink chamber (SKC)
each 170µL-volume (6mm-height; 6mm-diameter) connected by an open, hemispherical bridge channel
(2-mm-depth;

9-mm-length)

(Figure

3.4).

Both

PDMS

layers

are

fabricated

using

contact

photolithography and soft lithography techniques followed by bonding together of the two PDMS layers
and the composite PDMS layers to glass substrates. The SRC and SKC chambers are thus vertically and
fluidically connected with the underlying SRR and SKR reservoirs respectively, and the bridge channel
connects the SRC and SKC chambers in order to balance their solution volumes. The complete bridged
µ-Lane system is thus composed of an upper user interface layer with an open bridge channel that
connects the SRC and SKC chambers, as well as a bottom layer closed microchannel that connects the
SRR and SKR reservoirs [7].
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Figure 3.4: Design of the Bridged μ -lane Microfluidic Device – The schematic
shows the first layer PDMS with 9μl volume source (SRR) and sink (SKR) reservoirs
connected by a microchannel measuring 13mm (length), 90μm (depth), 100μm (width),
and 95μm (hydraulic diameter). The second layer PDMS, the user interface layer,
consists of a semi-circular open bridged channel that measures 9mm (length) and 2mm
(depth) and fluidically connects to the first layer via 170μl volume source and sink
chambers [7].

3.3.2.3: Fabrication Of The Bridged U-Lane Device
The fabrication of early microfluidic systems was inspired by technology derived from microelectronics
including photolithography and etching in silica and glass [400, 401]. The opacity of silica made it
unsuitable for optical detection of biological systems, while the amorphous nature of glass made etching
problematic and its use requires cleanroom facilities. Additionally, micro-fabrication with silica or glass
etching is an expensive and time-consuming venture [394]. Search for inexpensive manufacturing
methods led to the adoption of malleable polymers such as poly-dimethylsiloxane (PDMS), and its replica
molding on micro-patterned solid substrates to yield negative replicas of the substrate’s contoured
surfaces. Such solid substrates are machined from metal, acrylic or aluminum or etched on inert silicon
wafers using photolithography. Cured PDMS molds can then be peeled of the micro-patterned surfaces
and sealed on glass, replicating the desired hollow dimensions of miniaturized biological conduit systems.

The bridged u-Lane was fabricated in three major steps using conventional manufacturing processes:
Step 1: Fabrication of microchannel-patterned mold using contact photolithography (Rapid Prototyping) or
Computer Numerical Control (CNC) Router. Step 2: Replica Molding Of Double-Layer PDMS Using Soft
Lithography Step 3: Adhesion of PDMS polymers to substrate. These steps enabled the rapid
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manufacturing of the bridged u-lane microfluidic device and a schematic overview of the process is
provided in Figure 3.5a.

3.3.2.3.1:Step 1a - Fabrication Of Microchannel-Patterned Mold Using Contact Photolithography (Rapid
Prototyping)

In contact photolithography, microfluidic device design is performed on computer software programs
compatible with commercial image setters that print the designs on photomask transparencies. The
photomask designs are imprinted onto thin silicon wafers containing high contrast epoxy-based
photoresist material that forms structural crosslinks on exposure to

Figure 3.5a – Overview of fabrication
steps for the bridged μ -lane
microdevice – A computer aided
design of the first layer PDMS
dimensions of the bridged U-lane was
produced
on
photomask
transparencies which is then micropatterned on silicon wafers using
contact photolithography to produce an
SU-8 ‘Master’ mold (A). Rapid
prototyping of the first layer of the
bridged U-lane was then performed by
curing PDMS over the SU-8 ‘Master’ (B
& C). Adhesion of the PDMS polymer
to a glass flat-surface substrate (C)
completes the fabrication process for
st
nd
the 1 layer PDMS. The 2
layer
PDMS (user interface layer) is
produced by simply curing PDMS over
st
the 1 layer with defined source and
sink chamber compartments [14].

UV thermal radiation. Crosslinked photoresist is insoluble in common SU-8 developer solvents, and thus
covered photomask regions un-exposed to UV will be easily rinsed off leaving a positive relief ‘Master’ of
the design on the silicon wafer. Steps in standard photolithography protocols are outlined in Figure 3.5b
[394]. Following replica molding of PDMS on the SU-8 Masters, a cured negative replica of the Master
mold can be routinely fabricated for experimental uses. Rapid prototyping reduces time and cost for a
cycle of micro-device fabrication and testing of new ideas. Where chrome masks are used instead of
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transparencies, the resolution of the ‘Master’ relief obtained after photolithography is higher, but the
masks are more expensive [394].

In our experiments, silicon wafers (SVM, Santa Clara, CA) were rinsed with acetone and isopropyl alcohol
(Sigma-Aldrich Co., St. Louis, MO), followed by deionized water in succession. After drying, wafer
substrates are coated with a 100-µm-thick layer of negative photoresist, SU-8 2075, (MicroChem Inc.,
Newton, MA) using a spin coating apparatus (Laurell Tech. Corp., North Wales, PA). Wafers were prebaked on a hot plate at 65°C for 5mins and 95°C for 15mins, covered with both the computer-aided
design (CAD)-photomask containing desired patterns of the first layer of the bridged u-lane and a filter,
2

and then exposed to UV irradiation for 18 seconds (Intensity after filtering: 215-240 mJ/cm , Model 30-UV
light source, OAI San Jose, CA) to create a positive relief of the design known as the ‘Master.’ Wafers
were then re-baked for 2-5mins at 65°C and for 8-10mins at 95°C, allowed to cool at room temperature

Figure
3.5b:
Contact
Photolithography
A)
Computer-aided measurements
st
of the 1 PDMS layer are
imprinted
onto
photomask
transparencies and placed onto
thin silicon photoresist wafers.
B) Upon exposure to UV
thermal radiation, regions not
covered by the photomask
dissolve, exposing the positive
st
relief of the microdevice 1
layer design. C) Following
replica molding of PDMS on the
relief ‘Master’, cured negative
replicas of the ‘Master’ mold
can be replicated.

(25°C), and immersed in SU-8 developer (MicroChem Inc., Newton, MA) for approximately 10mins on a
slow shaker, or until photoresist patterns were visible. The SU-8 Master is then successively rinsed with
fresh developer, isopropyl alcohol and deionized water, and then completely dried for use.

97

3.3.2.3.2: Step 1b - Fabrication Of Microchannel-Patterned Mold Using A CNC Router

An alternative approach to fabricating a relief ‘Master’ patterned to dimensions of the bridged u-lane
device is by mechanically carving out molds from durable materials as acrylic, metal and aluminum.
Computer-aided designs (CADs) are programmed into milling machines as the CNC router (Rockler,
Buffalo, NY) followed precision cutting through substrate molds to achieve the microlane diameters useful
for mimicking biological systems.

In our study, a prototype metal cast mold for the bridged u-lane microfluidic device was fabricated using a
CNC Milling machine computer-controlled with SketchUp-fed (Trimble, Sunnydale, CA) design
specifications (Figures 3.6a and 3.6b). Metallic materials for the cast master were purchased from
McMaster-Carr Supply Company (Robbinsville, NJ) and the work was done in collaboration with the
Mechanical Engineering Department at City College, CUNY, where Mark Stasiak assisted in the CAD and
performed the metal milling procedure. Machining to produce imprints of precise dimensions of the
bridged u-lane was simplified by fabricating three metal plates – bottom, middle and top plates that line up
with two edge guide pins measuring 6mm in diameter (Figure 3.6a). The bottom plate contains four (4)
2.4mm diameter press fit pins, 2mm height forming the source and sink reservoirs of 9ul volumes each.
These pins are connected in pairs by two 90um (0.025inches) deep microchannels, and fits with the
middle plate to form casing for the first layer of the device. Placing the top plate containing four (4) 6mmdiameter/6mm-height pins over the unified plates marks out dimensions of the source and sink chambers
(170uL volumes) with the connecting bridged channel. Figure 3.6b shows top design view of the device
with relevant dimensions. Advantages to this design is that the double PDMS layers can be made during
one elastomeric PDMS molding cycle and thus significantly decrease device fabrication times.
Unfortunately, we realized that high temperatures attained within the metallic cast master during the
silicon polymerization step distorted shapes of the PDMS molds; thus using less heat conducting
materials would be encouraged. Most importantly, the CNC router available for use at the Mechanical
Engineering department failed to accurately machine 100um u-lane width microchannels in the bottom
plate producing channels five-fold in magnitude larger than requested.
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A second aluminum cast-master replica mold (ASCO, Detroit, MI) with identical micro-patterned
dimensions as design of the bridged u-Lane (Figure 3.7) was then adopted, and it yielded the desired
PDMS first layer and microchannel dimensions upon bonding to glass substrates. Work cones of 6mmdiameter pipette tips (VWR Bridgeport, NJ) placed above the first layer PDMS were used to estimate the
volumes of the source and sink chambers, and after pouring PDMS over the first layer formed the
chambers of the PDMS second layer. The bridged channel was then manually carved out to connect both
chambers after baking the PDMS double layer molds.

3.3.2.3.3: Step 2 – Replica Molding Of Double-Layer PDMS Using Soft Lithography

Once a ‘Master’ Mold is fabricated, we employ replica molding, a soft lithography technique to replicate
our desired design patterns in polymers such as PDMS. Soft Lithography represents a suite of techniques
that begins with the non-photolithographic fabrication of a ‘Master’ following by replica molding as an
alternative to accelerate the rapid prototyping of microfluidic devices [14, 402]. In its replica molding
application, a suitable pre-polymer is cast against the master generating a negative replica of the master
in the polymer; i.e. ridges on the Master appear as valleys in the replica and vice-versa. After curing the
polymer, the replica peeled of from the ‘Master’ will contain the desired etched pattern. The schematic in
Figure 3.5a outlines the basic steps in replica molding [394]. PDMS (Poly-dimethylsiloxane) is one of the
most commonly used elastomeric polymer and is an excellent material for replica molding of microfluidic
devices. It is a silicon polymer that is optically transparent down to 240nm allowing it to be used for varied
detection schemes including UV/Vis absorbance and fluorescence. It cures at low temperatures and its
non-toxic nature allows mammalian cells to be cultured directly on it. The elastomeric nature of PDMS
polymer also permits it to conform to different planar surfaces, and its inert surface chemistry can be
easily manipulated to facilitate sealing to surfaces and chemical modifications of cell binding interfaces
[14, 394, 402].
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Figure
3.6a:
Side-View
Design
Specifications for CNC Fabrication of
Micro-patterned Double-layered PDMS
Molds – By inputting the Sketch-Up design
into a Computer Numerical Controlled (CNC)
router, three metal plates could be machined
to design specifications and aligned to create
a positive relief ‘Master’ for a double-layered
PDMS Bridged U-lane microdevice. The
bottom plate contains four (4) 2.4mm
diameter pins as positive relief for the 9uL
source and sink reservoir volumes. The
13mm microchannel (Bridged channel in
diagram) connects the reservoirs at two
locations on the bottom plate. 6mm guide
pins attach the bottom middle and top metal
plates; middle plate placement on top of the
nd
bottom plate forms the 2
PDMS layer.
Placing the top plate containing four (4) 6mm
diameter pins over the bottom and middle
plate assemble demarcates the source and
sink chamber 170 µL volumes. Two doublelayered bridged µ-lane microdevices can be
fabricated in one PDMS elastomeric molding
cycle using computer-aided design (CAD)
above. Designs were made using the SketchUp 3D modeling software and a 1:2
horizontal scaling. Figure is courtesy of Mark
Stasiak, Mechanical Engineering Dept. City
College of New York	
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Figure 3.6b: Top and Edge-Side-View
Design
Specifications
for
CNC
Fabrication of Micro-patterned Doublelayered PDMS Molds – Dimensions used
in the fabrication of each of the three
individual metal plates are as specified in
section 3.3.2.3.2. The side-view panel
shows an image of the concatenation of
the three metal plates – bottom, middle
and top to reveal microchannel, reservoir
and chamber volumes on one side of the
microchannel device. Designs were made
using the Sketch-Up 3D modeling
software and a 1:2 horizontal scaling.
Figure is courtesy of Mark Stasiak,
Mechanical Engineering Dept. City
College of New York	
  

	
  

In the Maribel Vazquez lab, we used one of the most common PDMS elastomers, Sylgard 184 from Dow
Corning (VWR, Bridgeport, NJ). Sylgard is a two part resin system containing vinyl groups (part A) and
hydrosiloxane groups (part B) shown in (Figure 3.8). The two part A:B resin were thoroughly mixed
together as polymer base and curing agent in a ratio of 10:1 respectively to facilitate the formation of
cross-linked networks of dimethyl siloxane groups [12]. The PDMS pre-cured mixture is then completely
degassed twice for 5mins each in a vacuum desiccator and poured into the relief ‘Master’ aluminum mold
(see section 3.3.2.3.2) up to the tip of needles that provide the sink (SKR) and source (SRR) volume
reservoirs that form the bottom layer PDMS (Figure 3.7). After curing the PDMS polymer in an oven at
70 °C for 15-20mins, the top layer PDMS is cured with two pipet tips mimicking 170uL volumes of the sink
(SKC) and source (SRC) chambers. Alternatively, fluidic punch ports can be made using appropriately
sized drill punches into the first or second layer PDMS polymers. Due to the flexibility of PDMS, the
microfluidic device can easily be unmolded (peeled) from the cast master, leaving the master intact and
ready to produce another device. Once the device is peeled from the mold, it is prepared for assembly on
a glass substrate, by initially trimming off excess polymer around the bottom surface of the first layer
PDMS to facilitate bonding to the flat glass substrate.
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A
Positive relief for
Source/Sink Reservoir
Edge-line threading for
Microchannel volume
(0.1µl)

B

Aluminum encasing
for second layer
PDMS Mold

Figure 3.7: Aluminum Cast-Master Mold for the Bridged μ-lane Device – An alternative
pre-fabricated aluminum mold was employed as positive relief for doubled layered PDMS
st
microchannel. A) Depicts cast mold for 1 layer PDMS identifying loci for source and sink
nd
reservoirs and the microchannel. B) Aluminum encasing for 2 layer PDMS showing a
completely assembled cast mold for the double-layered PDMS bridged μ-lane. Piths for the
source and sink chambers are demarcated by placing two 6mm diameter pipette tips above
st
cured 1 layer PDMS polymer.
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PART A

PART B

Figure 3.8: PDMS Crosslinking Reactions - Two- component silicone elastomer mixture (Part A - base
monomer (pre-polymer) and Part B - curing agent) is poured over a cast ‘Master’ template in a mixed ratio of
10:1 for A:B to produce double-layered PDMS bridged U-lane devices. In terms of chemical structure, the base
pre-polymer (Part A) is composed of about 60 repeating units of-OSi(CH3)2- terminating with a vinyl-CH=CH2
group (Sylgard 184, Dow Corning). The curing agent (Part B) is similar, but is much smaller with only about ten
repeating units with periodic silicon hydride -OSiHCH3- units. During the curing step, a hydrosilation reaction
crosslink the base and the curing agent forming -Si-CH2-CH2-Si- complexes. The resulting structure is
insoluble and is completely cured [12].

3.3.2.3.4: Step 3 - Adhesion Of PDMS Polymers To Substrate.
Of the many advantages of PDMS as an elastomeric polymer for micro-fabrication, the ability to modify its
surface chemistry was utilized in our study to chemically bond the double-layered PDMS to glass. Being
an inert substance, modifying PDMS surface properties can be quite difficult but has been achieved using
oxygen plasma mixtures of ions, particles and electrons, corona discharges or ultraviolet (UV) light [14,
403]. On exposure to an energy stream, methylsiloxane (Si-CH3) groups on PDMS surfaces are oxidized
to silanol (Si-OH) groups which greatly facilitates the ability of the polymer to bond irreversibly to PDMS,
glass, silicon, polystyrene and polyethylene substrates [14, 404]. Upon contact, a nucleophilic siloxy
group on one substrate can attack electrophilic silicon in another forming a covalent bond across the
interface between the two materials. For PDMS and glass bonding, the reaction yields Si-O-Si bonds after
water loss (drying) [394, 404]. Utilizing higher voltages and frequency generators for an appropriate time
as well as 100% oxygen content of air plasma flow strengthens the irreversible nature of the covalent
bond [404]. Reversible sealing is also possible between PDMS and other silicon substrates via Vander
waals forces but this seal cannot withstand pressures greater than 5 psi [394].
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In preparation for sealing PDMS onto glass, the glass slides are thoroughly washed with laboratory
detergent, rinsed with water and placed in a beaker containing Nanostrip (Cyantek, Fremont, CA) for
30mins to 2hrs for chemical cleaning. After thorough rinsing under a constant water stream for 5mins,
glass slides are blow-dried using nitrogen (N2) gas and stored covered in a dry place until use to prevent
dust accumulation. Prior to bonding, both double-layered PDMS and glass surfaces are exposed to an
ozone plasma stream generated using a BD-10A High Frequency Generator 115V (ElectroTechnic,
Chicago, IL) 3cm from exposed surfaces for 25 seconds each and then immediately adhered together
with little pressure. The PDMS-on-glass is then cured in the oven for 5 hours to overnight at 70°C to
secure irreversibility of the covalent bonds. A completely assembled bridged U-Lane device set-up is
shown in Figure 3.9.

3.3.2.4: Innovative Operation Of The Bridged U-Lane

The bridged µ-Lane system works by using the large volume chambers and bridge channel of the upper
user interface layer to generate concentration gradients within the smaller volume microchannel in the
bottom layer. After incubating cells along the microchannel, the cell culture media is manually loaded until
it has filled the SRR, microchannel, SKR, SKC, and bridge channel. The test chemical solution is then
loaded drop-wise into the SRC until the sample makes contact with the solution within the bridge channel
to initiate system operation. The volume ratio of the chambers to the reservoirs (140:1) facilitates manual
micropipette/syringe loading which initiates gradual transport of chemicals into the bottom layer
microchannel with minimal channel entrance effects. This volume difference also maintains constant
reagent concentrations and gradient profiles during experiments without need for replenishment. The
bridged channel connects the SRC and SKC to balance their solution volumes eliminating hydrostatic
pressure differences between both chambers so that only density differences of the chamber reagents
exist to initiate minuscule convective velocities that assist molecular diffusion of chemotropic factors
through the 13mm-microchannel in the bottom layer.
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Bridged Channel
Source
Chamber
(170µL volume)

Sink Chamber
(170µL volume)

Source Reservoir
(9µL volume)

Sink Reservoir
(9µL volume)

microchannel

Figure 3.9: The Bridged μ-Lane Microfluidic Device - Functional bridged
u-lane microchannel fabricated by soft lithography of PDMS in dimensioned
aluminum casts followed by polymer-polymer bonding of first and second
PDMS layers and then bonding of PDMS to glass. Mass differences between
drop-wise loaded motogens in source chambers and control media in sink
chambers induces convective-diffusive chemical flow through the microfluidic
system with minimal hydrostatic pressures due to fluid volume equilibration by
the bridged channel.

This ultra-low bulk flow generates large differences in concentration gradients along the channel within a
shorter time compared to one-layer PDMS experiments where larger bulk flows persist to form smaller
concentration differences in the u-Lane, or where chemical transport by diffusion alone requires much
longer time spans for steady-state gradients to be established [7, 32]. Given the optically favorable
characteristics of PDMS, this microfluidic system thus allows sequential live optical monitoring of single
cell motility responses within predictable microenvironments that create precise spatial and temporal
profiles of chemical species.

3.3.2.5: Mathematical Modeling Of The Bridged U-Lane Microfluidic System
Two-dimensional ligand mass transport within the bridged µ-lane had previously been computed using
the constitutive relations of (1) 2D continuity, (2) convective-diffusion, (3) momentum, and (4) hydrostatic
equations as described below, on a Finite Element Method platform (FEMLab Version 3.4, Comsol Inc.,
Burlington, MA) with successful modeling and implementation of chemokine gradient profiles [7, 32, 405].

1) Continuity equation:

2) Convective-diffusion equation:
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3) Momentum equation:

4) Hydrostatic equation:

h=0

3

2

Key: ρ (kg/m ) is reagent density, u (m/s) is fluid velocity, C (g/l) is solution concentration, D (m /s) is the diffusion
coefficient of the reagent molecule, p (Pa) is hydrodynamic pressure, h (m) is the height of the first and second layer
PDMS with y and x (m) representing the vertical and horizontal directions respectively.

The first equation describes the steady state fluid dynamics of mass chemical particles entering or leaving
any part of the microsystem. The second equation computes diffusivity (
(C) over time (t) as a consequence of convective flow (

) of the chemical species

). The third equation represents linear

momentum of diffusing particles over time, while the fourth equation accounts for the negligible
hydrostatic fluid flow at constant velocity. FEMLAB simulations of the transport of three molecular species
– Dextran (10KDa), Epidermal Growth Factor (EGF, 6KDa), and Stromal-Derived Factor-1A (7.9KDa) within the microchannel of the bridged U-lane system have previously been experimentally validated and
described below.

3.3.2.5.1: Measurement of Dextran Transport

Bulk flows were optically measured at different positions along the microchannel using fluorescent beads
and values were inputted into the convective-diffusion transport model for numerical simulation of Dextran
transport. Mathematical modeling of molecular transport within the bridged U-lane system was initially
performed by measuring transport of fluorescently labeled 10KDa molecular weight Dextran at different
loci optically detected with bulk flow of 1.9um diameter fluorescent beads [7]. The fluorescent beads were
4

diluted in PBS to a concentration of 10 beads/ml and loaded into the microchannel, while the PBS was
added slowly to fill the SKC and bridged channel. Fluorescent dextran at 40ug/ml concentration was then
added dropwise into the SRC to initiate operation of the bridged U-lane (Figure 3.10a). Dextran density
differential at the source and sink reservoirs generated both minute diffusive flow (diffusivity = 0.82 X 10-6
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cm /s) [7, 406, 407], and ultra-low bulk flow velocities (0.17µm/s) in the microchannel with a system-wide
average of 0.37 um/s, and no significantly detectable bulk flow in the bridged channel indicative of
constant concentrations in the SRC and SKC during experiments [7]. These ultralow bulk flows occur due
to hydrostatic balance between both source (SRR) and sink chamber (SKR) volumes ensured by the
bridge channel, and enabled the attainment of a steady state gradient through the length of the
microchannel after only 40hrs of system operation with gradient profiles ranging from shallow profiles of
-3

1

10 ng/(ml.mm) near the SRR to 10 ng/(ml.mm) near the SKC [7]. Numerical simulation of Dextran
transport at loci 5mm away from the source reservoir (SRR) is presented in a 2-D plot of Dextran
concentration over time, and steady state gradients of dextran was mathematically predicted to be
attained after 11hrs and maintained steadily through the length of the microchannel for up to 72hrs
(Figure 3.10b)

3.3.2.5.2: Measurement of EGF Transport

Experimental measurement of one-dimensional Epidermal Growth Factor (EGF, mol.wt. ~ 6.0kDa)
-6

2

transport within the microchannel over time generated a diffusivity value of 2.0 X 10 cm /s [32]. Using
this value, mathematical models of EGF concentration profiles within the U-Lane as a function of time and
axial position were generated, and it was found that steady state EGF gradient through the entire length
of the microchannel was established after 18hrs of initiating system operation independent of initial SRC
EGF concentrations (Figure 3.10c) [32]. These numerical simulations were experimentally validated for
uniform (system-wide) and gradient concentrations (microchannel only) of 40ng/ml, 80ng/ml and
400ng/ml EGF. Investigations by the researchers revealed a convection-dominated transport system for
EGF in the microchannel which forms proximal shallow gradients through half of the channel length and
steeper gradients closer to the SKC when constant concentrations of EGF are established in these
regions (>18hrs). Bridged U-lane EGF gradient systems were also shown to stimulate greater cell
physiological responses than experiments using uniform system-wide EGF concentrations [32].
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3.3.2.5.3: Determination of SDF-1α Transport in the Bridged U-lane System
Understanding mechanistic flow in the microchannel of the bridged U-lane has enabled the predictive 3D
3

COMSOL modeling of SDF-1α concentration change in water (mol/m ) along the Y-axis length of the
microchannel from an infinite supply of 1M SDF in SRR (x,6500µm,y) to 0M SDF in SKR (x,-6500µm,y)
as a function of time (Figure 3.10d). 2D representation (Figure 3.10e) of changing SDF-1α gradient
profiles with increasing distance from SRR to SKR loci (8000>>-8000µm) predicted that steady SDF-1α
gradients were maintained for the first few thousand microns (~2700um) from the SRR after which
concentration fluxes became irregular. In the analysis, we assumed the chemical species diffused
through water from an infinite 1M reservoir (SRR) to sink (SKR) at either side of the microchannel and
that the entire system is governed by a standard transport of diluted species model within COMSOL. The
sides of the microchannel were modeled as perfectly impermeable. This modeling protocol has similarly
been applied to microfluidic systems in previous studies [408]. Simulation results obtained for SDF-1α are
similar to the gradient profiles formed by differing EGF concentrations in the microchannel (see section
above) and SDF-1α molecular transport in the microchannel would comparably be dominated by
-6

2

convective flow with minute diffusivity. Given the diffusion coefficient of SDF-1α ~ 1.11-1.7 X 10 cm /s
[409-411] within range of EGF (2.0 X 10

-6

2

-6

2

cm /s) and Dextran (0.82-2 X 10 cm /s) values, time

dependent attainment of SDF-1α steady-state gradients in the entire microchannel was estimated to be
between 18 and 40hrs following initiation of system operation.
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Figure 3.10: Mathematical Modeling of Molecular Transport in the Bridged μ-lane Microfluidic System – FEMLAB
simulations of molecular transport of three chemical species – Dextran (10kDa), Epidermal Growth Factor (EGF, 6kDa),
and Stromal-Derived Factor-1α (SDF-1α, 7.9kDa) - was used to model the establishment of their steady state gradients
in the 13mm microchannel of the bridged U-lane device over time: A) Dextran density differential at the source and sink
-6
2
reservoirs generated both minute diffusive flow (diffusivity = 0.82 X 10 cm /s) and ultra-low bulk flow velocities (0.17μ
m/s) that enabled the attainment of a steady state gradient through the length of the microchannel after only 40hrs of
system operation. These ultralow bulk flows occur due to hydrostatic balance between both source (SRR) and sink
chambers (SKR) by the bridge channel. Bulk flows were optically measured at different positions along the microchannel
using fluorescent beads and values were inputted into the convective-diffusion transport model for numerical simulation of
Dextran transport. B) Simulation of Dextran transport at loci 5mm away from the source reservoir (SRR) is presented in a
2-D plot of Dextran concentration over time, and steady state gradients of dextran was mathematically predicted to be
attained after 11hrs and maintained steadily through the length of the microchannel for up to 72hrs [7]. C) Mathematical
modeling of EGF concentration as a function of time (2, 5, 7, 10 and 18hr) and axial position in the microchannel displays
gradual attainment of steady state gradients until 18hrs when the change in EGF concentration remains relatively constant
along the 13mm length of the microchannel [32]. D) Understanding mechanistic flow in the microchannel of the bridged U3
lane has also enabled the predictive 3D-COMSOL modeling of SDF-1α concentration change in water (mol/m ) along the
Y-axis length of the microchannel from an infinite supply of 1M SDF in SRR (x,6500μm,y) to 0M SDF in SKR (x,-6500μ
m,y) as a function of time. E) Preliminary modeling results are better visualized in a 2-D plot monitoring change in SDF-1α
concentration gradient with increasing distance from SRR to SKR loci (8000>>-8000μm). Steady SDF-1α gradients were
maintained for the first few thousand microns (~2700um) away from SRR after which concentration fluxes became
irregular. In the absence of extensive experimental validation of SDF-1α transport phenomena in the microchannel and
given proportionality between previously assessed Dextran and EGF gradient generation profiles and their molecular
weights, we hypothesized attainment of sustained SDF-1α gradients to occur between 18-40hrs after introduction of the
ligand into the microfluidic system.
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3.3.2.6: Experimentation with the Bridged U-Lane

To assess cell motility responses to chemical gradients in the bridged µ-lane microfluidic system we used
methods previously established by the Vazquez laboratory [32]. Functional validation of chemotactic
interactions for candidate ligand receptor pairs: EGF-EGFR and SDF-1α-CXCR4 was performed in the
steady-state gradient system of the bridged µ-lane following bioinformatics predictions of motility
deterministic signaling in PPCs and RPCs by these molecules (see section 2.3.4.3). To ensure viability,
prior to microfluidic assays, cell suspensions were subjected to a Trypan Blue (Sigma-Aldrich, St. Louis,
MO) viability assay using a Brightline hematocytometer cell counter (Hausser Scientific, Horsham, PA)
(data not shown).

The microchannel was coated with 10µg/mL laminin (Life Technologies, Grand Island, New York, 23017015, in PBS) for 1hr at 37°C prior to cell incubation. After rinsing and aspirating excess unbound laminin,
6

0.1µl of PPC or RPC suspensions (1×10 viable cells/mL) in NB media supplemented with 10% FBS were
injected into the microchannel for a 2hr incubation period. The SRC, SRR, SKC, SKR and bridged
channel were also filled with NB media. Thereafter, growth medium is carefully aspirated from the entire
system, and fresh NB media containing no motogens are added to the microchannel, reservoirs, SKC and
bridged channel. NB media only (control) and NB media containing 100ng/ml SDF or 20, 40, or 400ng/ml
EGF are then added drop-wise into the SRC till the solution makes contact with media in the bridge
channel and initiate system operation. For inhibition studies performed using the bridged µ-lane, RPCs
were pre-incubated CXCR4 inhibitor AMD3100 for 30mins at 37°C prior to cell loading into the
microchannel. After filling, the system is placed in a micro-incubator at 37°C with 5% CO2/balanced air
supply mounted on the motorized stage of an inverted microscope for live cell imaging, tracking and
analysis. Three to five microfluidic systems per chemotactic factor concentration were used in
experiments
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3.3.2.7: Live-Cell Imaging of Bridged U-lane Microchannels

The bridged µ-Lane is mounted on the Proscan III motorized stage of a Nikon Eclipse Ti (Nikon
Instruments Inc., Melville, NY) inverted microscope housed in a humidified incubator (Okolabs, NA, Italy).
The temperature in the incubator is maintained at 37°C with 5% CO2/balanced air supply and >70%
humidity. Live cell images were obtained with a CFI60 Plan Fluor 10× (0.3 NA) microscope objective lens
at hourly intervals for 24-48hrs in three to five independent experiments per experimental condition to
account for time required to attain steady state gradients of growth factors tested. Where appropriate,
either brightfield or wide fluorescence images of RPCs or PPCs are taken in the microchannel of bridged
+

µ-lane devices. Transmitted light and emitted fluorescence from GFP -RPCs and PPCs are detected via
a cooled CCD camera (Cool SNAP HQ2, Photometrics, Tucson, AZ) and collated with Nikon software
(NIS Element 4.3AR with 6D module, Morrell Instrument Co. Inc., Melville, NY). The emitted GFP
fluorescence is also indicative of cell viability during cell microscopic observations along with cell
morphology and blebbing, clustering of fluorescent proteins, detachment from laminar matrix and cell
motility behavior as previously reported [412].

The dimensions of Brightfield images were 1392 X 1040pixels with a calibration of 0.65µm/pixel, and
obtained via Cool Snap exposure times ranging from 1.2ms - 3.4ms at readout speeds of 20MHz, while
wide fluorescence images measured 696 X 520 pixels with a calibration of 1.29µm/pixel. GFP was
excited with ~25% of 100W TI-DH Diascopic iIlumination Pillar filtered through a custom 440/491/561/638
dichroic mirror and a 520/35-nm band-pass 25mm ND4/ND8 epifluorescence filter cube controlled by a
Lambda A Shutter wheel. Optimization strategies to limit phototoxic effects and improve signal-to-noise
ratio during fluorescence live cell imaging involved increasing camera frame rate by manipulating binning
and thus minimizing energy impact of the 200ms to 1.5s exposure time range used on cell viability during
experiments. Figures 3.11a and 3.11b display sample brightfield and fluorescent images of RPCs and
PPCs respectively incubated in the bridged µ-lane microchannel during attainment of SDF-1α steady
state gradients. Approximately 70 individual cells per 13mm-microchannel length of the bridged µ-lane
were imaged to assess their motility response to each chemotactic factor concentration tested. Cell
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suspensions were loaded into the microchannel from a 0.1uL volume of 1×10 viable cells/mL
concentration of PPCs or RPCs as previously described (see section 2.5.2.6). Axial positioning of cells in
the microchannel was determined by their X,Y (width (um), length (um)) coordinates in sequential field
views 1mm equidistant from the SRR to the SKR, and over time, tracked cell trajectories per axial
coordinate per track (cell) per slice (hour) in um/min. Differences in optical resolution of tracked cell
images due to PDMS and laminar thickness of individually fabricated bridged U-lane microdevices was
accounted for by the autofocus feature of the NIS Element software (v.4.3AR with 6D module, Morrell
Instrument Co. Inc., Melville, NY) which calibrated the Z-axis of tracks (cells) based on user-defined
ranges that accommodate X,Y,Z coordinates with the best image resolution. Cell tracking was perform
both manually and using the automated tracking system in the NIS Elements Advanced Research (AR)
software and computed values were exported as excel files for statistical analysis.

A	
  

B	
  

Figure 3.11: Sample bright-field image of multi-passage
+
Actin-GFP retinal progenitor cells (RPCs) (A) and
+
fluorescent image of freshly isolated Crx-GFP
photoreceptor precursor cells (PPCs) (B) incubated in
microchannels of the bridged U-lane during attainment
of steady state SDF1-α gradients.
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3.3.2.8: Method Improvement Study: Tips for Bridged µ-lane Microfluidic Device fabrication and Live Cell

Microscopy of Retinal Stem Cells
During the micro-fabrication of the bridged µ-lane device, consequent incubation and live imaging of
cellular motility response to chemotactic factors, we encountered several experimental problems that
impeded accurate resolution of RPC and PPC migratory parameters. Incomplete reversible bonding of
PDMS to the glass substrate after application of ozone plasma streams to both bonding surfaces resulted
in leaky microchannels that subsequently increased the incubation volume and time required to attain
steady state gradients of chemotactic factors tested, as well as the nature of the gradient profiles
established along the 13mm length of the U-lane over time. Ozone plasma streams oxidize the
hydrophobic surface of PDMS to hydrophilic silanol containing groups which on conformal contact with
glass, yields Si-O-Si bonds forming the basis of a tight irreversible seal between the layers [394, 413].
Bond strength is affected by several factors including chamber pressure during ozone treatment and bond
forming processes, surface exposure times to plasma streams, and the power of ozone generators. Bond
strength has been reported to peak after 20 seconds of plasma exposure times due to optimal surface
wettability and texture characteristics of PDMS, while a decrease in bond strength was observed below
chamber pressures of 100mTorr [413, 414]. In our experiments, we observed that optimized glass slide
cleaning protocols with successive Alconox laboratory detergent, Nanostrip and water volumes, as well
as inert N2 gas cleaning of the PDMS surface increased glass-PDMS bonding efficiency by ~75% yielding
a greater percentage of fabricated microdevices that can withstand typical fluid pressure in microflows of
5-6 psi [415]. Contributing to the increased bonding efficiency was the extended overnight post-baking of
glass-bonded replica molds of the bridged U-lane in a 75°C oven that ensured a high pressure
environment for covalent bonding approaching optimal conditions [413].

An early issue encountered during live imaging and analysis of migration in bridged µ-lane devices was
the low cell survivability rates of PPCs and RPCs incubated in humidified microscope incubators. Within
short time-lapse durations of 6-8 hours, morphological and physiological changes in incubated cells,
including blebbing, necrosis, cell detachment, GFP signal attenuation and reduced cellular kinetics
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indicated an increased cell death rate once cells were removed from the confines of traditional laboratory
incubator. These changes have previously been shown as signs of cell environmental stressors [412,
416, 417] We thus postulated that stressful factors may have included phototoxicity from FITC-GFP
illumination using the 100W mercury lamp, variations in osmolarity of the µ-lane media due to low
humidity levels of the external chamber and the microincubator housing the microdevices on the
microscope stage, and waste accumulation leading to PH variability may account for observed cellular
apoptotic and necrotic behavior. A 10 millisecond exposure of cells to a 100W lamp similar to the one
used our studies had been found to reduce GFP signals to 80% levels [412], and primary mammalian
cells are fastidious in their environmental requirements, and thus physiologically reactive to even the
slightest changes in their surroundings [417]. After an extensive troubleshooting protocol was completed,
cell survivability increased by ~80%. Additional humidifiers were introduced into the cell incubation
chamber that maintained minimal humidity levels of 65% close to saturated vapor pressure of water at
37°C, increased flow rate of Air/5%CO2 mixture to >0.2nl/min supplied at ≥ 20mmHg pressure, image
acquisition using wide-field fluorescent filters was largely replaced by bright-field transmission microscopy
and only used for interval monitoring of cell health, employing microscopic settings that minimized cell
exposure to light at lower magnifications and very limited exposure times, and an NB culture media
formulation supplemented with 10mM HEPES to buffer PH changes in the cell culture media over the
duration of time-lapse recording experiments [412].

3.3.2.9: Data Analysis of Microfluidics Assay

Using cell tracking data exported into excel files, the cell motility parameters of center of mass (COM),
COM vector resolution in the Y-axis direction, maximum accumulated and maximum Euclidean distances
for each cell tracked over 24-48hrs, were resolved via sequential use of Nd-to-Image6d (National
Institutes of Health, Bethesda, USA), Manual Tracking (Fabrice Cordelières, Institut Curie, Orsay,
France), and Chemotaxis and Migration Tool 2.0 (ibidi, Verona MI) plug-ins (ImageJ) [418]. COM is a
strong parameter for evaluating chemotaxis, and measures the spatial average displacement of all cell
endpoints with positive or negative coordinates, depending on the direction of movement of a single cell
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or a population of cells. COM displacement in the Y-axis further specifies directionality of cell movement
towards the SRR from a normalized point of origin (0,0). Figure 3.12 illustrates the definitions of these
cell motility parameters for a single cell. Cell tracking data selected for analysis included only video
recordings of RPC and PPC movement after 18hrs post-incubation of cells in the microchannel to allow
for complete periods of sustained steady-state gradients of EGF and SDF-1α in bridged µ-lane system.
Mean COM, COM-Y-axis, Euclidean and accumulated distances of RPCs and PPCs in control channels
were then compared to values in channels inducted with steady-state gradients of the candidate
chemotactic factors using the Student’s t-test assuming unequal variances or the Dunnett statistical test
for single or multiple chemotactic factor concentrations respectively. These analyses were performed
using JMP (v 8.0; SAS technologies, NC) statistical software. A Tukey pairwise comparison test was also
used to resolve statistically significant differences between pairs of chemical concentrations tested with
significance level set to p <0.05.

3.3.2.10: Method Improvement Study: Comparing Manual Vs. Automated Cell Tracking Systems

The large amount of image frames acquired from datasets of time-lapse microscopy of large numbers of
cells in the bridged µ-lane microchannel poses an obvious problem for manual tracking and image
management purposes. Besides the obvious human error associated with manually tracking paths of
single cells or cell clusters every hour for every position and the excessive estimation of cell positions
associated with the task, we sought to use automated tracking software packages to enable the
measurement of cellular motility with ease of quantitation and analysis. These software programs offer
simultaneous cell centroid extraction capabilities on individual images, tracking of individual cell centroids,
and track monitoring with minimal post-tracking computation required [419]. The new possibilities offered
by recent advancements in software to aid imaging of cellular processes in space, time, and at multiple
wavelengths has made it evident that to ensure efficiency, consistency and completeness in handling the
wealth of data obtainable from even a single experiment, automation of computational image
management processing and analysis is an optimal approach [419, 420].
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Figure 3.12: Parameters for Tracking Migrating Retinal Stem Cells – Manual tracking of
migrating retinal progenitor cells (RPCs) and photoreceptor precursor cells (PPCs) was
performed via sequential use of Nd-to-image6d, Manual Tracking and Chemotaxis and
Migration Tool 2.0 software platforms. The diagram displays the definitions of the various
parameters used to monitor cell’s trajectory during experiments. Path of travel (_) from point
of origin (X) to point of destination ( ) is defined as the Accumulated distance while a straight
line connecting both points is the Euclidean distance. Maximal values of both distances were
computed for cells in our studies and travel distance, as a function of time is also an
obtainable data reference. A strong indicator of chemotaxis is the center of mass (COM)
parameter that accounts for directional mass movement of populations of cells. Selecting
COM (yi,end) assisted the determination of directional chemotactic movement of retinal stem
cells towards ligand source reservoir (SRR).

We adopted the automated tracking add-in tool on the Nikon NIS Element 4.3AR software platform
(Morrell Instrument Co. Inc., Melville, NY), to explore high throughput image processing of time-lapse
recordings of RPC migration in brightfield illumination and PPC migration viewed through a FITC
fluorescent filter. Typically, this automated tracking tool is implemented post-experimentation and uses
pre-processing algorithms to improve object separation from background. Steps involved in automatic
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tracking include removal of image background signals, detection and specification of maximal projection
for all image frames as well as image sharpening and contrast improvement. The Region of Interest (ROI)
tracking algorithm option with a built-in detection phase for segmented objects was then selected to
automatically define tracking objects per frame in both the transmission and fluorescence microscopy
experiments. A motion model that agrees the most with the captured motion is initially user-selected to
govern the computation of cell displacement over time or a best-fit algorithm can be adopted to ease
mode selection from options which include random motion, constant speed, circular motion or a
combination. Other principal motion parameters that can be pre-set include maximum cut-off speed for all
objects, standard deviation multiplication factor that uses your tracking history to represent a probability
that motion would be unexpected at certain track points, and maximum gap size to specifies limits to the
number of allowable image frames with no trackable cell movement.

Data output parameters can also be specified so that measurement of user-defined aspects of cellular
displacement behavior can be performed. Measurable cell movement parameters include; segment
length and speed which measures distance and time between two consecutive points in an object’s
trajectory, path length and speed which sum segment lengths from origin to object’s current position, rate
at which a destination is reached, acceleration, heading angle between the direction of the velocity vector
and X-axis or XY-axis (Elevation), and line length and speed which measures Euclidean distances of
tracked objects. A sample of automated tracking used to analyze time-lapse recording of the movement
of six PPCs over 24hrs is shown in figure 3.13 including graphed cell path lengths (Figure 3.13a), speeds
(Figure 3.13b) over time, comparable to accumulated distance and velocity measurements obtained in
the manual tracking protocol respectively, as well as line lengths (Figure 3.13c) and speeds (Figure
3.13d) over time which are commensurate to Euclidean distances. The range of output highlights the
efficiency of automated tracking compared to manual methods.
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Figure 3.13A-D: Measuring RPC
and
PPC
Motility
Using
Automated Tracking Systems –
The
need
for
efficient
management of image data
obtainable
from
time-lapse
microscopy of retinal stem cell
migration in microfluidic devices
necessitated a test adoption of
NIS Elements 4.3AR Automated
Tracking add-in to automate and
compute cell motility parameters.
A 20hr sample video recording of
the chemotaxis of six (6) freshly
isolated photoreceptor precursor
cells in SDF-1 α steady state
gradient in the bridged U-lane
microchannel was used to test
the adopted tracking tool by
automatically tracking movement
of the six cells. Measurable
migratory indices and display
options available include: A)
Pathlength as a function of time –
analogous
to
accumulated
distance of cell trajectory over
experimental time course. B)
Pathspeed as a function of time computing acceleration for the
cells. C) Line length as a function
of time - analogous to Euclidean
distance over time. D) Line speed
as a function of time - computing
velocity rates of cells.

D
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Additionally, a Kymograph utility option which displays 360° motion tracking view is also a possible output
style (Figure 3.13e) that further adds a strong directionality estimate to distance measurements,
compensating for the Center of Mass (COM) function used in the manual tracking protocol.

Figure 3.13E: Kymograph of Migrating PPCs – This
display option available using the NIS Elements 4.3AR
Tracking tool shows 360° motion tracking of the six
PPCs, and thus adds a strong directionality estimate to
distance measurements, compensating for the Center of
Mass (COM) function used in the manual tracking
protocol.

While automated tracking protocols have limitations including discernment of actual object tracks from
artifacts and distinguishing single cells from cell clusters [420], the larger variety of output data and
measurements resolvable, as well as the massive time saved when compared to manual tracking makes
automated tracking a more efficient approach. A comparison of tracking results obtained using manual
versus automated analysis of PPC motility in the presence of 100ng/ml SDF at 6 different positions along
the microchannel over 20hrs is presented in Table 3.1. The results reveal large differences in maximum
Euclidean and Accumulated distance and cell speed, although mean values of these measuring indices
rd

are similar as well as the patterns of peak cell distance and speed measurements around the 3 and 4

th

loci away from the source reservoir (SRR) was observed. Additionally, more cells were manually

119

trackable at different positions compared to automated tracking that at times, could not discern single
cells from clusters. It thus seems ideal to adopt one preferred tacking system for all analysis to ensure
consistency in cell motility parameter results obtained.

Automated Tracking
Max. Path
Max. Path
Speed
Length (um)
(um/min)
164.9
0.3432

Microchannel
Position

No. of
Tracks

1

7

2

4

77.4

0.117

69.15

3

7

111.9

0.1602

67.89

4

9

330.6

0.5502

298.4

7

4

45.58

0.03996

23.74

10

2

20.334

0.03474

10.904

125.12

0.21

86.97

Average

Manual Tracking
Max.
Accumulated
Max. Velocity
Distance
(um/min)
(um)
57.65
0.96

Max. Line
Length (um)
51.72

Microchannel
Position

No. of
Tracks

Max. Euclidean
Distance (um)

1

13

2

10

122.79

2.05

122.79

3

14

213.63

0.22

197.86

4

11

186.63

0.31

108.03

7

5

24.27

0.02

9.31

10

5

41.14

0.23

22.75

57.65

Average
107.69
0.60
86.40
Table 3.1: Comparing Manual Versus Automated Tracking Results – Both
types of tracking systems were used to analyze a 20hr sample time-lapse
fluorescence microscopy recording of migrating GFP+ populations of photoreceptor
precursor cells in bridged microfluidic system initiated by differential concentrations
of SDF-1α in the source (SRC) and sink (SKC) chambers. Cells were tracked at 6
different loci at increasing distance away from source reservoir (SRR) source of
chemotactic factor tested. Such data comparisons will illuminate inconsistencies in
data measurements and make more informed interpretations of cell chemotactic
behavior. Results indicate large variations in values obtained for Maximum Path
length/Maximum Accumulated Distance, Maximum Line length/Maximum
Euclidean Distance and Maximum Path Speed pairwise comparisons, but averages
of these measuring indices similar with a common pattern of peak travel distances
and speed around positions 3 and 4 away from the SRR can be observed.
Additionally, more cells were trackable using the manual tracking methodology
although sampling subsets of cells to analyze cell motility characteristics is
routinely employed in the field.
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CHAPTER 4:

RESULTS: MICROFLUIDIC GENERATED EGF-GRADIENTS INDUCE CHEMOKINESIS

OF TRANSPLANTABLE RPCs VIA THE JAK/STAT AND PI3KINASE SIGNALING PATHWAYS.

4.1: INTRODUCTION – EGF-EGFR INTERACTIONS AS MODULATORS OF TRANSPLANTABLE RPC
MOTILITY
Retinal transplantation studies that report successful integration rates of grafted cells into host retina,
employ a sub-retinal transplantation paradigm using PPCs isolated at early developmental stages [1, 112,
148, 230, 421]. It follows that an understanding of the molecular signaling associated with these PPCs at
the time of transplantation will inform strategies to improve migration and integration into appropriate
lamina. Recent findings show that over a two-week period, only ≤ 3% of grafted PPCs successfully
integrated in a damaged adult mouse retina model [112]; however, with large populations of rod and cone
replacement cells needed to restore vision function in damaged retina, a more efficient transplantation
strategy is needed [50, 112, 422]. Knowledge of the gene expression state and migratory response
properties of donor PPCs can allow us to select for or engineer genomic profiles advantageous to
movement and integration in host retina. Analogously, ectopic expression of selected chemokines in the
adult recipient mouse retina has been shown to significantly increase migration rates of PPCs [230],
highlighting the importance of biochemical signaling in host retinal microenvironments [422]. We thus
analyzed microarray gene datasets of transplantable mouse rod PPCs (GEO Accession GSE29318) [423]
and cone PPCs (GEO Accession GSE25607) [424] obtained at developmental times - post-natal day 4
(P4) for rods [163, 425, 426], and embryonic day 17.5 for cones [163, 425, 426] in close proximity to their
ontogenetic peaks. These temporal stages selected have been observed to be active migratory periods of
photoreceptor precursors to their laminar loci prior to terminal cell-type differentiation processes [163,
256, 263] allowing us postulate that the biochemical profile inherent in the genomic datasets will facilitate
the identification of signaling molecules and pathways favoring PPC motility. Additionally, these
photoreceptor cell type sources of the microarray data typify post-mitotic PPC sources widely used in
current transplantation studies [112, 230, 421].
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Following a rigorous bioinformatics-based data mining protocol as described in section 2.3.3, ligandreceptor cognate molecular pairs predicted to govern cellular movement in both rod and cone PPCs were
resolved to define four major families of signaling molecules – Matrix Metalloproteinase (MMP) regulatory
molecules, Neuregulin-ErbB signaling, Chemokine (CXC, C-C motifs) signaling, and Epidermal Growth
Factor receptor (EGFR) signaling interactions (Table 2.4). The migratory role of epidermal growth factor
family in nervous systems has been well studied for some of the members depicted in Table 2.4 including
amphiregullin, EGF, TGF-alpha, heparin-binding EGF (HB-EGF), betacellulin and epiregulin [367, 427,
428]. Muller cell proliferation and chemotaxis associated with retinal diseased states such as proliferative
vitreoretinopathy (PVR) has also been linked to high expression levels of both HB-EGF and EGF
receptors in mammals [429, 430]. We thus hypothesized that selective members of this ligand family
would influence retinal progenitor cell chemotaxis in vitro.

In the adult human and mouse retina, constitutive expression of the epidermal growth factor receptor
(EGFR) has been observed in ganglion, amacrine and horizontal cells, and synaptic regions of
photoreceptors [270, 431, 432]. Increased EGFR expression has also been described in the human retina
during proliferative diabetic retinopathy [433], and the activation of EGFR has similarly been correlated to
proliferation in RPCs [431] and both proliferation and motility of a range of neural progenitors [367, 384,
427] and retinal pigment epithelial cells [434]. PPCs transplanted into adult retina have been observed to
migrate through the outer limiting membrane (OLM) into the outer nuclear layer (ONL) and integrate by
extending apical neurite processes to synapse with second-order neurons at the outer plexiform layer
(OPL) forming outer segments [112, 435-437]. Other grafted populations localize to regions of the
interphotoreceptor matrix (IPM), photoreceptor outer segments and Muller glia end-feet. Leading
investigators believe that the glial processes, the retinal pigment epithelia and host neurosensory retinal
lamina layers all contribute chemical signals influencing PPC migration and integration [436-438]. As
adult human and mouse retinal ganglion cells have been shown to transcribe EGF mRNA [270, 432], and
after retinal damage, Muller glia up-regulate synthesis of EGF to levels driving histogenesis during retinal
development [431], it is plausible that a chemotactic gradient of EGF, among other target molecules, is
generated from the inner retina to diffuse to the outer nuclear layer to influence migration of EGFR-
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expressing RPCs in the inner interphotoreceptor matrix regions. Growth factor gradients have previously
been shown to stimulate proliferation and motility of neural progenitors [439], connective tissue-derived
cells [32], and cancer cells [398, 440] and are utilized in many related biological applications [441]. We
thus selectively investigated the motility effects of the EGF-EGFR pairwise signaling interaction using a
retinal progenitor cell model. To recapitulate gradient events reminiscent of retinal micro-environmental
conditions, steady-state nano-molar level gradients of EGF were generated in this study using a
bioengineered microfluidic system [7].

For cell motility to be elicited, EGF typically binds to its receptor on the plasma membrane, induces
dimerization of EGFR which activates its tyrosine kinase, followed by auto-phosphorylation and/or
internalization of receptor-ligand complexes [442]. Mediators such as phospholipase C-γ1 (PLC-γ1), focal
adhesion kinase (FAK) and Rho GTPases signal canonical downstream pathways including the
PI3Kinase [367] and MAPK signaling pathways [443] responsible for disruption of focal adhesions and
stimulation of cytoskeletal reorganization to facilitate cell motility [137, 444, 445]. We postulated that
similar signaling cascades overlap to govern EGF-induced migration of RPCs.

4.2: INTERACTIONS OF MAPK AND JAK/STAT SIGNALING PATHWAYS ARE PREDICTED TO
GOVERN EGF-INDUCED RPC MOTILITY
Prior to investigating ligand-induced RPC migratory phenomena, we sought the most conclusive ways of
selecting cellular markers for monitoring motility-deterministic genomic changes that may be influenced
by EGF induction. We decided on an in-silico bioinformatics approach to best elucidate the complex
biochemical interactions expected to accompany EGFR activation, and ensure ligand-, tissue-, and
function-type specification for the analysis of ligand-induced RPC movement. This analysis method also
possesses high predictive powers as information supporting resolved biochemical pathways are current,
peer-reviewed and extensive, with versatile tools provided to explore the bioinformatics data. A signaling
interactions network specific for the EGF ligand was thus generated using the Ingenuity Pathway Analysis
(IPA) (Ingenuity® Systems, www.ingenuity.com, Redwood City, CA) network pathway designer tool to
illustrate the molecular network orchestrating cellular decision-making processes stimulated by the ligand.
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Similar ligand-specific pathway designs have been resolved from microarray genomic data, and have
enabled the description of subsets of canonical pathways influencing neuroblast migration along the
rostral migratory stream to the olfactory bulb [297], delineation of transcriptional networks controlled by
the Crx homeobox gene [446], and deciphering EGF-induced signaling dynamics in human carcinoma
cells [447]. We simplified the in-silico technique by relying on a collation of experimental observations
curated in the IPA knowledgebase to predict EGF-induced signaling interactions in the retino-neural
system.

EGF was input into IPA as a seed gene, and direct and indirect molecular interactions associated with the
ligand were generated by annotation to IPA knowledgebase. The genes were then further specified for
their occurrence in the mammalian retino-neural system, and a functional analysis was performed to
identify the biological functions most significant to the resulting molecules in the network. A right-tailed
Fisher’s exact test calculated a p-value determining the probability that each biological function and/or
disease assigned to the EGF custom network was due to chance alone as has been previously
performed [339, 448]. Figure 4.1 displays the predictive network model showing only direct molecular
interactions induced by EGF in mammalian neural retina. Direct molecular connections denote
consecutive nodal binding interactions with high statistical predictability, and help prioritize candidates
when choosing signaling cascades induced by the EGF ligand. Molecules in the network pathway
relevant to the chemotaxis function were identified by a right-tailed Fischer test for statistical significance
(p=8.67E-10) and are outlined or shaded in red in Figure 4.1. Additional cellular functions resolved in this
analysis include cell proliferation, cell-to-cell signaling, gene regulation and cell cycle progression. The
network model also predicts two signaling pathways previously shown to be involved in EGF-induced
motility. Activation of phospholipase C-γ1 (PLCG1) and subsequent hydrolysis of phospho-inositide
bisphosphate (PIP) to yield products that activate protein kinase C (PRKCA) have been shown to
increase cytoplasmic calcium levels which in turn stimulates cytoskeleton reorganization for cell motility
[18, 443, 449]. PRKCA phosphorylates Raf1 (MAP kinase kinase kinase (MAP3K)) activating MAPK1/3
signaling [450]. Figure 4.1 also shows the coupling of EGFR activation to docking proteins GRB2
(Growth factor receptor bound)/SOS (Son of sevenless) via their SHC (Src homology) domain, an
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interaction that can activate HRas and its effector, the protein kinase of Raf1. Raf can initiate
phosphorylation events that activate the ERK1/2 signaling pathway leading to disruption of focal
adhesions in mouse fibroblasts, and enhanced membrane ruffling, both essential processes for cell
motility [18, 443, 451]. The same mechanism can phosphorylate insulin receptor substrate (IRS) and p85,
which result in the activation of phosphoinositide 3-kinase (PI3K) [360], identified to be indirectly involved
in the model network (Figure 4.1). Additionally, RAF1 directly associates with Janus Kinase (JAK) to
activate Signal Transducer and Activator of transcription (STAT) proteins which can bind specific nuclear
regulatory sequences to activate or repress transcription of target genes that are involved in cell motility
[450].

Our bioinformatics custom network model also predicts a potential cross-interaction between the
JAK/STAT and the EGFR tyrosine kinase (RTK)/Ras/MAPK pathways (Figure 4.1). Activated EGFR has
previously been shown to promote JAK-independent tyrosine phosphorylation of STATs, a process
possibly involving Src kinase [450]. MAPK has also been shown to specifically phosphorylate a serine
residue near the C-terminus of most STATs as our model predicts. Although this phosphorylation event
dramatically enhances transcriptional activity of STAT, it is not absolutely required for STAT activity [450].
Our bioinformatics model suggests that RPC motility signaling is a tightly regulated event involving a
chemotactic role for EGF and the MAPK and JAK-STAT signaling pathways, with indirect involvement of
the PI3K pathway. A custom network model displaying an overlay of both the direct and indirect molecular
connections induced by EGF-EGFR activation in mammalian retinal neurons is presented in
Supplemental Figure 4.1.
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Figure 4.1: EGF Signaling Pathways driving migration of RPCs Predicted network of direct molecular interactions influencing RPC migration
in the mammalian retina following induction by the EGF ligand. The network
was generated using Ingenuity Pathway Analysis (IPA) bioinformatics tool.
Molecular components of the EGF signaling pathway are localized to
extracellular space, plasma membrane, cytoplasm and nucleus. Arrows
indicate direct interactions between upstream and downstream pathway
molecules. Molecule shapes outlined or filled in red denote significant
association with chemotaxis as determined by a right-tailed Fischer test.
Molecules displayed on the left represent key chemical groups predicted to
participate indirectly in the network.

4.3:

EGF RECEPTOR IS EXPRESSED AND LOCALIZES TO PUNCTATE STRUCTURES ALONG

CELLULAR PROCESSES IN RPCS EXPOSED TO EGF

To determine the expression and localization of EGFR in RPCs exposed to EGF, we performed
immunofluorescence microscopic analysis of RPCs exposed to 20ng/ml EGF in comparison to controls
with no EGF. Antibodies recognizing both total EGFR and a phospho-specific form of EGFR were used to
detect ligand binding and activation states for the receptor respectively [431, 452, 453]. Our results show
that both non-phosphorylated and phosphorylated forms of EGFR are present in RPCs and that the
receptors localize to the cell body and cellular processes (Figures 4.2B and 4.2F, respectively). EGFR
expression on RPCs appeared similar between 20, 40 and 400ng/ml EGF concentrations and remained
relatively constant even at a saturating ligand concentration of 10000ng/ml (Supplemental Figure 4.2).
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No observable differences were detected between experimental conditions for RPCs adherent to
coverslips labeled with anti-total-EGFR and anti-phospho-EGFR. Immunostaining results were supported
by positive protein blots of EGFR expression obtained from lysates of RPCs exposed to only 20ng/ml,
40ng/ml and 10µg/ml EGF compared to control conditions (Figure 4.2I) and support our predictions that
ligand binding is necessary for EGFR activation. Optical XY sections (0.2-0.4µm apart) made of RPCs
labeled for total and phosho-EGFR were stacked to yield XY projection images (LSM 510, Carl Zeiss,
Thornwood, NY). These EGF-stimulated GFP-positive cells were illuminated using a 488nm argon laser,
and Dylight 594 secondary antibody was excited using a HeNe 594 laser (Figure 4.3). The labeling of
EGFR observed in this work correlates with other studies showing similar results across a range of high
and low EGF concentrations and in both RPCs and adult retinal cell types [431, 454, 455]. For this study,
activated EGFRs represent the requisite cell surface mechanism to activate downstream JAK-STAT and
PI3Kinase pathways involved in RPC motility.
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Figure 4.2I
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Figure 4.2. Immunocytochemical localization of RPC total and phosphorylated EGFR expression. Analysis of
EGFR localization on RPCs was performed using cells isolated from P3-5 transgenic mice expressing green fluorescent
protein (GFP) on the actin promoter (actin-GFP). A) Actin-GFP RPCs express GFP ubiquitously revealing cytoplasm
shape of two RPCs in 20ng/ml EGF, B) Rhodamine bound anti-total EGFR antibody staining reveals robust receptor
localization to cell membrane of soma and processes. C) DAPI labeling of nuclei, D) Overlay of A-C. Panels E-H show
identical imaging parameters as A-D, with the exception that F) utilizes anti-phosphorylated (activated) EGFR labeling.
Western blotting for EGFR expression in RPCs exposed to 0ng/ml, 20ng/ml, 40ng/ml and 10µg/ml EGF (I) show that
ligand binding is necessary for EGFR activation in the retinal progenitor cell types used in our investigations. Results of
control conditions are not shown. Scale: 10-20 microns.
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4.3.1: Exploring Endogenous Receptor Expression in Mitotic Retinal Progenitor Cells
The enrichment bioinformatics analysis approach initially employed in this study (section 2.3.2) entailed
firstly, selecting a set of ancestral motility-deterministic seed genes based on their frequency of
occurrence in association with the motility of retinal neurons in scientific peer-reviewed literature, followed
by a computational analysis for the statistical probability that the selected genes are involved in a nodal
connection, annotated in a functional or canonical signaling pathway, or are part of a network of
intersecting pathways. This analytical method was based on the hypothesis that, as retinal cells were
embryonically related to neuronal cell types, similarities in their genomic and subsequent proteomic
makeup are abound predicting a similar signaling profiles between both cell types. Resolved statistical
probabilities were then used to create predictive network models visualizing probable molecular targets
and probe-worthy biochemical interactions specific to the motility of retinal stem cells. Certain guidance
factors recurred through the step-wise in-silico gene-enrichment process including Chemokine (C-X-C)
motif ligand 12 (CXCL12), Netrin-1 (NTN1), Slit-1/2, Fibroblast growth factor (FGF-1) and its receptor
FGFR, Reelin (RELN) and its receptor Apolipoprotein E receptor 2 (ApoER2), Ephrin B ligand and its
receptor EphB2, and Insulin-like growth factor-1 (IGF-1). These genes were part of our original seed gene
list (Table 2.1), part of the resultant expounded network eligible genes (Table 2.2), and/or part of the
enrichment network of second messenger molecules (Table 2.3). The recurrences of these genes

Figure 4.3: Confocal Image of EGF-stimulated RPCs Confocal images of Actin-GFP+ RPCs stained with antiphospho EGFR to detect phosphorylated EGF receptor. A)
Dylight 594-conjugated anti-phospho EGFR was illuminated
using HeNe 594 laser. B) GFP was excited using an Argon 488
laser. C) displays an overlay of panels A and B. Optical XY
sections were imaged 0.2-0.4μm apart and stacked together
to yield the XY projection image. Scale: 55.6μm
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suggested that they were likely involved in the migration of RPCs or PPC, and merit analysis for their
effect on the migration.

To determine if RPCs endogenously express receptors needed to respond to these guidance factors, we
performed immunofluorescence analysis of four candidate receptors using techniques described above
(section 4.3). The receptors analyzed for included CXC receptor 4 (CXCR4) for CXCL12 ligand, Deleted
in Colorectal Cancer receptor for Netrin-1, Fibroblast Growth Factor Receptor (FGFR), and Roundabout-1
(Robo1) receptor for Slit-1 protein. Figure 4.4B displays Trit-C conjugative labeling of DCC receptor
localization on RPC soma and positive staining for Robo-1 receptors in Figure 4.4E. RPC cytoplasmic
GFP fluorescence appears in Figures 4.4A and 4.4D with DCC and Robo-1 receptor labeling in Figures
4.4B) and 4.4E. Figures 4.4C and 4.4F show overlay of GFP and Trit-C images for both DCC and Robo1 receptors respectively. Staining for the third FGFR using identical protocols gave negative
immunoreactivity results. Detection of CXCR4 expression in RPCs is reported in chapter 5. This selective
expression of receptors for these canonical guidance cues may be ascribed to dynamic genomic profiles
associated with the competence of RPCs and likely guide the chemotactic response of RPCs in vitro and
in vivo. Previous studies suggest that receptor expression of both FGF and EGF contribute to progenitor
motility [456, 457]. FGFR1 expression levels have been observed to decrease significantly with
maturation of freshly isolated rat RPCs while EGFR expression tends to increase[456, 457]. This
observation also raises the possibility that the differential receptor expression observed in our RPC
population is in a state of dynamic flux resulting from states of activation or inactivation of co-receptors
and/or adaptor genes as modeled in our enrichment network (Figure 2.4) and exemplified by the
modulatory role co-expression of ErbB receptors play of EGF binding affinity to its receptor [458] .
However, along with a host of other chemotactic molecules, we were able to correlate findings for these
protein expression studies to in vitro motility function tests. We next analyzed the effects of ligands
specific for our identified receptors on RPCs using Boyden Chamber assays and microfluidic steady state
gradient generators described in succeeding sections below.
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.Figure 4.4: Endogenous Receptor Expression Patterns in RPCs – Following step-wise bioinformatics analysis
for chemotactic molecules influencing RPC migration, the endogenous expression of receptors for four recurring
candidates was assessed in RPCs A) GFP+ RPCs with B) Trit-C conjugated anti- DCC shows receptors on RPC
cell bodies. C) Overlay of images A and B.. D) GFP+ RPCs with E) Positive staining for Robo-1 receptors reveals
punctate receptors on RPC cell bodies.F) Overlay image of D and E. Staining for the third receptor FGFR using
identical protocols gave negative immunoreactivity results. Detection of CXCR4 expression in RPCs is reported in
Figure 5. Scale: 10μm

	
  
4.4:

MOTILITY TESTS SUPPORT PREDICTED ROLE OF JAK-STAT AND PI3KINASE SIGNALING

IN EGF-INDUCED RPC MIGRATION

We used functional validation tests to support or refute the hypotheses that bioinformatics-derived
candidate molecules influence chemotaxis of RPCs and PPCs used in this study. One of the assessment
methods utilizes diffusive perpendicular gradients of test ligands generated in the lower chamber of a
modified Boyden Chamber assay (see section 3.3.1.1), to differentially test attractive or repulsive effects
of the ligands on cells in the upper chamber [364]. Prior to the motility assays, a time-optimization study
described in section 3.3.1.2 was performed using RPCs to identify the duration over which the most
effective motility response is obtained from RPCs on exposure to the EGF ligand. The study was
necessary given varied time intervals employed in many peer-reviewed Boyden Chamber motility studies
conducted with retino-neural and neuroglial cells for different ligands [365, 459] and even when the same
cell type and ligand are used [460, 461]. Given the canonical mitogenic role EGF plays in most cells, an
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MTT cell proliferation assay (section 3.1.3) was also performed before the cell motility tests to examine
growth rate of RPCs in varying concentrations of the EGF ligand over the same time period, so that total
RPC counts obtained upon completion of Boyden Chamber experiments result from ligand-induced
motility effects distinguishable from the proliferative effects EGF may have on RPCs. After determining
effective EGF concentrations driving RPC motility, we explored downstream signaling pathways that
translate EGF ligand-binding effects into executable cell movement phenotypes. Computational modeling
of motility-deterministic EGF signaling in RPCs predicted the roles of canonical MAPK and JAK-STAT
chemotactic pathways in driving RPC motility (Figure 4.1) and we tested our predictions using functional
migration analysis. A common approach that we employed is to chemically inhibit cytoplasmic and
nuclear protein cascades influencing cell motility or the expression of cognate signaling molecules up- or
downstream of pathways under investigation. Therefore, simultaneous identification of key cascade
molecules and hub molecules informed our functional network design specific for RPC movement.

Figure 4.5: Optimizing Incubation Times for Retinal
Progenitor Cell Motility Assay - RPCs were exposed to 40ng/ml
EGF chemotactic concentration for various time durations ranging
from 6-48hrs. Least square means plot modeling interaction
between EGF concentration and duration of incubation on
2
normalized migration of RPCs (N=218; R =0.501).
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4.4.1:

RPCs Exhibit Effective Migratory Phenomena after 24-hour duration in Boyden Chamber Assays.
4

RPC suspensions at a concentration of 5 X 10 cells/350uL media volume was added to transwell filters
submerged into 40ng/ml EGF chemotactic concentration in the lower compartment of a Boyden Chamber
assay for the following time durations: 6-hr, 12-hr, 18-hr, 24-hr and 48-hrs. After incubation at
37°C/5%CO2, Figure 4.5 shows that maximal stimulation of RPC motility was obtained after a 24-hr
incubation period (p=0.0026; Normalized Mean ± SD = 1.97 ± 0.30), and the 12-hr (p=0.0001) and 48-hr
(p<0.0001) incubation conditions (Table 4.1) also allowed for significantly higher RPC migratory rates
compared to control conditions by pairwise Tukey’s HSD statistics. To ensure optimal cell viability and
ligand stimulation the 24hr time-point was selected as the experimental run-times for all Boyden Chamber
motility assays in our studies

Incubation
Replicates
Normalized
p-value
Time (hrs)
(N)
Mean ± SEM
6
24
0.193 ± 0.05
0.6749
12
24
1.88 ± 0.18
0.0001*
18
15
1.29 ± 0.18
0.1067
24
15
1.97 ± 0.30
0.0026*
48
20
1.87 ± 0.21
<0.0001*
Table 4.1: Optimizing Incubation Times for Retinal Progenitor
Cell Motility Assay - Results indicate significant migratory effect
stimulated after 12-hr (p=0.0001), 24-hr (p=0.0026) and 48-hr
(p<0.0001) incubation periods with maximal normalized cell migration
obtained after 24hrs (Mean ± SD = 1.97± 0.30).

4.4.2: Retinal Progenitor Cell Growth rates are Independent of EGF Ligand Concentrations
Approximately 5,000 RPCs in 100µl media volumes per well were prepared in quadruplicates for EGF
concentrations of either 0, 20, 40 or 400ng/ml to which the cells are exposed for 24hrs in a 96-well plate.
An MTT viability assay was then used to assess the ligand concentration-dependent growth rates of the
cells on two different days. MTT is reduced by metabolically active cells in part by the action of their
ubiquitous endogenous cellular dehydrogenase enzymes, that generate reducing equivalents such as
NADH and NADPH causing a change in wavelengths of maximal absorbance [462]. This mitochondrial
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activity level is relatively constant in cells such that an increase in cell number will thus be directly
reflected by an increase in metabolic rates. A standard curve correlating absorbance of reduced
tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) at 575nm to serially diluted
RPC suspensions containing 1000, 2500, 5000, 7500, 10000, 15000, and 20000 cells was used to
compute RPC numbers obtained following the 24-hr growth time. Figure 4.6A shows the MTT
absorbance curve for RPCs created by a bivariate fit method (Absorbance = 0.0299449 + 3.5802e-6*Cell
Number; F(1,63) = 610.89; p<0.0001). Using this equation to compute RPC numbers from spectrometric
absorbance values, Figure 4.6B revealed no change in RPC proliferation rates with increasing EGF
concentrations. Using a Dunnett statistical test with the descriptive statistics for the MTT assay in Table
4.2 there was a doubling in cell number to almost 10,000 RPCs across all conditions over the 24hr time
period (0ng = 9431.1cells ± 1163.68 (p=1.0000); 20ng = 9219.5cells ± 713.36 (p=0.9611); 40ng =
9388.2cells ± 669.46 (p=0.9966) and 400ng= 8779.8cells ± 1544.60 (p=0.4956). This test not only
informs the typical growth rate of our RPCs in the presence of EGF, but also ensures that assessments of
chemotaxis to test ligands can be accurately determined by simply counting the number of transmigrated
RPCs in Boyden Chamber assays.
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Figure 4.6: RPC Proliferation is
Independent of EGF Ligand
Concentrations – To ensure that
characteristic motility effects
observed with RPCs when exposed
to varying EGF concentrations is
not a factor of their overall mitotic
activity, sets of 5,000 RPCs per
well were each exposed to either 0,
20, 40 or 400ng/ml EGF for 24hrs
and then subjected to an MTT
viability assay. A) Standard curve
correlating absorbance of reduced
MTT at 575nm to increasing RPC
number by bivariate fit method
(Absorbance = 0.0299449 +
3.5802e-6*Cell Number; F(1,63) =
610.89; p<0.0001). B) The
standard curve was then used to
compute RPC number following
incubation in the different EGF
concentrations over the same time
duration revealing no change in cell
proliferation as the ligand
concentration changes.
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MTT Assay
# Cell
[EGF]
# RPCs migrated
Dunnett Test
CultureW
(Mean ± SD)
p-Value
ells
0
8
9431.1 ± 1163.68
1.0000
20
8
9219.5 ± 713.36
0.9611
40
8
9388.2 ± 669.46
0.9966
400
8
8779.8 ± 1544.60
0.4956
Table 4.2: RPC Proliferation is Independent of EGF
Ligand Concentrations - Displays descriptive statistics for
the MTT assay with computed RPC numbers realized per
EGF concentration after a 24hr exposure period. For the MTT
proliferation assay, quadruplicate wells per EGF
concentration were used in two (2) different experiments and
results were compared to control conditions using a Dunnett
test.

4.4.3:

Retinal Progenitor Cells Migrate Preferentially to Optimal Physiologic Concentrations of EGF

The Boyden Chamber assay has proven to be one of the most versatile high throughput methods for
assessing the chemotactic influence of test ligands on cells [364, 463, 464], and the range of EGF
concentrations used to validate RPC chemotactic responses in this study have previously been shown to
drive motility in neuronal cell types in similar assays, and are relevant to the retinal microenvironment [32,
367, 465, 466]. Following a chemotactic assay for RPC motility in response to EGF concentrations
ranging from 20ng to 400ng/ml, Figure 4.7 shows a significant increase in RPC motility in response to the
20ng/ml and 40ng/ml experimental conditions compared to control (n=6 Boyden Chambers each) by the
Dunnett statistical test method. There was no significant comparative change in motility of RPCs exposed
to 400ng/ml. Descriptive statistics of RPC movement at each EGF concentration analyzed is reported in
Table 4.3 as normalized mean number of migrated RPCs, SEM and p-value: 0ng/ml = 1.0000 ± 0.09
(p=1.0000), 20ng/ml =3.0981 ± 0.40 (p=<0.0001*), 40ng/ml = 2.0340 ± 0.18 (p=0.0001*) and
400ng=1.1885 ± 0.12 (p=0.7816).
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Table 4.3
[EGF]
ng/ml
0
20
40
400

# of cell
counting fields
30
25
25
25

Mean ± SEM

p-Value

1.00000 ± 0.09152
3.09807 ± 0.40443
2.03397 ± 0.17810
1.18846 ± 0.12303

1.0000
<.0001*
0.0001*
0.7816

Figure 4.7: Boyden Chamber analysis
of
RPCs
to
establish
optimal
physiologic
range
of
EGF
concentrations. The Boyden chamber
provided a high throughput screen to
analyze
EGF
concentrations
and
exposure times. Results demonstrate an
optimal physiologic level of EGF, which
facilitated significant RPC migration over
24hrs. Each unit of normalization equals
122 cells and each error bar is
constructed using 1 standard error from
the mean. Analysis of Boyden chambers
containing either 20ng/ml or 40ng/ml
EGF revealed significant migration
compared to control, 3.0981 ± 0.40
(p=<0.0001*), 2.0340 ± 0.18 (p=0.0001*)
respectively (Table 4.3). * Depicts
significant difference in number of
migrated cells. While 400ng/ml EGF
increased migration, this did not result in
significant migration above control
1.1885 ± 0.12 (p=0.7816). Pooled data
from n=5-6 chambers are presented as
normalized mean ± SEM.

4.4.3.1: Exploratory High-throughput Analysis for Motility-Deterministic Motogens - Additional Transwell
Validation Experiments
Through the course of step-wise bioinformatics analysis to predict motility-inducing chemicals for RPCs,
the Boyden Chamber assay served to validate hypothesis-driven selections made of chemotactic
molecules. Certain other molecules tested were canonical motogens in other cell culture systems
recurring in our analysis and/or suggested by cell migration expert collaborators. Wide range chemotaxis
assays were thus performed using RPCs incubated for 24hrs with selective chemokines in triplicates on
two different days using protocols described in section 3.3.1.1. Results of the chemotactic assays are
presented in Figure 4.8 as mean normalized cell migration numbers by concentration compared to
control conditions using Dunnett tests with pairwise comparison by Tukey’s HSD analysis.

Gama-aminobutyric acid (GABA), a prominent inhibitory neurotransmitter in the mature mammalian CNS,
has been postulated as a chemoattractant to migratory cortical plate neurons during mammalian
embryonic development [239, 467] and for activating glial-dependent induction of neuronal migration
rates in the anterior sub-ventricular zone (SVZ) and rostral migratory stream (RMS) of immature and adult
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mice [468, 469]. Synergistic activity between GABA and glutamate has been shown to affect proliferation
and migration rates of cortical neuron populations along the rostral migratory stream and in the
telencephalon [470-472], and the expression of glutamate receptors has been associated with the
modulation of integrin-mediated migration of oligodendrocyte precursors [473]. The concentrationdependent motility effects of both neurotransmitters are mediated by intracellular cytoplasmic calcium
fluxes that stimulate cytoskeletal rearrangements for cell movement [470-473]. In testing relevant
neuronal concentration of both chemicals on our RPCs, selective increase in GABA concentrations from
5µM to 10µM significantly increased the number of migrating cells (p=0.05*), an indication of an effective
concentration range for our cell type [468]. However, in comparison to control conditions, there was no
significant change in migration rates using
the tested concentrations of both GABA (N=6 wells, F3,47=2.67; p=0.06) and glutamate (N=6 wells,
F3,47=1.33; p=0.28). Growth factors including Vascular endothelial growth factor (VEGF, N=6 wells,
F3,10=3.78; p=0.07) and Platelet-derived growth factor-AA (PDGF-AA, N=6 wells, F3,10=0.48; p=0.71), as
well as Tumor necrosis factor (TNF, N=8 wells, F2,49=2.46; p=0.10) and Glial-derived neurotrophic factor
(GDNF, N=8 wells, F2,49=0.38; p=0.68) similarly did not stimulate RPC migratory responses that were
significantly different from controls.

Importantly, at optimal concentrations, certain chemokines did change the migratory behavior of RPCs.
Transforming growth factor (TGF-α) concentration differential from 0.01µM to 0.02µM dramatically
increased RPC migration rates (p=0.0241) Also 1.5µg/ml (p=0.0135) was determined to be an optimal
chemo-repellant concentration for Fibroblast growth factor acidic (FGF-a, N=6 wells, F3,59=3.60; p=0.02)
for our cell type. Hepatocyte growth factor (HGF) at a concentration of 0.01µM facilitated peak RPC
migration (p=0.0473) as well as 100ng/ml Netrin-1 concentration (p=0.05). The CXC motif ligand 3
(CXCL3, N=8 wells, F3,49=9.80; p=0.0003) stimulated more RPC transmigration as its concentration
increased from 50ng/ml to 100ng/ml (p=0.0002) adding to the list of potential chemotactic factors worthy
of future investigations. The chemokines tested have previously demonstrated chemotactic potential for
neuronal progenitors and adult neural cells [210, 474-476], juvenile and adult retinal cell types [375, 477,
478], and diseased state cells [433, 479, 480] all with correlated expression in neuro-retinal cell types
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[477, 481-483],. Some ligands tested were canonical motogens for a broad range of cell types [238, 460,
484-487], or candidate signaling pathway molecules in the bioinformatics network predicted to govern
RPC migration (section 2.3.2 to 2.3.4, Chapter 5).
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Figure 4.8: High Throughput Analysis for Chemotactic Molecules Inducing RPC Chemotaxis – Through the course of step-wise
bioinformatics analysis to predict motility-inducing chemicals for retinal stem cells, the Boyden Chamber assay served to validate hypothesis-driven
selections made of chemotactic molecules. All assays were performed using P12-P17 retinal progenitor cells (RPCs) incubated for 24hrs with
selective chemokines in triplicates on two different days using the protocol described in section 3.3.1.1. A, D, F) There was a significant increase in
the number of migrated RPCs with increase in concentrations of Gamma- aminobutyric acid (GABA, 5-10μM; p=0.05), Transforming Growth
Factor (TGF-α, 0.01-0.02μM; p=0.0241), and Hepatocyte Growth Factor (HGF, 0.001-0.01μM; p=0.0473). G, J) For Netrin-1 (p=0.05) and CXC
motif ligand 3 (CXCL3, p=0.0002), increased RPC migration observed was determinant upon exposure to specific concentrations of 100ng/ml of
each of the chemicals respectively. Fibroblast Growth Factor-acidic (FGF-a), a candidate pathway molecule was significantly chemo-repellant to
RPCs at maximal concentrations of 1500ng/ml. Asterisks denote significant change in number of migrated RPCs. Similar exploratory validation for
motility-deterministic molecules was also performed using photoreceptor precursors and results are presented in Chapter 5.

140

4.4.4:

Protein Inhibition Assays Validate Key signaling molecules in predicted EGF-induced motility

signaling pathway

To identify which molecules in the EGF signaling pathway contribute to RPC motility, inhibition studies
were performed based on signaling pathways identified in initial bioinformatics analysis at 20ng and
40ng/ml concentrations shown to be significant in Boyden Chamber studies. RPCs were treated with
inhibitors prior to the 24hr motility assay. We compared RPC migration from two independent
experiments for 20ng/ml and 40ng/ml EGF and controls (n=6 chambers each) with each pharmacologic
inhibitor. Statistical significance was determined using the Dunnett test. For each condition, results are
reported as normalized mean of migrated RPCs, SEM and p-value: In 20ng/ml condition, no Inhibition =
1.0000 ± 0.08 (p=1.0000), PD 98059 = 0.7722 ± 0.05 (p=0.1341), AG 490 = 0.5913 ± 0.02 (p=0.0012*),
Wortmanin = 0.4699 ± 0.04 (p=<.0001*), Anti-EGFR = 0.4499 ± 0.10 (p=<.0001*) and AG 1478 = 0.3427
± 0.06 (<.0001*) (Table 4.4). At 20ng/ml, the majority of inhibitors effectively reduced migration. RPCs in
the 40ng/ml condition appeared to exhibit a decreased response to selected inhibitors: in 40ng/ml, no
Inhibition = 1.0000 ± 0.09 (p=1.0000), PD 98059 = 1.5810 ± 0.12 (p=0.0001*), AG 490 = 0.8619 ± 0.04
(p=0.7727) Wortmanin = 0.7779 ± 0.04 (p=0.3368) Anti-EGFR = 0.4370 ± 0.12 (p=0.0002*) and AG 1478
= 0.9433 ± 0.14 (p=0.9933) (Table 4.4). To determine if ligand binding to EGFR and receptor activity
influenced observed increases in RPC motility, we incubated cells with either a monoclonal antibody to
EGFR (anti-EGFR) or a specific EGFR tyrosine kinase inhibitor (Tyrphostin AG1478) to inhibit
phosphorylation of the receptor cytoplasmic domain (Figure 4.9A). Our results show that inhibition of
ligand binding to EGFR or receptor tyrosine kinase selectively inhibited motility of RPCs exposed to
20ng/ml EGF but not to 40ng/ml EGF (Figure 4.9A).

To determine which downstream signaling

pathways were involved in the EGF-induced motility, we also treated cells with inhibitors either to STAT3
(AG490), ERK1/2 (PD98059), or PI3K (Wortmanin). Results in Figure 4A show that inhibition of the JAKSTAT and PI3K pathways led to a significant reduction in RPC motility in response to 20ng/ml EGF. A
significant change was not observed in cells treated with 40ng/ml of EGF. Inhibition of ERK1/2 of the
MAPK signaling pathway did not significantly alter RPC motility in either 20 or 40ng/ml of EGF (Figure
4.9A).
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EGF induces a range of biological responses including proliferation, differentiation and motility by binding
to its receptors and eliciting receptor dimerization and auto-phosphorylation, leading to downstream
signaling cascades [431, 488]. Using western blot analysis, the activation states of ERK1/2, STAT3, and
PI3Kinase intracellular proteins in RPCs incubated in either 20 or 40ng/ml of EGF for 24hr were
determined. Our results show that all three proteins were phosphorylated in RPCs incubated with 20ng/ml
but not 40ng/ml of EGF (Figure 4.9B). Immunofluorescence results in Figure 2 confirm the presence of
phosphorylated EGFR in RPCs exposed to 20ng/ml. These findings suggest that 20ng/ml EGF optimally
stimulates EGFR tyrosine kinase activity and cell motility in our RPC population. The intracellular
signaling cascades involving JAK-STAT and PI3K signaling appear necessary for EGF-induced RPC
motility. The central role of ERK1/2-associated signaling predicted by our model network (Figure 1) may
explain the activated state of the protein in RPCs incubated in 20ng/ml EGF.

142

*	
  

Table 4.4

Figure 4.9: Pharmacologic inhibition of Signaling Pathways Predicted to influence RPC migration
- RPCs were treated with selected inhibitors of signaling pathways identified in IPA bioinformatics
analysis and evaluated for migration over 24hrs using n=6 Boyden Chamber assays per inhibitor. A)
Analysis of RPC migration following pre-treatment with selected inhibitors reveal that significant inhibition
of migration was observed in low 20ng EGF condition using anti-EGFR (0.4499 ± 0.10 SEM (p=<.0001*)
to antagonize EGFR cell-surface binding, AG1478 0.3427 ± 0.06 SEM (<.0001*) to inhibit
phosphorylation of the EGFR cytoplasmic domain, AG490 (0.5913 ± 0.02 SEM (p=0.0012*) to inhibit
STAT3 activity and Wortmanin (0.4699 ± 0.04 SEM (p=<.0001*) to inhibit PI3K activity (Table 4.4). The
use of PD98059 to inhibit ERK1/2 activity did not result in significant inhibition of migration. In the
presence of a higher 40ng/ml concentration of EGF, significant inhibition of migration was observed with
anti-EGFR (0.4370 ± 0.12 SEM (p=0.0002*), while PD98059 1.5810 ± 0.12 SEM (p=0.0001*) increased
migration (Table 4.4). Statistical significance was determined using Dunnett analysis and data are
presented as normalized mean. Each unit of normalization equals 227 cells and each error bar is
constructed using 1 standard error from the mean. Drug inhibition was also numerically computed by
expressing the ratio of cells migrating towards EGF in the presence and absence as % inhibition values
(Table 4.4). Consistent high % inhibition values for anti-EGFR inhibitor indicate that ligand-receptor
binding kinetics appears most relevant in determining RPC chemotactic response to EGF. Negative
values denote unsuccessful inhibition results. B) Robust activation of identified signaling pathways was
observed in 20ng/ml EGF concentrations. Western Blot analysis demonstrated the presence of both
non-phosphorylated (inactivated) and phosphorylated (activated) STAT3, ERK1/2 and P13K proteins
RPCs. Inhibition with significant p-values are denoted with an asterisk.
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4.5: EPIDERMAL GROWTH FACTOR (EGF) GRADIENTS STIMULATE CHEMOKINETIC MIGRATION
OF INDIVIDUAL RPCS IN BRIDGED µ-LANE MICROFLUIDIC SYSTEM ANALYSIS.
Temporal control and quantitation of stable chemical gradients are difficult to accomplish in Boyden
chamber assays [364] but are needed physical parameters to recapitulate endogenous retinal
microenvironmental gradients. In this study, we accomplish this task by employing the bridged µ-lane
system, and we show that the concentration of EGF varies in a mathematically defined manner, is
spatially and temporally quantifiable, and becomes constant for a defined period, once steady-state
gradients are achieved (Figure 3.10C and [211, 489]). A number of studies have shown that EGF is
capable of stimulating motility in the form of chemotaxis (directional migration) and chemokinesis (random
migration) [427, 490, 491]. The employment of the bridged µ-lane system has enabled time-lapse imaging
of individual RPC responses to different gradients and concentrations of EGF along the microchannel,
providing data to distinguish between chemotactic and chemokinetic migratory dynamics (Figure 4.10).
After exposing RPCs to gradients of 20, 40 and 400ng/ml EGF in the microchannel system, we analyzed
accumulated maximum distance of migration and single cell center of mass (COM) directionality. COM
defines the average point of all cell endpoints and quantifies migration direction. Analysis of three
independent microfluidic experiments per condition revealed that RPCs exposed to gradients generated
from 20ng/ml EGF exhibited significantly higher motility including accumulated maximum distances
(328.3±109.04 SD) compared to control channels without EGF (238.4±68.16 SD) (Dunnett test,
p=0.0129) (Figure 4.11). Accumulated distance migrated by RPCs in 40ng/ml EGF (237.71 ± 49.50 SD)
and 400ng/ml EGF (293.53 ± 78.98 SD) microchannel conditions compared to control did not yield
significant differences, p= 1.0000 and p= 0.1445 respectively. Analysis of center of mass (COM) of RPCs
yielded non-significant differences in both medians (Brown-Forsythe, p=0.1622) and means among test
groups indicating no significant chemotactic or directed migration between EGF concentrations compared
to control: 20ng/ml (0.27 ± 54.06; p=0.7965, 40ng/ml (0.21 ± 31.71 p=0.7774) and 400ng/ml (4.00 ± 37.45
p=0.5776) (Figures 4.10 and 4.11).

=
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Figure 4.10. Trajectory analysis
paradigm for RPC migration in
microfluidic
gradients
at
increasing distances from the EGF
source. Positional tracking of RPCs
migrating in steady state gradients of
EGF generated in a 13mm bridged
μ -lane device over a 24hr period
was visualized using Ibidi Migration
software to generate wind-rose plots
(A-D). A) Cell tracking results are
depicted at increasing distances from
the source reservoir (SRR): 0-500μ
m (I), 2000-3500μm (II), 5000-7000
μ m (III). B-D) Depiction of RPC
trajectory plot mapping in steadystate gradients of 20, 40, and
400ng/ml EGF analyzed from source
reservoirs (SRR) to sink reservoirs
(SKR).
A
trend
of
reduced
chemokinetic migratory migratory
dynamics can be observed with
increasing EGF concentrations up to
400ng/ml. Red and black traces
indicate RPCs with negative and
positive COM, respectively. Statistics
resulting
from
trajectory
data
depicted here and analyzed for
maximum distance and center of
mass are reported in Table 4.5. The
xand
y-axis
denote
RPC
displacement in horizontal and
vertical directions, respectively.

In Figure 4.10, chemokinetic motility is visualized in trajectory plots of RPC movement tracked for 24hrs
across EGF gradients. In Figure 4.10, red trajectories depict negative COM or cell movement away from
the EGF source reservoir while black trajectories depict positive COM or cell movement towards the
source reservoir. Greater multi-directional displacement of RPCs in the 20ng/ml EGF condition can be
observed in this figure compared to other EGF gradient conditions. The degree of chemokinetic
movement is also seen to decrease with increasing distance from the EGF source reservoir. A sample
time-lapse video recording corresponding to the trajectory plot of RPC movement in EGF-gradients
(Figure 4.10) is provided as Supplemental Movie S1.
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4.6:

4.6.1:

SUMMARY OF FINDINGS

Bioinformatics Modeling of Signaling Networks

To refine targets from the wide range of biochemical signaling molecules involved in neural progenitor
migration, we performed bioinformatics analysis using IPA software. Our bioinformatics-derived network
molecules identified two signaling pathways previously shown to be involved in EGF-induced motility
(Figure 1). Gene network databases have been used to predict connectivity of genes involved in
chemotactic pathways of migrating adult neural progenitors to specific lamina [245, 251]. Bioinformatics
approaches have also been used to validate molecular network interactions directing adult neuronal
progenitor chemotaxis during neurogenesis in the sub-ventricular zone and cortex [247-250]. In this
study, the bioinformatics predicted EGF signaling network resulted in valid molecular targets that were
shown to influence RPC motility at the receptor and second-messenger level in Boyden chamber and
microfluidic devices.
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We successfully used bioinformatics to map intracellular EGF signaling pathways in RPCs, inhibit
pathway molecules, and evaluate the influence on motility. Bioinformatics modeled gene networks have
previously been shown to successfully predict and target molecular interactions in vitro and in vivo [247,
492]. Here, RPC migratory dynamics were analyzed in response to nanomole EGF concentrations alone
and in the presence pharmacologic modulation of signaling pathways [454]. Stimulation and inhibition
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Figure 4.11: Analysis of RPC maximum accumulated distance and center of mass dynamics in microfluidic
bridged μ-lane EGF gradients - A) RPC maximum displacement was analyzed in the absence or presence of varying
EGF gradients measured post-steady-state within a 24hr period, and results are expressed as mean ± standard deviation
for three independent studies per EGF concentration. Only RPCs cultured in 20ng/ml EGF exhibited significantly higher
maximum displacement compared to cells in the control microchannel (328.26 ± 109.04, p=0.0166), Dunnett Test. B)
Similar measurements for center of mass (COM) of RPCs yielded non-significant differences in both means and medians
among test groups (Brown-Forsythe, p=0.1622) indicating no significant chemotactic or directed migration between EGF
concentrations. This reveals that the increased Maximum accumulated distance response can be defined as chemokinetic.
Table 4.5) displays averaged maximum distance accumulated and COM of RPCs in defined EGF concentration gradients
with their respective standard deviation and p-values results from the Dunnett statistical test. Significant p-values are
denoted with an asterisk.
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parameters were initially screened using high-throughput Boyden assays. In the presence of optimized
exposure time and concentration parameters, individual RPC migratory dynamics were analyzed in
bioengineered microfluidic devices with defined quantifiable EGF gradients. Our results show that low
nanomole EGF concentration ranges stimulate activity of JAK-STAT and PI3K pathways resulting in
increased chemokinesis of RPCs. The results shown in this study further our understanding of molecular
and biochemical interactions necessary for RPC motility and may help guide the development of
optimized cell-replacement transplantation paradigms.

4.6.2:

Boyden and Microfluidic Approach

Our Boyden analysis demonstrated that EGF stimulates migration of RPCs at selective uniform
concentrations (Figure 4.7). In Boyden chamber assays, steep gradients of EGF generated at the start of
experiments dissipate and rapidly become uniform. We utilized Boyden analysis as a high-throughput
screen of multiple concentrations and incubation times. In contrast, microfluidic analysis provides steadystate gradients maintained along the length of the microchannel as a function of time. The bridged µ-lane
system can sustain steady state concentrations and concentration gradients of ligands over time spans of
48-96 hours. The double-layered PDMS design exploits the ultralow bulk velocities generated by density
differences of test ligand concentrations that ensure continuous one-dimensional transport within the
microchannel by convective diffusion. Numerical simulation of mass transport within the bridged µlane
system combines quantification of 2D continuity, convective-diffusion, momentum, and hydrostatic
pressure that are computed using the Finite Element Method [7]. Previously, the microfluidic device has
been used to generate gradient profiles that span over five orders of magnitude and over time scales that
approach the microenvironments generated in vivo. Microfluidic technology has proven highly valuable in
the creation of biomimetic microenvironments [7] and has been used to assess proliferative, survival and
differentiation responses of neural progenitor cells to concentration gradients of extracellular signaling
molecules [439, 493]. In this study, live-cell time-lapse microchannel data was analyzed for maximal
accumulated distance and COM. The data revealed that steady-state EGF gradients were capable of
influencing RPC motility and that chemokinesis was enhanced at low concentrations (Figures 4.10 &
4.11).
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4.6.3:

RPC Motility is influenced by low EGF ligand concentrations

Earlier investigations using retinal Muller glia and neurons revealed that binding of EGF to its receptor is
highly specific, concentration dependent, and saturates at approximately 80-100ng/ml EGF [432, 494,
495]. Specificity of EGF binding has been associated with higher numbers [494] and/or varying states of
EGFRs [454, 495]. High and low affinity receptor states differ in their associations with the EGF ligand,
and their activation differentially influences cellular function [454, 494, 495]. The number of high-affinity
receptors has been suggested to be 5-10% of the total EGFR number [454, 455, 495]. Similarly, the type
and proportion of EGFRs recruited and activated may differ with varying concentrations of EGF. Low
levels of EGF have been reported to bind primarily high affinity receptors which trigger intracellular
signaling proteins including Erk, Akt, Shc1, CrkL and Gab1, while higher concentrations of EGF bind lowaffinity receptors activating PLCγ1 and the Stat proteins [454]. Low- and high-affinity EGF receptors are
derived from the same mRNA transcript and low affinity receptors can be converted to high affinity
receptors to modify cell response dynamics [454]. Low-affinity receptor activation has been shown to
modify integrin receptor levels and decrease cell adhesion. EGF concentrations capable of activating both
high and low-affinity EGF receptors have been shown to facilitate cell motility in vitro and in vivo [384,
427, 454]. Our results showing stimulation of RPC migration at low EGF concentrations of 20ng/ml and
40ng/ml suggest that the increased motility is mediated in part by high-affinity receptor signaling. Further
analysis could reveal specific ratios of high and low affinity EGFR dynamics involved in RPC motility.

4.6.4:

RPC Motility is Directed by the EGFR JAK-STAT Pathway

Our results showing reduced motility of RPCs in response to steric inhibition of EGFR and chemical
inhibition of receptor activity strongly suggest the involvement of EGFR and downstream activity in EGFinduced RPC motility. EGF signal transduction pathways are shaped by interactions of many components
of signaling networks. A subtle difference in input signals and/or interaction kinetics may result in
differential response patterns. The kinetics (i.e. the transient and steady-state behavior) of the cellular
response to EGF depends on many factors, including the number of receptors displayed on the cell
surface; the concentration of the growth factor, docking, and target proteins; and their initial activity states
[496]. Moreover, other signaling pathways that share or interact with one or more components of the
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EGFR pathway can influence the kinetic pattern of EGFR signaling [497]. EGF receptors form either
homo- or hetero-dimers following ligand binding, each dimer showing different affinity for ligands and
different signaling properties. Often, components of different pathways interact, resulting in complex
signaling networks, components some of which are described in Figures 1 and 4. These networks exhibit
emergent properties such as integration of signals across multiple time scales, generation of distinct
outputs depending on input strength and duration, and self-sustaining feedback loops. Furthermore, there
are slower processes involving receptor internalization and its subsequent degradation in lysosomes,
which have an important role in EGF-induced signaling [496, 498]. In this study, RPCs stimulated with
20ng/ml of EGF expressed activated forms of EGFR, ERK1/2, STAT3 and PI3K. Analysis of Inhibition of
individual downstream signaling pathways suggests that EGF-stimulated motility involves the JAK-STAT
and PI3K pathways and not the ERK1/2 pathway. These findings suggest differential activation and
inhibition of canonical EGF signaling pathways.

Additional studies could explore additional factors

involved in EGF signaling including multiple interacting ligands; receptor density/degradation and
overlapping signaling network dynamics.

4.6.5:

RPCs Show Chemokinetic Migratory Response in low nanomole EGF Microfluidic Gradients

Defined steady-state gradients generated using microfluidics provide mathematically modeled,
quantitative information about ligand concentrations in a controlled environment. By carefully choosing
the concentration of the input, a wide variety of gradient steps and concentration ranges can be created in
microfluidic devices [364]. Applying a 20ng/ml EGF media concentration in the bridged µ-lane device
stimulated the greatest chemokinetic responses at regions closest to the source reservoir (SRR), where
the chemical gradient is steepest (Figure 5). The ligand concentration at 18hrs in the region of the
channel closest to the SRR is approximately 63% of the starting EGF concentration [32] suggesting that
RPCs respond to steep gradients of low EGF concentrations. The results are supported by several
studies describing saturating effects of EGF in signal transduction and motility [32, 454, 494]. Our study
is the first demonstration of the effect of controlled gradients on RPC motility in vitro.
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Findings from this study defining EGF receptor ligand interactions and emergent motility dynamics may
be useful towards developing in vitro models of endogenous signaling guiding transplanted RPC motility
in vivo. Sub-retinally transplanted RPCs migrate through interphotoreceptor matrix to reach appropriate
retinal lamina for repair. To accurately model RPC migration, future microfluidics studies may replicate the
topological and biochemical properties of the interphotoreceptor matrix by employing three-dimensional
biomimetic extracellular matrix gel composed of laminin, fibronectin and collagen proteins as well as
chondroitin sulfate proteoglycans and glycosaminoglycans [499, 500]. An ECM substrate available for
initial testing is MaxGel, and engineered hydrogels can be covalently modified with chondroitin and
heparin-sulfate proteoglycans and peptides [501, 502]. Transparent synthetic ECM matrices form porous
soft gels along the length of the microchannel, allowing formation of a chemical gradients and visual
tracking for quantitative assessment of morphology and motility. A number of recent studies have shown
that stem and progenitor cells cultured in 3D gels attach to and remodel their extracellular matrix
environments allowing for proliferative and migratory dynamics comparable to those observed in vivo
[503-505]. The use of 3D gels to mimic the retinal microenvironment could enhance future in vitro models
analyzing RPC motility.

In summary, we present experimental work showing a mode of migration of RPCs in microfluidic
environments, which was previously not described. We demonstrate that EGFR activation of downstream
JAK-STAT signaling pathways in our population of RPCs is optimal at low EGF concentrations. The
inhibition of these pathways results in inhibition of migration. In addition live-cell imaging of RPCs in
defined gradients demonstrates that EGF induces chemokinetic migratory dynamics. This work
represents an important step in the analysis of transplantable RPC populations in physiologic
concentrations comparable to those found in developing and disease retina [431]. The data presented
here provides a model of stem and progenitor cell migratory analysis to inform future transplantation
strategies.
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CHAPTER 5:

RESULTS: MODULATORY EFFECT OF STROMAL DERIVED FACTOR-1Α ON

TRANSPLANTABLE RPC and PPC CHEMOTAXIS VALIDATES COMPUTATIONAL MODELING TO
PREDICTING MOTILITY-DETERMINISTIC SIGNALING.

5.1:

Introduction

In this chapter, biomimetic in-silico modeling of signaling present during retinal transplantation was
performed by resolving ligand-receptor interactions and their downstream signaling pathways influencing
migration of PPCs in the extracellular matrix of light-damaged retina. Figure 2.7 displays a flowchart of
the bioinformatics analysis protocol used to analyze combinations of microarray gene expression
datasets that represent the interacting tissues. Among the chemotactic interactions identified from the
bioinformatics analysis, stromal derived factor (SDF-1α) and its C-X-C motif receptor 4 (CXCR4) were
found to key mediators of PPC chemotaxis, exerting their effect on PPCs in a gradient-dependent manner
via the canonical JAK-STAT signaling pathway. The in silico prediction model was then validated in vitro
using cell migration assays to generate uniform and steady state gradients in environments typifying the
laminar matrix of the host retina.

5.2:

Preliminary Functional Annotation and Selective Canonical Pathway Analysis of Matched Dataset

Pairs
To effectively examine the molecular basis for PPC motility after transplantation into damaged retina, we
modeled typical donor and recipient tissue interaction by pairing microarray data of 10-week old lightdamaged retinal pigment epithelium (RPE) and neurosensory retina (NSR) (Geo Accession GSM928109)
[340] with genomic data obtained from either donor E17.5 Bac-Crx-EGFP cone (Geo Accession
GSE25607) [424] or P4 mouse Rho-EGFP rod (Geo Accession GSE29318) [423] precursor cells. At
these ontogenetic stages, the post-mitotic PPCs have been observed to exhibit optimal migration and
integration into host retina upon sub-retinal transplantationAlso the developmental time range of isolation
coincides with periods of PPC migration to appropriate laminar loci [112, 230, 506]. We compiled fourmatched dataset pairs - NSR/Rod, NSR/Cones, RPE/Rod and RPE/Cones, and vetted our compilation by
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selecting only genes with statistically significant expression over their negative FAC-sorted counterparts
using a right-tailed Fisher Exact test T-test threshold of p≤0.05.

We next employed an Ingenuity Pathway Analysis (IPA) network algorithm (Ingenuity Systems, Qiagen,
Redwood City, CA) to map seed gene identifiers in the p-value sorted matched datasets to small
networks in the IPA knowledgebase based on their connectivity to the curated network molecules. A righttailed Fisher exact test (p<0.05) then calculated the probabilistic fit between the networks, lists of
biological functions and canonical pathways sourced from results of published experimentally data
curated in the IPA knowledgebase. Scores were assigned to networks based on their probability of
containing molecules in our data sets by random chance [507]. IPA analysis parameters specified 140
molecules per network for the top 10 functional networks associated with each matched dataset. Figure
5.1 presents an overview of the top ten (10) functional clusters in the IPA knowledgebase associated with
the NSR/Rods (Figure 5.1A) and RPE/Cones (Figure 5.1C) datasets. These functional categories are
plotted against the negative logarithm of the Fisher exact test p-value and higher bars denote functions
with greater likelihood of occurrence given the expression states of genes in our datasets. Cellular
movement function ranked highest for genes in both NSR/Rods (4.11E-83≥p≤8.73E-14; N=507
molecules) and RPE/Cone (2.55E-24≥p≤3.36E-06; N=194 molecules) datasets. Other top predicted
molecular and cellular functions common to both NSR/Rod and RPE/cone dataset pairs include cell-tocell signaling and interactions, and tissue and cellular development. Of utmost importance to this study
are the expression profiles of genes mapped to the cellular movement function. An IPA molecular activity
prediction tool was used to further analyze these gene expression profiles for their interaction effects on
PPC motility.

Canonical cytokine and growth factor signaling pathways in the IPA knowledgebase that contain
significantly expressed genes from each of our matched datasets were also ranked based on their
probability of containing the molecules in our datasets by chance alone in a right-tailed Fisher’s exact
test. Figures 5.1B and 5.1D displays graphical results of the canonical pathway analyses for the
NSR/Rods and RPE/Cone datasets respectively showing a p-value threshold of 0.05, and ratios
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comparing the number of our matched dataset genes in each canonical pathway to the total number of
genes originally designated to the respective pathway in the IPA knowledgebase. Resolved canonical
pathways common to both NSR/Rod and RPE/Cone matched datasets include interleukins IL-1 and IL-8
signaling, C-X-C motif receptor 4 (CXCR4) signaling, Transforming Growth Factor (TGF-β) signaling and
transcriptional regulator high mobility group box 1 (HMGB1) signaling. Z-scores predicting the likelihood
that a signaling pathway will be activated (orange bars) or inhibited (blue bars) given the expression state
of genes in our datasets was used to color-code the bar chart, with color gradations corresponding to
degrees of activation or inhibition. These Z-scores infer likely canonical pathway activity based on a
model that represents experimentally observed causal relationships between the genes when the
canonical pathway is activated or inhibited. Even though over 80% of the predicted canonical pathways
are common to both NSR/Rods and RPE/Cone datasets as shown in Figures 5.1B and 5.1D,
comparative Z-score valuations of individual canonical pathways in both matched datasets reflect the
unique gene expression profiles of each cell/tissue type and may inform future selections of donor
photoreceptor precursor cells for reparative transplantation experiments. For instance, inhibition of
CXCR4 signaling activity is predicted in the NSR/Rods dataset (Z= -1.706; p= 9.37E-07; 29/152
molecules (Ratio= 0.191)), however the reverse is predicted in the RPE/Cones dataset although with
lower statistical confidence (Z= 1.00; p= 4.59E-02; 9/152 molecules (Ratio=0.059)). In some other
instances, consistent canonical pathway activity is predicted as with IL-8 signaling in the NSR/Rods (Z= 1.732; p= 5.53E-06; 31/183 molecules (Ratio=0.169)) and RPE/Cone (Z= -0.832; p=4.5E-03; 13/183
molecules (Ratio=0.071)) datasets, and the acute phase response signaling indicative of tissue trauma in
both NSR/Rods (Z=1.964; p =8.48E-06; 29/169 (0.172)) and RPE/Cones (Z=1.387; p=4.99E-06; 18/169
molecules (Ratio =0.169). Although some of the canonical pathway Z-scores fall below the conventional
threshold (-2.0≥ Z ≤2.0), they illuminate dynamic underlying physiological signaling cascades that may be
triggered at onset of rod or cone PPC grafting into damaged adult retina. Results of summary analysis of
RPE/Rods and NSR/Cones matched datasets are presented as supplemental figures 5.1A/C and
5.1B/D respectively.
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Figure 5.1: Summary Results of Bioinformatics Core Analysis of Matched PPC Receptor / ECM ligands from Damaged Retina – Using the Ingenuity
Pathway Analysis (IPA) software platform, extracellular matrix genes of damaged retinal models matched to plasma membrane receptors of either rod or cone
photoreceptor precursors were analyzed to resolve canonical pathways and molecular and physiological functions annotated to each respective matched dataset.
Analysis parameters specified 140 molecules per network for the top 10 functional networks associated with each matched dataset by random chance using a
right-tailed Fisher Exact test (p<0.05). A) Top ten functional clusters in the IPA knowledgebase associated with ECM molecules of neurosensory retina (NSR) and
rod receptors (NSR/Rods, N=2013 genes) reveals cellular movement function as the top functional category (outlined in red). C) Similar results were obtained
using matched dataset of retinal pigment epithelial ECM molecules and cone receptor genes (RPE/Cones, N=667 genes). B and D) Cytokine and Growth factor
canonical signaling pathways that significantly overlapped with each matched dataset were selectively ranked based on their probability of annotating curated
seed genes in our molecular datasets by chance alone using a right-tailed Fisher exact test with a p-value threshold of 0.05 (shown in graphs). Ratios comparing
the number of our matched dataset genes in each canonical pathway to the total number of genes originally designated to the pathway are also depicted on the
Y-axis with individual pathway values connected by a line graph. This ranking is also color-coded by assigned Z-scores that predict activation (positive Z-score,
orange bars) or inhibition (negative Z-score, blue bars) of the canonical signaling pathways based on the expression state of genes in our matched datasets.
Resolved canonical pathways common to both NSR/Rod (B) and RPE/Cone (D) matched datasets include interleukins IL-1 and IL-8 signaling, C-X-C motif
receptor 4 (CXCR4) signaling, Transforming Growth Factor (TGF-β) signaling and transcriptional regulator high mobility group box 1 (HMGB1) signaling.
Summary analysis of RPE/Rods and NSR/Cones matched datasets are presented as supplemental figures 5.1A/C and 5.1B/D respectively.
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Following functional annotation and canonical pathway analyses of our matched datasets, molecules
specified to IPA’s cellular movement function cluster were used to design custom signaling networks
predicting direct ligand-to-receptor interactions governing PPC motility in the light-damaged retina. The
predictions were based on our dataset gene expression profiles, and the consequent effect of the
expression profiles on tissue interactions, and on cellular movement function. In examining the gene
expression states of these cell movement genes culled from our ligand-receptor matched data sets,
Figure 5.2 displays sample volcano plots correlating fold change ratios of the genes (X-axis) to the
overall significance of the change in their expression (Y-axis) from two of our four matched donorrecipient dataset pairs (NSR/Rods, N=507 cell motility genes) and (RPE/Cone, N=194 cell motility genes).
In the figure genes are represented as dots colored to depict their subcellular localization revealing that
less than 10% of the cell motility genes exhibited more than 2-fold change in expression levels in both the
NSR/Rods (Figure 5.2A) and RPE/Cones (Figure 5.2B) datasets. It is possible that low levels of receptor
expression in both rod and cone PPcs may explain limited motility by these cells in transplantation
studies.

Low PPC integration rates have been reported even when donor cells were grafted into

damaged retinal microenvironments where on would predict an optimal level of released extracellular
cues are present [112, 148, 230]. If the impedance in PPC motility is attributable to low receptor
expression levels, it may be a result of PPC receptor desensitization following isolation from their native
retinal environment and deprivation of exogenous ligand stimulation, stress responses or structural
aberrations [278, 508, 509]. Modified volcano plots of cell motility genes resolved from the NSR/Cones
and RPE/Rods matched datasets are also provided as Supplemental Figures 5.2A and 5.2B
respectively. A listing of these genes that correlate cell movement functional cluster in IPA are presented
according to their subcellular locations as plasma membrane receptors expressed on rods
(Supplemental table 5.1A) and cones (Supplemental table 5.1B) and ligands released from
neurosensory retina (NSR) (Supplemental table 5.1C) and retinal pigment epithelia (Supplemental
table 5.1D), ranked by their fold change values.

We postulated that chemotactic interactions resolved in our custom network designs would be supported
by experimental testing, serving as proof-of-principle of the biological applicability of in-silico
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Figure 5.2: Modified volcano plots of cellular movement genes with statistically
significant expression states resolved from transplantable photoreceptors and damaged
recipient adult retina matched microarray dataset pairs – To mimic typical transplantation
paradigms, normalized gene transcripts of donor mouse P4 Rho-EGFP rod and mouse E17.5
Bac-Crx-EGFP cone photoreceptors and light-damaged adult mouse recipient retina were
sorted by their tissue and subcellular localization, filtered for their statistical difference (p=0.05,
T-test) from negative-FAC-sorted replicates, and ligand-receptor pairs matched. Following
bioinformatics analysis, genes annotated to the cellular movement function in the Ingenuity
Pathways Analysis (IPA) knowledgebase were graphed. A) Cell motility genes from matched
pairs of rod receptors and extracellular membrane (ECM) ligand of damaged neurosensory
retina (NSR) (N=507 genes). The negative logarithm of their p-values was plotted against fold
change. These genes were used to design signaling interaction networks predicting activating
or inhibitory interactions between ligand and receptor pairs based on their expression states. B)
A similar analysis was performed using resolved cellular movement molecules from matched
ECM genes released from the light-damaged retinal pigment epithelia (RPE) and receptors
expressed on transplantable cone precursor cells (N=194 genes). Volcano plots of NSR/Cone
Receptor and RPE/Rod cell motility genes are also presented as supplemental figures 5.2A and
5.2B respectively. Tables listing these selected gene pairs are presented in supplemental tables
5.1A and 5.1B for NSR/Rods and RPE/Cones matched datasets respectively.

157

simulation of PPC transplantation paradigms. In silico modeling has potential to be a cost-effective
method to investigate biochemical interactions in multitudes of tissue types and disease conditions.
Systems-level analyses of microarray data from retino-neural tissue lysates have similarly been used to
successfully predict gene ontology and biological function under healthy and diseased conditions [245,
297, 340, 510-513]. We explore this mode of analysis by correlating changes in individual gene
expression states to predicted interaction effects and cellular functions specific to motility. The probability
that an interaction between two such gene products would activate or inhibit a function is determined by
the statistical fit of the expression states of genes in our data set, to the gene expression states for
functional activation or inhibition in the IPA database. Using cellular movement as the selected function,
the resultant networks hold predictive powers, as individual components of resolved chemotactic
signaling cascades that can be manipulatied to improve transplantable PPC migration..

5.3:

Motility-deterministic network pathways characterize biochemical interactions governing migration

of transplantable PPCs in light-damaged adult mouse retina.

In designing motility-deterministic network pathways, significantly expressed genes from each of our
matched dataset libraries that map to the cell movement functional cluster – (NSR/Rods = 507 molecules;
NSR/Cones = 223 molecules; RPE/Rods = 479 molecules; RPE/Cones = 194 molecules), were specified
to extracellular matrix and plasma membrane locations, and their direct connections determined by
experimentally reported connections in the IPA knowledgebase. Overlaying the expression profile of
these genes using the IPA molecular activity prediction (MAP) tool enabled the prediction of each gene’s
effect on its cognate downstream molecule. From each matched dataset pairing, we selected for only
released ligands predicted to activate or inhibit their downstream cognate receptor at their current
expression states. This approach identifies active motogenic stimulation initiated in the light-damaged
retina. Figures 5.3A and 5.3B displays custom signaling network designs for the NSR/Rods and
RPE/Cones matched datasets while network designs for NSR/Cones and RPE/Rods gene sets are
displayed as supplemental figures 5.3A and 5.3B respectively. In these figures, the connecting edge
lines between genes identify their native interactions and the line coloring represent overlaid MAP
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predictions of the outcome of the interactions between the genes at their up-regulated (red gene color) or
down-regulated (green gene color) expression states. The MAP algorithm predicts downstream activation
(orange line color) or inhibition (blue line color) of non-IPA annotated molecules by their biochemical
interactions with a seed gene set of “known” neighboring molecules in our dataset. A Z-score is then used
to quantify the confidence of the prediction, which decreases with nodal distances away from the “known”
seed gene. Literature findings of a variety of biochemical interactions are taken into consideration in
making the predictions including transcription, phosphorylation, translocation and proteolytic activity. In
predictions where the expression state of the downstream molecule in our dataset does not coincide with
IPA-curated experimental findings with respect to the expression state of the upstream gene, a “Findings
inconsistent” yellow line color is used to differentiate such relationships.

In Figure 5.3A, upregulated matrix metalloproteinase (MMP14) expression is predicted to inhibit
endocytic and ECM clearance activities of LRP-1 gene product LDL receptor-related protein (LRP-1) [9],
and regulation of cell-ECM binding by discoidin domain receptor (DDR1) [28]

and transmembrane

proteoglycan syndecan (SDC1) [35], important requisites for PPC migration and invasion. Leukemia
inhibitory factor (LIF) release could be a result of the Muller glial-derived neuro-protective mechanism
typical in injured retina [36], and is predicted to activate its receptor, which may trigger replication of
downstream transcriptional and protein modification processes [37]. Canonical chemotactic factors C-X-C
motif chemokine 12 (CXCL12), glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor
(BDNF) and transforming growth factor beta 3 (TGFB3) are all expressed in the light-damaged retina and
predicted to interact with their cognate receptors raising the possibility that effective migratory phenotypes
can be induced. In Figure 5.3B, activation of the chemokine C-X-C receptor 4 (CXCR4) by
chemoattractant cytokine macrophage migration inhibitory factor (MIF), and kinase insert domain receptor
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Extracellular Space

Figure 5.3A: Molecular Activity Prediction Identifies Downstream Ligand-Receptor Motility-Deterministic
Interactions in the Matched NSR/Rods Dataset – Downstream signaling interactions between motogenic ECM
ligands released from light-damaged neurosensory retina (NSR) and their cognate receptors expressed on rod PPCs
were correlated to the expected causal interaction between each molecular pair at their given expression state (upregulation (red genes) or down-regulation (blue genes)) using the molecular activity prediction tool of the Ingenuity
Pathway Analysis (IPA) protocol suite. Predictions of activating (orange connections) or inhibitory (blue connections)
effects on downstream genes were then computed based on similarities or differences between a causal effect model
of known gene expression states and the expression profile of our resolved matched dataset genes. Yellow
connecting lines denote interactions between genes whose expression states differ from the curated information in the
IPA knowledgebase supporting such an interaction. Molecular interactions whose downstream effects are not
predicted, as well as all upstream signaling relationships have been excluded from the network for clarity. Upregulated
matrix metalloproteinase (MMP14) expression is predicted to inhibit endocytic and ECM clearance activities of LRP-1
gene product LDL receptor-related protein (LRP-1) [9], and regulation of cell-ECM binding by Discoidin Domain
Receptor 1 (DDR1) [28] and transmembrane proteoglycan Syndecan (SDC1) [35], important requisites for PPC
migration and invasion. Leukemia inhibitory factor (LIF) release could be a result of the Muller glial-derived neuroprotective mechanism typical in injured retina [36], and is predicted to activate its receptor, which may trigger
replication of downstream transcriptional and protein modification processes common during retinogenesis [37].
Canonical chemotactic factors CXCL12, GDNF, BDNF and TGFB3 are also predicted to interact with their cognate
receptors. Asterisks denote genes whose expression profiles were computed after resolving duplicate gene identifiers
in our matched dataset. Replicate network pathway designs for motility genes resolved from NSR/Cones and
RPE/Rods dataset pairings are presented as supplemental figures 5.3A and 5.3B respectively. Further analysis of
the causal effect of these network interactions on cellular movement function was performed and results are
presented in Table 5.2A. 	
  

(KDR) by vascular endothelial growth factor (VEGF) natively occur but are predicted to be negatively
regulated at their respective expression states. The plasminogen activating system by urokinase (PLAU)
promotes cytoskeletal organization and cell adhesion that regulate neuronal cell motility during
development and is predicted to activate G-protein-regulated inducer of neurite outgrowth (GRIN1)
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expressed in cone receptors [4]. Supplemental Tables 5.2A-D pairs these resolved motility-deterministic
network ligands and their downstream cognate receptor from the NSR/Rods, RPE/Cones, NSR/Cones
and RPE cell motility gene datasets respectively, describing the native biochemical interaction canonically
existent between the paired genes, and the predicted interaction based on their expression states.
Resolving downstream signaling perpetuated by these ligand-receptor interactions is key to complete
understanding of motility-specific networks.

To specify the causal effects of our network gene interactions on the cellular movement function, ligandreceptor pairs predicted to activate or inhibit at least eight (8) out of ten (10) subcategories of cellular
movement function were selected using IPA’s ‘Grow’ function tool. These cell movement sub-types are
curated in the IPA knowledgebase and ranked by p-value computing the causal effect of each network
gene and its expression state on the activation or inhibition of the activity of each cell movement
subcategory using a right-tailed fisher exact test. Tables 5.1-D displays the top ten (10) cellular
movement subcategories and their rankings resolved for the A) NSR/Rod, B) RPE/Rod, C) NSR/Cone, D)
RPE/Cone ligand-receptor networks respectively including the number of network genes associated with
each cellular movement sub-type. Criterion selection resolved twenty-three (23) and seventeen (17)
ligand-receptor pairs from the NSR/Rod and RPE/Rod signaling networks respectively. Three (3) ligandreceptor pairs each were resolved from the RPE/Cone and NSR/Cone motility-deterministic networks
respectively. In all resolved molecular pairs, at least one gene in the pair exhibited an activating or
inhibiting effect in at least 80% of the top ten (10) p-value sorted cell movement subcategories. Selected
ligand-receptor pairs are presented in Tables 5.2A-D for the NSR/Rod, RPE/Rod, NSR/Cone, RPE/Cone
custom ligand-receptor signaling networks respectively outlining the fraction of cellular movement
subcategories activated or inhibited per gene. Genes are also color-coded by their up-regulated (red) or
down-regulated (green) expression states, which consequently determined the predicted effect on the
activity of the downstream molecule in each ligand-receptor gene pair.
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Figure 5.3B: Molecular Activity Prediction Identifies Downstream Ligand-Receptor Motility-Deterministic
Interactions in the Matched RPE/Cones Dataset – Similar to the downstream signaling NSR/Rods network pathway,
motogenic ligands released from light-damaged retinal pigment epithelium (RPE) predicted to directly affect their cognate
cone receptors were resolved. At their expression states, activation of the chemokine C-X-C receptor 4 (CXCR4) by
chemoattractant cytokine macrophage migration inhibitory factor (MIF), and kinase insert domain receptor (KDR) by
vascular endothelial growth factor (VEGF) are negatively regulated. The plasminogen activating system by urokinase
(PLAU) promotes cytoskeletal organization and cell adhesion that regulate neuronal cell motility during development and is
predicted to activate G-protein-regulated inducer of neurite outgrowth (GRIN1) expressed on cone receptors [4]. Asterisks
denote genes whose expression profiles were computed after resolving duplicate gene identifiers in our matched dataset.
Further analysis of the causal effect of these network interactions on cellular movement function was performed and
results are presented in Table 5.2D
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Table 5.1: Functional Categorization of Motility Deterministic Network Pathway Molecules. Motilitydeterministic networks of ligand-receptor interactions resolved from our matched datasets were assessed
for their causal effects on the top ten cell movement functional sub-types curated in the IPA
knowledgebase, based on their expression state using a right-tailed Fisher Exact test. A) Displays analysis
results for the NSR/Rod network with the number of network genes involved in each cell movement
category placed in parenthesis. P-values score the probability that network genes at their expression states
activate or inhibit each respective cell movement subcategory, and are used in ranking the functional subtypes. B) RPE/Rods network genes were also categorized for cell motility function along with C) NSR/Cone
and D) RPE/Cone networks. Genes with significant activating or inhibiting effects in at least 8 out of these
top 10 cell movement subcategories are presented in Table 5.2 and represent our repertoire of candidate
molecules for in vitro testing of their effects on cell motility and for designation of their downstream signaling
interactions.	
  

The predicted “ACTIVATION” or “INHIBITION” effect of a ligand on its downstream cognate receptor is
described, and where the predicted ligand’s effect on the receptor is inconsistent with curated interactions
in the IPA knowledgebase given the observed expression states of the genes, the native biochemical
effect of ligand binding to the receptor is indicated in small letters as “activation” or “inhibition.” A
comprehensive listing of both native and predicted activation states for each downstream receptor and
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Table 5.2. Top predicted retinal ligand-PPC receptor pairs involved in migration. To refine
motility-deterministic ligand-receptor interactions, we correlated ligand-receptor expression state
to the effect of each gene on the functioning of at least 80% of the top ten p-value-sorted cellular
movement subcategories (Table 5.1A & B, Supplemental Tables 5.3A & B). Ratios of cell
movement subtypes activated or inhibited by the genes are displayed. Gene levels are colorcoded, up-regulated (red) or down-regulated (green) and assigned “ACTIVATION” or
“INHIBITION” when expression states are consistent with IPAs database. Where the expression
state is inconsistent with curated information in the IPA database, the native predicted effect of
ligand- receptor signaling is indicated as “activation” or “inhibition.” Ligand-receptor pairs
associated with a high percentage of cellular movement categories and exhibiting high ratios of
activation or inhibition, identifies target motility-deterministic signaling pairs whose predicted
downstream effect influences cell motility. A) Notable interacting pairs in the NSR/Rods gene set
include chemoattractant CXCL12 and its CXCR4 receptor, and fibronectin (FN1) and RAC1
interactions, B) the RPE/Rods gene set include inflammatory cytokine SPP1-ITGAV (α-integrin),
VEGFA-KDR and macrophage migration inhibitory factor (MIF) and CXCR4, C) NSR/Cones
ligand-receptor network predicts CXCR4 receptor binding to both CXCL12 and MIF, both strongly
predicted to affect cellular movement function determined by the gene expression states, D)
RPE/Cones ligand-receptor network reveals interaction between macrophage migration inhibitory
factor (MIF) and CXCR4, strongly predicted to inhibit cellular movement function.
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their effector ligands observed in all four motility-deterministic custom network designs are provided in
Supplemental Table 5.2A-D.

The number of cellular movement subcategories in which a gene is involved, as well as the predicted
ratios of cellular movement subtypes differentially activated or inhibited by motility-deterministic ligandreceptor pairs prioritized the selection criteria for chemotactic interactions active in our custom network
designs. Additionally, the computed downstream effect of the ligand on its receptor expression state
determines the direction of function (increased or decreased activity) of the different categories of cellular
movement. In exemplifying the selection criteria, an analysis of the NSR/Rods custom network presented
in Table 5.2A indicates significant statistical predictions of functional effects on PPC movement by
fibronectin (FN1) interacting with alpha-integrin (ITGAV) and Rac1 membrane bound GTPase. These
reactions are known to signal diverse cell functions including cell migration of human corneal epithelial
cells [514] and hepatocellular carcinoma cells [515]. Evidently, the collective down-regulated states of the
receptors conflicts with IPA-annotated predictions of their downstream phenotypes leading to
indeterminable conclusions as to the consequences of the pairwise ligand-receptor gene interactions.
However, these molecular pairs remain likely candidate chemotactic genes for consideration due to the
high number of cellular movement subcategories they are each involved in, the high fraction of these cell
movement subtypes they each activate or inhibit, and the native activation of the downstream receptors
canonically associated with the molecular interaction and identified in the table with “activation.” As earlier
noted, analyses results depicted in Table 5.2 containing a preponderance of receptor down-regulation
may explain the low migration and integration rates observed in transplantation studies using freshly
isolated FACS-sorted PPCs [83, 148, 168, 516]. Other candidate chemotactic interactions affected by the
downstream receptor expression states include activation of α-integrin (ITGAV) activity by inflammatory
secreted phosphoprotein (SPP1), and macrophage migration inhibitory factor (MIF) and the C-X-C motif
receptor 4 (CXCR4) interactions. In the mammalian retina, vascular endothelial growth factor (VEGFA)
binds kinase insert domain receptor (KDR) expressed on retinal microvascular endothelial cells for
downstream signaling to facilitate growth and migration of these cells during hypoxia-induced
neovascularization [517]. However, an inhibitory effect is predicted at the given gene expression states.
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On the other hand, CCL5, the T-cell specific RANTES protein is predicted to activate its downstream
CCR3 receptor. However, the low number of cellular movement subtypes activated by the CCR3 receptor
(5/10) suggests a lower ranked chemotactic interaction even though both genes are predicted to activate
all cell movement subtypes in which they are involved. In understanding the biological implications of the
selection criteria, we performed a literature review of CCL5-CCR3 biochemical interactions and realized
that although CCL5 is a known leukocyte chemoattractant and tumor cell motility factor [518-520] its
specific motility functions in neuronal cell types have rarely been established. In a similar manner, low cell
movement subtype counts for GDNF family receptor alpha (GFRA1) excludes it and its upstream GDNF
ligand from consideration even though the GDNF ligand has been reported to attract GFRA1-expressing
mouse GABAergic cortical cells [521], rat glioma cells [460, 522] and mouse corneal epithelial cells [304].
The fact that the GDNF ligand also serves various neurotrophic and retino-protective functions in normal
and diseased mammalian retinal models [43, 483, 523], and requires heteromeric multicomponent
receptor signaling suites for its downstream signaling activity [524, 525] may altogether affect the degree
to which it is specified to affect cell motility, validating the ranking paradigm used in our selection criteria.

5.3.1: CXCL12-CXCR4 interaction is predicted to influence the migration of transplantable PPCs in lightdamaged retinal tissue

Of the selected ligand-receptor pairs displayed in Table 5.2, the interaction effects of stromal-derived
factor-1 alpha SDF1α (CXCL12) binding to G-protein-coupled CXC-motif receptor 4 (CXCR4) is of
particular interest to our study for many cogent reasons. Both molecules remain the only resolved motilitydeterministic ligand-receptor pair among all selected pairs that activate or inhibit almost 100% of the top
ten cellular movement subtypes across all matched datasets. Being a canonical chemoattractant,
CXCL12 has been shown to regulate axon guidance and path-finding cell activities that precede neuronal
and endothelial progenitor cell migration, trafficking and homing during organogenesis, tissue
regeneration, inflammatory responses and tumor metastasis and vascularization [330, 526-528].
However, similar to most analyzed molecular pairwise interactions in our datasets, the down-regulated
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state of CXCR4 in the NSR/Rods and NSR/Cones dataset (table 5.2A&C) is inconsistent with IPAannotated experimental findings of the receptor’s expression state when interacting with its CXCL12
ligand. Nonetheless, such broad-spectrum involvement in physiological cell motility subtypes is a key
characteristic of potential motogens, and unlike the binding interaction described for the GDNF-GFRA1
pair, CXCL12 expression has been shown to promote activation of its receptor, a phenomenon
suggesting that exposure of PPCs to optimal amounts of the ligand may induce functional expression of
higher levels of CXCR4 and activate downstream signals required for cell movement to occur. Indeed,
several findings report time- and concentration-dependent increases in expression of CXCR4 in rat
microglial cells [361], rabbit lung tissue [529], human hematopoietic stem cells [530], and human breast
cancer cell lines [531] on exposure to optimal concentrations of the CXCL12 ligand. These ligand effects
on the CXCR4 genes can also be cell type-dependent, as CXCL12-stimulated phosphorylation,
internalization and rapid desensitization of its cognate receptor in CXCR4-expressing cancer cell lines
have also been reported [531-533]. Surprisingly, hepatocyte growth factor (HGF) increased expression
following mouse liver damage was observed to promote CXCR4 upregulation with consequent CXCL12–
mediated directional migration of human CD34+ progenitor cells [530]. For CXCL12-induced migration of
most cells, the specific requirement for co-expression of both the ligand and receptor observed during
development and invitro, differentiates CXCL12-CXCR4 signaling from many other canonical chemokine
signaling pathways where knockout effects of one component of the signaling axis can largely be
compensated for by overlapping motogens [34, 534, 535]. Additionally, increased CXCL12 mRNA levels
following mouse RPE NaIO3 chemical damage [371], or mouse hepatic injury by irradiation [530] is
supported by the up-regulated state of the ligand displayed in the NSR/Rods (Figure 5.3A) and
NSR/Cones (supplemental figure 5.3A) motility-deterministic networks, and correlates to increased
migration of the respective stem cells involved. A review of the IPA literature knowledgebase used to
statistically annotate functional interactions between SDF-1 and CXCR4, and map their ontologies to
respective cellular movement subcategories, strongly support a chemotactic influence of these molecules
on neuronal precursors [303, 536-538].
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Reported expression of SDF-1α in the outer segments of human photoreceptors and retinal pigment
epithelium (RPE), and the spatiotemporal localization of its CXCR4 receptor in the inner segment of
photoreceptors in normal and diseased neurosensory retina and on Muller glial cells [273, 362], is
suggestive of a role for this ligand-receptor pair in targeting sub-retinally transplanted PPCs to their
+

laminar destination. Neonatal CXCR4 RPCs migrate towards emergent tissues exhibiting higher SDF1
concentrations during human fetal retinogenesis and neovascularization [330], suggesting a gradientinduced cellular response to the ligand. Following these findings, we hypothesized that constitutive SDF1CXCR4 signaling will significantly modulate motility characteristics of transplantable RPCs and PPCs in a
concentration-gradient dependent manner. To investigate this paradigm, Boyden chambers and bridged
µ-lane microfluidic devices capable of generating uniform and steady state chemical gradients
respectively were used to test the migratory response of freshly isolated post-natal day 1-4 photoreceptor
precursor cells (PPCs) and multi-passage RPCs to SDF1α. This work helps pioneer efficient systemsbased approaches to understanding the effects of small molecule signaling on RPC and PPC motility.

5.3.2: IPA Downstream Effect Analysis Identifies Cytoplasmic and Nuclear Signaling in MotilityDeterministic Network Pathways

We extended our evaluation of molecular interactions downstream of the custom ligand-receptor pair
networks to specify nuclear and cytoplasmic genes that transduce the biochemical signals resulting from
ligand-induced receptor activation once PPCs are transplanted into light-damaged retina. After combining
these motility-deterministic ligand-receptor pairs with significantly expressed, directly interacting nuclear
and cytoplasmic genes from source rod, cone, NSR and RPE datasets, an IPA molecular activity
prediction algorithm was used to generate downstream network pathways predicted to regulate cell
motility in the light-damaged retinal microenvironment. These downstream relationships were further
streamlined using the ‘Grow’ function tool to retain only nuclear and cytoplasmic genes significantly
affecting activity of at least two (2) out of the following four (4) cell motility subtypes - 1) cell movement
(5.14E-46≥p≤1.97E-06), 2) migration of cells (5.45E-42≥p≤4.87E-06), 3) cell movement of tumor cell lines
(4.14E-29≥p≤3.08E-05), 4) migration of tumor cell lines (5.68E-28≥p≤9.27E-05). These four physiological
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categories were top ranked and commonly recurred among all cell motility subtypes annotating the
nuclear and cytoplasmic genes in the IPA knowledgebase. The p-value rankings computed the causal
effect of our nuclear and cytoplasmic gene set on the activity of each cell movement subcategory. For
each subcategory, the ranges of p-values resolved across the four (4) custom datasets are provided in
parentheses. Figures 5.4A-D display network pathway designs of these custom datasets with the
complete array of A) NSR/Rods, B) RPE/Rods, C) NSR/Cones and D) RPE/Cones chemotactic genes
respectively categorized by their subcellular localization. Relationships where effects on the downstream
genes are not predicted were removed for clarity.

In Figure 5.5A, downstream signaling for CXCL12-CXCR4 ligand-receptor pair in the NSR/Rods custom
network pathway is highlighted and predicted to involve phosphorylation by Janus Kinase (JAK) providing
docking sites for signal transducer and activator of transcription (STAT), which is eventually recruited to
the nucleus to bind specific DNA promoters and increase transcription rates affecting a number of
important biological processes including cell migration [8]. However, this downstream JAK-STAT
signaling is not predicted to occur in the network pathway given the down-regulated state of the CXCR4
gene in freshly isolated FAC-sorted P4 Rho-EGFP rod PPCs. The hypoxic conditioning of these freshly
isolated cells may account for activated hypoxia-inducible factor (HIF1A) known to up-regulate CXCR4
mRNA in mouse mesenchymal stem cells [378]. To explore possible downstream signaling paradigms
when the CXCR4 receptor is up-regulated, we used a gene specification tool in IPA to exclusively upregulate CXCR4 expression in this custom network pathway (Figure 5.5B) and resolved signaling
interactions 2-nodal steps away from the CXCR4 receptor (blue outline). Results predict activation of
JAK-STAT as the major motility-deterministic signaling pathway for the CXCL12-CXCR4 ligand-receptor
interaction. Further simulation of downstream signaling events reveals the cooperation of hypoxiainducible factor-1 alpha (HIF-1a) and nuclear factor-kb (NFKB1A) in regulating transcription rates of the
CXCL12-CXCR4 pair, as occurs during regenerative processes in damaged tissue [34]. In vitro functional
activation and inhibition of individual components of the postulated network molecular cascade will
validate the delineated SDF-CXCR4 signaling specific for PPC motility.
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5.4:

Preliminary chemotaxis screens confirm SDF-1α as a broad-spectrum chemoattractant for both

RPCs and PPCs.

To assess the potential for SDF-1α to induce chemotaxis of our RPCs and PPCs, two canonical migratory
systems were employed. An initial chemotactic screen was performed using a modified Boyden chamber
assay, which quantified transmembrane migration of respective RPC and PPC populations to dissipating
SDF-1α gradients along a single axis. Steady state gradients of the chemokine were also generated in a
bridged µ-Lane microfluidic system where single cell responses were correlated to specific gradient
characteristics in a two-dimensional laminar matrix. Figure 5.6A displays analysis of variance (ANOVA)
results comparing mean number of migrated RPCs in 50ng/ml and 100ng/ml SDF1α concentrations
compared to control conditions (F(2,49)= 5.44, p=0.0075*) in a Boyden chamber transwell assay. A posthoc Tukey’s HSD test revealed concentration-specific migration of RPCs towards media supplemented
with 100ng/ml SDF1α compared to control conditions (p=0.0083*). PPCs exhibited a robust migratory
response to all SDF1α concentrations tested (F(2,44)= 5.64; p=0.0068*) (Figure 5.6B). The ligand
concentration ranges used in these motility assays optimally stimulate chemotaxis of retinal and neuronal
precursors [368, 539, 540]. Overall, approximately 0.3-0.6% of seeded viable RPCs and PPCs had
migrated through the 8µm transwell pores after the 24hr experimental time period.
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Figure 5.4: Motility-deterministic Downstream Signaling Networks in PPCs - Following the selection of
candidate ligand-receptor pairs predicted to govern PPC motility in the light-damaged retinal microenvironment
(Table 5.2), an IPA molecular activity prediction (MAP) algorithm connected significantly expressed nuclear and
cytoplasmic genes transducing biochemical signaling of activated or inhibited PPC receptors. The nuclear and
cytoplasmic genes were selected for involvement in at least 2 out of 4 cellular movement subcategories, which were
sorted by p-values that compute the causal effect of our nuclear and cytoplasmic gene set on each cell movement
subcategory. A) Shows a custom network pathway for NSR/Rod-PPCs, B) RPE/Rod-PPCs, C) NSR/Cone-PPCs and
D) RPE/Cone-PPCs. In these pathways ECM genes are displayed with a blue outline. Each line connecting edge
(arrow or bar) between genes describes native interactions and line colors represent IPA-MAP algorithm predictions
of outcomes derived from up-regulated genes (red color) or down-regulated gene (green color) expression states.
The MAP algorithm also describes downstream activation (orange line), inhibition (blue line) of non-IPA annotated
molecules by their biochemical interactions with a seed gene set of “known” neighboring molecules in our dataset. In
predictions where the expression level of the downstream molecule in our dataset is not the same as in cell types in
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the IPA-database, with respect to the expression state of the upstream gene, an inconsistent (yellow line) is used. A
Z-score is then used to quantify the confidence of the prediction, which decreases with nodal distances away from the
“known” seed gene. Literature findings of a variety of biochemical interactions are taken into consideration in making
the predictions including transcription, phosphorylation, translocation and proteolytic activity. In figures A and B,
network interactions were limited to only downstream signaling 2-nodal steps away from key plasma membrane
genes for clarity.

Figure 5.5: PPC SDF-CXCR4 downstream signaling pathway with receptor activation - A)
Using the NSR/Rod-PPC network pathway to highlight target interactions, downstream signaling
cascades initiated via binding of candidate chemotactic factor CXCL12 to its CXCR4 receptor is
shown to involve the canonical JAK-STAT pathway, which increases rates of transcription of
migration signaling molecules [8]. Isolated rod-PPC CXCR4 expression is down-regulated (green
with bold outline) relative to other cells in the light-damaged retina and migration activation is
supported as a native function. B) With downstream signaling following CXCR4 up-regulation (red)
via ligand exposure, we observe migration activation as a native function and with expression levels
comparable to other cell types in IPAs database. Enhanced activation is observed between CXCR4
and JAK-STAT (orange arrow) as well as with MIF activation of CXCR4. Further downstream
signaling events reveal the involvement of hypoxia-inducible factor-1 alpha (HIF-1α) and nuclear
factor-kb (NFKB1A) in regulating transcription of the CXCL12-CXCR4 pair which increase chemoattraction in damaged neural tissue [34].	
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Figure 5.6: Assessment of RPC and PPC chemotaxis to uniform gradients of SDF-1α using
modified Boyden Chamber Assays. - In-silico bioinformatics analysis resolved SDF-1α as a
potential chemotactic cue in the extracellular matrix (ECM) of light-damaged adult retina whose
predicted effect on PPC motility would need experimental verification due to the expression state of
its CXCR4 receptor (Figure 3C). Being a canonical chemoattractant to neuronal precursors, we
screened SDF migratory effect on freshly isolated photoreceptor precursor cells (PPCs) in
comparison to multi-passage retinal progenitor cells (RPCs) using a transwell assay protocol. A)
SDF-1α (F(2,49) = 5.44; p= 0.0075*) chemokine induction of RPC migration is concentrationdependent and optimal at 100ng/ml. 1 unit of normalization represents 65.5 cells. B) PPCs displayed
very robust concentration-independent migration to SDF (0.0068≥p<0.0001*). 1 unit of normalization
represents 87.3 cells. All assays were carried out in triplicates for 2-3 independent experiments. C)
Segment of a transwell filter showing transmigration of PPCs indicated by red arrows. Overall,
approximately 0.3-0.6% of seeded cells migrated through the 8µm transwell filters over 24hrs due to
ligand induction. Statistical analysis of all data was carried out using ANOVA and post-hoc Tukey
HSD. Each error bar is constructed using 1 standard error from the mean. Asterisks denote
significant difference in number of migrated cells compared to control transwells.
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5.5:

PPCs innately express CXCR4 while RPCs require induction by the SDF-1α ligand.

Constitutive expression of chemokine (C-X-C motif) receptor 4 (CXCR4) in non-mammalian zebrafish and
embryonic chick retinal tissue, has previously been associated with survival, proliferation, axonal
guidance and chemotaxis of retinal cells [272, 541], and photoreceptor regeneration after light damage in
zebrafish [509]. In the mammalian retina, CXCR4 immunoreactivity predominates in the retinal ganglion
cell layer, inner nuclear layer, photoreceptor inner segments and the retinal pigment epithelia [273, 362,
539, 542], while the expression of its cognate SDF-1α ligand in the neighboring outer plexiform layer and
margins of inner retina increases in retinal degeneration models [362, 385, 542]. These loci facilitate
ligand-receptor binding that has been shown to modulate rates of ocular neovascularization [543]
photoreceptor apoptosis and inflammatory responses during retinal damage in vivo [362, 542]. Human
RPE and retinal endothelial cells expressing CXCR4 migrate to motogenic concentrations of SDF-1α
[330, 368, 385, 539], however, the present study pioneers characterization of motility-deterministic
signaling for SDF-1α-CXCR4 interaction in PPCs.

We performed immunofluorescence detection of CXCR4 on RPCs and PPCs. Rabbit polyclonal antiCXCR4 antibodies detected innate expression of the receptor on freshly isolated PPCs (Figure 5.7B).
+

Punctate receptors localized over oblong-shaped Crx-GFP photoreceptor inner segments (Figure 5.7A)
containing spherule bi-nucleoids (Figure 5.7C) consistent with immature rod morphology [136, 162].
RPCs displayed more diffuse CXCR4 staining (Figure 5.7H) in the periphery of soma (Figure 5.7G.I),
and along axons following incubation overnight with 100ng/ml SDF-1α but not in non-stimulated RPCs
(compare control Figures 5.7D-F). Semi-quantitative analysis of RPC confocal Trit-C images taken from
control and SDF-treatment slides resolved mean density values for each image. USing Image J as a
measure of cell surface receptor density, subtracting background intensity and comparing results using a
student’s T-test, RPCs incubated in 100ng/ml exhibited significantly higher intensity values compared to
control slides (Figure 5.7J, p<0.0001). This heterogeneity in receptor expression between PPCs and
RPCs is mostly likely the result of both the ontogenetic state of the cells and conditions of the
extracellular environment. Physiologically relevant SDF-1α levels are detectable in the mouse retina
[542] and will induce cell surface receptor expression in PPCs via homologous and heterologous
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phosphorylation and priming mechanisms [531, 533], unlike multi-passage RPCs long deprived of ligand
stimulation over successive proliferative cycles. Upon stimulation with the ligand, western blot analysis of
RPC lysates reveals distinct 47kDa bands of glycosylated CXCR4 absent in control blots (Figure 5.7K).
Blotting of PPC lysates also show faint bands of the glycosylated form of the receptor indicating that
agonist-induced internalization and basal receptor turnover processes are active in freshly isolated
photoreceptor precursors [544, 545].

5.6:

SDF-1α gradients stimulate chemotaxis of RCPs and PPCs in a bridged µ-lane microfluidic

system
The bridged µ-Lane microfluidic system, a type of flow-resistive gradient generator [364], maintains
distinct regions of constant ligand concentrations that form time-invariant gradients along the
microchannel. Chemokines travel down the channel by diffusive transport caused by mass differences
between ligand source and sink reservoirs, while minimizing fluid convection [7]. Modeling mathematical
derivations of similarly weighted epidermal growth factor (EGF, 6.8kDa) and 10kDa dextran transport
within the bridged µ-Lane [7, 32] verified that duration of SDF-1α steady state gradients would range from
18hrs to 40hrs after ligand addition into the source reservoir. Figures 5.8A and 5.8B show that although
PPCs exposed to steady state SDF-1α gradients traveled significantly shorter distances compared to
control conditions (Max. Euclidean: t(60.26) = -5.37, p<0.0001*; Max. Accumulated.: t(66.92) = -5.63,
p<0.0001*), their spatial averaged end-points (center of mass (COM)) after the time course of
experimentation, was significantly displaced towards the positive Y-axis containing higher ligand
concentration gradients (Figure 5.8D, COM-Yaxis: t(57.91) = 3.06, p= 0.0033*).
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Figure 5.7: Heterogeneity in CXCR4 expression by ontogenetically variant transplantable RPCs and
+
PPCs – Wide-field fluorescence images of Crx-GFP cytoplasm (A) and Rhodamine bound antibody staining
(B) of punctate SDF1α receptors (CXCR4) constitutively expressed in freshly isolated photoreceptor
precursor cells (PPCs). An overlay image of both fluorochromes is shown in (C) and includes DAPI nuclear
staining results (blue), Scale: 10µm. In comparison, multi-passage retinal progenitor cells (RPCs) do not
innately express CXCR4 as observed in control cell cultures with no added chemokines (E) but display robust
CXCR4 localization in the periphery of their soma and along axonal processes only after overnight preincubation in 100ng/ml SDF-1α, and staining with NL637 fluorochrome conjugated to monoclonal anti-CXCR4
antibodies (H). Images of RPC Crx-GFP+ cytoplasm (D,G), and an image overlay (F,I) is described, scale:
20µm. J) Normalized pixel intensity values obtained for RPC confocal images of SDF treatment slides on an
image J platform, was significantly different (student’s T, p<0.0001*) from control slide images, for triplicate
measurements/slide in two independent assays (Error bars: ±SEM) and confirmed results obtained from
fluorescence microscopy. Immunocytochemistry results were also validated by the successful detection of
CXCR4 protein in neonatal PPCs and in SDF-induced multi-potent RPCs but not from control RPC lysates
(K). Heat-shock-protein 90 (HSP90) was used to assess blotting efficiency, informative of the stressed states
of the cells.
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The COM is a major index for evaluating directed chemotaxis with either positive or negative coordinates
indicating the direction in which the population of cells have drifted, and a magnitude that measures the
difference between cell population COM at the beginning and at the end of the experiment [418]. RPCs
also migrated towards increasing concentrations of SDF1α, exhibiting significantly higher maximal
Euclidean distance (Figure 5.8A, t(83.1) = 2.29; p= 0.0247*), and mean COM Y-axis (Figure 5.8C, t(82.25) =
2.52; p=0.0138*) compared to cells in control microchannels. Table 5.3 displays descriptive statistics for
the microfluidic assay including the number of cells tracked and values of motility parameters measured.
Time-lapse video recordings of RPC and PPC chemotaxis in different cell culture conditions are provided
as supplemental movie files IV and V respectively. Representative trajectory plots of RPC and PPC
chemotaxis at increasing distances (1-6.5mm) from the SDF-1α source reservoir are presented as
Figures 5.9A-B and 5.9C-D respectively.

5.7:

SDF-1α induces PPC and RPC chemotaxis via binding to their cognate CXCR4 receptor

Given results of Boyden chamber and microfluidic assays, we sought to verify whether SDF ligand
binding to its CXCR4 receptor influenced the observed increases in ligand-induced RPC and PPC
migration. CXCR4 expression is a requisite for the intracellular transduction of SDF-1α signaling during
migration and organogenesis of many stem cell and tissue types [34, 534]. However, by inhibiting ligandreceptor binding in RPCs and PPCs using the CXCR4 antagonist AMD3100, we pioneer the assessment
of receptor-mediated SDF-1α signaling in these specific retinal stem cell types that are essential for cell
replacement therapies. Figure 5.10A displays results of the AMD3100 inhibition of CXCR4 on RPC and
PPC populations using a Boyden chamber assay. An analysis of variance test revealed significant
difference in mean number of migrated RPCs between experimental and control conditions (F(2,31)= 4.5;
p=0.0198*). Post-hoc Tukey HSD verified that significantly more RPCs migrated through transwell filters
in the presence of 100ng/ml SDF-1α compared to control (p= 0.0467*), the migration rates were
significantly reduced to rates comparable to control conditions (p=0.0364*), after pre-incubation with the
receptor antagonist for 30mins at 37°C/5% CO2. A replicate inhibition assay performed using PPCs in
transwells, did not show statistically significant differences in mean number of migrated cells (F(2,8)= 2.3;
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p=0.1818) between culture conditions but AMD3100 reduced PPC migration rates (Figure 5.10A).
Inhibition effects of AMD3100 on RPCs incubated in bridged microchannels maintaining SDF steady state
gradient conditions was not evident as travel distances did not differ significantly from control conditions
(Figure 5.10B-D). However, AMD3100 did reduce directed RPC chemotaxis towards the SDF1α source reservoir, although not significantly. Summary results indicate that SDF-1α binding to its
cognate CXCR4 receptor is a pre-requisite for ligand-induced motility effects on both RPCs and PPCs.

5.8:

CONCLUSION

We were able to demonstrate that within statistically predictable limits, bioinformatics protocols can be
used to simulate molecular signaling governing cellular physiological states using microarray expression
data. The uniqueness of our approach lies in the fact that the prevalent gene expression states of
classified molecules were used to make determinations as to their connectivity and to the consequent
effect of their interactions on a biological function, advancing current methods that utilize gene
annotations and expression states as independent entities in making predictions of gene function. Using a
combination of molecular activity prediction and deductive-inferential analytical tools available in the
Ingenuity Pathway software suite, and gene datasets resolved from ontogenetically appropriate tissues
sorted based on their significant expression over non-target cell types, statistically meaningful
relationships were established between gene fold change values, gene-gene interactions, and gene
interaction and function. As a test of the efficacy of our predictions, we verified the role of SDF-1α as a
chemoattractant to RPCs ad PPCs in vitro. 	
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Figure 5.8: Microfluidics
analysis of Retinal Stem
Cell chemotaxis in steady
state gradients of SDF-1α
generated in bridged uLane microhannels. A-B)
PPCs in control
microchannels traveled
longer accumulated and
euclidean distances
compared to cells in SDF
gradients while distances
covered by RPCs were
longer in the presence of
the ligand. C-D)
Interestingly, the spatial
averaged endpoints for
both retinal cell types after
24hrs in SDF steady state
gradients was analyzed by
Student’s T-test and
showed significant
propagation towards the Yaxis source reservoir of the
ligand compared to cells in
control microhannels. This
result infers ligand-induced
directed chemotaxis and
the longer distances
exhibited by cells in control
channels would imply
random migration
phenomena. All assays
were carried out in
triplicates. Each blue/black
error bar is constructed
using 1 standard error from
the mean. Asterisks denote
significant mean difference
in pairwise comparisons.
Table 5.3 displays results
of descriptive statistics
including number of tracked
cells, mean, standard error
of mean (SEM) and pvalues of independent
samples t-tests used for
analysis of 2-3 runs per
experimental condition.
	
  

179

Number of
Cell
Tracked
Type
Cells (N)/
([SDF] ng/ml)

RPCs

438 / (0)
242 / (100)

PPCs

476 / (0)
394 / (100)

Max. Accumulated Distance (
Max. Euclidean Distance (μ
μm)
m) (Mean ± SEM)
(Mean ± SEM)
0

100

403.37 ± 460.86 ±
18.9
28.2

224.77 ±
18.2

87.27 ±
16.3

P-value
0.0925

<0.0001*

0

100

Center of Mass – Y axis (μ
m) (Mean ± SD)

P-value

0

100

P-value

144.42 ± 176.98 ±
8.97
11.1

0.0242*

-6.64 ±
37.86

16.23 ±
47.26

0.0135*

179.36 ±
14.2

<0.0001*

-31.75 ±
62.73

-1.78 ±
17.36

0.0033*

67.49 ±
15.2

Table 5.3: Descriptive statistics of Cell Motility Parameters obtained following Migration of Retinal Precursor Cells in
steady state SDF-1α gradients generated in a bridged μ-lane Microfluidic Device

We demonstrate that ligand activation of the CXCR4 receptor can be inhibited and activates downstream
signaling leading to statistically significant RPC and PPC migration in uniform and steady state ligand
gradient sources. Further bioinformatics analysis of SDF-1α-induced intracellular signaling pathways
mediating PPC motility identified the JAK-STAT canonical pathway as the culprit signaling cascade.
Additionally, other chemotactic interactions resolved using our selection criterion (see section 5.4) serve
as target motogens for future functional validation studies using fresh PPC isolates. An interesting
proposition will be to automate the decision-making paradigm employed in our deductive inferential
analysis using mathematical algorithms possessing the flexibility for use as plug-in applications for varied
tissue-type gene analyses. Finally, investigations using our cellular movement gene datasets revealed
that most transplantable PPC receptor genes were downregulated compared to expression states of ECM
ligands. It is possible that when PPCs are transplanted into damaged host retina, they do not express
receptor levels sufficient to be induced by cytokine levels in damaged NSR or RPE, accounting for the
poor migration and integration rates observed in leading photoreceptor transplantation studies.
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Figure 5.9: Wind-Rose plots tracking RPC and PPC chemotaxis in steady-state gradients of SDF-1
α. PPC and RPC motility parameters were assessed over a 24hr period in a 13mm bridged μ-lane
device generating steady state SDF gradients, and visualized using Ibidi Chemotaxis and Migrating tool
2.0 as wind-rose plots. Cell tracking results are depicted at increasing distances from the source reservoir
(SRR): 1000-2500μm (I), 4500-6500μm (II). A) PPC migration in control conditions and B) 100ng/ml
SDF-1α steady-state gradients. Measurements of migration parameters were performed between 1842hr cell incubation in the microchannels representing times of sustained steady state SDF gradients. C)
RPC motility in the absence of SDF gradient (control) and D) RPC motility in 100ng/ml SDF-1α gradient.
Both RPCs and PPCs show significant difference in their center of mass (COM) toward Y-axis source of
the chemotactic factor (Figure 6: PPCs p=0.0033, RPCs p=0.0135). Red and black traces indicate cells
with negative and positive COM respectively. Complete descriptive statistics of the trajectory data
depicted here are reported in Table 4. The X- and Y-axis denote cell displacement in horizontal and
vertical directions, respectively.
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Figure
5.10:
Effects
of
AMD3100
inhibition
on
migration of PPCs and RPCs
in uniform and steady state
SDF-1α
gradients.
A)
Antagonistic
effects
of
AMD3100 (CXCR4 inhibitor)
significantly
reduced
the
number of RPCs migrating in
uniform SDF1α gradients to
levels observed in control
conditions (** p=0.0364) using
a transwell assay protocol.
Each unit of normalization
equals 1208 cells. Similarly,
drug inhibition of the receptor
on PPCs decreased their rate of
migration but not to statistically
significant levels (1 unit of
normalization = 200 RPCs).
Further investigation of the
drug’s effects on cells in steady
state
SDF-1α
gradients
generated in bridged µ-lane
microhannels revealed that
AMD3100 had no effect on
RPC accumulated distances (B)
or Euclidean distances (C), and
minimally reduced center of
mass-Y-axis values (D), even
though the ligand continues to
stimulate directed chemotaxis
as previously observed (* p=
0.0108). Cell tracking data was
obtained during 24hrs of SDF
steady state gradient. All
statistical
analyses
were
performed using ANOVA and
post-hoc Tukey HSD to resolve
mean differences in pairwise
comparisons. Error bars depict
mean ± SEM for three
independent experiments.
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CHAPTER 6:

SYSTEMS PHARMACOLOGICAL APPROACH TO IDENTIFICATION OF NOVEL

SMALL MOLECULES AND DRUGS TO MODULATE TRANSPLANTABLE RPC and PPC MIGRATION

6.1:

INTRODUCTION

To advance a translational approach involving modulation of defined chemotactic signaling networks in
transplantable PPCs, we performed computational drug analysis which generated a library of FDA
approved drugs and small molecules predicted to modulate motility-deterministic networks in PPCs. In
collaboration with the Ma’ayan Laboratory (Icahn School of Medicine at Mount Sinai (MSSM), NY), we
employed the Expression2Kinases software to identify pharmacologic drug that modulate the
transcriptional regulatory genes governing the expression of selected PPC chemotactic receptors.
Following our drug analysis, we then validated the motogenic effects of the candidate drug
aminophenazone, a pyrazolone determined to enhance CXCR4 receptor expression in RPCs using the
Boyden Chamber motility assay. We then advanced our drug analysis using a more robust LINCS drug
computational algorithm in which we entered our selected PPC migratory gene targets, which refined our
library of pharmaceuticals to enhance transplantable RPC and PPC migration in response to ligands
present in damaged retina.

6.2:

Systems Pharmacological Analysis of Novel Drugs and Small molecules Targeting RMS

Neuroblast Migration

We began our bioinformatics studies by modeling the characterization of radial and tangential motility
guidance networks governing mouse neuroblast migration in the canonical rostral migratory stream
(RMS) of the adult mouse brain previously conducted by Khodosevich et al [546] (Section 2.3.2, Chapter
2). In the study, the authors compared gene expression patterns between two populations of neuroblasts.
One population was obtained from the subventricular zone, so called the origin, and another subset of
cells closer to the olfactory bulb, the migration destination (Figure 1.11, Chapter 1). Genes significantly
expressed between both populations were predicted to govern neuroblast migration in the study. Using
differentially expressed RMS neuronal motility-deterministic genes guiding neuroblast migration, we
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sought to identify analogous or conserved chemotactic signaling pathways that may drive RPC and PPC
migration (Table 2.2, Chapter 2). We also sought to identify potential upstream regulatory cell signaling
pathways responsible for the significant changes in the gene expression patterns exhibited by the
neuroblast populations in the RMS. Having the advantage of a robust computational architecture and
linked knowledgebase platforms, the Expression2Kinases (X2K) software program [547] developed by
our collaborator Dr. Avi Ma’ayan was employed to identify transcription factors that are most likely
involved in regulating the expression of the RMS motility genes. The program was also used to connect
identified transcription factors using known protein-protein interactions to build a transcriptional regulatory
subnetwork, and to identify protein kinases that have enriched substrates within the subnetwork. Figure
6.1 displays the regulatory subnetwork governing differential up-regulation of genes facilitating migration
of neuroblast in the RMS of the adult mouse brain. The top ten (10) transcription factors (TFs, cyan nodes
on the left) identified were connected using known protein-protein interactions (gray nodes in the center)
from literature reviews compiled in the X2K software knowledgebase, and the top ten (10) protein kinases
(green nodes on the right) that are enriched in substrates within the transcriptional complex were also
identified using the Kinase Enrichment Analysis tool. Rankings of transcription factors and protein kinases
are based on a combination of a Fisher Exact test p‐value, that scores the degree to which a TF or a
protein kinase selectively regulates or phosphorylates target motility genes or proteins in the
transcriptional regulatory network above other TFs and protein kinases in the knowledgebase and a
z‐score comparing ranked genes to background rank, if the TF or protein kinase enrichment was applied
to random set of genes. The sizes of the nodes correspond to the degree of connectivity associated with
each TF, interacting protein or protein kinase. The transcriptional regulatory network data was graphically
represented using the yED graph editor.
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Genes of the transcriptional regulatory network were used as input data for the X2K drug prediction tool
to identify FDA approved drugs and other small molecules predicted to regulate the activity of genes in
the transcriptional regulatory network. The drug analysis was performed using a Fisher exact test that
ranked drugs based on their ability to selectively induce or decrease gene expression and on the number

Fig. 6.1: Resolving molecular regulators of motility-deterministic genes of neuronal rostral migratory stream
(RMS) using Expression2Kinase (X2K) – X2K identified ten (10) transcription factors (cyan nodes on the left) that are
likely upstream regulators of the differentially up-regulated genes governing migration of mouse cortical neuroblasts
between the anterior and posterior subventricular zones [6]. These transcription factors are connected using known
protein-protein interactions from the literature (gray nodes in the center). Finally, protein kinases (green nodes on the
right) that are enriched in substrates within the transcriptional complex are identified using the Kinase Enrichment
Analysis tool. All enrichment analyses implemented a Fisher test and a z‐score test which both assess the probability
that elements of the transcriptional regulatory network affect neuronal motility genes of the RMS by random chance
only. Node size is proportional to degree of connectivity. Resolved gene data is graphically represented using the yED
graph editor.

of genes affected based on drug testing experiments collated in the Broad Institute Connectivity Map
database (Cambridge, MA, http://www.broadinstitute.org/cmap/) [548]. Table 6.1 displays lists of the top
ten (10) unique drugs that can potentially be used to induce or reverse up-regulation of genes that
increase in expression during migration of neuroblasts in the RMS of adult mouse brain. The overlapping
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genes columns show the number of genes that the drug induces or suppresses in the right direction
whereas conflicting genes show the number of genes the drug induces or suppresses gene expression in
the opposite unwanted direction.

Drugs (inducing up- Overlapping Conflicting
regulation)
genes
genes
Metanephrine
35
10
Ribostamycin
31
6
Vorinostat
32
8
PF-00562151-00
31
8

Drugs (reversing
up-regulation)
Irinotecan
Phenoxybenzamine
Pargyline
Khellin

Overlapping Conflicting
genes
genes
46
5
36
11
32
7
29
5

Wortmannin
Adiphenine
Disopyramide
Trichostatin A
Phenazone

27
33
32
36
32

5
11
11
15
11

Josamycin
5230742
Phenoxybenzamine
Androsterone
Glimepiride

31
30
34
35
30

8
8
12
14
9

Hydroflumethiazide

31

10

Acepromazine

30

9

Table 6.1. Potential drug targets for RMS neuroblast migration - Top 10 unique drugs that can
potentially be used to induce or reverse up-regulation of genes that increase in expression during
migration of neuroblasts in the rostral migratory stream (RMS) of adult mouse brain. The overlapping
genes columns show the number of genes that the drug induces or suppresses in the right direction
whereas conflicting genes show the number of genes the drug induces or suppresses in the opposite
unwanted direction. Drug analysis was performed using the drug prediction tool of the X2K gene
expression analysis software (MSSM, NY). 	
  

6.3:

Systems Pharmacological Analysis of Novel Drugs and Small molecules Targeting Retinal

Progenitor and Photoreceptor Precursor Cell Migration

A unique focus of this study was to describe transcriptional networks regulating migratory gene
expression and to identify drugs to modulate network expression to enhance migration of transplantable
RPCs and PPCs. Following the resolution of candidate chemotactic molecules and signaling networks
from our bioinformatics studies (Chapter 5), we reasoned that by modulating the expression of genes that
regulate the expression of target chemotactic receptors, we could pharmacologically drive optimal
receptor expression levels to improve migration of RPCs and PPCs in vitro and when transplanted into
damaged host retina. In this light, we applied the X2K analysis, initially used to identify motogenic genes
of migrating RMS neuroblasts, to define transcriptional regulatory networks and drug targets that can
potentially affect expression of the candidate receptor protein C-X-C motif receptor 4 (CXCR4). CXCR4
was identified in our previous bioinformatics analysis (Chapter 5) as a likely motogenic receptor affecting
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RPC and PPC migration. Using CXCR4 as a singular input gene in X2K, we resolved the top ten (10)
transcription factors (TFs, red nodes on left), their protein-protein interconnectivities (yellow nodes in the
center, N=72), and top ten (10) protein kinases enriching the transcriptional regulatory network (green
nodes on the right) using the Kinase Enrichment Analysis tool (Figure 6.2). Node sizes in the
transcriptional regulatory network correspond to the degree of interconnectivity associated with each
gene, a marker of their relative overall effect on the whole regulatory network.

Notable

upstream

regulators

of

CXCR4

expression

include

the

transcription

factors

avian

myelocytomatosis viral oncogene (MYC), signal transducer and activator of transcription 3 (STAT3),
interconnecting proteins signal transducer and activator of transcription 1 (STAT1), hypoxia inducible
factor 1 alpha (HIF1A), and protein kinases PRKCD and mitogen activated protein kinase 3 (MAPK3).
These transcription factors have been previously identified as key genes in intracellular signaling
cascades transducing SDF-1 ligand binding effects on CXCR4 (Figure 5.5A, Chapter 5). However, the
node sizes of the genes depicted in X2K regulatory network illustrate the relative strength of effect of
these signaling molecules on CXCR4 expression. We then compiled these regulatory network genes as
input data for the X2K drug prediction analysis tool and identified drugs that target these regulatory
proteins influencing CXCR4 expression and consequent migration of transplantable RPCs and PPCs.
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Fig. 6.2: Identifying transcriptional modulators specific for CXCR4 expression using Expression2Kinase (X2K) – Given
the motility-deterministic potential of CXCR4 for PPCs and RPCs determined in chapter 5, we sought to resolve transcriptional
regulatory networks potentially controlling its expression and thus, its subsequent effect on cell motility. The top ten (10)
transcription factors (red nodes on the left), their protein interconnectivities (yellow nodes, N=72) and protein kinases enriched
within the transcriptional network (green nodes on the right, N=10) were resolved using X2K and graphically displayed with the
yED graph editor. Protein kinases were identified using the Kinase Enrichment Analysis tool. Node size is proportional to the
degree of connectivity associated with each gene. Further analysis was performed using X2K to identify drug targets that
significantly affect summary expression of these regulatory networks (See Table 6.5).

Drug analysis results depicted in Table 6.2 reveals the top ten (10) pharmacologic molecules specified for
CXCR4 regulation, the number of genes in the regulatory network whose up-regulation they induce or
repress, and the number of genes that conflict with the desired drug-induced regulatory activity. Given the
native down-regulated expression state of CXCR4 in the resolved microarray data of cone and rod PPCs
(Figure 5.5, Chapter 5), we were primarily interested in drugs predicted to upregulate the expression of
the receptor as a potential strategy to activate migratory phenotypes in RPCs and PPCs. After a literature
review of the specificity of the identified CXCR4-inducing drug targets, we selected the candidate drug
Aminophenazone (AMP) to up-regulate CXCR4 expression on RPCs prior to cell motility assays that
validate the efficacy of the drug to induce the desired cell migratory phenotype.
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Top Ranked Drugs (inducing
up-regulation)

Overlapping
genes

Conflicting
genes

Top Ranked Drugs (inducing
down-regulation)

Overlapping
genes

Conflicting
genes

Streptomycin

14

2

propantheline bromide

16

1

Cefotiam

15

3

trichostatin A-1971

16

2

Dropropizine

16

5

trichostatin A-5209

14

1

Ticarcillin

13

2

PHA-00767505E

15

2

Sulfadiazine

14

3

trichostatin A-6916

16

3

Flecainide

15

4

acetylsalicylic acid

14

1

Aminophenazone

13

3

8-azaguanine

14

2

1

trichostatin A-3428

13

1

demecarium bromide

11

Carmustine

12

2

trichostatin A-6579

14

2

(-)-atenolol

10

1

oxybutynin

16

4

Table 6.2: Potential pharmacological drugs targeting CXCR4 expression – X2k was further used to identify top 10 unique drugs that
can potentially induce or reverse up-regulation of CXCR4 by a concatenation of their effects on gene targets in the transcriptional
regulatory network resolved in Figure 6.3. Drug ranking was performed using a Fisher Exact test for their effects on transcriptional genes
from experimental results collated in the Broad Institute Connectivity Map [548]. The four-digit numbers differentiating identical drug
selections references the specific connectivity Map experiment. The overlapping genes columns show the number of genes that each
respective drug induces or suppresses in the right direction whereas conflicting genes show the number of genes the drug induces or
suppresses in the opposite unwanted direction. Candidate drug Aminophenazone (AMP, bold in red), a pyrazolone, was selected to
upregulate CXCR4 in PPCs and RPCs and validate its motogenic effects given its reported specificity for the receptor.	
  

6.4:

Validating the Efficacy of Aminophenazone (AMP) induction of CXCR4 Expression and

Consequent RPC migration Potential.
Aminophenazone (AMP) (4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one; M.W=231.2g/mol) is a
small molecule phenylpyrazole that used to be widely used in clinical practice for its with analgesic, antiinflammatory, and antipyretic properties, but has since been largely replaced by safer alternatives. After
oral administration, the drug is rapidly and almost completely absorbed from the gastrointestinal tract, and
then evenly distributed throughout body water [549], explaining its current use in measuring body water
volumes in clinical practice. AMP is also currently under assessment for use in non-invasive breath tests
to measure cytochrome P-450 metabolic activity in liver function tests augmenting traditional liver
biopsies [550], and to determine residual hydrogen peroxide activity in catalase activity assays via an
oxidative coupling reaction with benzenesulfonic acids [551]. However, with the reported acute toxicity
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LD50 of 2.88 mol/kg in rats, variations from optimal dosages has caused life-threatening agranulocytosis
in mammals with increased risk of infections with up to 50% mortality rates [552, 553].

In addition to up-regulating the expression of key regulatory proteins to increase CXCR4 expression, X2K
analysis reveals that AMP also directly contributes to sustained receptor expression when compared to
other top-ranked drugs in the category. Currently the FDA has withdrawn its approval for the antiinflammatory and anti-pyretic clinical use of AMP due to adverse toxicity reports. We reasoned that in
vitro treatment of PPCs at safe dosage concentrations, followed by rinsing prior to migration assays or
transplantation into retina, the drug may be re-purposed to serve a novel cytological role in upregulating
the migratory CXCR4 receptor thereby enhancing migration. To initiate in vitro cell incubation trials with
the drug, we firstly assessed the toxic effects of AMP at recommended dosage concentration of
5

0.231ug/ml on the viability of RPCs using a trypan blue cell viability count. Approximately 1X10 cells/ml
were plated in 6-well culture plates and exposed to the drug for 2 hours at either room temperature or
37°C given that there was inconsistent information regarding standardized cell experimentation protocols
using the drug. Live/dead cell counts were obtained before and after drug exposure to cells and results of
the assay are displayed in Table 6.3. Results indicate that at the optimal incubation temperature of 37°C,
AMP resulted in the death of about 20% more RPCs than control cell cultures not exposed to the drug.
We then tested whether the drug specifically affected CXCR4 protein expression using western blot
analysis with an anti-CXCR4 antibodiy to compare receptor protein levels in lysates isolated from control
non-AMP exposed RPCs and experimental AMP-exposed RPCs. Results depicted in Figure 6.3B
qualitatively demonstrate that one effect of AMP on RPCs is the slight observable increase of CXCR4 in
the drug-exposed condition (on the left) compared to control (on the right).
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+AMP
RPC
Incubation
Temperature

-AMP

0 hrs.

120375
48.53%

Dead Cell
concentration
(cells/ml)/ % of
total cell
concentration
127687
51.47%

2 hrs.

32625
21.48%

119250
78.52%

35437
27.75%

92250
72.25%

0 hrs.

120375
48.53%

127687
51.47%

120375
48.53%

127687
51.47%

2 hrs.

23625
21.99%

83812.5
78.01%

25875
41.07%

37125
58.93%

Duration
of Drug
Induction

25°C

Live cell
Concentration
(cells/ml)/ % of total
cell concentration

Live cell
Concentration
(cells/ml)/ % of total
cell concentration

Dead Cell
concentration
(cells/ml)/ % of total
cell concentration

120375
48.53%

127687
51.47%

37°C

Table 6.3: Trypan Blue Viability Assay to determine Aminophenazone (AMP) toxicity properties on mouse retinal
progenitor cells (mRPCs) - Sequential identification of transcription factors, intermediate signaling proteins and protein kinases
that significantly affect the expression of resolved receptors on mouse RPCs was performed using a Kinase Enrichment Analysis
algorithm in the Expression2Kinase (X2K) software [547]. X2K was then further used to resolve FDA approved drugs and other
small molecules that can regulate the activity of the predicted transcription factors in this protein connectivity sub-network [554].
AMP was identified as one of the target drugs that induces increased CXCR4 expression via transcriptional factor activation and
was assessed for its effect on P23-RPC viability over the recommended 2 hour duration of incubation at either room temperature
(25°C) or 37°C to optimize protocols for subsequent cell motility assays using the drug. Results indicate that AMP at
recommended dosage concentrations of 0.231ug/ml caused approximately 20% more cell death at optimal culturing temperature
of 37°C over the course of 2hrs. In control conditions at 37°C, only 7% increase in RPC death was recorded. Cell death rate at
room temperature remained constant in both treatment conditions.

We next ascertained the chemotactic effect of AMP-induced up-regulation of CXCR4 in RPCs cultured in
both uniform and steady state gradients of the stimulatory SDF-1α ligand using Boyden Chambers and
the bridged µ-lane microfluidic chamber respectively. In the Boyden assay, prior RPC exposure to AMP
stimulated a slight increase in transmigration of cells to 100ng/ml of SDF-1α through the 8µm pore PET
filters, although there was no significant difference in the number of migrating cells between control and
drug-treated conditions (Figure 6.3A). Detailed examination of cyto-chemotactic parameters influenced
by AMP drug-treatment was performed by live-cell imaging of RPCs over a 24hr period in steady state
SDF-1α following the 2hr AMP-exposure compared to control RPC motility phenotype without prior
exposure to the drug. Results depicted in Figure 6.4A reveal that RPCs exhibited higher accumulated
distances but traveled shorter Euclidean distances in the drug-treated condition compared to movement
in control conditions, although mean differences between both treatment groups were not statistically
significant in a Student T-test. There was also no significant difference in overall chemotaxis towards the
SDF-1α ligand source, given very similar center of mass (COM) values in the Y-axis direction observed in
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both treatment conditions (Figure 6.4B). Table 6.2 displays results of descriptive statistics including
number of tracked cells, mean, standard error of mean (SEM) and p-values of independent samples ttests used for analysis. These preliminary results suggest that AMP exposure induced modest increases
in RPC chemokinesis but not chemotaxis towards the chemotactic ligand, however, more replicate
microfluidic runs are required before this AMP-induced migratory phenomena can be confirmed.
6

Additionally, at the cell concentration of 10 cells/ml used in the microfluidic assays, RPCs readily formed
clusters within microchannels that were then tracked for analysis. As such, the nature of chemotaxis of 	
  
clusters versus single cells would also need to be taken into consideration.

6.5:

Method Improvement Study – Drug Analysis for PPC Chemotaxis Using LINCS (Library of

Integrated Network-Based Cellular Signatures) Software.

Several factors likely contribute to the tentative results obtained for preliminary drug effect tests of AMP
on RPC chemotaxis and CXCR4 receptor expression. X2k drug prediction tools rank drug relevance to

Mean (Number of Migrated Cells)

A

Table 6.4
Drug
# of cell
Induction counting fields
-AMP
60
+AMP
64

1000
800
600

pValue

848.94 ± 91.7
878.48 ± 119.57

0.8450

B
+AMP

400

200
0

Mean ± SEM

LD

-AMP

CXCR4
-AMP

+AMP

Aminophenazone (AMP) Drug Test

Figure 6.3: Transwell Assay for Effects of drug-Induced activation of CXCR4 receptors on RPC chemotaxis - A)
P17 mouse RPCs were pre-incubated in 0.231μg/ml of Aminophenazone (AMP) for 2hours at 37°C to stimulate
upregulation of CXCR4 receptors prior to 24hr transmigration assays in Boyden Chambers containing 100ng/ml SDF-1α
ligand. There was no significant difference in the number of migrated cells in a T-test (t0.05 = 1.960; p=0.8450) although
more RPCs did migrate following drug induction (Table 6.4). Each error bar is constructed using 1 standard error from the
mean. B) Western blots comparing CXCR4 receptor expression levels in RPCs before and after drug exposure reveal
slightly increased band intensity in the drug-treated lysates although a more quantitative assessment of protein levels will
be required to validate the drug’s effect. (LD = Protein Ladder).	
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molecular regulatory signaling without stipulating cell-type specific drug dosage requirements, or
temperature and cell incubation times that yield optimal cyto-physiological effects. In addition, there is the
need to characterize drug-induced effects on individual molecules of the targeted transcriptional
regulatory networks that facilitate the desired motility phenotypes in RPCs. To address some of these
limitations, we tested a more robust drug computational analysis platform, the LINCS software program
upon recommendation by our collaborator, Dr. Avi Maya’an. LINCS employs the L1000 technology to
catalogue changes in gene expression that occur when cells are exposed to perturbing agents, into a set
of differentially expressed gene signatures [3]. Related to our study, drug-induced molecular
B

A

100

Center of Mass - Y axis (µm)

Distance Traveled (um)

400
350
300
250
200
150
100
50
0

-AMP

+AMP

Drug Treatment

50

0

-50

-100
-AMP

+AMP
Drug Treatment

Cell Motility Parameters
Mean(Max. Euclidean Distance (µm))
Mean(Max. Accumulated Distance (µm))
Figure 6.4: Microfluidics analysis of retinal progenitor cell chemotaxis in steady state gradients of SDF1α following drug induction of Aminophenazone (AMP) CXCR4 receptor upregulator - P17 mouse
RPCs were pre-incubated in 0.231μg/ml of AMP for 2hours at 37°C to stimulate upregulation of CXCR4
receptors prior to migration assays in steady state gradients of 100ng/ml SDF-1α ligand generated in the
bridged μ-lane microfluidic device. A) RPCs traveled higher accumulated distances but lower Euclidean
distances when exposed to AMP although mean differences were not statistically significant in a Student’s Ttest. B) There was also no significant difference in overall cell movement towards the ligand source with
mRPCs in both treatment conditions scoring very similar center of mass (COM) values in the Y-axis direction.
Table 6.5 displays results of descriptive statistics including number of tracked cells, mean, standard error of
mean (SEM) and p-values of independent samples t-tests used for analysis. These preliminary results seem to
indicate that AMP induced an increased degree of chemokinesis in mRPCs but not chemotaxis towards the
SDF-1α chemotactic ligand source. It is worthy of note that in this preliminary drug analysis, only single runs
per experimental condition were performed and more replicate assays would be required before a definitive
assertion can be made of the inductive ability of AMP and its consequent effect on RPC migration. Additionally,
6
at the cell concentration of 10 cells/ml used in the microfluidic assays, RPCs readily formed clusters within
microchannels that were then tracked for analysis. As such, nature of chemotaxis of clusters versus single cells
would also need to be considered. Each blue/black error bar is constructed using 1 standard error from the
mean. 	
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Table 6.5: Descriptive statistics results of microfluidics analysis of retinal progenitor cell
chemotaxis in steady state gradients of SDF-1α following drug induction of Aminophenazone
(AMP) CXCR4 receptor upregulator 	
  
Max. Accumulated
Max. Euclidean Distance (
Number of
Center of Mass – Y axis (
Distance
(μm)
μm)
Drug
Cell Clusters
μm) (Mean ± SEM)
(Mean ± SEM)
(Mean ± SEM)
Induction Tracked (N)
0
-AMP

48

+AMP

75

314.97 ± 37.02
351.43 ± 35.57

P-value
0.4848

100
173.46 ± 19.55
120.32 ± 18.78

P-value
0.0622

0
26.7 ± 12.01
22.74 ± 11.54

P-value
0.8138

perturbations can thus be characterized through the molecular regulatory mechanisms those
perturbations induce, and linked to their cellular phenotypes. L1000 technology improves upon
computational algorithms utilized in the CMAP program of X2K drug prediction tool by concatenating over
1 million gene expression profiles into a LINCS canvas browser user interface composed of two separate
analyses types: A) a measurement of about 1000 genes per experiment for over 22,000 unique
perturbations applied to approximately 56 different cellular contexts of human origin, including only
primary cell lines and cancers cells. These perturbations include small molecule and chemical drug tests,
as well as genetic perturbations such as silencing and gene overexpression experiments, B) a gene set
enrichment analysis that allows for perturbation-induced genetic signatures to be associated with curated
biological functions ranked by statistical probability that they contain the specific gene list patterns queried
by chance alone. Experimental conditions facilitating the production of each gene expression profile are
also stipulated. An exemplary schematic of drug prediction analysis protocol using an input set of genes
is displayed in Figure 6.5.

We thus employed LINCS to query our resolved PPC motility-deterministic signaling network genes for
applicable therapeutic molecules that may affect their expression and the signaling events of their
upstream and downstream regulators with predictable accuracy, while specifying the experimental
conditions associated with the perturbation. To exemplify the application of the LINCS program, we
queried the motility-deterministic signaling network of the NSR/Rod (PPC) matched dataset (Table 5.5A,
Chapter 5) to specify small molecules that can potentially upregulate receptor expression of rod PPCs
with a special focus on our candidate CXCR4 receptor. We performed this task to support our postulate
that the native down-regulated state of isolated PPC receptors observed in statistical analysis of source
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PPC microarray data, may account for low migratory rates of PPCs frequently observed in current
transplantation studies. Using CXCR4 singly and in combination with other downregulated migratory rodPPC receptor genes as input data in the LINCS canvas browser, we sourced drug targets that reverse the

Figure 6.5: Exemplary Schematic of Drug Prediction Analysis Protocol Using the LINCS Canvas
Browser Search Interface. Differentially expressed genes are computed for each condition and stored in two
large text files. The search engine takes as input the lists of genes and other selected options. After scoring
overlap with the back-end dataset, the resultant list of matching experiments is returned for visualization.
Figure adapted from ‘LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS
L1000 gene expression signatures. (2014). Duan Q, Flynn C, Niepel M et al. Nucleic Acids Res.:42: W449460 [3].’

downregulated states of the receptors based on their correlation to differentially expressed gene lists
curated in the LINCS gene signatures and obtained from perturbation experiments. Output results
provided in Table 6.6 reveal the top matching experiments that upregulate the expression of CXCR4
alone and in a group with all motility-deterministic downregulated receptors expressed on rod PPCs
including ITGAV, TSHR, FYN, EGFR, RAC1, PTPRZ1, CDH2, LRP1, DDR1, SDC1, RET, GFRA1, AXL,
TYRO3 (See Table 5.2, Chapter 5). Experiments were selected based on an overlap score quantifying
correlation between our input gene list and the Z-score signatures of the 1000 genes measured per
experiment using Pearson’s correlation. The Z -score signature is a vector of moderated Z -scores
calculated by the CMAP group at the Broad Institute from the replicates of an experimental condition as it
compares with the population background [3]. Drug targeting CXCR4 upregulation was used at a dosage
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of 10µM for either 6hrs or 24hrs on human prostate cancer cell lines VCaP and PC3 of experimental
batch CPC003 and resolved an overlap score of 0.02. Drugs up-regulating the group list of receptor
genes displayed overlap scores of 0.06-0.08. Overlap scores increase with increased correlation between
our input genes and back-end gene signatures, and higher number of input query genes. Tolazamide,
Flucloxacillin sodium and Enrofloxacin were identified as small molecules that commonly up-regulate
CXCR4 (bold, in red) and target the gene list of rod PPC receptors. These newly identified small
molecules serve as candidates for pharmacologic modulation of RPCs and PPCs migration. Additional
LINCS queries using gene lists of whole rod and cone motility-deterministic network pathways sorted by
up- or down-regulated gene expression states yielded lists of applicable experiments containing
significant overlap in genes that change expression due to chemical perturbation, are presented as
supplemental tables 6.1-6.5.

THESIS CONCLUSION
Given the intrinsic complexity of biological systems, which is further compounded in diseased states,
many scientists have over the years forecasted the predominance of computational biologic approaches
able to process the dynamic molecular interrelationships characterizing such systems, and thereby
sourcing solutions for the most enduring human disorders, including retinal degeneration [23, 555].
Systems biology extracts hidden patterns from huge quantities of experimental and observational
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CXCR4 Receptor Up-regulation
(Overlap Score = 0.02; Dosage = 10 μM; Cell Batch No. =
CPC003)
Incubation
Chemical Perturbation
Cell Type
Time (hrs.)
Estradiol
24
VCAP
Bufalin
6
VCAP
Bongkrekic acid
24
PC3

Motogenic Rod Receptors
Group Gene Up-regulation (Overlap Score = 0.06)
Chemical Perturbation

Dosage (μM)

Salbutamol (z = 0.08)
Valsartan
Tolazamide
nor-Binaltorphimine
dihydrochloride
Nobiletin

10
10
10

Incubation
Time (hrs.)
24
24
24

10

Cell Type

Batch No.

MCF7
VCAP
VCAP

CPC011
CPC011
CPC020

24

HT29

CPC005

10

6

VCAP

CPC011

Vincristine Sulfate

6

VCAP

Vinblastine Sulfate

24

PC3

Trap 101

24

VCAP

Modafinil

10

24

MCF7

CPC011

Tolazamide

6

VCAP

Dolasetron

10

24

VCAP

CPC010

TCB2

24

PC3

Benactyzine

10

24

VCAP

CPC011

TC 2559 difumarate
Sulpiride
SCH 442416
Remacemide hydrochloride
RS 100329 hydrochloride

6, 24
6
24
24
24

VCAP
VCAP
PC3
VCAP
PC3

Zoxazolamine
VU0418946-2
TPCA-1
Phenoxazine
PX12

10
10
0.4
10
30

24
24
6h
6
6

PC3
MCF7
MCF7
SKMEL1
NOMO1

CPD001
CPC008
LJP002
CPC006
CPC006

Rhizocarpic acid
RG-14620
Quinidine hydrochloride monohydrate

6
6
24

VCAP
VCAP
PC3

Protryptyline Hydrochloride
Penicillic Acid
PAC 1

6
6
24

MCF7
A549
PC3

CPC004
CPC005
CPC006

Podofilox

6

VCAP

Oxyphenbutazone

10
10
10
10

6

MCF7

CPD003

Pinacidil

6

VCAP

NCGC00184891-01

10

6

VCAP

CPC008

Nizatidine

6

VCAP

NCGC00183242-01

10

24

MCF7

CPC007

Nitrocaramiphen hydrochloride

6

VCAP

NCGC00182833-01

10

6

A549

CPC007

Nonoxynol-9

6

VCAP

NCGC00167118-01

10

6

VCAP

CPC008

MRS 1220

24

VCAP

Methoxy-6-harmalan

10

24

HCC515

CPC004

MR 16728 hydrochloride

24

VCAP

JZL-184,11

1

24

A549

CPC006

Loreclezole hydrochloride

6

VCAP

JWE-035,

6

MCF7

LJP002

Leoidin Dimethyl Ether

6

VCAP

JAS07_008

2
10

24

PC3

CPC007

Kawain

6

VCAP

Ingenol 3, 20-dibenzoate

10

6

SNUC5

CPC006

Ivermectin

6

VCAP

IKK Inhibitor X

CL34

CPC006

6
6

VCAP
VCAP

Flucloxacillin sodium
FPL 64176

6
10
10

6

Hippeastrine hydrobromide
Hexamethylquercetagetin

24
6

VCAP
NCIH596

CPC003
CPC006

197

GW 405833

6

VCAP

Enrofloxacin

10

24

HCC515

CPC003

24

MCF7

CPC014

VCAP
VCAP
PC3

CPC005
CPC005
CPD001

Glipizide

6, 24

VCAP

EI-335,

10

Fluvoxamine maleate
Flurofamide
Flucloxacillin sodium

6
24
24

VCAP
VCAP
VCAP

DPO-1
Dihydro-obliquin
Clofilium tosylate

10
10
10

24
24
24

Fillalbin

6

VCAP

CHR 2797

80

6

NOMO1

CPC006

Flumethasone

6

VCAP

BAPTA-AM

10

24

VCAP

CPC001

Enrofloxacin

24

VCAP

AZD6244

MCF7

LJP001

24

PC3

ABT-751

2
10

6

Doxorubicin hydrochloride

6

A673

CPC006

Daunorubicin hydrochloride

24

PC3

2512-0754

10

6

HT29

CPC013

Deguelin (-)

6

VCAP

1069-0075

10

6

A549

CPC013

VCAP

CPCCOEt

6

CGS 12066B

24

PC3

Biperiden hydrochloride

24

VCAP

Bucladesine

24

VCAP

Bicalutamide

6

VCAP

BAY 59-3074

24

VCAP

Altanserin hydrochloride

6

VCAP

AG 490

24

VCAP

Table 6.6: L1000 Analysis for Drug Perturbations Reversing Down-regulated Receptor Expression state of Rod Photoreceptors – Analysis of rod
photoreceptor microarray data using IPA bioinformatics tools revealed an overall downregulated expression state of receptor proteins, postulated to cause the low
migration rates in current transplantation studies. Using the L100 LINCS search tool we queried input gene CXCR4 singly and in combination with other downregulated motility-deterministic receptor genes for drugs and small molecules that can reverse the expression states of our gene lists. Listed are top ranked
experimental drugs and their testing conditions that potentially upregulate CXCR4 expression alone, or as part of the group of motogenic receptors as follows:
ITGAV, TSHR, FYN, EGFR, RAC1, PTPRZ1, CXCR4, CDH2, LRP1, DDR1, SDC1, RET, GFRA1, AXL, TYRO3, culled from results of IPA bioinformatics analysis
of NSR/Rod matched dataset depicted in Table 5.2 (Chapter 5). Rankings of chemical perturbation experiments was performed using an overlap score that
quantifies the correlation between our input gene list and z-score gene expression signatures of the 1000 genes measured per experiment using Pearson’s
correlation. Drug targeting CXCR4 upregulation were used at a dosage of 10μM for either 6hrs or 24hrs on human prostate cancer cell lines VCaP and PC3 of
experimental batch CPC003 and resolved an overlap score of 0.02. Drugs up-regulating the group list of receptor genes displayed overlap scores of 0.06-0.08,
and overlap scores increase with increased correlation between our input genes and back-end gene signatures, and higher number of input query genes. Ranked
experiments were performed in a variety of cancer cell lines including lung carcinoma (NCIH596, HCC515, A549), intestinal (CL34) and gastric (SNUC5)
carcinoma, breast (MCF7), muscle (A673), colon (HT29), melanoma (SKMEL1) and myeloid leukemia (NOMO1). Tolazamide, Flucloxacillin sodium and
Enrofloxacin are highlighted in bold red color as they were identified as small molecules that commonly up-regulate CXCR4 (bold, in red) and the gene list of rod
PPC receptors, and may serve as candidates for future drug effects tests on transplantable PPCs. Additional LINCS queries using gene lists of whole rod and
cone motility-deterministic network pathways sorted by up- or down-regulated gene expression states yielded lists of applicable experiments containing significant
overlap in genes that change expression due to the chemical perturbation, and are presented as supplemental Tables 6.1-6.5.
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scientific data to form hypotheses that can be tested with in silico applications, which in turn provide
predictions verifiable by in vitro and in vivo studies [23]. We exemplify this systems biology approach
through the course of our laboratory investigations, by configuring a step-wise bioinformatics paradigm for
analyzing tissue- and disease-specific microarray data yielding streamlined, statistically determined
chemotactic molecules inducing intracellular biochemical signaling that drives the movement of
transplantable PPCs in light-damaged retina. We were also able to establish the accuracy of our in silico
analytic method by validating the motogenic influence of resolved ligand SDF-1α on PPCs and
multipotent RPCs, and providing evidence supporting our hypothesis of the gradated nature of the
ligand’s influence on motility. In the fabricated microenvironments suitably generating these uniform and
steady state chemical gradients, we were also able to distinguish the chemokinetic nature of EGF’s
inductive effect on RPCs, the chemotactic effect of sdf1 on RPCs and PPCs and characterize
downstream signaling supporting these cell motility phenomena.

Kitano Hiroaki had earlier proposed a functional linkage between the computational biology approach and
drug discovery, with the potential to provide individualized treatment regimes as depicted in Figure 7.1
[23], a symbiosis currently hailed as the strategy for future personalized medicine [556, 557]. In this
systemic relationship, bioinformatics-resolved and experimentally validated genetic and molecular
markers associated with specific tissue physiological or disease conditions can be targeted to express a
desired phenotype or reverse diseased conditions on a per-patient basis. Similarly we were able to target
retinal precursor cell-specific chemotactic molecular markers resolved from our bioinformatics analysis for
FDA-approved small molecular drugs that can influence their expression in a damaged retinal
microenvironment, and potentially enhance migration of the cells post-transplantation, achieving our
desired investigative goal. We have compiled libraries of RPC and PPC motility markers and defined
protocols to identify potentially effective pharmacological drugs that may positively affect the motility
phenotypes of these cells.
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Figure 7.3: Linkage of a basic systems-biology research cycle with drug discovery and treatment cycles – Systems
biology is an integrated process of computational modeling, system analysis, technology development for experiments, and
quantitative experiments. With sufficient progress in basic systems biology, this cycle can be applied to drug discovery and the
development of new treatments. In the future, in silico experiments and screening of lead candidates and multiple drug systems
as well as introduced genetic circuits, will have a key role in the upstream processes of the pharmaceutical industry,
significantly reducing costs and increasing the success of product and service development. Figure adapted from
‘Computational systems biology. Kitano H. (2002), Nature. 2002;420:206-210 [23]
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APPENDIX

Supplemental Figures

Supplemental Figure 4.1: Predicted EGF-induced Network of Direct and Indirect
Molecular Interactions influencing RPC migration - The network was generated using
Ingenuity Pathway Analysis (IPA) bioinformatics tool. Molecular components of the EGF
signaling pathway are localized to extracellular space, plasma membrane, cytoplasm and
nucleus. Solid and dashed arrows indicate direct and indirect interactions between upstream
and downstream pathway molecules. Molecules significantly associated with the chemotaxis
function as determined by a right-tailed Fisher test is identified by an overlay of green
connected lines. The overlay of the indirect molecular connections highlights many relevant
cascades including the EGF-induced phospholipase C-γ-1 (PLCG) mediated hydrolysis of
Phosphatidylinositol-4,5-bisphosphate (PIP2) to yield Inositol tris-phosphate (IP3) that
modulates activation and release of Ca2+ and its regulatory motility-deterministic pathways
[18].
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Supplemental Figure 4.2: Immunocytochemical localization of RPC total and phosphorylated EGFR expression
upon exposure to a saturated EGF concentration of 10μg/ml - Analysis of phosphorylated EGFR (A-D) and total
EGFR localization (E-H) were performed on RPCs isolated from P3-5 transgenic mice expressing green fluorescent
protein (GFP) on the actin promoter (actin-GFP). A) Actin-GFP RPCs express GFP ubiquitously revealing the more
primitive multipolar retinal neuron morphology with a cell body and hollow nuclear location (C) extending a long axonic
process with whiplash synaptic ends B) Rhodamine bound anti-phospho (activated) EGFR antibody staining reveals
receptor concentration around the periphery of the cell body and punctate receptor localization along the length of the
axon C) DAPI labeling of nuclei, D) Overlay of A-C. Panels E and F show identical imaging parameters as A and D,
with the exception that F) utilizes anti-total EGFR labeling. Scale: 20 microns.
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Supplemental Figure 5.1: Summary Results of Bioinformatics Core Analysis of Matched PPC Receptor / ECM ligands from
Damaged Retina – Using the Ingenuity Pathway Analysis (IPA) software platform, extracellular matrix genes of damaged retinal models
matched to plasma membrane receptors of either rod or cone photoreceptor precursors were analyzed to resolve canonical pathways and
molecular and physiological functions annotated to each respective matched dataset. Analysis parameters specified 140 molecules per
network for the top 10 functional networks associated with each matched dataset by random chance using a right-tailed Fisher Exact test
(p<0.05). A) Top ten functional clusters in the IPA knowledgebase associated with ECM molecules of retinal pigment epithelium (RPE) and
rod receptors (RPE/Rods, N=1945 genes) reveal cellular movement function as the top functional category (outlined in red). C) Similar
results were obtained using matched dataset of neurosensory retina ECM molecules and cone receptor genes (NSR/Cones, N=735 genes).
B and D) Cytokine and Growth factor canonical signaling pathways that significantly overlapped with each matched dataset were selectively
ranked based on their probability of containing our molecular datasets by chance alone using a right-talied Fisher’s Exact test with threshold
p-value of 0.05. Ratios comparing the number of our matched dataset genes in each canonical pathway to the total number of genes
originally designated to the pathway were also quantified and connected by a line graph. This ranking is also color-coded by assigned Zscores that predict activation (orange bars) or inhibition (blue bars) of the canonical signaling pathways based on the expression state of
molecules in our datasets. Resolved canonical pathways common to both RPE/Rods (B) and NSR/Cones (D) matched datasets include
interleukins IL-1 and IL-8 signaling, C-X-C motif receptor 4 (CXCR4) signaling, acute phase response signaling and transcriptional regulator
high mobility group box 1 (HMGB1) signaling.
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Supplemental Figure 5.2: Modified volcano plots of cellular movement genes with
statistically significant expression states resolved from transplantable photoreceptors
and damaged recipient adult retina matched microarray dataset pairs – To mimic typical
transplantation paradigms, normalized gene transcripts of donor P4 rod and E17.5 cone PPCs
and light-damaged adult recipient retina were sorted by their tissue and subcellular localization,
and filtered for their statistical difference (p=0.05, T-test) from negative-FAC-sorted replicates,
and ligand-receptor pairs matched. Following bioinformatics analysis, genes annotated to the
cellular movement function in the Ingenuity Pathways Analysis (IPA) knowledgebase were
graphed. A) Cell motility genes resolved from matched pairs of rod receptors and extracellular
matrix (ECM) ligands of damaged retinal pigment epithelia (RPE) (N=479 genes). The negative
logarithm of their p-values was plotted against fold change. These genes were used to design
signaling interaction networks predicting activating or inhibitory interactions between ligand and
receptor pairs based on their expression states. B) A similar analysis was performed using
resolved cellular movement molecules from matched ECM genes released from the
neurosensory retina (NSR) after light-damage and receptors expressed on transplantable cone
photoreceptors (N=223 genes). Tables listing these selected gene pairs are presented in
supplemental tables 5.1C and 5.1D for RPE/Rods and NSR/Cones matched datasets
respectively.
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Extracellular Space

Plasma Membrane

Supplemental Figure 5.3A: Molecular Activity Prediction Identifies Downstream Ligand-Receptor MotilityDeterministic Interactions in the Matched NSR/Cones Dataset - Downstream signaling interactions between motogenic
ECM ligands released from light-damaged neurosensory retina (NSR) and their cognate receptors expressed on cone
PPCs were correlated to the expected causal interaction between each molecular pair at their given expression state (upregulation (red genes) or down-regulation (blue genes)) using the molecular activity prediction tool of the Ingenuity
Pathway Analysis (IPA) protocol suite. Predictions of activating (orange connections) or inhibitory (blue connections)
effects on downstream receptor genes were then computed based on similarities or differences between a causal effect
model of known gene expression states and the expression profile of our resolved matched dataset genes. Yellow
connecting lines denote interactions between genes whose expression states differ from the curated information in the IPA
knowledgebase supporting such an interaction. Molecular interactions whose downstream effects are not predicted, as well
as all upstream signaling relationships have been excluded from the network for clarity. Asterisks denote genes whose
expression profiles were computed after resolving duplicate gene identifiers in our matched dataset. Further analysis of the
causal effect of these network interactions on cellular movement function was performed and results are depicted in Table
5.2C.
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Extracellular Space

Supplemental Figure 5.3B: Molecular Activity Prediction Identifies Downstream Ligand-Receptor MotilityDeterministic Interactions in the Matched RPE/Rods Dataset – Downstream signaling interactions between cell
motility ECM ligands released from light-damaged retinal pigment epithelium (RPE) and their cognate receptors
expressed on rod PPCs are presented. Asterisks denote genes whose expression profiles were computed after
resolving duplicate gene identifiers in our matched dataset. Further analysis of the causal effect of these network
interactions on cellular movement function was performed and results are depicted in Table 5.2B.
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Supplemental Tables

	
  
5.1A: Plasma Membrane Molecules from Rod Photoreceptor Precursors
Gene
Symbol
RHO
DMD

Entrez Gene Name
rhodopsin

Fold
Change
3.54
2.42

PLA2R1

dystrophin
solute carrier family 11 (proton-coupled divalent metal ion transporter),
member 1
phospholipase A2 receptor 1, 180kDa

WDPCP

WD repeat containing planar cell polarity effector

1.91

NFASC

neurofascin

1.83

ADRB2

adrenoceptor beta 2, surface

1.80

SLC11A1

2.09
1.98

ITGA3

integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)

1.69

SLC12A5

solute carrier family 12 (potassium/chloride transporter), member 5

1.67

LIFR

leukemia inhibitory factor receptor alpha

1.65

MC1R

melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)

1.63

FGFR3

fibroblast growth factor receptor 3

1.63

CDH13

cadherin 13

1.62

STX3

syntaxin 3

1.62

CLDN7

claudin 7

1.60

ARHGEF26

Rho guanine nucleotide exchange factor (GEF) 26

1.53

RAMP3

receptor (G protein-coupled) activity modifying protein 3

1.53

SCUBE3

signal peptide, CUB domain, EGF-like 3

1.51

INADL

InaD-like (Drosophila)

1.50

PTP4A3

protein tyrosine phosphatase type IVA, member 3

1.50

SIRPA

signal-regulatory protein alpha

1.46

MAP2

microtubule-associated protein 2

1.45

Col17a1

collagen, type XVII, alpha 1

1.44

GNB1

guanine nucleotide binding protein (G protein), beta polypeptide 1

1.39

NT5E

5'-nucleotidase, ecto (CD73)

1.39

CADM1

cell adhesion molecule 1

1.38

ADRA2A

adrenoceptor alpha 2A

1.37

CD8A

CD8a molecule

1.36

EPS8

epidermal growth factor receptor pathway substrate 8

1.35

DNM2

dynamin 2

1.34

SCN8A

sodium channel, voltage gated, type VIII, alpha subunit

1.32

PARD6B

par-6 family cell polarity regulator beta

1.30

CXCR6

chemokine (C-X-C motif) receptor 6

1.30

SCARB1

scavenger receptor class B, member 1

1.29

Podxl

podocalyxin-like

1.29

LIMS1

LIM and senescent cell antigen-like domains 1
membrane associated guanylate kinase, WW and PDZ domain containing
2

1.29

MAGI2

1.28
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PGLYRP1

peptidoglycan recognition protein 1

1.28

PKP2

plakophilin 2

1.27

SLC12A6

solute carrier family 12 (potassium/chloride transporter), member 6

1.27

VLDLR

very low density lipoprotein receptor

1.27

ACVRL1

activin A receptor type II-like 1

1.26

GPR183

G protein-coupled receptor 183

1.25

CD276

CD276 molecule

1.24

STAB2

stabilin 2

1.24

RAB28

RAB28, member RAS oncogene family

1.23

USP9X

ubiquitin specific peptidase 9, X-linked

1.22

ANGPTL1

angiopoietin-like 1

1.22

HTR2B

5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled

1.22

TREML2

triggering receptor expressed on myeloid cells-like 2

1.20

PKD1

polycystic kidney disease 1 (autosomal dominant)

1.19

EPB41L5

erythrocyte membrane protein band 4.1 like 5

1.19

NTRK3

neurotrophic tyrosine kinase, receptor, type 3

1.19

ADAM9

ADAM metallopeptidase domain 9

1.19

ITGAM

integrin, alpha M (complement component 3 receptor 3 subunit)

1.18

VCL

vinculin

1.18

F2RL3

coagulation factor II (thrombin) receptor-like 3

1.18

IFNGR1

interferon gamma receptor 1

1.18

PTAFR

1.17

TRPM7

platelet-activating factor receptor
guanine nucleotide binding protein (G protein),
alpha inhibiting activity polypeptide 1
transient receptor potential cation channel, subfamily M, member 7

SLC1A2

solute carrier family 1 (glial high affinity glutamate transporter), member 2

1.16

SDC4

1.16

STIM1

syndecan 4
colony stimulating factor 2 receptor, beta, low-affinity (granulocytemacrophage)
synovial sarcoma, X breakpoint 2 interacting protein
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-betagalactosyltransferase 1
stromal interaction molecule 1

LAT

linker for activation of T cells

1.15

CD4

CD4 molecule

1.15

FLOT1

flotillin 1

1.15

GNAI1

CSF2RB
SSX2IP
C1GALT1

1.17
1.16

1.16
1.15
1.15
1.15

EDNRA

endothelin receptor type A

1.14

ROBO4

roundabout, axon guidance receptor, homolog 4 (Drosophila)

1.14

GNAS
TNFRSF10
A
CMKLR1

GNAS complex locus

1.14

tumor necrosis factor receptor superfamily, member 10a

1.14

chemokine-like receptor 1

1.14

SNPH

syntaphilin

1.14

CCR3

chemokine (C-C motif) receptor 3

1.13
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HLA-A

major histocompatibility complex, class I, A

1.13

CCR10

chemokine (C-C motif) receptor 10

1.13

CLEC1B

C-type lectin domain family 1, member B

1.12

TLR5

toll-like receptor 5

1.12

FLT4

fms-related tyrosine kinase 4

1.12

TRPM2

1.12

MARVELD3

transient receptor potential cation channel, subfamily M, member 2
colony stimulating factor 2 receptor, alpha, low-affinity (granulocytemacrophage)
MARVEL domain containing 3

P2RX7

purinergic receptor P2X, ligand-gated ion channel, 7

1.12

PLXNA2

plexin A2

1.11

IL20RA
TNFRSF11
B
PVRL1

interleukin 20 receptor, alpha

1.11

tumor necrosis factor receptor superfamily, member 11b

1.11

poliovirus receptor-related 1 (herpesvirus entry mediator C)

1.11

TGFBR2

transforming growth factor, beta receptor II (70/80kDa)

1.10

ENTPD1

ectonucleoside triphosphate diphosphohydrolase 1

1.10

OSBPL8

1.10

BDKRB2

oxysterol binding protein-like 8
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary
glycoprotein)
bradykinin receptor B2

TNFSF8

tumor necrosis factor (ligand) superfamily, member 8

1.10

UNC5A

unc-5 homolog A (C. elegans)

1.10

C5AR1

complement component 5a receptor 1

1.10

ABCC1

ATP-binding cassette, sub-family C (CFTR/MRP), member 1

1.09

LTB4R2

leukotriene B4 receptor 2

1.09

ITGB7

integrin, beta 7

1.08

MBOAT7

membrane bound O-acyltransferase domain containing 7

1.08

SCNN1A

sodium channel, non-voltage-gated 1 alpha subunit

1.07

PPP3CB

protein phosphatase 3, catalytic subunit, beta isozyme

1.07

FPR2

formyl peptide receptor 2

1.07

SCN2B

sodium channel, voltage-gated, type II, beta subunit

1.07

JAM2

junctional adhesion molecule 2

1.07

PRNP

prion protein

1.07

RGS1

regulator of G-protein signaling 1

1.06

PLP1

proteolipid protein 1

1.06

CSF2RA

CEACAM1

1.12
1.12

1.10
1.10

HRH2

histamine receptor H2

1.06

TNFRSF4

tumor necrosis factor receptor superfamily, member 4

1.06

FUZ

fuzzy planar cell polarity protein

1.06

CXADR

1.06

GPR182

coxsackie virus and adenovirus receptor
guanine nucleotide binding protein (G protein),
beta polypeptide 2
G protein-coupled receptor 182

AQP4

aquaporin 4

1.05

GNB2

1.06
1.06
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MSR1

macrophage scavenger receptor 1

1.05

LRPAP1

low density lipoprotein receptor-related protein associated protein 1

1.05

INPP5B

inositol polyphosphate-5-phosphatase, 75kDa

1.05

CR1L

complement component (3b/4b) receptor 1-like

1.05

CLEC4M

C-type lectin domain family 4, member M

1.05

HRH4

histamine receptor H4

1.05

HAS1

hyaluronan synthase 1

1.05

DRD3

dopamine receptor D3

1.04

TGFBR3

transforming growth factor, beta receptor III

1.04

TNFRSF9

tumor necrosis factor receptor superfamily, member 9

1.04

ORAI1

ORAI calcium release-activated calcium modulator 1

1.03

CD247

CD247 molecule

-1.02

HAS2

hyaluronan synthase 2

-1.03

SDC3

syndecan 3

-1.03

GPER1

G protein-coupled estrogen receptor 1

-1.03

GJB1

gap junction protein, beta 1, 32kDa

-1.04

BMPR2

bone morphogenetic protein receptor, type II (serine/threonine kinase)

-1.05

Cdc42

cell division cycle 42

-1.05

RAP2A

RAP2A, member of RAS oncogene family

-1.06

DAG1

dystroglycan 1 (dystrophin-associated glycoprotein 1)

-1.06

SH2B3

SH2B adaptor protein 3

-1.06

IL17RA

interleukin 17 receptor A

-1.06

NCKAP1

NCK-associated protein 1

-1.06

IGHM

immunoglobulin heavy constant mu

-1.06

TRPV2

transient receptor potential cation channel, subfamily V, member 2

-1.06

FCGR2B

Fc fragment of IgG, low affinity IIb, receptor (CD32)

-1.06

PIP5K1C

-1.07

GRIN1

phosphatidylinositol-4-phosphate 5-kinase, type I, gamma
sema domain, transmembrane domain (TM), and cytoplasmic domain,
(semaphorin) 6C
glutamate receptor, ionotropic, N-methyl D-aspartate 1

DIAPH1

diaphanous-related formin 1

-1.07

WASF2

WAS protein family, member 2

-1.08

IGF2R

insulin-like growth factor 2 receptor

-1.08

ACTR2

-1.08

AQP5

ARP2 actin-related protein 2 homolog (yeast)
solute carrier family 12 (sodium/potassium/chloride transporter), member
2
aquaporin 5

JAM3

junctional adhesion molecule 3

-1.08

LTK

leukocyte receptor tyrosine kinase

-1.08

ARRDC3

arrestin domain containing 3

-1.09

SEMA6C

SLC12A2

-1.07
-1.07

-1.08
-1.08

RYK

receptor-like tyrosine kinase

-1.09

ADAM10

ADAM metallopeptidase domain 10

-1.09

BMPR1A

bone morphogenetic protein receptor, type IA

-1.10
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CTTN

cortactin

-1.10

GNA11

guanine nucleotide binding protein (G protein), alpha 11 (Gq class)

-1.11

SFRP4

secreted frizzled-related protein 4

-1.11

IGSF8

immunoglobulin superfamily, member 8

-1.11

PARD3

par-3 family cell polarity regulator

-1.11

TGFBR1

transforming growth factor, beta receptor 1

-1.11

ARF6

ADP-ribosylation factor 6

-1.11

CAP1

CAP, adenylate cyclase-associated protein 1 (yeast)

-1.11

AJAP1

adherens junctions associated protein 1

-1.12

CTNNAL1

catenin (cadherin-associated protein), alpha-like 1

-1.12

SELP

selectin P (granule membrane protein 140kDa, antigen CD62)

-1.12

VASP

vasodilator-stimulated phosphoprotein

-1.13

PTH1R

parathyroid hormone 1 receptor

-1.14

Abcb1b

ATP-binding cassette, sub-family B (MDR/TAP), member 1B

-1.15

EPHB4

EPH receptor B4

-1.15

DSG2

desmoglein 2

-1.15

EVL

Enah/Vasp-like

-1.15

F3

coagulation factor III (thromboplastin, tissue factor)

-1.15

SDCBP

syndecan binding protein (syntenin)

-1.16

ABCA1

ATP-binding cassette, sub-family A (ABC1), member 1

-1.17

ANO6

anoctamin 6

-1.17

PLXNA1

plexin A1

-1.17

Cd99

CD99 antigen

-1.17

GPR173

G protein-coupled receptor 173

-1.17

GNA13

-1.18

NRP1

guanine nucleotide binding protein (G protein), alpha 13
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29
includes MDF2, MSK12)
guanine nucleotide binding protein (G protein),
q polypeptide
neuropilin 1

ACKR1

atypical chemokine receptor 1 (Duffy blood group)

-1.19

ABCB4

ATP-binding cassette, sub-family B (MDR/TAP), member 4

-1.19

GEM

GTP binding protein overexpressed in skeletal muscle

-1.19

CD99L2

-1.19

Marcks

CD99 molecule-like 2
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding
protein Rac1)
myristoylated alanine rich protein kinase C substrate

CD47

CD47 molecule

-1.20

ITGB5

integrin, beta 5

-1.20

DAB2

Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)

-1.20

EPHB6
TNFRSF12
A
SPRY4

EPH receptor B6

-1.20

tumor necrosis factor receptor superfamily, member 12A

-1.20

sprouty homolog 4 (Drosophila)

-1.21

ITGB1
GNAQ

RAC1

-1.18
-1.19
-1.19

-1.19
-1.19
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GNG12

guanine nucleotide binding protein (G protein), gamma 12

-1.21

LGR4

leucine-rich repeat containing G protein-coupled receptor 4

-1.21

EPHA5

-1.21

EFNB3

EPH receptor A5
sema domain, transmembrane domain (TM), and cytoplasmic domain,
(semaphorin) 6D
ephrin-B3

FGFR4

fibroblast growth factor receptor 4

-1.22

EPHB2

EPH receptor B2

-1.22

CELSR2

cadherin, EGF LAG seven-pass G-type receptor 2

-1.23

JUP

junction plakoglobin

-1.23

LDLR

low density lipoprotein receptor

-1.23

NRAS

neuroblastoma RAS viral (v-ras) oncogene homolog

-1.24

NOTCH1

notch 1

-1.24

GPM6A

glycoprotein M6A

-1.25

CDH2

cadherin 2, type 1, N-cadherin (neuronal)

-1.26

GNA12

guanine nucleotide binding protein (G protein) alpha 12

-1.27

PHACTR4

phosphatase and actin regulator 4

-1.27

MRAS

muscle RAS oncogene homolog

-1.28

SSTR2

somatostatin receptor 2

-1.28

NOTCH3

notch 3

-1.28

KCNK2

potassium channel, subfamily K, member 2

-1.29

ITGA4

-1.29

RASSF5

integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3),
member 3 regulator 1
Ras association (RalGDS/AF-6) domain family member 5

RECK

reversion-inducing-cysteine-rich protein with kazal motifs

-1.31

RAP2B

RAP2B, member of RAS oncogene family

-1.32

P2RX4

purinergic receptor P2X, ligand-gated ion channel, 4

-1.32

IL4R

interleukin 4 receptor

-1.33

TNFRSF19

tumor necrosis factor receptor superfamily, member 19
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM)
and
short cytoplasmic domain, (semaphorin) 4C
low density lipoprotein receptor-related protein 5

-1.33

-1.34

CNTN1

EPH receptor B3
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM)
and
short cytoplasmic domain, (semaphorin) 4D
contactin 1

ANK3

ankyrin 3, node of Ranvier (ankyrin G)

-1.35

Cald1

-1.36

CLIC4

caldesmon 1
guanine nucleotide binding protein (G protein), alpha inhibiting activity
polypeptide 2
chloride intracellular channel 4

CD151

CD151 molecule (Raph blood group)

-1.36

SEMA6D

SLC9A3R1

SEMA4C
LRP5
EPHB3
SEMA4D

GNAI2

-1.22
-1.22

-1.30
-1.31

-1.33
-1.34

-1.34
-1.35

-1.36
-1.36
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SLC12A4

solute carrier family 12 (potassium/chloride transporter), member 4

-1.38

PAG1

phosphoprotein membrane anchor with glycosphingolipid microdomains 1

-1.38

NOTCH4

notch 4

-1.40

RRAS2

related RAS viral (r-ras) oncogene homolog 2

-1.40

FYN

FYN proto-oncogene, Src family tyrosine kinase

-1.40

GPC1

-1.41

PTPRM

glypican 1
membrane associated guanylate kinase,
WW and PDZ domain containing 1
protein tyrosine phosphatase, receptor type, M

EPHB1

EPH receptor B1

-1.42

EPHA2

EPH receptor A2

-1.43

PTPRF

protein tyrosine phosphatase, receptor type, F

-1.43

PPAP2B

phosphatidic acid phosphatase type 2B

-1.44

PTPRJ

protein tyrosine phosphatase, receptor type, J

-1.44

MDGA1

MAM domain containing glycosylphosphatidylinositol anchor 1

-1.44

ST14

suppression of tumorigenicity 14 (colon carcinoma)

-1.46

APP

amyloid beta (A4) precursor protein
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM)
and
short cytoplasmic domain, (semaphorin) 4A
syntaxin 4

-1.46

AMOT

angiomotin

-1.46

FAT3

FAT atypical cadherin 3

-1.47

FZD3

frizzled class receptor 3

-1.47

DDR1

discoidin domain receptor tyrosine kinase 1

-1.47

FAT1

FAT atypical cadherin 1

-1.47

AMOTL1

angiomotin like 1

-1.47

EFNA1

ephrin-A1

-1.48

TNS3

tensin 3

-1.49

DCC

DCC netrin 1 receptor

-1.50

MAGI1

SEMA4A
STX4

-1.41
-1.41

-1.46
-1.46

Cd59a

CD59a antigen

-1.52

PEAK1

pseudopodium-enriched atypical kinase 1

-1.52

ZYX

zyxin

-1.52

ANXA5

annexin A5

-1.52

RHOC

ras homolog family member C

-1.52

EZR

ezrin

-1.53

LRP1

low density lipoprotein receptor-related protein 1

-1.53

SMO

smoothened, frizzled class receptor

-1.54

PCDH10

protocadherin 10

-1.54

SPATA13

spermatogenesis associated 13

-1.56

GAP43

growth associated protein 43

-1.56

TSHR

thyroid stimulating hormone receptor

-1.56

GPR124

G protein-coupled receptor 124

-1.58
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GFRA1

GDNF family receptor alpha 1

-1.59

Cd24a

CD24a antigen

-1.59

CADPS2

Ca++-dependent secretion activator 2

-1.60

KDR

kinase insert domain receptor (a type III receptor tyrosine kinase)

-1.62

ITGAV

integrin, alpha V

-1.62

NRCAM

neuronal cell adhesion molecule

-1.62

EFNB1

ephrin-B1

-1.62

DLL1

delta-like 1 (Drosophila)

-1.63

PTPRK

protein tyrosine phosphatase, receptor type, K

-1.64

CD9

CD9 molecule

-1.65

S1PR2

sphingosine-1-phosphate receptor 2

-1.65

ADAM19

ADAM metallopeptidase domain 19

-1.66

FGFR1

fibroblast growth factor receptor 1

-1.66

MAPT

microtubule-associated protein tau

-1.67

ROBO3

roundabout, axon guidance receptor, homolog 3 (Drosophila)

-1.68

MGLL

monoglyceride lipase

-1.68

PTPRG

protein tyrosine phosphatase, receptor type, G

-1.68

ROR1

receptor tyrosine kinase-like orphan receptor 1

-1.70

CTNND2

catenin (cadherin-associated protein), delta 2

-1.70

GAS1

growth arrest-specific 1

-1.70

SFRP2

secreted frizzled-related protein 2

-1.73

GRID2

glutamate receptor, ionotropic, delta 2

-1.73

ACVR1

activin A receptor, type I

-1.73

NTRK2

neurotrophic tyrosine kinase, receptor, type 2

-1.73

EFNA5

ephrin-A5

-1.74

PALLD

palladin, cytoskeletal associated protein

-1.74

PDPN

podoplanin

-1.74

ADAM12

ADAM metallopeptidase domain 12

-1.75

NRP2

neuropilin 2

-1.76

CNTNAP2

contactin associated protein-like 2

-1.76

BMPR1B

bone morphogenetic protein receptor, type IB

-1.76

S1PR3

sphingosine-1-phosphate receptor 3

-1.77

CELSR1

cadherin, EGF LAG seven-pass G-type receptor 1

-1.77

EFNB2

ephrin-B2

-1.77

TYRO3

TYRO3 protein tyrosine kinase

-1.78

DOCK4

dedicator of cytokinesis 4

-1.79

ENPP2

ectonucleotide pyrophosphatase/phosphodiesterase 2

-1.80

GRIA3

glutamate receptor, ionotropic, AMPA 3

-1.83

GPR56

G protein-coupled receptor 56

-1.84

CTNNA2

catenin (cadherin-associated protein), alpha 2

-1.85

AXL

AXL receptor tyrosine kinase

-1.86
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NGFR

nerve growth factor receptor

-1.86

NRXN1

neurexin 1

-1.87

TPBG

trophoblast glycoprotein

-1.88

PMP22

peripheral myelin protein 22

-1.88

CD1D

CD1d molecule

-1.88

MCAM

melanoma cell adhesion molecule

-1.89

GPC3

glypican 3

-1.91

SLC1A3

solute carrier family 1 (glial high affinity glutamate transporter), member 3

-1.91

NOTCH2

notch 2

-1.92

TNFRSF21

tumor necrosis factor receptor superfamily, member 21

-1.92

CD200

CD200 molecule

-1.93

TENM2

teneurin transmembrane protein 2

-1.94

PDGFRA

platelet-derived growth factor receptor, alpha polypeptide

-1.94

DRD1

dopamine receptor D1

-1.94

ITGB8

integrin, beta 8
sema domain, transmembrane domain (TM), and cytoplasmic domain,
(semaphorin) 6A
coagulation factor II (thrombin) receptor

-1.95

-2.00

FZD7

contactin 4
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM)
and
short cytoplasmic domain, (semaphorin) 4F
frizzled class receptor 7

CD44

CD44 molecule (Indian blood group)

-2.03

KIT

v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog

-2.04

CDH11

cadherin 11, type 2, OB-cadherin (osteoblast)

-2.05

PLXNC1

plexin C1

-2.06

PON2

paraoxonase 2

-2.06

CNR1

cannabinoid receptor 1 (brain)

-2.07

RET

ret proto-oncogene

-2.08

SEMA6A
F2R
CNTN4
SEMA4F

-1.97
-1.99

-2.01
-2.03

MSN

moesin

-2.08

FLRT3

fibronectin leucine rich transmembrane protein 3

-2.09

GPR161

G protein-coupled receptor 161

-2.09

GLRB

glycine receptor, beta

-2.10

LRRC4C

leucine rich repeat containing 4C

-2.16

SLC8A1

solute carrier family 8 (sodium/calcium exchanger), member 1

-2.17

EDNRB

endothelin receptor type B

-2.19

CXCR4

chemokine (C-X-C motif) receptor 4

-2.23

EPHA4

-2.25

ROBO1

EPH receptor A4
sema domain, seven thrombospondin repeats (type 1 and type 1-like),
transmembrane domain (TM) and short cytoplasmic domain,
(semaphorin) 5A
roundabout, axon guidance receptor, homolog 1 (Drosophila)

EGFR

epidermal growth factor receptor

-2.76

SEMA5A

-2.39
-2.47
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PDGFRB

platelet-derived growth factor receptor, beta polypeptide

-2.78

GRIA2

glutamate receptor, ionotropic, AMPA 2

-2.82

PTPRZ1

protein tyrosine phosphatase, receptor-type, Z polypeptide 1

-2.97

SDC1

syndecan 1

-3.58

	
  
	
  
	
  
	
  
	
  
5.1B: Plasma Membrane Molecules from Cone Photoreceptor Precursors
Gene
Symbol
SLC1A2

solute carrier family 1 (glial high affinity glutamate transporter), member 2

Fold
Change
3.86

PTPRO

protein tyrosine phosphatase, receptor type, O

2.35

Entrez Gene Name

STX3

syntaxin 3

2.27

PLXNA2

plexin A2

2.23

JAM2

junctional adhesion molecule 2

2.21

KCNMA1

potassium large conductance calcium-activated channel, subfamily M, alpha member 1

1.99

MDGA1

MAM domain containing glycosylphosphatidylinositol anchor 1

1.64

L1CAM

L1 cell adhesion molecule

1.41

INSR

insulin receptor

1.36

APP

amyloid beta (A4) precursor protein

1.35

HTR2B

5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled

1.33

GNAI1

guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1

1.25

SLC9A1

solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1

1.24

C1GALT1

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1

1.19

CD200

CD200 molecule

1.16

CD93

CD93 molecule

1.15

MC1R

melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)

1.15

ADAM9

ADAM metallopeptidase domain 9

1.11

TNFRSF4

tumor necrosis factor receptor superfamily, member 4

1.11

CD38

CD38 molecule

1.10

TACR1
MARVELD
3
ENG

tachykinin receptor 1

1.09

MARVEL domain containing 3

1.08

endoglin

1.06

GRIN1

glutamate receptor, ionotropic, N-methyl D-aspartate 1

1.05

SH2B3

SH2B adaptor protein 3

1.05

ADAM21

ADAM metallopeptidase domain 21

1.03

Cdc42

cell division cycle 42

1.03

IL20RA

interleukin 20 receptor, alpha

1.02

AMOTL1

angiomotin like 1

1.02

SCN5A

sodium channel, voltage-gated, type V, alpha subunit

1.02

216

SPN
CATSPER
1
PLVAP

sialophorin

-1.03

cation channel, sperm associated 1

-1.03

WASF2

plasmalemma vesicle associated protein

-1.06

WAS protein family, member 2

-1.07

CD97

CD97 molecule

-1.07

ALPL

alkaline phosphatase, liver/bone/kidney

-1.07

SFRP5

secreted frizzled-related protein 5

-1.07

TMEM102

transmembrane protein 102

-1.08

F2RL3

coagulation factor II (thrombin) receptor-like 3

-1.08

TM4SF4

transmembrane 4 L six family member 4

-1.09

TLR2

toll-like receptor 2

-1.09

ANXA1

annexin A1

-1.10

LRP1

low density lipoprotein receptor-related protein 1

-1.10

ICAM1

intercellular adhesion molecule 1

-1.11

CTTN

cortactin

-1.12

TRPC1

transient receptor potential cation channel, subfamily C, member 1

-1.12

MGLL

monoglyceride lipase

-1.13

SEMA6A

sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A

-1.14

Klra4

killer cell lectin-like receptor, subfamily A, member 4

-1.14

RAB28

RAB28, member RAS oncogene family

-1.16

PVRL2

poliovirus receptor-related 2 (herpesvirus entry mediator B)

-1.18

SCUBE3
ICOSLG/L
OC102723
996
RECK

signal peptide, CUB domain, EGF-like 3

-1.21

inducible T-cell co-stimulator ligand

-1.23

reversion-inducing-cysteine-rich protein with kazal motifs

-1.25

MC4R

melanocortin 4 receptor

-1.26

SLC4A2

solute carrier family 4 (anion exchanger), member 2

-1.32

MRC2

mannose receptor, C type 2

-1.33

ZYX

zyxin

-1.34

LIMS1

LIM and senescent cell antigen-like domains 1

-1.36

SLC12A4

solute carrier family 12 (potassium/chloride transporter), member 4

-1.40

PALLD
ARPIN/C1
5orf38AP3S2
ERBB2

palladin, cytoskeletal associated protein

-1.41

C15orf38-AP3S2 readthrough

-1.42

v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2

-1.48

EPHB4

EPH receptor B4

-1.52

FAT1

FAT atypical cadherin 1

-1.53

GRID2

glutamate receptor, ionotropic, delta 2

-1.59

EPHB1

EPH receptor B1

-1.73

PMP22

peripheral myelin protein 22

-1.76

KDR

kinase insert domain receptor (a type III receptor tyrosine kinase)

-1.82
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SLC2A1

solute carrier family 2 (facilitated glucose transporter), member 1

-1.89

CXCR4
ARHGEF2
6
SLC1A3

chemokine (C-X-C motif) receptor 4

-1.97

Rho guanine nucleotide exchange factor (GEF) 26

-2.06

solute carrier family 1 (glial high affinity glutamate transporter), member 3

-2.29

PTPRZ1

protein tyrosine phosphatase, receptor-type, Z polypeptide 1

-2.29

PON2

paraoxonase 2

-2.64

	
  
	
  
	
  
	
  
5.1C: Extracellular Matrix (ECM) Molecules from Neurosensory Retina
Gene
Symbol
Ccl2

chemokine (C-C motif) ligand 2

Fold
Change
3.22

SERPINA3

serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3

2.13

LIF

leukemia inhibitory factor

2.11

Entrez Gene Name

A2M

alpha-2-macroglobulin

2.05

SPP1

secreted phosphoprotein 1

1.99

IL1A

interleukin 1, alpha

1.90

LCN2

lipocalin 2

1.86

CCL3L3

chemokine (C-C motif) ligand 3-like 3

1.75

CXCL3

chemokine (C-X-C motif) ligand 3

1.70

SERPING1

serpin peptidase inhibitor, clade G (C1 inhibitor), member 1

1.67

TIMP1

TIMP metallopeptidase inhibitor 1

1.64

LGALS1

lectin, galactoside-binding, soluble, 1

1.63

CHI3L1

chitinase 3-like 1 (cartilage glycoprotein-39)

1.59

PROS1

protein S (alpha)

1.57

CXCL10

chemokine (C-X-C motif) ligand 10

1.55

FGF2

fibroblast growth factor 2 (basic)

1.55

RBP1

retinol binding protein 1, cellular

1.53

PENK

proenkephalin

1.48

BTC

betacellulin

1.48

LYZ

lysozyme

1.43

HBEGF

heparin-binding EGF-like growth factor

1.43

ADAMTS1

ADAM metallopeptidase with thrombospondin type 1 motif, 1

1.41

IL1B

interleukin 1, beta

1.40

IL33

interleukin 33

1.40

MGP

matrix Gla protein

1.39

CSF1

colony stimulating factor 1 (macrophage)

1.37

MMP14

matrix metallopeptidase 14 (membrane-inserted)

1.36

SERPINB2

serpin peptidase inhibitor, clade B (ovalbumin), member 2

1.34

ERAP1

endoplasmic reticulum aminopeptidase 1

1.33

CXCL16

chemokine (C-X-C motif) ligand 16

1.32
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EDN2

endothelin 2

1.30

TNFAIP6

tumor necrosis factor, alpha-induced protein 6

1.29

C3

complement component 3

1.29

CCL17

chemokine (C-C motif) ligand 17

1.28

MATN2

matrilin 2

1.27

PLAT

plasminogen activator, tissue

1.26

NDP

Norrie disease (pseudoglioma)

1.26

ANGPT1

angiopoietin 1

1.25

CYR61

cysteine-rich, angiogenic inducer, 61

1.23

Ccl7

chemokine (C-C motif) ligand 7

1.22

NAMPT

nicotinamide phosphoribosyltransferase

1.22

LGALS3

lectin, galactoside-binding, soluble, 3

1.22

TIMP3

TIMP metallopeptidase inhibitor 3

1.22

EDN1

endothelin 1

1.22

KITLG

KIT ligand

1.22

IGFBP5

insulin-like growth factor binding protein 5

1.21

TGFB2

transforming growth factor, beta 2

1.21

Saa3

serum amyloid A 3

1.20

FN1

fibronectin 1

1.20

VAV3

vav 3 guanine nucleotide exchange factor

1.19

CXCL2

chemokine (C-X-C motif) ligand 2

1.18

TIMP2

TIMP metallopeptidase inhibitor 2

1.17

CCL5

chemokine (C-C motif) ligand 5

1.17

CXCL12

chemokine (C-X-C motif) ligand 12
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1),
member 1
hepatocyte growth factor (hepapoietin A; scatter factor)

1.17

SERPINE1
HGF

1.16
1.16

TAC1

tachykinin, precursor 1

1.15

IL1RN

interleukin 1 receptor antagonist

1.14

IL21

interleukin 21

1.14

COCH

cochlin

1.13

GDNF

glial cell derived neurotrophic factor

1.13

FAM60A

family with sequence similarity 60, member A

1.13

CXCL6

chemokine (C-X-C motif) ligand 6

1.12

IL34

interleukin 34

1.12

Ceacam10

carcinoembryonic antigen-related cell adhesion molecule 10

1.12

INHBB

inhibin, beta B

1.12

LRIG1

leucine-rich repeats and immunoglobulin-like domains 1

1.11

GRN

granulin

1.10

BDNF

brain-derived neurotrophic factor

1.10

THPO

thrombopoietin

1.10

CARTPT

CART prepropeptide

1.10
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PRSS3

1.09

HDGF

protease, serine, 3
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV
collagenase)
hepatoma-derived growth factor

IL4

interleukin 4

1.08

FGL2

fibrinogen-like 2

1.08

SPOCK3

sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3

1.08

TNF

tumor necrosis factor

1.08

NDNF

neuron-derived neurotrophic factor

1.08

CFB

complement factor B

1.07

SPARC

secreted protein, acidic, cysteine-rich (osteonectin)

1.06

HTRA1

HtrA serine peptidase 1

1.06

C4A/C4B

complement component 4B (Chido blood group)

1.05

KDM6B

lysine (K)-specific demethylase 6B

1.05

IL12A

interleukin 12A

1.05

MBP

myelin basic protein

1.05

MIF

macrophage migration inhibitory factor (glycosylation-inhibiting factor)

1.04

Defb3

defensin beta 3

1.04

LGALS8

lectin, galactoside-binding, soluble, 8

1.04

SLIT2

slit homolog 2 (Drosophila)

1.03

CATSPERD

catsper channel auxiliary subunit delta

1.02

CST3

cystatin C

-1.02

ZP3

zona pellucida glycoprotein 3 (sperm receptor)

-1.03

WNT11

wingless-type MMTV integration site family, member 11

-1.03

FBN1

fibrillin 1

-1.03

COL1A1

collagen, type I, alpha 1

-1.04

VASH1

vasohibin 1

-1.04

MMP2

1.09
1.08

CCL4

chemokine (C-C motif) ligand 4

-1.04

PNOC

prepronociceptin

-1.05

COL7A1

collagen, type VII, alpha 1

-1.05

TNFSF13B

tumor necrosis factor (ligand) superfamily, member 13b

-1.05

TFF1

trefoil factor 1

-1.05

SFTPC

surfactant protein C

-1.05

ANGPT4

angiopoietin 4

-1.05

DEF6

-1.05

FGF8

differentially expressed in FDCP 6 homolog (mouse)
sema domain, immunoglobulin domain (Ig) short basic domain, secreted,
(semaphorin) 3D
fibroblast growth factor 8 (androgen-induced)

IGFBP1

insulin-like growth factor binding protein 1

-1.06

KIRREL3

kin of IRRE like 3 (Drosophila)

-1.06

LTBP2

latent transforming growth factor beta binding protein 2

-1.06

BBS1

Bardet-Biedl syndrome 1

-1.06

PRTN3

proteinase 3

-1.06

SEMA3D

-1.05
-1.06
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IL17C

interleukin 17C

-1.07

BMP7

bone morphogenetic protein 7

-1.07

PRSS27

-1.07

MDK

protease, serine 27
sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3F
midkine (neurite growth-promoting factor 2)

ADAMTS7

ADAM metallopeptidase with thrombospondin type 1 motif, 7

-1.07

IFNB1

interferon, beta 1, fibroblast

-1.07

REN

renin

-1.07

IL25

interleukin 25

-1.07

NPPC

natriuretic peptide C

-1.07

KLK3

kallikrein-related peptidase 3

-1.08

SEMA3F

-1.07
-1.07

MST1

macrophage stimulating 1 (hepatocyte growth factor-like)

-1.08

TGFB3

transforming growth factor, beta 3

-1.08

GAS6

growth arrest-specific 6

-1.08

WNT4

wingless-type MMTV integration site family, member 4

-1.09

COL3A1

collagen, type III, alpha 1

-1.10

KLK6

kallikrein-related peptidase 6

-1.10

MFGE8

milk fat globule-EGF factor 8 protein

-1.10

PLTP

phospholipid transfer protein

-1.11

AZGP1

alpha-2-glycoprotein 1, zinc-binding

-1.11

BMP4

bone morphogenetic protein 4

-1.12

SAA1

serum amyloid A1

-1.13

DKK3

dickkopf WNT signaling pathway inhibitor 3

-1.13

VTN

vitronectin

-1.13

JAG1

jagged 1

-1.14

NGF

nerve growth factor (beta polypeptide)

-1.15

APOE

apolipoprotein E

-1.15

Ifnz

interferon zeta

-1.15

IGF2

insulin-like growth factor 2

-1.16

WISP3

WNT1 inducible signaling pathway protein 3

-1.16

COL4A3

collagen, type IV, alpha 3 (Goodpasture antigen)

-1.18

PLA2G5

phospholipase A2, group V

-1.19

PLA2G7

phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)

-1.22

PTN

pleiotrophin

-1.28

OLFM4

olfactomedin 4

-1.43
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5.1D: Extracellular Matrix (ECM) Molecules from Retinal Pigment Epithelium (RPE)
Gene
Fold
Entrez Gene Name
Symbol
Change
MMP3
matrix metallopeptidase 3 (stromelysin 1, progelatinase)
4.15
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
SERPINA3
3.71
antitrypsin), member 3
LCN2
lipocalin 2
3.22
MMP12

matrix metallopeptidase 12 (macrophage elastase)

3.11

TIMP1

TIMP metallopeptidase inhibitor 1

2.51

IL6

interleukin 6

2.43

NMU

neuromedin U

2.18

TNC

tenascin C

1.92

PTX3

pentraxin 3, long

1.66

Ccl2

chemokine (C-C motif) ligand 2

1.62

SPP1

secreted phosphoprotein 1

1.58

CXCL10

chemokine (C-X-C motif) ligand 10

1.58

PROS1

protein S (alpha)

1.58

CHI3L1

chitinase 3-like 1 (cartilage glycoprotein-39)

1.46

Ccl9

chemokine (C-C motif) ligand 9

1.42

C3

complement component 3

1.42

C4A/C4B

complement component 4B (Chido blood group)

1.42

ANGPTL4

angiopoietin-like 4

1.40

PLAU

plasminogen activator, urokinase

1.38

ALB

albumin

1.36

Saa3

serum amyloid A 3

1.34

LOX

lysyl oxidase

1.33

FBLN5

fibulin 5

1.32

TGFBI

transforming growth factor, beta-induced, 68kDa

1.31

MMP19

matrix metallopeptidase 19

1.31

CSF1

colony stimulating factor 1 (macrophage)

1.31

ERAP1

endoplasmic reticulum aminopeptidase 1

1.24

EFEMP1

EGF containing fibulin-like extracellular matrix protein 1

1.24

A2M

alpha-2-macroglobulin

1.23

VCAN

versican

1.22

HTRA1

HtrA serine peptidase 1

1.21

LIF

leukemia inhibitory factor

1.20

CXCL2

1.18

MATN2

chemokine (C-X-C motif) ligand 2
serpin peptidase inhibitor, clade E (nexin, plasminogen
activator inhibitor type 1), member 1
matrilin 2

FN1

fibronectin 1

1.16

CXCL14

chemokine (C-X-C motif) ligand 14

1.16

Ccl6

chemokine (C-C motif) ligand 6

1.15

SERPINE1

1.18
1.17
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CCL25

chemokine (C-C motif) ligand 25

1.15

LRIG1

leucine-rich repeats and immunoglobulin-like domains 1

1.15

TGFB2

transforming growth factor, beta 2

1.14

CCL20

chemokine (C-C motif) ligand 20

1.14

EMILIN2

1.13

PMCH

elastin microfibril interfacer 2
aminoacyl tRNA synthetase complex-interacting
multifunctional protein 1
pro-melanin-concentrating hormone

INHBB

inhibin, beta B

1.11

LGALS1

lectin, galactoside-binding, soluble, 1

1.11

TRIP6

thyroid hormone receptor interactor 6

1.11

DKK3

dickkopf WNT signaling pathway inhibitor 3

1.11

AIMP1

1.12
1.12

Defb3

defensin beta 3

1.10

NAMPT

nicotinamide phosphoribosyltransferase

1.09

THBS4

thrombospondin 4

1.08

PRSS3

protease, serine, 3

1.07

CFB

complement factor B

1.07

MFGE8

milk fat globule-EGF factor 8 protein

1.07

PROK2

prokineticin 2

1.05

HDGF

hepatoma-derived growth factor

1.05

LAMA5

laminin, alpha 5

1.05

CLEC11A

C-type lectin domain family 11, member A

1.04

KLK6

kallikrein-related peptidase 6

1.04

MMP10

matrix metallopeptidase 10 (stromelysin 2)

1.02

SPARC

secreted protein, acidic, cysteine-rich (osteonectin)

-1.01

RBP1

retinol binding protein 1, cellular

-1.03

VEGFC

vascular endothelial growth factor C

-1.04

VEGFB

vascular endothelial growth factor B

-1.04

MOG

myelin oligodendrocyte glycoprotein

-1.06

BBS1

Bardet-Biedl syndrome 1

-1.06

DLL4

delta-like 4 (Drosophila)

-1.06

THBS1

thrombospondin 1

-1.06

TFF2

-1.06

NPY

trefoil factor 2
macrophage migration inhibitory factor (glycosylationinhibiting factor)
neuropeptide Y

BMP4

bone morphogenetic protein 4

-1.07

IL16

interleukin 16

-1.07

IFNL3

interferon, lambda 3

-1.07

GPI

glucose-6-phosphate isomerase

-1.08

APOE

apolipoprotein E
angiotensinogen (serpin peptidase inhibitor, clade A,
member 8)

-1.08

MIF

AGT

-1.07
-1.07

-1.08
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NPTX1

neuronal pentraxin I

-1.09

RETN

resistin

-1.09

PLTP

phospholipid transfer protein

-1.09

CFH

complement factor H

-1.09

MMP11

matrix metallopeptidase 11 (stromelysin 3)

-1.10

JAG1

jagged 1

-1.11

APOA1

apolipoprotein A-I

-1.11

GDF5

growth differentiation factor 5

-1.11

TIMP3

TIMP metallopeptidase inhibitor 3

-1.11

FAM60A

family with sequence similarity 60, member A

-1.11

BDNF

brain-derived neurotrophic factor

-1.11

PDGFA

-1.12

FSTL1

platelet-derived growth factor alpha polypeptide
serpin peptidase inhibitor, clade H (heat shock protein 47),
member 1, (collagen binding protein 1)
follistatin-like 1

FGF13

fibroblast growth factor 13

-1.13

LAMB1

-1.14

COL18A1

laminin, beta 1
phospholipase A2, group VII (platelet-activating factor
acetylhydrolase, plasma)
collagen, type XVIII, alpha 1

TIMP2

TIMP metallopeptidase inhibitor 2

-1.16

FGF1

fibroblast growth factor 1 (acidic)

-1.16

PLA2G5

phospholipase A2, group V

-1.17

PGF

placental growth factor

-1.17

SERPINH1

PLA2G7

-1.13
-1.13

-1.14
-1.14

CCBE1

collagen and calcium binding EGF domains 1

-1.18

DCDC2

doublecortin domain containing 2

-1.19

BMP7

bone morphogenetic protein 7

-1.19

FGF7

fibroblast growth factor 7

-1.19

FBN1

fibrillin 1

-1.19

COL4A3

collagen, type IV, alpha 3 (Goodpasture antigen)

-1.19

MIA

melanoma inhibitory activity

-1.21

VEGFA

vascular endothelial growth factor A

-1.21

IL18

interleukin 18

-1.21

CYR61

cysteine-rich, angiogenic inducer, 61

-1.23

IGF2

insulin-like growth factor 2

-1.24

NTN4

netrin 4

-1.24

BMP2

bone morphogenetic protein 2

-1.24

IL25

interleukin 25

-1.24

GIP

gastric inhibitory polypeptide

-1.25

IGFBP2

insulin-like growth factor binding protein 2, 36kDa

-1.26

MMP16

matrix metallopeptidase 16 (membrane-inserted)

-1.27

BMP6

bone morphogenetic protein 6

-1.29

PDGFD

platelet derived growth factor D

-1.57
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Supplemental Table 5.1: Listing of Resolved Cellular Movement Genes – An
Ingenuity Pathway (IPA) core analysis of significantly expressed genes (right-tailed
Fisher Exact Test; p<0.05) culled from our ligand-receptor matched dataset pairs
revealed cellular movement as the top functional annotation ascribed to our gene
datasets. The genes correlating to this cellular movement function cluster in IPA are
tabulated according to their subcellular localization and presented as plasma membrane
molecules expressed on rods (5.1A; N=360 genes) and Cones (5.1B; N=75 genes), and
extracellular matrix ligands released from the neurosensory retina (NSR) (5.1C; N=147
genes) and retinal pigment epithelia (RPE) (5.1D; N=119 genes). These genes are
ranked by their fold change values and after the appropriate ligand-receptor matches,
will be analyzed to resolve ligands that exhibit downstream effects on their cognate
receptor to modulate migration of our photoreceptor precursor cells (PPCs).
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5.2A: NSR/Rod

Gene
Symbol

BDNF

Ligand
Entrez Gene
Name

brain-derived
neurotrophic factor

Fold
Change

1.10

BTC

betacellulin

1.48

C3

complement
component 3

1.29

CCL5
CXCL12

chemokine (C-C
motif) ligand 5
chemokine (C-X-C
motif) ligand 12

1.17
1.17

DEF6

differentially
expressed in
FDCP 6 homolog
(mouse)

-1.05

EDN1

endothelin 1

1.22

Downstream Cognate Receptor
Gene
Fold
Entrez Gene Name
Symbol
Change
nerve growth factor
NGFR
-1.86
receptor
neurotrophic tyrosine
NTRK2
kinase, receptor,
-1.73
type 2
neurotrophic tyrosine
NTRK3
kinase, receptor,
1.19
type 3
epidermal growth
EGFR
-2.76
factor receptor
integrin, alpha M
(complement
ITGAM
1.18
component 3
receptor 3 subunit)
chemokine (C-C
CCR3
1.13
motif) receptor 3
chemokine (C-X-C
CXCR4
-2.23
motif) receptor 4
ras-related C3
botulinum toxin
substrate 1 (rho
RAC1
-1.19
family, small GTP
binding protein
Rac1)
endothelin receptor
EDNRA
1.14
type A
endothelin receptor
EDNRB
-2.19
type B

FGF8

fibroblast growth
factor 8
(androgeninduced)

-1.06

FGFR4

FN1

fibronectin 1

1.20

TSHR
RAC1

fibroblast growth
factor receptor 4
thyroid stimulating
hormone receptor
ras-related C3

Native Gene
Interaction

Predicted Gene
Interaction

ACTIVATION

INCONSISTENT

ACTIVATION

INCONSISTENT

ACTIVATION

ACTIVATION

ACTIVATION

INCONSISTENT

ACTIVATION

ACTIVATION

ACTIVATION

ACTIVATION

ACTIVATION

INCONSISTENT

ACTIVATION

INHIBITION

ACTIVATION

ACTIVATION

ACTIVATION

INCONSISTENT

-1.22

ACTIVATION

INHIBITION

-1.56

ACTIVATION

INCONSISTENT

-1.19

ACTIVATION

INCONSISTENT
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FYN
EGFR
ITGAV
GAS6

growth arrestspecific 6

-1.08

AXL
TYRO3

GDNF

glial cell derived
neurotrophic factor

1.13

GFRA1

1.13

RET

botulinum toxin
substrate 1 (rho
family, small GTP
binding protein
Rac1)
FYN protooncogene, Src family
tyrosine kinase
epidermal growth
factor receptor
integrin, alpha V
AXL receptor
tyrosine kinase
TYRO3 protein
tyrosine kinase
GDNF family
receptor alpha 1
ret proto-oncogene
epidermal growth
factor receptor
amyloid beta (A4)
precursor protein
interleukin 4 receptor

-1.40

ACTIVATION

INCONSISTENT

-2.76

ACTIVATION

INCONSISTENT

-1.62

ACTIVATION

INCONSISTENT

-1.86

ACTIVATION

INHIBITION

-1.78

ACTIVATION

INHIBITION

-1.59

ACTIVATION

INCONSISTENT

-2.08

ACTIVATION

INCONSISTENT

-2.76

INHIBITION

INHIBITION

-1.46

ACTIVATION

INCONSISTENT

-1.33

ACTIVATION

INCONSISTENT

-1.28

ACTIVATION

INHIBITION

1.65

ACTIVATION

ACTIVATION

HTRA1

HtrA serine
peptidase 1

1.06

EGFR

IL1B

interleukin 1, beta

1.40

APP

IL4

interleukin 4

1.08

IL4R

JAG1

jagged 1
leukemia inhibitory
factor
leucine-rich
repeats and
immunoglobulinlike domains 1
macrophage
migration inhibitory
factor
(glycosylationinhibiting factor)

-1.14

NOTCH3

2.11

LIFR

1.11

EGFR

epidermal growth
factor receptor

-2.76

INHIBITION

INHIBITION

1.04

CXCR4

chemokine (C-X-C
motif) receptor 4

-2.23

ACTIVATION

INCONSISTENT

-1.26

INHIBITION

INHIBITION

-1.47

INHIBITION

INHIBITION

-1.53

INHIBITION

INHIBITION

LIF
LRIG1

MIF

MMP14

matrix
metallopeptidase
14 (membraneinserted)

CDH2
1.36
DDR1
LRP1

notch 3
leukemia inhibitory
factor receptor alpha

cadherin 2, type 1,
N-cadherin
(neuronal)
discoidin domain
receptor tyrosine
kinase 1
low density
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SDC1
NGFR
NGF

nerve growth
factor (beta
polypeptide)

-1.15

NTRK2
NTRK3

PROS1

protein S (alpha)

1.57

TYRO3

PRTN3

proteinase 3

-1.06

F2R

PTN

pleiotrophin

-1.28

PTPRZ1

1.99

ITGAV

-1.08

TGFBR3

1.19

RAC1

SPP1
TGFB3

VAV3

secreted
phosphoprotein 1
transforming
growth factor, beta
3
vav 3 guanine
nucleotide
exchange factor

lipoprotein receptorrelated protein 1
syndecan 1
nerve growth factor
receptor
neurotrophic tyrosine
kinase, receptor,
type 2
neurotrophic tyrosine
kinase, receptor,
type 3
TYRO3 protein
tyrosine kinase
coagulation factor II
(thrombin) receptor
protein tyrosine
phosphatase,
receptor-type, Z
polypeptide 1
integrin, alpha V
transforming growth
factor, beta receptor
III
ras-related C3
botulinum toxin
substrate 1 (rho
family, small GTP
binding protein
Rac1)

-3.58

INHIBITION

INHIBITION

-1.86

INHIBITION

INHIBITION

-1.73

INHIBITION

INHIBITION

1.19

ACTIVATION

INCONSISTENT

-1.78

ACTIVATION

INCONSISTENT

-1.99

INHIBITION

INCONSISTENT

-2.97

INHIBITION

INCONSISTENT

-1.62

ACTIVATION

INCONSISTENT

1.04

ACTIVATION

INCONSISTENT

-1.19

ACTIVATION

INCONSISTENT

	
  
	
  
5.2B: RPE/Cone

Gene
Symbol

Ligand
Entrez Gene
Name

Fold
Change

ALB

albumin

1.36

IGF2

insulin-like growth

-1.24

Downstream Cognate Receptor
Gene
Entrez Gene
Fold
Symbol
Name
Change
amyloid beta
APP
(A4) precursor
1.35
protein
INSR
insulin receptor
1.36

Native Gene
Interaction

Predicted Gene
Interaction

INHIBITION

INCONSISTENT

ACTIVATION

INCONSISTENT
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factor 2

MIF

macrophage
migration inhibitory
factor
(glycosylationinhibiting factor)

PLAU

plasminogen
activator,
urokinase

VEGFA
VEGFC

vascular
endothelial growth
factor A
vascular
endothelial growth
factor C

-1.07

1.38

CXCR4

GRIN1

-1.21
KDR
-1.04

chemokine (C-XC motif) receptor
4
glutamate
receptor,
ionotropic, Nmethyl Daspartate 1
kinase insert
domain receptor
(a type III
receptor tyrosine
kinase)

-1.97

ACTIVATION

INHIBITION

1.05

ACTIVATION

ACTIVATION

-1.82

ACTIVATION

INHIBITION

	
  
	
  
	
  
	
  
	
  
	
  
	
  
5.2C: NSR/Cone
Ligand
Gene
Symbol
CXCL12
MIF
IGF2

Entrez Gene Name
chemokine (C-X-C
motif) ligand 12
macrophage
migration inhibitory
factor (glycosylationinhibiting factor)
insulin-like growth
factor 2

Downstream Cognate Receptor
Gene
Entrez Gene
Fold
Symbol
Name
Change

Native Gene
Interaction

Predicted Gene
Interaction

CXCR4

chemokine (C-XC motif) receptor
4

-1.97

ACTIVATION

INCONSISTENT

-1.16

INSR

insulin receptor

1.36

ACTIVATION

INCONSISTENT

1.35

ACTIVATION

ACTIVATION

-1.10

INHIBITION

INHIBITION

Fold
Change
1.17
1.04

IL1B

interleukin 1, beta

1.40

APP

MMP14

matrix
metallopeptidase 14
(membrane-

1.36

LRP1

amyloid beta (A4)
precursor protein
low density
lipoprotein
receptor-related
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inserted)

protein 1

PTN

pleiotrophin

-1.28

PTPRZ1

TAC1

tachykinin, precursor
1

1.15

TACR1

protein tyrosine
phosphatase,
receptor-type, Z
polypeptide 1
tachykinin
receptor 1

-2.29

INHIBITION

INCONSISTENT

1.09

ACTIVATION

ACTIVATION

Native Gene
Interaction

Predicted Gene
Interaction

INHIBITION

INHIBITION

ACTIVATION

INHIBITION

ACTIVATION

INHIBITION

ACTIVATION

INCONSISTENT

ACTIVATION

INHIBITION

ACTIVATION

ACTIVATION

-1.66

ACTIVATION

INHIBITION

-1.40

ACTIVATION

INCONSISTENT

	
  
	
  
	
  
5.2D: RPE/Rod

Gene
Symbol

Ligand
Entrez Gene
Name

Fold
Change

ALB

albumin

1.36

APOA1

apolipoprotein
A-I

-1.11

BDNF

brain-derived
neurotrophic
factor

-1.11

C3

complement
component 3

1.42

FGF1

fibroblast
growth factor 1
(acidic)

-1.16

FN1

fibronectin 1

1.16

Downstream Cognate Receptor
Gene
Entrez Gene
Fold
Symbol
Name
Change
amyloid beta (A4)
APP
-1.46
precursor protein
ATP-binding
cassette, subABCA1
-1.17
family A (ABC1),
member 1
neurotrophic
NTRK2
tyrosine kinase,
-1.73
receptor, type 2
neurotrophic
NTRK3
tyrosine kinase,
1.19
receptor, type 3
nerve growth
NGFR
-1.86
factor receptor
integrin, alpha M
(complement
ITGAM
component 3
1.18
receptor 3
subunit)
FGFR1

FYN
TSHR

fibroblast growth
factor receptor 1
FYN protooncogene, Src
family tyrosine
kinase
thyroid

-1.56
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ITGAV
EGFR
HTRA1
JAG1
LIF

LRIG1

MIF

PDGFA

PLAU

PROS1
SPP1

HtrA serine
peptidase 1
jagged 1
leukemia
inhibitory factor

1.21

EGFR

-1.11

NOTCH3

1.20

LIFR

stimulating
hormone receptor
integrin, alpha V
epidermal growth
factor receptor
epidermal growth
factor receptor
notch 3
leukemia
inhibitory factor
receptor alpha

-1.62
-2.76
-2.76

INHIBITION

INHIBITION

-1.28

ACTIVATION

INHIBITION

1.65

ACTIVATION

ACTIVATION

leucine-rich
repeats and
immunoglobulin
-like domains 1
macrophage
migration
inhibitory factor
(glycosylationinhibiting factor)
platelet-derived
growth factor
alpha
polypeptide

1.15

EGFR

epidermal growth
factor receptor

-2.76

INHIBITION

INHIBITION

-1.07

CXCR4

chemokine (C-XC motif) receptor
4

-2.23

ACTIVATION

INHIBITION

-1.12

PDGFRA

-1.94

ACTIVATION

INHIBITION

plasminogen
activator,
urokinase

1.38

GRIN1

-1.07

ACTIVATION

INCONSISTENT

1.58

TYRO3

-1.78

ACTIVATION

INCONSISTENT

1.58

ITGAV

integrin, alpha V

-1.62

ACTIVATION

INCONSISTENT

-1.38

ACTIVATION

INHIBITION

-1.20

ACTIVATION

INHIBITION

protein S
(alpha)
secreted
phosphoprotein
1

platelet-derived
growth factor
receptor, alpha
polypeptide
glutamate
receptor,
ionotropic, Nmethyl Daspartate 1
TYRO3 protein
tyrosine kinase

THBS1

thrombospondin
1

-1.06

ITGB1

integrin, beta 1
(fibronectin
receptor, beta
polypeptide,
antigen CD29
includes MDF2,
MSK12)

THBS1

thrombospondin
1

-1.06

CD47

CD47 molecule
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TNC

tenascin C

1.92

EGFR

VEGFA

vascular
endothelial
growth factor A

-1.21

KDR

ITGB1
VEGFC

vascular
endothelial
growth factor C

-1.04
KDR

FLT4

epidermal growth
factor receptor
kinase insert
domain receptor
(a type III
receptor tyrosine
kinase)
integrin, beta 1
(fibronectin
receptor, beta
polypeptide,
antigen CD29
includes MDF2,
MSK12)
kinase insert
domain receptor
(a type III
receptor tyrosine
kinase)
fms-related
tyrosine kinase 4

-2.76

ACTIVATION

INCONSISTENT

-1.62

ACTIVATION

INHIBITION

-1.38

ACTIVATION

INHIBITION

-1.62

ACTIVATION

INHIBITION

1.12

ACTIVATION

INCONSISTENT

Supplemental Table 5.2: Matching ECM Ligands Predicted to Exhibit Downstream Signaling Effects to their Cognate
PPC Receptors - Following IPA resolution of cellular movement genes from our matched datasets, released motogenic
ligands from light-damaged retinal tissues that are predicted to directly interact with their downstream receptors on cone and
rod PPCs were selectively used to create custom signaling networks (Figure 5.3 and Supplemental Figure 5.3). These
network genes are compiled and presented as matched interacting ligand-receptor molecular pairs in A-D resolved from the
NSR/Rods, RPE/Cones, NSR/Cones, and RPE/Rods cellular movement gene networks respectively. The native interaction
between the ligands and receptors described with reference to curated interactions of each model gene pair in the IPA
knowledgebase are presented along with the predicted interactions between gene pairs based on their expression states.
Predictions of gene interactions described to be ‘INCONSISTENT’ represent downstream ligand effects on receptors whose
expression states differ from expected receptor gene expression in an IPA causal effect model of the interacting molecular pair
when downstream activation or inhibition of the receptor gene occurs.
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

232

Receptor

ITGAV

Overlap Score
(Up-regulation)
0.0132

(Perturbation, Dose, Time, Cell,
Batch)
TNFA,100ng/ul,6h,MCF7,LJP004

Overlap Score
(Down-regulation)
0.0122

(Perturbation, Dose, Time, Cell,
Batch)
bNGF,1ng/ul,24h,SKBR3,LJP004

0.012

EPG,100ng/ul,1h,MCF10A,LJP004

0.0122

HBEGF,1ng/ul,3h,MCF10A,LJP004

0.0118

SCF,3ng/ul,1h,MDAMB231,LJP004

0.012

EGF,0.1ng/ul,24h,MCF10A,LJP004

0.0118

IL6,1ng/ul,24h,HS578T,LJP004

0.0116

bNGF,1ng/ul,24h,BT20,LJP004

0.0115

IL1,1ng/ul,3h,MCF10A,LJP004

0.0116

INS,1ng/ul,6h,SKBR3,LJP004

0.0115

HRG,1ng/ul,6h,SKBR3,LJP004

0.0112

0.011

HRG,100ng/ul,24h,SKBR3,LJP004

0.0112

0.0108

0.0112
0.0111

IL6,1ng/ul,6h,SKBR3,LJP004

0.0111

AR,100ng/ul,3h,HS578T,LJP004

0

bNGF,1ng/ul,6h,HS578T,LJP004
FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
Ethisterone,10um,24h,VCAP,CPC003

PDGFBB,1ng/ul,3h,BT20,LJP004
MCSF,100ng/ul,24h,MDAMB231,LJP00
4
EGF,1ng/ul,3h,MCF10A,LJP004

0

Estrone,10um,24h,VCAP,CPC003

0.0127

EPR,1ng/ul,3h,HS578T,LJP004

0

Equilin,10um,24h,VCAP,CPC003

0.0123

IGF2,100ng/ul,3h,MDAMB231,LJP004

0

Eplerenone,10um,24h,VCAP,CPC003

0.012

IL6,100ng/ul,1h,MCF10A,LJP004

0

0.0118

IL1,100ng/ul,6h,MCF10A,LJP004

0

FINASTERIDE,10um,24h,VCAP,CPC0
03

0

FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003

0

Ethisterone,10um,24h,VCAP,CPC003

0

Estrone,10um,24h,VCAP,CPC003

0

Equilin,10um,24h,VCAP,CPC003

0

Eplerenone,10um,24h,VCAP,CPC003

0.02

EUGENITOL,10um,24h,VCAP,CPC003
ETHYL-beta-CARBOLINE-3CARBOXYLATE,10um,24h,VCAP,CPC
003
ESTRADIOL
ACETATE,10um,24h,VCAP,CPC003
ERYTHROMYCIN,10um,24h,VCAP,CP
C003
ERGOCORNINE,10um,24h,VCAP,CPC
003
EPITESTOSTERONE,10um,24h,VCAP,
CPC003
ETHYL-beta-CARBOLINE-3CARBOXYLATE,10um,24h,VCAP,CPC
003
vorinostat,10um,24h,VCAP,CPC003

0.02

0.02

trichostatin A,10um,24h,VCAP,CPC003

0.02

0.02

cis-(Z)-

0.02

deoxyrhapontin,10um,6h,PC3,CPC003
cis-(Z)FLUPENTHIXOL,10um,24h,PC3,CPC0
03
bongkrekic

0
0

0
TSHR

0
0
0
0
0

FYN

233

0.02

FLUPENTHIXOL,10um,24h,VCAP,CPC
003
XYLAZINE,10um,24h,VCAP,CPC003

0.02

XYLAZINE,10um,6h,PC3,CPC003

0.02

WEB 2086,10um,24h,VCAP,CPC003

0.02

0.02

WAY 170523,10um,24h,VCAP,CPC003

0.02

0.02

Vincamine,10um,24h,VCAP,CPC003

0.02

Vincamine,10um,24h,HA1E,CPC003
VERAPAMIL
HYDROCHLORIDE,10um,24h,VCAP,C
PC003
Timolol maleate
salt,10um,24h,PC3,CPC003
TYRPHOSTIN B44 (),10um,24h,VCAP,CPC003
TESTOSTERONE
PROPIONATE,10um,6h,PC3,CPC003

0.02
0.02
0.02
0.02
0.02
0.02
0.02
EGFR

0.02

Vitexin,10um,6h,VCAP,CPC003
THIOTHIXENE,10um,6h,VCAP,CPC00
3
SCOPOLAMINE
HYDROBROMIDE,10um,6h,VCAP,CP
C003

0.02
0.02
0.02

Skimmianine,10um,6h,VCAP,CPC003

0.02

deoxyrhapontin,10um,6h,PC3,CPC003

0.02
0.02
0.02
0.02

deoxyrhapontin,10um,24h,HCC515,CP
C003
VERAPAMIL
HYDROCHLORIDE,10um,24h,HCC515
,CPC003
THIABENDAZOLE,10um,6h,HA1E,CPC
003
TEMEFOS,10um,24h,PC3,CPC003

0.02

SCH 442416,10um,6h,VCAP,CPC003

0.02

0.02

SC-514,10um,24h,VCAP,CPC003

0.02

0.02

0.02
0.02

SB 366791,10um,6h,HA1E,CPC003

0.02

SC 560,10um,24h,VCAP,CPC003
S-(+)ibuprofen,10um,24h,VCAP,CPC003
Racecadotril,10um,24h,VCAP,CPC003

TELMISARTAN,10um,24h,PC3,CPC00
3
SCH
442416,10um,6h,HCC515,CPC003
SB 366791,10um,6h,HCC515,CPC003

0.02

SB 221284,10um,6h,HCC515,CPC003

0.012

IL6,1ng/ul,24h,MCF10A,LJP004

0.0143

IL1,100ng/ul,1h,MDAMB231,LJP004

0.012

IL4,100ng/ul,3h,MDAMB231,LJP004

0.0132

IL6,1ng/ul,3h,MCF7,LJP004

0.0115

IL4,1ng/ul,24h,MCF10A,LJP004

0.0127

PDGFBB,100ng/ul,1h,BT20,LJP004

0.0111

IL4,100ng/ul,3h,SKBR3,LJP004

0.0122

MCSF,1ng/ul,3h,MDAMB231,LJP004

0.02

RAC1

VINCRISTINE
SULFATE,10um,24h,VCAP,CPC003
TUBAIC
ACID,10um,24h,VCAP,CPC003
TRAMADOL
HYDROCHLORIDE,10um,6h,VCAP,CP
C003
deoxyrhapontin,10um,24h,VCAP,CPC0
03
ZOLMITRIPTAN,10um,24h,VCAP,CPC
003

acid,10um,6h,HCC515,CPC003
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0.0111

IFNA,1ng/ul,3h,MDAMB231,LJP004

0.0122

EGF,0.1ng/ul,24h,MCF7,LJP004

0.0111

EGF,0.1ng/ul,3h,MCF7,LJP004

0.012

INS,1ng/ul,3h,MCF10A,LJP004

0.0109

INS,100ng/ul,3h,HS578T,LJP004
FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
Ethisterone,10um,24h,VCAP,CPC003

0.0118

IFNA,1ng/ul,6h,MCF10A,LJP004

0.0114

HGF,1ng/ul,24h,BT20,LJP004

0.0112

PDGFBB,100ng/ul,24h,BT20,LJP004

0.0104

MCSF,1ng/ul,6h,HS578T,LJP004

0.0123

MSP,1ng/ul,24h,MCF7,LJP004

0.0123

FGF1,100ng/ul,3h,BT20,LJP004

0.0119

IL17,100ng/ul,24h,MCF10A,LJP004
PDGFBB,100ng/ul,3h,MDAMB231,LJP
004
HGF,100ng/ul,3h,MDAMB231,LJP004

0.012

0.0118

TNFA,100ng/ul,1h,MCF10A,LJP004

0

0.0118

IFNG,100ng/ul,1h,MCF7,LJP004

0

0.0115

HGF,1ng/ul,1h,MCF7,LJP004
TGFa,100ng/ul,24h,MDAMB231,LJP00
4
IL17,1ng/ul,6h,MCF10A,LJP004
FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003

0

EGF,0.1ng/ul,6h,HS578T,LJP004
FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
Ethisterone,10um,24h,VCAP,CPC003

0

Estrone,10um,24h,VCAP,CPC003

0

Equilin,10um,24h,VCAP,CPC003

0

Eplerenone,10um,24h,VCAP,CPC003

0

EUGENITOL,10um,24h,VCAP,CPC003

0.02

estradiol,10um,24h,VCAP,CPC003

0.02

0.02

bufalin,10um,6h,VCAP,CPC003

0.02

0
0
0
0.0122
0.0119

PTPRZ1

0.0112
0.0111
0
0

0.02
CXCR4

0.02
0.02

bongkrekic
acid,10um,24h,PC3,CPC003
VINCRISTINE
SULFATE,10um,6h,VCAP,CPC003
VINBLASTINE
SULFATE,10um,24h,PC3,CPC003

0.02
0.02
0.02

0.02

Trap 101,10um,24h,VCAP,CPC003

0.02

0.02

TOLAZAMIDE,10um,6h,VCAP,CPC003

0.02

0.02

TCB2,10um,24h,PC3,CPC003

0.02

ZM 323881
hydrochloride,10um,24h,VCAP,CPC003
VARDENAFIL
HYDROCHLORIDE,10um,24h,PC3,CP
C003
TRIAMTERENE,10um,24h,VCAP,CPC
003
THIABENDAZOLE,10um,24h,HCC515,
CPC003
TAMOXIFEN
CITRATE,10um,24h,VCAP,CPC003
Seneciphylline,10um,24h,VCAP,CPC00
3
SR-95639A,10um,6h,VCAP,CPC003
SCOPOLAMINE
HYDROBROMIDE,10um,6h,PC3,CPC0
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03

0.012

TC 2559
difumarate,10um,6h,VCAP,CPC003
TC 2559
difumarate,10um,24h,VCAP,CPC003
IL4,100ng/ul,1h,MCF10A,LJP004

0.0116

IGF2,100ng/ul,3h,BT20,LJP004

0.0119

IL1,1ng/ul,24h,MCF10A,LJP004

0.0115

TNFA,1ng/ul,6h,MCF7,LJP004

0.0116

IL4,100ng/ul,1h,BT20,LJP004

0.0114

BTC,1ng/ul,6h,MCF7,LJP004

0.0115

EPR,100ng/ul,24h,MCF7,LJP004

0.0112

bNGF,100ng/ul,24h,SKBR3,LJP004

0.0112

KGF,100ng/ul,24h,MDAMB231,LJP004

0.0112

EGF,100ng/ul,1h,MCF7,LJP004

0.011

0.011

SCF,3ng/ul,6h,HS578T,LJP004

0.0109

IFNG,100ng/ul,1h,MDAMB231,LJP004

0.0108

HGF,100ng/ul,6h,MCF7,LJP004

0

EPR,100ng/ul,3h,MCF7,LJP004
FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
Ethisterone,10um,24h,VCAP,CPC003

0.0106

0

Estrone,10um,24h,VCAP,CPC003

0

0.0122

TNFA,100ng/ul,1h,BT20,LJP004

0.012

IFNG,100ng/ul,1h,MCF10A,LJP004
FINASTERIDE,10um,24h,VCAP,CPC0
03
EPR,1ng/ul,24h,SKBR3,LJP004

0.012

IL17,1ng/ul,24h,MCF7,LJP004

0.0119

IGF2,1ng/ul,3h,SKBR3,LJP004

0.0118

bFGF,100ng/ul,24h,BT20,LJP004

0.0116

TGFa,1ng/ul,6h,BT20,LJP004

0.0115

SCF,300ng/ul,6h,SKBR3,LJP004

0.0116

FGF1,1ng/ul,24h,MDAMB231,LJP004

0.0115

MSP,1ng/ul,24h,BT20,LJP004

0.0116

BTC,100ng/ul,1h,MCF10A,LJP004

0.0114

GAS6,100ng/ul,1h,SKBR3,LJP004

0.0115

IL4,1ng/ul,1h,MDAMB231,LJP004

0.0112

GDNF,100ng/ul,6h,SKBR3,LJP004

0.0111

EGF,1ng/ul,24h,MDAMB231,LJP004

0.0108

0.011

INS,1ng/ul,24h,MDAMB231,LJP004

0.011

EPR,100ng/ul,6h,MDAMB231,LJP004

0.0109

IL4,100ng/ul,6h,HS578T,LJP004

0.02

0.02

MCSF,100ng/ul,1h,BT20,LJP004
FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
wortmannin,10um,24h,VCAP,CPC003
geldanamycin,10um,24h,VCAP,CPC00
3
estradiol,10um,24h,VCAP,CPC003

0.02

ZOLMITRIPTAN,10um,6h,PC3,CPC003
ZOLMITRIPTAN,10um,24h,HCC515,C
PC003
YM 976,10um,6h,VCAP,CPC003

0.02

WY 14643,10um,24h,VCAP,CPC003

0.02

XYLAZINE,10um,24h,HA1E,CPC003

0.02
0.02

CDH2

0
0

LRP1

0
0
0.02
DDR1

0.02

0.02

SC 560,10um,6h,PC3,CPC003

0.02

SC 560,10um,24h,PC3,CPC003

0.02
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0.02

VERAPAMIL
HYDROCHLORIDE,10um,24h,VCAP,C
PC003

0.02

0.02

Trap 101,10um,24h,VCAP,CPC003

0.02

0.02

TER14687,10um,24h,VCAP,CPC003
TC 2559
difumarate,10um,24h,VCAP,CPC003

0.02

0.02

SULPIRIDE,10um,24h,VCAP,CPC003

0.02

0.02

SU1498,10um,24h,VCAP,CPC003

0.02

Timolol maleate
salt,10um,6h,VCAP,CPC003
TRIOXSALEN,10um,24h,PC3,CPC003
TRIOXSALEN,10um,24h,HCC515,CPC
003
TOLBUTAMIDE,10um,24h,VCAP,CPC0
03
TEMEFOS,10um,24h,HA1E,CPC003

0.012

IL6,1ng/ul,3h,MDAMB231,LJP004

0.0132

GDNF,100ng/ul,24h,BT20,LJP004

0.0116

PDGFBB,1ng/ul,6h,HS578T,LJP004

0.013

IL1,1ng/ul,1h,SKBR3,LJP004

0.0116

0.013

IGF1,1ng/ul,24h,SKBR3,LJP004

0.013

HRG,100ng/ul,1h,MCF10A,LJP004

0.0128

IFNA,1ng/ul,24h,SKBR3,LJP004

0

EGF,0.1ng/ul,3h,MCF10A,LJP004
FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
Ethisterone,10um,24h,VCAP,CPC003

0.0127

INS,100ng/ul,3h,SKBR3,LJP004

0

Estrone,10um,24h,VCAP,CPC003

0.0125

IGF1,1ng/ul,24h,BT20,LJP004

0

Equilin,10um,24h,VCAP,CPC003

0.0125

FGF1,100ng/ul,24h,MCF10A,LJP004

0

Eplerenone,10um,24h,VCAP,CPC003

0.0123

SCF,3ng/ul,6h,BT20,LJP004

0

EUGENITOL,10um,24h,VCAP,CPC003

0.0123

IL6,1ng/ul,24h,BT20,LJP004

0.0125

TGFa,100ng/ul,1h,HS578T,LJP004

0.0133

IFNA,100ng/ul,6h,MDAMB231,LJP004

0.0123

KGF,1ng/ul,3h,MCF7,LJP004

0.0123

FGF1,100ng/ul,6h,MCF10A,LJP004

0.0123

IL17,100ng/ul,6h,BT20,LJP004

0.0122

GAS6,1ng/ul,1h,MDAMB231,LJP004

0.0119

HGF,1ng/ul,6h,HS578T,LJP004

0.012

HRG,100ng/ul,24h,MCF7,LJP004

0.0118

KGF,1ng/ul,1h,BT20,LJP004

0.012

EGF,100ng/ul,1h,MDAMB231,LJP004

0.0116

bNGF,1ng/ul,24h,SKBR3,LJP004

0.0119

EGF,100ng/ul,3h,BT20,LJP004

0.0116

IL17,100ng/ul,6h,SKBR3,LJP004

0.0118

IL1,1ng/ul,6h,MCF10A,LJP004

0.0114

IGF2,1ng/ul,1h,MCF7,LJP004

0.0116

bFGF,1ng/ul,1h,MDAMB231,LJP004

0.011

SCF,3ng/ul,6h,HS578T,LJP004

0.0116

bFGF,100ng/ul,24h,MCF10A,LJP004

0.0109

IL4,1ng/ul,6h,BT20,LJP004

0.0116

HBEGF,1ng/ul,24h,HS578T,LJP004

0.0127

bFGF,100ng/ul,6h,MCF10A,LJP004

0.0118

EGF,100ng/ul,1h,BT20,LJP004

0.0123

PDGFBB,100ng/ul,6h,MCF7,LJP004

0.0111

PDGFBB,1ng/ul,3h,HS578T,LJP004

0.02

0
SDC1

RET

GFRA1

0

0.02

Triamcinolone,10um,24h,PC3,CPC003
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0

FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
Ethisterone,10um,24h,VCAP,CPC003

0

FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
Ethisterone,10um,24h,VCAP,CPC003

0
0

Estrone,10um,24h,VCAP,CPC003

0

Estrone,10um,24h,VCAP,CPC003

Equilin,10um,24h,VCAP,CPC003

0

Equilin,10um,24h,VCAP,CPC003

0

Eplerenone,10um,24h,VCAP,CPC003

0

Eplerenone,10um,24h,VCAP,CPC003

0

0

0.013

EUGENITOL,10um,24h,VCAP,CPC003
ETHYL-beta-CARBOLINE-3CARBOXYLATE,10um,24h,VCAP,CPC
003
HGF,100ng/ul,3h,MCF10A,LJP004

0.0122

EUGENITOL,10um,24h,VCAP,CPC003
ETHYL-beta-CARBOLINE-3CARBOXYLATE,10um,24h,VCAP,CPC
003
HBEGF,1ng/ul,3h,MCF10A,LJP004

0.013

EPR,100ng/ul,6h,MCF10A,LJP004

0.0116

FGF1,1ng/ul,24h,MDAMB231,LJP004

0.0125

GDNF,100ng/ul,3h,MCF7,LJP004

0.0115

bNGF,100ng/ul,6h,BT20,LJP004

0.0123

EPG,100ng/ul,1h,BT20,LJP004

0.0112

MCSF,1ng/ul,24h,MCF7,LJP004

0.0122

TGFa,100ng/ul,24h,SKBR3,LJP004

0.0109

GAS6,100ng/ul,6h,MCF10A,LJP004

0.0122

SCF,300ng/ul,6h,MCF7,LJP004

0.0106

0.0119

BTC,100ng/ul,24h,BT20,LJP004

0

0.0118

BTC,100ng/ul,3h,MCF7,LJP004

0

0.0116

bNGF,1ng/ul,24h,SKBR3,LJP004

0

IFNG,100ng/ul,3h,BT20,LJP004
FINASTERIDE,10um,24h,VCAP,CPC0
03
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
Ethisterone,10um,24h,VCAP,CPC003

0.0115

IL17,1ng/ul,1h,MCF10A,LJP004

0

Estrone,10um,24h,VCAP,CPC003

0.0128

bFGF,100ng/ul,6h,SKBR3,LJP004

0.0132

MSP,100ng/ul,1h,SKBR3,LJP004

0.0127

INS,1ng/ul,6h,MDAMB231,LJP004

0.0122

PDGFBB,100ng/ul,24h,HS578T,LJP004

0.0119

HBEGF,100ng/ul,24h,BT20,LJP004

0.0119

FGF1,100ng/ul,1h,SKBR3,LJP004

0.0115

IGF1,1ng/ul,3h,BT20,LJP004

0.0118

IL1,1ng/ul,1h,MCF10A,LJP004

0.0114

MCSF,1ng/ul,24h,SKBR3,LJP004

0.0118

IL1,100ng/ul,6h,MCF10A,LJP004

0.0114

IL17,1ng/ul,3h,BT20,LJP004

0.0116

EGF,10ng/ul,6h,BT20,LJP004

0.0112

IFNG,100ng/ul,1h,HS578T,LJP004

0.0115

GDNF,1ng/ul,6h,MCF10A,LJP004

0.0111

IGF2,100ng/ul,24h,BT20,LJP004

0.0114

MSP,1ng/ul,1h,MCF10A,LJP004

0.0111

EPR,1ng/ul,24h,SKBR3,LJP004

0.0111

IL1,100ng/ul,24h,SKBR3,LJP004

0.0109

TGFa,1ng/ul,1h,MCF7,LJP004	
  

0.0106

TNFA,100ng/ul,3h,MCF10A,LJP004	
  

0
0

0

AXL

TYRO3

0
0

0
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Supplemental Table 6.1: L1000 Analysis for drug perturbations potentially influencing down-regulated receptor expression states of
rod photoreceptors – Listed are top 10 ranked experiments that potentially reverse (up-regulate) or aggravate (down-regulate) the expression
of each resolved down-regulated motility-deterministic rod receptor culled from results of IPA bioinformatics analysis of NSR/Rod matched
dataset depicted in Table 5.2 (Chapter 5). Rankings of chemical perturbation experiments was performed using an overlap score that
quantifies the correlation between our input gene list and z-score gene expression signatures of the 1000 genes measured per experiment
using Pearson’s correlation. Experimental conditions associated with selected drugs and small molecule effectors are presented as clickable
URL links to the LINCS Canvas Browser user interface where the drug analysis was performed [3].
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Overlap Score
(Down-regulation)

(Perturbation, Dose, Time, Cell, Batch)

Overlap Score
(Up-regulation)

(Perturbation, Dose, Time, Cell, Batch)

0.18

Sertindole,10um,24h,PC3,CPD002

0.18
0.16
0.16
0.16
0.16

PLX4032,0.4um,6h,MCF10A,LJP001
PAC 1,10um,24h,PC3,CPC006
OSI-027,0.4um,6h,MDAMB231,LJP001
O-2050,10um,24h,PC3,CPC001
NCGC00183223-01,10um,6h,A549,CPC007
Methoxy-6harmalan,10um,24h,HCC515,CPC004
GSK429286A,10um,6h,MCF10A,LJP001
DIETHYLCARBAMAZINE
CITRATE,10um,6h,HA1E,CPC004
CARBAMAZEPINE,10um,24h,HCC515,CPC0
04

0.16
0.16
0.14
0.14
0.14

(+)-Isoproterenol (+)-bitartrate
salt,10um,24h,MCF7,CPD003
KUC104236N,10um,24h,HT29,CPC007
Roxithromycin,10um,24h,MCF7,CPD003
3-methyladenine,10um,6h,SNUC5,CPC006
Anabasine,10um,6h,PC3,CPC002
ARRY-704,0.4um,24h,MCF7,LJP002

0.14

atenolol,10um,6h,HCC515,CPC020

0.16

0.14

corticosterone,10um,24h,VCAP,CPC010

0.16

0.14

Cortisone,10um,24h,MCF7,CPC005

0.16

0.14

D-64131,10um,24h,HCC515,CPC002

0.16

0.16

0.14
0.14

Dorzolamide
hydrochloride,10um,24h,MCF7,CPD003
Ethotoin,10um,24h,MCF7,CPD002
flumazenil,10um,24h,PC3,CPC011
GDC-0879,10um,6h,SKBR3,LJP002
Gliquidone,10um,6h,HCC515,CPC002
GW 583340
dihydrochloride,10um,24h,HCC515,CPC001
H-8,10um,24h,VCAP,CPC003
Isradipine,10um,24h,HA1E,CPC005

0.14

JWE-035,10um,6h,SKBR3,LJP002

0.14
0.14
0.14
0.14
0.14
0.14

0.14
0.14
0.14
0.14
0.14
0.14
0.14

LIQUIRITIGENIN DIMETHYL
ETHER,10um,6h,MCF7,CPC005
loxoprofen,10um,6h,HEPG2,CPC011
N-(4-(5-(benzo[d][1,3]dioxol-5-yl)-3-methoxy1H-1,2,4-triazol-1-yl)phenyl)-2(phenylthio)acetamide Secin
H3,10um,6h,MCF7,CPC007
Norcyclobenzaprine,10um,6h,HCC515,CPC00
3
Parthenolide,10um,24h,HCC515,CPC006
PCI-32765,2um,24h,MCF7,LJP002
PD0325901,10um,24h,MDAMB231,LJP002

0.14

sulfisoxazole,10um,6h,A375,CPC020

0.14
0.14
0.14
0.14

probenecid,10um,24h,PC3,CPC020
manumycin A,9.08um,6h,HT115,CPC006
erastin,4.8um,6h,CL34,CPC006
duremesin,10um,6h,MCF7,CPC020
Tubocurarine chloride pentahydrate
(+),10um,24h,HCC515,CPC001
TOLAZAMIDE,10um,6h,SKMEL1,CPC006
TBB,10um,24h,HCC515,CPC002
STAT3 Inhibitor VI, S31201,160um,6h,SNUC4,CPC006

0.14
0.14
0.14
0.14
0.14

SID 26681509,88.8um,6h,NOMO1,CPC006

0.14

S1205,10um,6h,A549,CPC014

0.14

Nutlin-3,44.4um,6h,SKMEL28,CPC006

0.14
0.14
0.14
0.14

NF-kB Activation Inhibitor II, JSH23,6um,6h,OV7,CPC006
NCGC00242557-01,10um,24h,VCAP,CPC008
NCGC00188488-01,10um,6h,A375,CPC008
N-(2-ethoxyphenyl)-4-morpholino-6-(pyrrolidin-
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0.14
0.14
0.14
0.14
0.14
0.14
0.14
0.14

0.14
0.14
0.14
0.14
0.14
0.14
0.14
0.14

0.14
0.14

PD0325901,2um,24h,MDAMB231,LJP002
SAFROLGLYCOL,10um,6h,HT29,CPC005
SB 202190,10um,24h,VCAP,CPC002
SB525334,0.08um,24h,MCF7,LJP002
SC-9,10um,6h,PC3,CPC003
SID 26681509,88.8um,6h,PL21,CPC006
sirolimus,10um,6h,SKM1,CPC006
SPIPERONE,10um,24h,HCC515,CPC004
SR 57227
hydrochloride,10um,24h,VCAP,CPC002
THIOTEPA,10um,6h,MCF7,CPC004
Tpl2,40um,6h,HCC515,CPC006

0.14

triamterene,10um,6h,HA1E,CPC020

0.14

0.14

trichostatin A,10um,24h,VCAP,CPC001

0.14

0.14

trichostatin A,10um,24h,VCAP,CPC010

0.14

0.14

trichostatin A,10um,6h,HA1E,CPC011

0.14

0.14

Tyrphostin AG
1478,56.78um,6h,LOVO,CPC006

0.14

0.14

0.14
0.14

Tyrphostin AG
1478,56.78um,6h,SNUC5,CPC006
Tyrphostin AG
1478,56.78um,6h,VCAP,CPC006

0.14
0.14
0.14

1-yl)-1,3,5-triazin-2-amine hw-gcact07,10um,24h,A549,CPC007
MDL-28170,10um,6h,PC3,CPC002
JAS07_006,10um,24h,HA1E,CPC007
Iodipamide,10um,24h,PC3,CPC001
HTS 12526,10um,24h,PC3,CPC014
H5902,10um,6h,HT29,CPC012
FELAMIDIN,10um,6h,PC3,CPC002
ENROFLOXACIN,10um,24h,HCC515,CPC003
Closantel,10um,24h,PC3,CPD002
Canrenoic acid potassium
salt,10um,24h,PC3,CPC003
CDC,10um,24h,VCAP,CPC001
C247,10um,24h,PC3,CPC014
Adamantamine
fumarate,10um,24h,PC3,CPD002
7-chloro-4H-benzo[b]thieno[3,4e][1,4]diazepin-10(9H)-one KAJ3,10um,6h,HCC515,CPC007
4-morpholino-N-phenyl-6-(pyrrolidin-1-yl)1,3,5-triazin-2-amine hw-gcact03,10um,6h,PC3,CPC007
3027-0077,10um,6h,MCF7,CPC014
3-(5-oxopyrrolidin-2-yl)-N-((S)-1phenylethyl)propanamide RA5,10um,6h,A549,CPC007

0.14

2541665-P2,80um,6h,RMGI,CPC006

0.14

2541665-P1,11.1um,6h,U937,CPC006

0.14

vorinostat,10um,24h,VCAP,CPC007

0.14

0.14

VU0415011,10um,24h,MCF7,CPC008

0.14

0.14

W-5 hydrochloride,10um,6h,HT29,CPC005

0.14

0.14
0.14

Y27632,4um,6h,PC3,CPC006
Z2777,10um,6h,VCAP,CPC014

2-(4-(5-chloro-2-isopropoxyphenylamino)-6(pyrrolidin-1-yl)-1,3,5-triazin-2-ylamino)ethanol
wh-gc-round5-68,10um,24h,PC3,CPC010
17757146,0.35um,6h,RMGI,CPC006
1-tert-butyl-3-(naphthalen-1-ylmethyl)-1Hpyrazolo[3,4-d]pyrimidin-4-amine CAL-NCGC023,10um,6h,PC3,CPC010

Supplemental Table 6.2: L1000 Analysis for drug perturbations potentially influencing the expression state of all motility-
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deterministic down-regulated genes of rod photoreceptors – Listed are top-ranked experimental drugs and their testing conditions that
potentially reverse (up-regulate) or aggravate (down-regulate) the expression of all resolved down-regulated motility-deterministic gene culled
from results of IPA bioinformatics analysis of NSR/Rod matched dataset depicted in Figure 5.4A (Chapter 5). Resolved down-regulated motility
genes analyzed are localized to the plasma membrane, cytoplasm and nucleus of rod photoreceptors. Rankings of chemical perturbation
experiments was performed using an overlap score that quantifies the correlation between our input gene list and z-score gene expression
signatures of the 1000 genes measured per experiment using Pearson’s correlation [3].

Overlap Score
(Up-regulation)

(Perturbation, Dose, Time, Cell, Batch)

Overlap Score
(Down-regulation)

(Perturbation, Dose, Time, Cell, Batch)

0.12

moban,10um,6h,HA1E,CPC020

0.12

BMY 14802
hydrochloride,10um,24h,VCAP,CPC001

0.1

venlafaxine hcl,10um,6h,VCAP,CPC011

0.1
0.1

minoxidil,10um,6h,SW948,CPC006
betulinic acid,10um,24h,HCC515,CPC002
YM 298198
hydrochloride,10um,24h,VCAP,CPC001
RIZATRIPTAN
BENZOATE,10um,6h,HA1E,CPC004
PZ0005,10um,24h,PC3,CPC014
O-2050,10um,24h,VCAP,CPC001
MLS-0390945.0001,10um,6h,HT29,CPC013
MLS-0390837.0001,10um,6h,A549,CPC012
IKK Inhibitor X,6um,24h,PC3,CPC006
DY131,10um,6h,HCC515,CPC001
AZD-6482,0.08um,24h,HS578T,LJP001
AG-370,10um,6h,HCC515,CPC002
5540735,10um,24h,MCF7,CPC013
spironolactone,10um,6h,HT29,CPC020
nadolol,10um,6h,HA1E,CPC020
m-Chlorophenylbiguanide
hydrochloride,10um,24h,VCAP,CPC002

0.12
0.12
0.1
0.1

VINBLASTINE
SULFATE,10um,6h,HCC515,CPC003
Erlotinib,0.08um,24h,HS578T,LJP002
wortmannin,10um,6h,SKM1,CPC006
Sulfamethoxypyridazine,10um,24h,PC3,C
PD002

0.1

0.1

S1475,10um,6h,A549,CPC014

0.1

0.1
0.1
0.1
0.08
0.08
0.08
0.08
0.08
0.08
0.08
0.08

Merbromin,10um,24h,PC3,CPD002
IMD 0354,10um,6h,U937,CPC006
71820,10um,24h,PC3,CPC014
zacopride,10um,6h,VCAP,CPC011
wortmannin,10um,6h,VCAP,CPC003
wortmannin,10um,24h,MCF7,CPD002
wortmannin,10um,24h,MCF7,CPC010
wortmannin,10um,24h,MCF7,CPC008
tropicamide,10um,6h,PC3,CPC020
tripelennamine,10um,6h,A375,CPC011
tolazamide,10um,24h,PC3,CPC020

0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.08
0.08

0.08

tofranil,10um,6h,MCF7,CPC020

0.08
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0.08
0.08
0.08
0.08
0.08

0.08
0.08
0.08
0.08
0.08

ginsenoside-Rc,10um,24h,HCC515,CPC001
doxycycline,10um,24h,MCF7,CPC020
chloramphenicol,10um,6h,HA1E,CPC020
S2005,10um,24h,VCAP,CPC013
S1472,10um,6h,A375,CPC014

0.08

Ro 08-2750,10um,24h,HCC515,CPC001

0.08

RWJ 21757,10um,24h,PC3,CPC003

0.08
0.08

theophylline,10um,6h,MCF7,CPC020
oxyphenonium,10um,6h,PC3,CPC010
minoxidil,10um,24h,PC3,CPC020
linezolid,10um,6h,PC3,CPC011
fluticasone,10um,24h,VCAP,CPC011
fluocinolone
acetonide,10um,6h,HCC515,CPC020
fluocinolone
acetonide,10um,6h,A549,CPC020
fluocinolone acetonide 21acetate,10um,6h,MCF7,CPC020
docetaxel,10um,6h,VCAP,CPC011
depo-medrol,10um,6h,MCF7,CPC020

0.08

budesonide,10um,6h,HCC515,CPC020

0.08

0.08
0.08
0.08

0.08

VARDENAFIL
HYDROCHLORIDE,10um,24h,HCC515,C
PC003
TL_HRAS24 BRDK93060291,10um,6h,A375,CPC008
ROTENONIC
ACID,10um,24h,PC3,CPC002
Naltriben
mesylate,10um,6h,HA1E,CPC001
Medrysone,10um,6h,PC3,CPC002
MLS0013618.0001,10um,24h,MCF7,CPC008
JTC 801,10um,24h,PC3,CPC003

0.08

Docetaxel,10um,24h,MCF7,CPD003

0.08
0.08
0.08
0.08
0.08
0.08

0.08
0.08

DICYCLOHEXYLUREA,10um,6h,HCC515
,CPC003
Clorgyline
hydrochloride,10um,6h,PC3,CPD001

0.08
0.08
0.08

ROTENONIC
ACID,10um,6h,HCC515,CPC002
Piperacetazine,10um,24h,VCAP,CPC001
Norethindrone,10um,24h,HCC515,CPC001
NYLIDRIN
HYDROCHLORIDE,10um,6h,HA1E,CPC002

0.08

MLS0435556.0001,10um,24h,VCAP,CPC013

0.08

LFM-A13,10um,24h,PC3,CPC002

0.08

L-692,585,10um,6h,HA1E,CPC003

0.08

HY-11000,10um,6h,A549,CPC013

0.08

HY-10228,10um,6h,A549,CPC014
Gabexate
mesylate,10um,24h,VCAP,CPC002
G-220,10um,24h,MCF7,CPC014
Flavoxate
hydrochloride,10um,6h,HA1E,CPC002

0.08
0.08
0.08
0.08

F3103-0039,10um,24h,VCAP,CPC014

0.08

Dibucaine,10um,6h,MCF7,CPD001

0.08

CARPROFEN,10um,24h,HA1E,CPC003

0.08

0.08

C1386,10um,6h,A375,CPC013

0.08

0.08

Bisacodyl,10um,24h,MCF7,CPD002

0.08

0.08

Bicalutamide,10um,24h,MCF7,CPD003
5-(benzenesulfonyl)-N-[4-(1,1,1,3,3,3hexafluoro-2-hydroxypropan-2-

0.08

Caffeic acid phenethyl
ester,10um,6h,PC3,CPC001
CIGLITAZONE,10um,6h,HCC515,CPC002
Benoxinate
hydrochloride,10um,24h,VCAP,CPC001
BL-080,10um,6h,HA1E,CPC014

0.08

BL-076,10um,24h,PC3,CPC014

0.08

243

0.08
0.08
0.08

yl)phenyl]thiophene-2sulfonamide,10um,6h,HCC515,CPC008
2-Phenyl-quinoline-4-carboxylic acid [4(thiazol-2-ylsulfamoyl)-phenyl]-amide
MLS0206672.0001,10um,24h,PC3,CPC008
2-(trifluoromethyl)-10Hphenothiazine,10um,6h,A375,CPC008
(-)-MK 801 hydrogen
maleate,10um,6h,PC3,CPD003

0.08

BENZO[a]PYRENE,10um,6h,HCC515,CPC0
01

0.08

BD 1047
dihydrobromide,10um,24h,VCAP,CPC002

0.08

7910663,10um,6h,HEPG2,CPC013

0.08
7706-0139,10um,6h,MCF7,CPC014
0.08
5-azacytidine,10um,6h,HA1E,CPC020
0.08
19-norethindrone,10um,6h,A375,CPC020
Supplemental Table 6.3: L1000 Analysis for drug perturbations potentially Influencing the expression state of all motilitydeterministic up-regulated genes of rod photoreceptors – Listed are top-ranked experimental drugs and their testing conditions that
potentially reverse (down-regulate) or aggravate (up-regulate) the expression of all resolved up-regulated motility-deterministic gene
culled from results of IPA bioinformatics analysis of NSR/Rod matched dataset depicted in Figure 5.4A (Chapter 5). Resolved upregulated motility genes analyzed are localized to the plasma membrane, cytoplasm and nucleus of rod photoreceptors. Rankings of
chemical perturbation experiments was performed using an overlap score that quantifies the correlation between our input gene list and
z-score gene expression signatures of the 1000 genes measured per experiment using Pearson’s correlation [3].

Overlap Score
(Down-regulation)

(Perturbation, Dose, Time, Cell, Batch)

Overlap Score
(Up-regulation)

(Perturbation, Dose, Time, Cell, Batch)

0.02

estradiol,10um,24h,VCAP,CPC003

0.02

bufalin,10um,6h,VCAP,CPC003

0.02

0.02
0.02

bongkrekic acid,10um,24h,PC3,CPC003
VINCRISTINE
SULFATE,10um,6h,VCAP,CPC003
VINBLASTINE
SULFATE,10um,24h,PC3,CPC003
Trap 101,10um,24h,VCAP,CPC003
TOLAZAMIDE,10um,6h,VCAP,CPC003

0.02

TCB2,10um,24h,PC3,CPC003

0.02

TC 2559 difumarate,10um,6h,VCAP,CPC003
TC 2559
difumarate,10um,24h,VCAP,CPC003
SULPIRIDE,10um,6h,VCAP,CPC003
SCH 442416,10um,24h,PC3,CPC003

0.02

ZM 323881
hydrochloride,10um,24h,VCAP,CPC003
VARDENAFIL
HYDROCHLORIDE,10um,24h,PC3,CPC003
TRIAMTERENE,10um,24h,VCAP,CPC003
THIABENDAZOLE,10um,24h,HCC515,CPC0
03
TAMOXIFEN
CITRATE,10um,24h,VCAP,CPC003
Seneciphylline,10um,24h,VCAP,CPC003
SR-95639A,10um,6h,VCAP,CPC003
SCOPOLAMINE
HYDROBROMIDE,10um,6h,PC3,CPC003
SC 560,10um,6h,PC3,CPC003

0.02

SC 560,10um,24h,PC3,CPC003

0.02

0.02
0.02

Rimexolone,10um,24h,VCAP,CPC003
Reserpinic acid

0.02
0.02

0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02

0.02
0.02
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0.02

hydrochloride,10um,24h,VCAP,CPC003
Ranitidine
hydrochloride,10um,6h,PC3,CPC003
Ranitidine
hydrochloride,10um,24h,HCC515,CPC003
RS 45041-190
hydrochloride,10um,24h,PC3,CPC003
RESERPINE,10um,24h,VCAP,CPC003

0.02

Proxyfan maleate,10um,6h,PC3,CPC003

0.02

0.02

PSOROMIC ACID,10um,6h,PC3,CPC003
PSOROMIC
ACID,10um,6h,HCC515,CPC003
PROTHIONAMIDE,10um,24h,HCC515,CPC0
03

0.02

Remacemide
hydrochloride,10um,24h,VCAP,CPC003
RS 100329
hydrochloride,10um,24h,PC3,CPC003
RHIZOCARPIC
ACID,10um,6h,VCAP,CPC003
RG-14620,10um,6h,VCAP,CPC003
Quinidine hydrochloride
monohydrate,10um,24h,PC3,CPC003
PODOFILOX,10um,6h,VCAP,CPC003

0.02

PINACIDIL,10um,6h,VCAP,CPC003

0.02

Nizatidine,10um,6h,VCAP,CPC003

0.02

PNU 282987,10um,6h,PC3,CPC003

0.02

0.02

PINACIDIL,10um,24h,VCAP,CPC003
Nitrocaramiphen
hydrochloride,10um,24h,HCC515,CPC003
METHYL
EVERNINATE,10um,6h,PC3,CPC003
Levocabastine
hydrochloride,10um,6h,PC3,CPC003
LIDOCAINE
HYDROCHLORIDE,10um,6h,PC3,CPC003
INDOLE-3CARBINOL,10um,6h,PC3,CPC003
HYDRASTINE (1R,
9S),10um,24h,VCAP,CPC003

0.02

Nitrocaramiphen
hydrochloride,10um,6h,VCAP,CPC003
NONOXYNOL-9,10um,6h,VCAP,CPC003

0.02

MRS 1220,10um,24h,VCAP,CPC003

0.02

HOMOSALATE,10um,6h,PC3,CPC003

0.02

0.02

HOMOSALATE,10um,24h,VCAP,CPC003

0.02

0.02
0.02
0.02

0.02
0.02

0.02
0.02
0.02
0.02
0.02
0.02

0.02
0.02
0.02
0.02
0.02

HAEMATOXYLIN
PENTAACETATE,10um,24h,HCC515,CPC00
3
GBR 13069,10um,6h,HCC515,CPC003
GBR 13069,10um,24h,VCAP,CPC003
GAMMA-LINOLENIC ACID (18:3 n6),10um,6h,HCC515,CPC003
Fillalbin,10um,6h,PC3,CPC003

0.02
0.02
0.02
0.02

0.02
0.02
0.02

MR 16728
hydrochloride,10um,24h,VCAP,CPC003
Loreclezole
hydrochloride,10um,6h,VCAP,CPC003
LEOIDIN DIMETHYL
ETHER,10um,6h,VCAP,CPC003

0.02

KAWAIN,10um,6h,VCAP,CPC003

0.02

IVERMECTIN,10um,6h,VCAP,CPC003
Hippeastrine
hydrobromide,10um,6h,VCAP,CPC003
HEXAMETHYLQUERCETAGETIN,10um,6h,
VCAP,CPC003

0.02

GW 405833,10um,6h,VCAP,CPC003

0.02
0.02

GLIPIZIDE,10um,6h,VCAP,CPC003
GLIPIZIDE,10um,24h,VCAP,CPC003
Fluvoxamine
maleate,10um,6h,VCAP,CPC003
Flurofamide,10um,24h,VCAP,CPC003

0.02
0.02
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0.02

Felodipine,10um,24h,VCAP,CPC003

0.02

0.02
0.02
0.02

Fananserin,10um,24h,PC3,CPC003
Ethisterone,10um,6h,PC3,CPC003
Eplerenone,10um,24h,VCAP,CPC003

0.02
0.02
0.02

0.02

EUGENITOL,10um,24h,PC3,CPC003

0.02

0.02

Co 102862,10um,24h,PC3,CPC003

0.02

Flucloxacillin
sodium,10um,24h,VCAP,CPC003
Fillalbin,10um,6h,VCAP,CPC003
FLUMETHASONE,10um,6h,VCAP,CPC003
ENROFLOXACIN,10um,24h,VCAP,CPC003
Doxorubicin
hydrochloride,10um,24h,PC3,CPC003
Daunorubicin
hydrochloride,10um,24h,PC3,CPC003

0.02

Carbenoxolone disodium
salt,10um,6h,PC3,CPC003
CETIRIZINE
HYDROCHLORIDE,10um,24h,VCAP,CPC00
3
CCMQ,10um,24h,VCAP,CPC003

0.02

CCMQ,10um,24h,HA1E,CPC003

0.02

0.02
0.02

Bemegride,10um,24h,HCC515,CPC003
BEZAFIBRATE,10um,24h,HCC515,CPC003
Altanserin
hydrochloride,10um,24h,HCC515,CPC003

0.02
0.02

CGS 12066B,10um,24h,PC3,CPC003
Biperiden
hydrochloride,10um,24h,VCAP,CPC003
BUCLADESINE,10um,24h,VCAP,CPC003
BICALUTAMIDE,10um,6h,VCAP,CPC003

0.02

BAY 59-3074,10um,24h,VCAP,CPC003

0.02
0.02

0.02

0.02

DEGUELIN(-),10um,6h,VCAP,CPC003

0.02

CPCCOEt,10um,6h,VCAP,CPC003

0.02

Altanserin
hydrochloride,10um,6h,VCAP,CPC003
0.02
AG 555,10um,24h,VCAP,CPC003
0.02
AG 490,10um,24h,VCAP,CPC003
Supplemental Table 6.4: L1000 Analysis for drug perturbations potentially influencing the expression state of all motilitydeterministic down-regulated genes of cone photoreceptors – Listed are top-ranked 50 experimental drugs and their testing conditions
that potentially reverse (up-regulate) or aggravate (down-regulate) the expression of all resolved down-regulated motility-deterministic genes
culled from results of IPA bioinformatics analysis of RPE/Rod matched dataset depicted in Figure 5.4B (Chapter 5). Resolved downregulated motility genes analyzed are localized to the plasma membrane, cytoplasm and nucleus of rod photoreceptors and include:
CTNNB1, PRDX1, KDR, CXCR4. Rankings of chemical perturbation experiments was performed using an overlap score that quantifies the
correlation between our input gene list and z-score gene expression signatures of the 1000 genes measured per experiment using Pearson’s
correlation [3].
0.02

AG 9,10um,6h,HCC515,CPC003

0.02
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Overlap Score
(Up-regulation)
0.0225
0.0135
0.0135
0.0132
0.0132
0.013
0.0128
0.0128
0.0127
0.0127
0.0125
0.0125
0.0125
0.0123
0.0123
0.0123
0.0123
0.0122
0.0122
0.0122
0.0122
0.012
0.012
0.012
0.012
0.012
0.012
0.012
0.0119
0.0118
0.0118
0.0118
0.0116
0.0116
0.0116

(Perturbation, Dose, Time, Cell,
Batch)
EGF,100ng/ul,3h,MCF10A,LJP004
IFNA,100ng/ul,3h,SKBR3,LJP004
AR,100ng/ul,1h,SKBR3,LJP004
TNFA,100ng/ul,6h,MCF7,LJP004
IL1,100ng/ul,3h,BT20,LJP004
IL1,100ng/ul,1h,BT20,LJP004
IL6,100ng/ul,6h,SKBR3,LJP004
IFNA,100ng/ul,24h,HS578T,LJP004
IFNG,1ng/ul,6h,BT20,LJP004
IFNG,100ng/ul,6h,MCF10A,LJP004
TGFa,100ng/ul,1h,HS578T,LJP004
IL1,100ng/ul,1h,MDAMB231,LJP004
EPR,1ng/ul,24h,MCF7,LJP004
TGFa,100ng/ul,1h,BT20,LJP004
IL6,100ng/ul,1h,MCF10A,LJP004
EGF,100ng/ul,1h,HS578T,LJP004
EGF,0.1ng/ul,1h,MCF10A,LJP004
TNFA,100ng/ul,6h,BT20,LJP004
SCF,300ng/ul,24h,BT20,LJP004
HGF,1ng/ul,1h,MCF10A,LJP004
EGF,100ng/ul,1h,SKBR3,LJP004
bFGF,100ng/ul,1h,HS578T,LJP004
TGFa,100ng/ul,1h,MDAMB231,LJP004
MSP,1ng/ul,6h,SKBR3,LJP004
MCSF,100ng/ul,24h,HS578T,LJP004
IL4,100ng/ul,1h,MCF10A,LJP004
IL1,1ng/ul,1h,BT20,LJP004
BTC,100ng/ul,1h,BT20,LJP004
IL6,100ng/ul,1h,SKBR3,LJP004
KGF,1ng/ul,6h,BT20,LJP004
IFNA,1ng/ul,24h,MDAMB231,LJP004
EPG,1ng/ul,1h,MCF10A,LJP004
GAS6,100ng/ul,3h,SKBR3,LJP004
GAS6,100ng/ul,24h,MCF7,LJP004
FGF1,100ng/ul,6h,BT20,LJP004

Overlap Score
(Down-regulation)
0.0247
0.0222
0.0133
0.0125
0.0125
0.0125
0.0123
0.0122
0.012
0.0119
0.0119
0.0116
0.0116
0.0116
0.0116
0.0116
0.0116
0.0115
0.0115
0.0114
0.0114
0.0114
0.0114
0.0114
0.0112
0.0111
0.0111
0.0111
0.0111
0.011
0.011
0.0109
0.0108
0.0108
0.0106

(Perturbation, Dose, Time, Cell, Batch)
IL6,1ng/ul,24h,MDAMB231,LJP004
IL1,100ng/ul,1h,BT20,LJP004
bNGF,1ng/ul,24h,HS578T,LJP004
bNGF,100ng/ul,3h,BT20,LJP004
GAS6,100ng/ul,6h,BT20,LJP004
EPR,100ng/ul,24h,MCF10A,LJP004
HRG,100ng/ul,24h,MCF10A,LJP004
EPG,100ng/ul,24h,MCF10A,LJP004
KGF,1ng/ul,24h,MDAMB231,LJP004
INS,1ng/ul,3h,SKBR3,LJP004
EGF,0.1ng/ul,6h,SKBR3,LJP004
INS,1ng/ul,6h,SKBR3,LJP004
IGF2,100ng/ul,3h,BT20,LJP004
HBEGF,100ng/ul,24h,MCF7,LJP004
FGF1,1ng/ul,1h,SKBR3,LJP004
EGF,10ng/ul,24h,HS578T,LJP004
EGF,0.1ng/ul,3h,SKBR3,LJP004
IL17,1ng/ul,6h,SKBR3,LJP004
HGF,100ng/ul,1h,BT20,LJP004
MSP,1ng/ul,1h,MCF7,LJP004
MSP,1ng/ul,1h,HS578T,LJP004
IFNG,100ng/ul,6h,MCF7,LJP004
HBEGF,100ng/ul,6h,MCF7,LJP004
BTC,1ng/ul,6h,MDAMB231,LJP004
GAS6,100ng/ul,24h,BT20,LJP004
bFGF,1ng/ul,3h,MCF10A,LJP004
KGF,1ng/ul,24h,BT20,LJP004
IL4,100ng/ul,3h,SKBR3,LJP004
HGF,1ng/ul,1h,MDAMB231,LJP004
TGFa,100ng/ul,1h,BT20,LJP004
FGF1,100ng/ul,3h,SKBR3,LJP004
HGF,1ng/ul,24h,MCF10A,LJP004
IL1,100ng/ul,1h,HS578T,LJP004
EPR,100ng/ul,6h,MCF10A,LJP004
IGF1,100ng/ul,24h,MCF10A,LJP004
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0.0116

EPR,1ng/ul,24h,MDAMB231,LJP004

0.0106

0.0115

bNGF,100ng/ul,1h,SKBR3,LJP004

0

0.0115

bFGF,1ng/ul,1h,SKBR3,LJP004

0

0.0115
0.0115
0.0115
0.0115
0.0114

MCSF,100ng/ul,1h,MCF7,LJP004
KGF,1ng/ul,6h,MDAMB231,LJP004
IGF1,1ng/ul,24h,MCF7,LJP004
GAS6,1ng/ul,24h,BT20,LJP004
TNFA,100ng/ul,6h,SKBR3,LJP004

0
0
0
0
0

0.0114

KGF,1ng/ul,24h,MCF10A,LJP004

0

0.0114

IL4,1ng/ul,3h,MDAMB231,LJP004

0

0.0114

HGF,100ng/ul,6h,HS578T,LJP004

0

0.0114

EGF,100ng/ul,6h,HS578T,LJP004

0

0.0112

TNFA,1ng/ul,24h,MCF7,LJP004

0

0.0112

KGF,100ng/ul,1h,SKBR3,LJP004

0

0.0112

IL1,100ng/ul,1h,SKBR3,LJP004

0

EPG,100ng/ul,1h,MCF10A,LJP004
FINASTERIDE,10um,24h,VCAP,CPC00
3
FARNESYLTHIOACETIC
ACID,10um,24h,VCAP,CPC003
Ethisterone,10um,24h,VCAP,CPC003
Estrone,10um,24h,VCAP,CPC003
Equilin,10um,24h,VCAP,CPC003
Eplerenone,10um,24h,VCAP,CPC003
EUGENITOL,10um,24h,VCAP,CPC003
ETHYL-beta-CARBOLINE-3CARBOXYLATE,10um,24h,VCAP,CPC0
03
ESTRADIOL
ACETATE,10um,24h,VCAP,CPC003
ERYTHROMYCIN,10um,24h,VCAP,CPC
003
ERGOCORNINE,10um,24h,VCAP,CPC0
03
EPITESTOSTERONE,10um,24h,VCAP,
CPC003
ENROFLOXACIN,10um,24h,VCAP,CPC
003
ANANDAMIDE (20:3,n6),10um,24h,VCAP,CPC003

Supplemental Table 6.5: L1000 Analysis for Drug Perturbations Potentially Influencing the expression state of all
motility-deterministic up-regulated genes of Cone Photoreceptors – Listed are top-ranked 50 experimental drugs and their
testing conditions that potentially reverse (down-regulate) or aggravate (up-regulate) the expression of all resolved up-regulated
motility-deterministic genes culled from results of IPA bioinformatics analysis of RPE/Rod matched dataset depicted in Figure
5.4B (Chapter 5). Resolved up-regulated motility genes analyzed are localized to the plasma membrane, cytoplasm and nucleus
of rod photoreceptors and include: GRIN1, SOCS3, STAT2, ITCH, JAK2. Rankings of chemical perturbation experiments was
performed using an overlap score that quantifies the correlation between our input gene list and z-score gene expression
signatures of the 1000 genes measured per experiment using Pearson’s correlation [3].
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